↑ 疾患リストへ　← 戻る

 6. パーキンソン病　［臨床試験数：1,307，薬物数：1,322（DrugBank：270），標的遺伝子数：161，標的パスウェイ数：166］ 

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04147949July 20204 November 2019AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaRandomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaParkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic UseDrug: AV-101;Drug: PlaceboVistaGen Therapeutics, Inc.Not recruiting30 Years80 YearsAll20Phase 2
2NCT03309514June 20207 October 2019Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's DiseaseClinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's DiseaseParkinson's DiseaseBiological: Intracerebral microinjectionsNeuroGenerationNot recruiting35 Years85 YearsAll12Phase 1/Phase 2
3NCT02967250April 1, 202011 November 2019Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA TreatmentParkinson DiseaseDrug: ursodeoxycholic acidUniversity of MinnesotaNot recruiting18 YearsN/AAll20Phase 1United States
4NCT04152655January 1, 202011 November 2019A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson DiseaseA Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)REM Sleep Behavior Disorder;Parkinson DiseaseDrug: Idebenone;Drug: Placebo oral tabletSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNot recruiting18 YearsN/AAll180Phase 2/Phase 3China
5NCT03436953December 201915 April 2019A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's DiseaseA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's DiseaseParkinson's Disease;TremorDrug: CX-8998;Drug: PlaceboCavion, Inc.Not recruiting40 Years80 YearsAll60Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT04154072December 201911 November 2019A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's DiseaseParkinson DiseaseDrug: NLY01;Drug: VehicleNeuraly, Inc.Not recruiting30 Years80 YearsAll240Phase 2
7ChiCTR19000272102019-11-0111 November 2019Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's diseaseEffects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's diseaseDelirium1:Total Intravenous Anesthesia;2:Balance Anesthesia;Tsinghua University Yuquan HospitalRecruitingFemale1:60;2:60;Phase 0China
8NCT03652870November 1, 201917 September 2018Antidepressants Trial in Parkinson's DiseaseA Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's DiseaseDepression;Parkinson DiseaseDrug: Nortriptyline;Drug: Escitalopram;Drug: PlaceboUniversity College, LondonLondon North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS LothianNot recruiting18 Years85 YearsAll408Phase 3
9NCT04148391November 1, 201911 November 2019Evaluate NYX-458 in Subjects With MCI-PDA Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's DiseaseParkinson's Disease;Mild Cognitive ImpairmentDrug: Placebo Oral Capsule;Drug: NYX-458AptinyxCogState Ltd.;Worldwide Clinical TrialsNot recruiting50 Years80 YearsAll135Phase 2
10NCT04097080November 20197 October 2019Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's DiseaseComparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's DiseaseParkinson DiseaseDrug: NBTX-001;Drug: Standard of CareNobilis Therapeutics Inc.Recruiting18 YearsN/AAll60Phase 1Russian Federation
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11NCT04117178November 201914 October 2019Monitoring Anti-Dementia Drugs by Serum LevelsMonitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer DiseaseDrug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drugZealand University HospitalEpilepsihospitalet FiladelfiaNot recruiting18 YearsN/AAll110Phase 4
12NCT04127695October 31, 201928 October 2019A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ABBV-0805;Drug: Placebo ABBV-0805AbbVieNot recruitingN/A85 YearsAll32Phase 1United States
13ChiCTR19000269562019-10-2128 October 2019Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's diseaseMinimum alveolar concentration-awake of sevoflurane in patients with Parkinson's diseaseParkinson’s diseaseParkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction;The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaNot Recruiting4064BothParkinson’s disease group:30;Non-Parkinson’s disease group:30;N/AChina
14NCT04157933October 16, 201911 November 2019Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's DiseaseA Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's DiseaseParkinson's DiseaseDrug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossoverAlexza Pharmaceuticals, Inc.Recruiting30 Years85 YearsAll32Phase 1Netherlands
15NCT04146454October 14, 20194 November 2019Smartphone-based Wearable TelerehabilitationA New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's DiseaseParkinson DiseaseOther: Smartphone-based balance exercisesUniversity of HoustonEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Recruiting50 Years75 YearsAll44N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
16JPRN-jRCTs03119011511/10/20195 November 2019PK & PD of coadministration of XOR inhibitor and inosinePharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosineParkinson's disease
neurodegenerative disease		Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosineNaoyuki KamataniRecruiting>= 20age old<= 40age oldMale28Phase 1none
17NCT03987750October 20191 July 2019Safinamide for Levodopa-induced Dyskinesia (PD-LID)A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor FluctuationsDyskinesia, Drug-Induced;Parkinson DiseaseDrug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placeboZambon SpANot recruiting30 YearsN/AAll300Phase 3
18NCT04127578October 20194 November 2019Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)A Phase 1/2a Randomized, Double-Blind, Sham Procedure-Controlled, Ascending Dose Study to Evaluate the Safety of PR001A in Patients With Parkinson's Disease With at Least One GBA1 MutationParkinson DiseaseBiological: PR001A;Other: Sham procedurePrevail TherapeuticsRecruiting40 Years75 YearsAll16Phase 1/Phase 2United States
19NCT03905811September 23, 201930 September 2019Terazosin for Parkinson's DiseaseA Pilot Study of Terazosin for Parkinson's DiseaseParkinson DiseaseDrug: Terazosin 5 MG;Drug: Placebo oral capsuleJordan SchultzUniversity of IowaNot recruiting40 Years90 YearsAll20Phase 1/Phase 2
20ChiCTR19000258942019-09-1116 September 2019Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's diseaseParallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's diseaseparkinson diseaseexperimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening;Kaida WangRecruitingBothexperimental group:45;control group:23;Phase 0China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
21NCT03568968September 1, 201918 December 2018A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's DiseaseA Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK StudyParkinson DiseaseDietary Supplement: Nicotinamide Riboside;Drug: PlaceboHaukeland University HospitalNot recruiting18 YearsN/AAll200N/A
22NCT03968133September 1, 201911 June 2019Treating Anxiety in Parkinson's Disease With a Multi-Strain ProbioticTreating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled TrialParkinson Disease;AnxietyDietary Supplement: Probiotic;Dietary Supplement: PlaceboUniversity of British ColumbiaThe W. Garfield Weston FoundationNot recruiting40 Years80 YearsAll72Phase 2/Phase 3Canada
23NCT04064983September 1, 20197 October 2019Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's DiseaseIndividual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's DiseaseParkinson DiseaseDrug: HB-adMSCHope BiosciencesNot recruiting18 YearsN/AAllN/AUnited States
24NCT03665493September 201915 July 2019Dopamine Effect on Inhibitory ControlDopamine Effect on Inhibitory ControlIdiopathic Parkinson's DiseaseDrug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ONGiovanni MirabellaNot recruiting40 Years70 YearsAll102N/A
25NCT03947216September 20193 June 2019Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's DiseaseParkinson DiseaseDrug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoringUniversity Hospital, Strasbourg, FranceNS-PARK;EUCLID;F-CRINNot recruiting35 Years75 YearsAll130Phase 2France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
26NCT03959540September 20193 June 2019Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseA Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseParkinson DiseaseDrug: Opicapone;Drug: Levodopa (L-DOPA) + Standard careBial - Portela C S.A.Not recruiting75 YearsN/AAll100Phase 3
27NCT04075318August 29, 201916 September 2019Study of UB-312 in Healthy Participants and Parkinson's Disease PatientsA Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's DiseaseParkinson Disease;ParkinsonismBiological: UB-312;Biological: PlaceboUnited Neuroscience Ltd.Centre for Human Drug Research, Netherlands;Worldwide Clinical TrialsRecruiting40 Years85 YearsAll62Phase 1Netherlands
28NCT04006210August 27, 20194 November 2019A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)Parkinson's DiseaseCombination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mgNeuroDerm Ltd.Recruiting30 Years80 YearsAll300Phase 3United States
29NCT04070495August 27, 201916 September 2019A Drug Interaction Study of KW-6356 and Clarithromycin or RifampicinA Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)Parkinson's DiseaseDrug: KW-6356;Drug: Clarithromycin;Drug: RifampicinKyowa Kirin Co., Ltd.Recruiting20 Years44 YearsMale20Phase 1Japan
30ChiCTR19000253722019-08-1827 August 2019Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanismsQuantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanismsParkinson's disease1:rehabilitation;1:take levodopa;30:Wear wearable devices;Tianjin Huanhu HospitalNot RecruitingBoth1:30;1:30;30:30;Phase 0China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
31NCT04062526August 14, 201928 October 2019Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CTEvaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)Parkinson Disease;Healthy VolunteerDrug: [18F]NOSUniversity of PennsylvaniaRecruiting18 Years70 YearsAll30Early Phase 1United States
32NCT03976349August 12, 201911 November 2019A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's DiseaseA Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's DiseaseParkinson's DiseaseDrug: BIIB094;Drug: PlaceboBiogenIonis Pharmaceuticals, Inc.Recruiting35 Years80 YearsAll62Phase 1United States
33NCT04043338August 11, 201930 September 2019Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult SubjectsA Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult SubjectsParkinson's DiseaseDrug: XC130-A10H;Drug: PlaceboXoc PharmaceuticalsCelerionRecruiting18 Years75 YearsAll40Phase 1United States
34ChiCTR19000237252019-08-0111 June 2019Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)PD-Placebo:Placebo;PD-Butylphthalide:Butylphthalide;VP-Placebo:Placebo;VP-Butylphthalide:Butylphthalide;MSA-Placebo:Placebo;MSA-Butylphthalide :Butylphthalide ;PSP-Placebo:Placebo;PSP-Butylphthalide:Butylphthalide;Zhujiang Hospital of Southern Medical UniversityNot Recruiting1880MalePD-Placebo:50;PD-Butylphthalide:50;VP-Placebo:50;VP-Butylphthalide:50;MSA-Placebo:50;MSA-Butylphthalide :50;PSP-Placebo:50;PSP-Butylphthalide:50;Phase 0China
35NCT03808961August 1, 201927 May 2019Niacin for Parkinsons DiseaseNAPS: Niacin for Parkinsons DiseaseParkinson's DiseaseDietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: PlaceboVA Office of Research and DevelopmentNot recruiting35 YearsN/AAll100N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
36NCT03881371August 1, 20192 September 2019A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaA Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaParkinson DiseaseDrug: Safinamide;Other: PlaceboZambon SpARecruiting18 YearsN/AAll306Phase 3China
37NCT04056689July 23, 201914 October 2019Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseA Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: DNL151 low dose;Drug: DNL151 high dose;Drug: PlaceboDenali Therapeutics Inc.Recruiting30 Years75 YearsAll24Phase 1Netherlands;United Kingdom
38NCT03575195July 15, 201926 August 2019Microbiota Intervention to Change the Response of Parkinson's DiseaseMicrobiota Intervention to Change the Response of Parkinson's DiseaseParkinson DiseaseDrug: Rifaximin;Other: PlaceboUniversity of California, San FranciscoNova Southeastern University;Gateway Institute for Brain ResearchRecruiting30 YearsN/AAll86Phase 1/Phase 2United States
39ChiCTR19000217082019-07-0111 March 2019Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphiStudy for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphismParkinson's DiseaseHealthy control group:No;tremor-dominant phenotype PD patients group:pramipexole;Department of Neurology, Brain Hospital Affiliated to Nanjing Medical UniversityNot Recruiting5070BothHealthy control group:80;tremor-dominant phenotype PD patients group:80;Phase 0China
40NCT03815916July 1, 201926 August 201931P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's DiseaseA Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's DiseaseParkinson's DiseaseDrug: Gold NanocrystalsClene NanomedicineUniversity of Texas Southwestern Medical CenterRecruiting30 Years80 YearsAll24Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
41NCT03956979July 201911 June 2019A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiAA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010DyskinesiasDrug: JM-010 A group;Drug: JM-010 B group;Drug: PlacebosContera PharmaBukwang PharmaceuticalNot recruiting18 Years80 YearsAll81Phase 2
42NCT03977441July 201917 June 2019the Efficacy and Safety of Agomelatine in the Patients With Parkinson's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's DiseaseParkinson Disease;Depression;Sleep Disorders;Circadian Rhythm DisordersDrug: Agomelatine or PIaceboSecond Affiliated Hospital of Soochow UniversityNot recruiting30 Years75 YearsAll240Phase 4
43NCT03970239June 14, 201915 July 2019Serotonin in Impulse Control Disorders in Parkinson's DiseaseRole of the Serotoninergic System in Impulse Control Disorders in Parkinson's DiseaseParkinson Disease;Impulse Control DisordersDrug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)Hospices Civils de LyonRecruiting30 Years80 YearsAll45N/AFrance
44NCT03938922June 13, 201926 August 2019A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease DementiaA Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.Parkinson Disease;DementiaDrug: Active Investigational Treatment ENT-01Enterin Inc.Not recruiting30 Years90 YearsAll40Phase 1United States
45NCT03939559June 10, 201927 May 2019The Efficiency of Home Based Dual Task Training in Parkinson DiseaseThe Efficiency of Home Based Dual Task Training in Parkinson DiseaseParkinson DiseaseProcedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual taskIstanbul University-CerrahpasaNot recruiting30 Years80 YearsAll60N/A
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
46JPRN-UMIN0000369522019/06/0416 July 2019A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.18F-FDOPA, 11C-Raclopride PETNagoya City Rehabilitation AgencyRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
47ChiCTR19000225342019-06-0123 April 2019Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trialEfficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trialnon-motor symptoms of Parkinson’s diseaseentacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;pramipexole group:Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.;Geriatric Hospital of HainanNot Recruiting4075Bothentacapone group:194;pramipexole group:194;N/AChina
48NCT03924414June 1, 201929 April 2019Trial of Parkinson's And Zoledronic AcidTOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's DiseaseParkinson Disease;OsteoporosisDrug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: PlaceboCalifornia Pacific Medical Center Research InstituteNational Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's FoundationNot recruiting65 YearsN/AAll3500Phase 4
49NCT04064294June 1, 20199 September 2019Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase InhibitorsPreventing Levodopa Induced Dyskinesia in Parkinson?s Disease With StatinsParkinson Disease;Dyskinesia, Drug-InducedDrug: Intravenous InfusionVA Office of Research and DevelopmentOregon Health and Science UniversityRecruiting50 YearsN/AAll120Phase 1United States
50NCT03971617May 29, 201917 June 2019Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's DiseaseA Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Hydrogen;Drug: Placebo oral tabletStony Brook UniversityRecruiting40 Years80 YearsAll70Phase 2/Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
51NCT03970798May 22, 201926 August 2019A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinA Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinParkinson's DiseaseDrug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356Kyowa Kirin Co., Ltd.Not recruiting20 Years44 YearsMale50Phase 1Japan
52NCT03671785May 15, 201926 August 2019Study of the Fecal Microbiome in Patients With Parkinson's DiseaseA Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: PRIM-DJ2727;Drug: Placebo oral capsuleThe University of Texas Health Science Center, HoustonKelsey Research FoundationRecruiting55 Years75 YearsAll12Phase 1United States
53NCT03693872May 15, 201911 June 2019Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsEvaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsParkinson DiseaseDrug: Apomorphine;Drug: Dopaminergic Agonist + ApomorphineRennes University HospitalRecruiting18 YearsN/AAll42N/AFrance
54NCT03958708May 13, 20193 June 2019Modulation of Gut Microbiota by Rifaximin in PD PatientsModulation of Gut Microbiota by Rifaximin in PD PatientsParkinson Disease;InflammationDrug: Rifaximin 550 MGTaipei Medical University Shuang Ho HospitalRecruiting45 Years70 YearsAll20Phase 1/Phase 2Taiwan
55NCT03840837May 2, 201913 May 2019Cholinergic Neurotransmission in Mobility and Cognition in Parkinson DiseaseCholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson DiseaseParkinson DiseaseDrug: Rivastigmine transdermal patchUniversity of MarylandNational Institute on Aging (NIA)Recruiting18 YearsN/AAll100Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
56ChiCTR19000227152019-05-015 May 2019Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's diseaseAccurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's diseaseParkinson's DiseaseAnteversion group:DBS;Balance dysfunction group:DBS;Gait abnormality group:DBS;Tianjin Huanhu HospitalRecruitingBothAnteversion group:40;Balance dysfunction group:40;Gait abnormality group:40;N/AChina
57NCT03552068May 1, 201928 October 2019Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized TrialParkinson's Disease;Mpulse Control DisordersDrug: placebo;Drug: ClonidineHospices Civils de LyonRecruiting30 Years80 YearsAll38Phase 2France
58NCT03903549May 201915 April 2019Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy VolunteersA Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)Parkinson DiseaseDrug: [18F]P17-059Five Eleven Pharma, Inc.Not recruiting45 Years90 YearsAll26Phase 1United States
59NCT03781167April 29, 201928 October 2019A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's DiseaseParkinson's Disease (PD)Drug: ABBV-951AbbVieRecruiting30 YearsN/AAll130Phase 3United States;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom
60NCT03899324April 26, 201926 August 2019Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's DiseaseA Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's DiseaseParkinson DiseaseDrug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tabletB&A TherapeuticsRecruiting40 Years80 YearsAll40Phase 2France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
61JPRN-JapicCTI-19476322/4/201916 July 2019Safety and PK study of LY03003An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch.Parkinson's DiseaseIntervention name : Rotigotine
INN of the intervention : Rotigotine
Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week.
Control intervention name : Rotigotine
INN of the control intervention : Rotigotine
Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day.		Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.Recruiting20BOTH32Phase 1Japan
62NCT03661125April 11, 201926 August 2019SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisA Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.Parkinson Disease PsychosisDrug: Saracatinib;Drug: Placebo Oral TabletKing's College LondonAstraZeneca;King's College Hospital NHS TrustRecruiting40 YearsN/AAll30Early Phase 1United Kingdom
63NCT03775096April 4, 201924 June 2019Adrenergic Blockers for Cardiac Changes in Early Parkinson's DiseaseThe Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's DiseaseREM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson DiseaseDrug: CarvedilolMichele Tagliati, MDRecruiting30 Years75 YearsAll15Phase 2United States
64NCT03877510April 3, 201928 October 2019Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor FluctuationsAn Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor FluctuationsParkinson DiseaseDrug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mgImpax Laboratories, LLCRecruiting40 YearsN/AAll300Phase 3United States;Czechia;Germany;Italy;Spain
65JPRN-jRCTs05118021429/03/201910 September 2019The usefulness of flutemetamol for diagnostic imaging of neurogenerative diseaseThe usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative diseaseAlzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy		Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously		Yoshiaki ItohRecruitingAges 20 and overN/ABoth100N/Anone
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
66NCT03922711March 26, 201914 October 2019A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's DiseaseA 14-week, Double-blind, Randomized, Three-arm, Parallel Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)Parkinson DiseaseDrug: Pridopidine;Drug: PlaceboPrileniaRecruiting30 Years85 YearsAll135Phase 2United States
67NCT03716570March 12, 201930 September 2019A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's DiseaseA Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: BIIB054;Drug: PlaceboBiogenRecruiting40 Years80 YearsAll24Phase 1Japan
68ChiCTR19000217602019-03-0930 April 2019Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofolEffect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofolParkinson’s diseaseParkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil;The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaRecruiting4064MaleParkinson’s disease:25;Non-Parkinson’s disease:25;N/AChina
69NCT03816020March 9, 201920 May 2019NAD-supplementation in Drug naïve Parkinson's DiseaseNAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesDietary Supplement: Nicotinamide Riboside;Other: PlaceboHaukeland University HospitalRecruiting18 YearsN/AAll30N/ANorway
70NCT03887884March 5, 201926 August 2019Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: CVT-301;Drug: SinemetAcorda TherapeuticsNot recruiting30 Years85 YearsAll23Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
71NCT03865121March 4, 201911 November 2019Pilot Trial of Transnasal Nicotine in Parkinson DiseaseUncontrolled Pilot Trial of Transnasal Nicotine in Parkinson DiseaseParkinson DiseaseDrug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezHoward UniversityNot recruiting60 YearsN/AAll6Phase 2Mexico
72JPRN-jRCTs03118024801/03/201922 July 2019N/AIntervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PDParkinson's diseaseArm with treatment of Istradefylline and levodopa
Treatment with Istradefylline will be started at a dose of
20 mg administered once daily at Week 0. The dose of
Istradefylline will be increased to 40 mg once daily if
the patient has no tolerability issues and still has motor
symptoms at Week 1. Dose reduction is possible if the
patient has tolerability issues.
Patients will visit every 4 weeks from the following day
of Week0, and 50mg levodopa will be added of if CGI-S score
>=4 every time. Dose reduction is possible if the patient
has tolerability issues.
Arm without treatment of Istradefylline
50mg levodopa will be added at Week 0. Patients will visit
every 4 weeks from the following day of Week0, and 50mg
levodopa will be added of if CGI-S score >=4 every time.
Dose reduction is possible if the patient has tolerability
issues.		Taku HatanoKyowa Hakko Kirin Co., LtdRecruiting>=30 age old<=84 age oldBoth100N/Anone
73NCT03858270March 1, 201911 March 2019Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineInhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineParkinson DiseaseDrug: Memantine;Other: PlaceboWayne State UniversityNot recruiting45 Years85 YearsAll50Phase 3
74NCT03820037March 201911 February 2019Relative Bioavailability and Bioequivalence of OpicaponeA Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy SubjectsParkinson DiseaseDrug: Ongentys;Drug: BIA 9-1067 (test)Bial - Portela C S.A.Not recruiting18 Years55 YearsAll45Phase 1United Kingdom
75NCT03841604February 28, 201918 March 2019Effect of Safinamide on Parkinson's Disease Related Chronic PainA Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic PainIdiopathic Parkinson DiseaseDrug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placeboZambon SpARecruiting30 YearsN/AAll177Phase 4Austria;France;Germany;Italy;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
76NCT03830528February 26, 201925 March 2019A Study of Single and Multiple Doses of KW-6356 in Healthy SubjectsA Phase I Study of KW-6356 in Japanese and Caucasian Healthy AdultsParkinson's DiseaseDrug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: PlaceboKyowa Hakko Kirin Co., LtdRecruiting20 Years44 YearsMale48Phase 1Japan
77NCT03655236February 18, 201928 October 2019PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's DiseaseEarly Parkinson DiseaseDrug: K0706;Other: placeboSun Pharma Advanced Research Company LimitedRecruiting50 YearsN/AAll504Phase 2United States;Hungary
78NCT03968744February 18, 201911 June 2019Effect of Safinamide on Sleep Quality in Patients With Parkinson's DiseaseA Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep StudyIdiopathic Parkinson's Disease (at Later Stage)Drug: SafinamideAlain KaelinClinical Trial Unit Ente Ospedaliero CantonaleRecruiting18 YearsN/AAll23Phase 4Switzerland
79NCT03413384February 15, 20194 March 2019To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaA Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaParkinson's Disease DementiaDrug: Ceftriaxone;Other: PlaceboBrainX CorporationRecruiting50 Years80 YearsAll106Phase 2Taiwan
80NCT03815071February 1, 201911 February 2019A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem CellsClinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's DiseaseParkinson DiseaseDrug: Ips-nsc cellsAllife Medical Science and Technology Co., Ltd.The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial Hospital;Beijing HospitalNot recruiting18 Years60 YearsAll10Early Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
81NCT03845387February 20194 March 2019A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.Parkinson DiseaseDrug: KDT-3594;Drug: PramipexoleKissei Pharmaceutical Co., Ltd.Recruiting20 Years79 YearsAll100Phase 2Japan
82NCT03790670January 30, 201926 August 2019Biomarker Assessments of Leukine During Treatment of Parkinson's DiseaseSafety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot StudyParkinson DiseaseDrug: sargramostimUniversity of NebraskaNot recruiting35 Years85 YearsAll5Phase 1United States
83EUCTR2017-002426-20-AT22/01/201930 April 2019Effect of Safinamide on Parkinson’s Disease Related Chronic PainA randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain studyIdiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the “ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain.
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Zambon SpAAuthorised Female: yes
Male: yes		177Phase 4Spain;Austria
84NCT03826134January 17, 201923 April 2019A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy SubjectsInterventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy SubjectsParkinson DiseaseDrug: [11C]PXT012253H. Lundbeck A/SNot recruiting20 Years50 YearsAll7Early Phase 1Sweden
85JPRN-UMIN0000356022019/01/112 April 2019Hydrogen gas inhalation randomized double blinded trial for Parkinson's diseaseParkinson's diseasehydrogen gas16 weeks inhalation
two times of the inhalation for 60 minutes per day
8 weeks obsebation after the inhalation
placebo gas
16 weeks inhalation
two times of the inhalation for 60 minutes per day
8 weeks obsebation after the inhalation		Juntendo University Koshigaya HospitalRecruiting40years-old80years-oldMale and Female20Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
86NCT03638479January 8, 201911 June 2019Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement DisordersUtilizing Smart Devices to Identify New Phenotypical Characteristics in Movement DisordersParkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical ParkinsonismOther: Data CaptureWestfälische Wilhelms-Universität MünsterRecruiting18 YearsN/AAll500Phase 2Germany
87NCT03659682January 2, 201917 September 2018GLP1R in Parkinson's DiseaseEffect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's DiseaseParkinson DiseaseDrug: SemaglutideOslo University HospitalNot recruiting40 Years75 YearsAll120Phase 2
88NCT03727295January 1, 201912 November 2018Idebenone Treatment of Early Parkinson's DiseasesymptomsA Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor SymptomsOxidative Stress is an Important Cause of Parkinson's DiseaseDrug: Idebenone/placeboSecond Affiliated Hospital of Soochow UniversityQilu Pharmaceutical Co., Ltd.Not recruiting30 Years80 YearsAll180Phase 4
89ChiCTR18000199422018-12-3110 December 2018A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s DiseaseA Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s DiseaseParkinson’s DiseaseExperimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan Granules placebo combined with Pramipexole;The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)Not Recruiting3085BothExperimental group:150;Control group:150;New Treatment Measure Clinical StudyChina
90NCT03391882December 19, 201811 November 2019A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor FluctuationsMotor OFF Episodes Associated With Parkinson's DiseaseDrug: APL-130277;Drug: subcutaneous apomorphineSunovionRecruiting18 YearsN/AAll106Phase 3Austria;France;Germany;Italy;Spain;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
91NCT03781791December 10, 201829 July 2019Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)Constipation;Parkinson DiseaseDrug: Active Investigational Treatment ENT-01;Drug: Placebo TreatmentEnterin Inc.Not recruiting30 Years90 YearsAll72Phase 2United States
92NCT03710707December 4, 201817 June 2019Study to Evaluate DNL201 in Subjects With Parkinson's DiseaseA Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: DNL201 low dose;Drug: DNL201 high dose;Drug: PlaceboDenali Therapeutics Inc.Recruiting30 Years75 YearsAll30Phase 1United States
93NCT03944447December 1, 20187 October 2019Outcomes Mandate National Integration With Cannabis as MedicineOutcomes Mandate National Integration With Cannabis as MedicineChronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar DisorderDrug: Cannabis, MedicalOMNI Medical Services, LLCRecruiting7 YearsN/AAll100000Phase 2United States
94NCT03639064December 201827 August 2018Cannabis Oil for Pain in Parkinson's DiseaseA Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's DiseaseParkinson DiseaseDrug: Cannabis OilUniversity Health Network, TorontoParkinson Society CanadaNot recruiting18 YearsN/AAll15Phase 2
95NCT03942172November 27, 201827 May 2019Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance GlassesTreatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance GlassesParkinson DiseaseDevice: SpotOn balance glassesSpotOn Therapeutics Ltd.Not recruiting30 YearsN/AAll50N/AIsrael
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
96NCT03822364November 26, 20189 September 2019Staccato Apomorphine Single and Multi Dose PKA Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: 009-5;Drug: 009-4;Drug: 009-3;Drug: 009-2;Drug: 009-0;Drug: active comparator;Drug: 009-1Alexza Pharmaceuticals, Inc.Not recruiting18 Years60 YearsAll56Phase 1Netherlands
97NCT03823638November 20, 201811 February 2019Safety, Tolerability and Effects of Mannitol in Parkinson's DiseaseA Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's DiseaseParkinson DiseaseDietary Supplement: Oral D-Mannitol of PlaceboHadassah Medical OrganizationRecruiting40 Years75 YearsAll60Phase 2Israel
98NCT03713957November 12, 201822 October 2019A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentParkinson DiseaseDrug: GRF6021;Other: PlaceboAlkahest, Inc.Michael J. Fox Foundation for Parkinson's ResearchRecruiting40 Years85 YearsAll90Phase 2United States;Australia
99NCT03733561November 9, 201811 March 2019A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproA Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersParkinson DiseaseDrug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal PatchLuye Pharma Group Ltd.Recruiting18 Years45 YearsAll40Phase 1United States
100NCT03667404November 6, 201811 November 2019Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability StudyGut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability StudyParkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary ModificationDietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrinNorthwestern UniversityUniversity of Illinois at ChicagoRecruiting60 YearsN/AAll30Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
101NCT03670953November 6, 201811 November 2019A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor FluctuationsA Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor FluctuationsParkinson's Disease (Disorder)Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placeboImpax Laboratories, LLCRecruiting40 YearsN/AAll510Phase 3United States;Czechia;France;Germany;Italy;Spain
102NCT03069911November 1, 201826 August 2019Trial of OnabotulinumtoxinA for Depression in Parkinson DiseaseRandomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson DiseaseParkinson Disease;DepressionBiological: OnabotulinumtoxinA;Biological: ControlJohns Hopkins UniversityNot recruiting18 Years95 YearsAll3Phase 1United States
103NCT03727139November 1, 201819 November 2018Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term SafetyAZILECT Tablets Special Drug Use-Results Survey Survey on Long-term SafetyParkinson's DiseaseDrug: RasagilineTakedaRecruitingN/AN/AAll1000N/AJapan
104EUCTR2017-003415-19-ES31/10/20187 January 2019A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: JM-010
Product Code: JM-010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Buspirone hydrochloride
CAS Number: 33386-08-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
INN or Proposed INN: Zolmitriptan
CAS Number: 139264-17-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.8-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: JM-010
Product Code: JM-010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Buspirone hydrochloride
CAS Number: 33386-08-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
INN or Proposed INN: Zolmitriptan
CAS Number: 139264-17-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.8-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Contera PharmaAuthorisedFemale: yes
Male: yes		81Phase 2France;Spain;Germany
105ChiCTR18000179492018-10-3027 August 2018Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the diseaseClinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the diseaseParkinson's diseaseGroup 1:Selegiline and Shudipingchan granule;Group 2:Selegiline and simulant TCM granule;Longhua Hospital Shanghai University of Traditional Chinese MedicineNot Recruiting3085BothGroup 1:72;Group 2:72;New Treatment Measure Clinical StudyChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
106ChiCTR18000180172018-10-303 September 2018Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the diseaseClinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the diseaseParkinson's diseaseTreatment group:Selegiline+Shudipingchan granule;Control group:Selegiline+TCM simulant;Longhua Hospital Shanghai University of Traditional Chinese MedicineNot Recruiting3085BothTreatment group:92;Control group:92;New Treatment Measure Clinical StudyChina
107EUCTR2017-002426-20-ES19/10/20187 January 2019Effect of Safinamide on Parkinson’s Disease Related Chronic PainA randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain studyIdiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the “ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain.
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Zambon SpAAuthorisedFemale: yes
Male: yes		177Phase 4Spain
108NCT03720418October 17, 201816 September 2019Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's DiseaseA Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: OXB-102;Other: Imitation Surgical Procedure (ISP)Axovant Sciences Ltd.Oxford BioMedicaRecruiting48 Years70 YearsAll30Phase 1/Phase 2France;United Kingdom
109EUCTR2016-004610-95-DE01/10/20184 December 2018Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARKParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB054
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: n/a
Current Sponsor code: BIIB054
Other descriptive name: BIIB054
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use		Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes		311Phase 2France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
110NCT03703570September 29, 201828 January 2019A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsA Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing PreparationsParkinson's DiseaseDrug: KW-6356;Drug: PlaceboKyowa Hakko Kirin Co., LtdRecruiting20 Years80 YearsAll486Phase 2Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
111NCT03665454September 24, 201826 August 2019PF 06412562 in Subjects With Advanced Stage Parkinson's DiseaseA Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's DiseaseParkinson DiseaseDrug: PF-06412562;Drug: Standard of Care PlaceboMilton S. Hershey Medical CenterPfizerNot recruitingN/AN/AAll8Phase 1United States
112NCT03582137September 17, 20184 February 2019A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's DiseaseA Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's DiseaseParkinson DiseaseDrug: Cannabidiol;Other: PlaceboUniversity of Colorado, DenverColorado Department of Public Health and EnvironmentRecruiting40 Years85 YearsAll75Phase 2United States
113NCT03608371August 31, 201817 June 2019BTRX-246040 Study in Subjects With Parkinson's Disease With Motor FluctuationsPhase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor FluctuationsParkinson Disease;Motor DisorderDrug: BTRX-246040;Drug: PlaceboBlackThorn Therapeutics, Inc.Not recruiting30 Years76 YearsAll24Phase 2United States
114NCT03229174August 23, 201830 September 2019Brain Perfusion & Oxygenation in Parkinson's Disease With NOHEvaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus PlaceboParkinson Disease;Neurogenic Orthostatic HypotensionDrug: Droxidopa;Drug: PlaceboWilliam Ondo, MDLundbeck LLCRecruiting18 Years85 YearsAll28Phase 4United States
115NCT03621046August 20, 201821 January 2019Use of Low-dose Zolpidem in Parkinson's DiseaseA Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson'sParkinson DiseaseDrug: Zolpidem;Other: PlaceboAston UniversityUniversity Hospital Birmingham NHS Foundation TrustRecruiting40 Years80 YearsAll28Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
116NCT03567447August 17, 20184 November 2019Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)Parkinson Disease;Falls PatientDrug: Droxidopa;Other: PlaceboSt. Joseph's Hospital and Medical Center, PhoenixH. Lundbeck A/S;Arizona State UniversityRecruiting30 Years83 YearsAll10Phase 2United States
117NCT03675282August 14, 20187 October 2019Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and ControlsQuantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and ControlsParkinson Disease;REM Sleep Behavior Disorder;HealthyDrug: (11C)PE2IWeill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting20 Years100 YearsAll100Phase 1/Phase 2United States
118NCT03773796August 6, 20187 October 2019Nabilone for Non-motor Symptoms in Parkinson's DiseaseNabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and EfficacyParkinson DiseaseDrug: Nabilone 0.25 mgMedical University InnsbruckRecruiting30 Years100 YearsAll48Phase 3Austria
119ChiCTR18000169492018-08-019 July 2018Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's diseaseEfficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's diseaseParkinson's diseaseRasagiline early start group:rasagiline-rasagiline;Rasagiline delay start group:placebo-rasagiline;Beijing HospitalNot Recruiting3080BothRasagiline early start group:130;Rasagiline delay start group:130;New Treatment Measure Clinical StudyChina
120ChiCTR18000170842018-08-0127 August 2019Investigation of new approaches and technologies in the management of Parkinson's diseaseThe efficacy of Butylphthalide on cognitive impairment of patients with idiopathic PD and DBS patients: A Randomized, double-blind, placebo-controlled, multicenter trialParkinson's diseaseButylphthalide group:Butylphthalide, 2 capsules/time, 3 times/day, for 48 weeks;Control group:Placebo, 2 capsules/time, 3 times/day, for 48 weeks;Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting1880BothButylphthalide group:140;Control group:140;Phase 4China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
121JPRN-UMIN0000332852018/08/0122 July 2019The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trialThe preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial - The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's diseaseParkinson's diseaseOral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks
Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks		Department of Orthopaedic Surgery, Niigata University Medical and Dental HospitalDepartment of Neurology, Nishi-Niigata Chuo HospitalNot Recruiting50years-oldNot applicableMale and Female100Not selectedJapan
122EUCTR2017-005170-19-SE30/07/20187 January 2019A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension StudyA Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study - Long-Term Follow-up Safety After DDS Implantation with/without CDNF InfusionsIdiopathic Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor
Concentration unit: µg/µl microgram(s)/microlitre
Concentration type: equal
Concentration number: 1.0-		Renishaw plcAuthorisedFemale: yes
Male: yes		20Phase 1;Phase 2Sweden
123NCT03599726July 30, 201826 August 2019Improving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilImproving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilParkinson DiseaseDrug: Donepezil;Drug: PlaceboOregon Health and Science UniversityMedical Research Foundation, OregonRecruiting50 Years90 YearsAll20Early Phase 1United States
124NCT03611569July 25, 201830 September 2019Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseInterventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseHealthy;Parkinson DiseaseDrug: Lu AF82422;Drug: PlaceboH. Lundbeck A/SRecruiting18 Years80 YearsAll44Phase 1United States
125NCT03587168July 20, 20185 November 2018The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's DiseaseThe Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's DiseaseParkinson DiseaseOther: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale;Other: Berg Balance Scale;Other: the timed 360° turn testGazi UniversityNot recruiting40 YearsN/AAll86Phase 3Turkey
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
126JPRN-jRCTs05218015819/07/201822 July 2019The effect of rehabilitation robots for patients with Parkinson's disease.A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.Parkinson's Disease;D010300Robot group: The participants performs twelve per a session, 2sessions per a week for 8 weeks.
Control group: The participants receives balance exercise by physical therapist twice a week for 8 weeks.		Kazuhisa DomenRecruiting40 age old80 age oldBoth50N/Anone
127NCT03594656July 15, 201811 June 2019Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's DiseaseEffects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled TrialParkinson DiseaseDrug: Ganoderma;Drug: PlacebosXuanwu Hospital, BeijingRecruiting30 Years80 YearsAll288Phase 3China
128NCT03624920July 12, 20187 October 2019Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime SleepinessSafety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime SleepinessParkinson DiseaseDrug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage CTheranexusNot recruiting18 Years80 YearsAll71Phase 2United States;Czechia;France;Germany;Hungary
129NCT03774459July 9, 201826 August 2019ANAVEX2-73 Study in Parkinson's Disease DementiaA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With DementiaParkinsons Disease With DementiaDrug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsuleAnavex Life Sciences Corp.Anavex Germany GmbHRecruiting50 Years85 YearsAll120Phase 2Australia;Spain
130NCT03146130July 5, 201820 August 2018Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control DisordersStudy of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's DiseaseImpulse Control Disorder;ParkinsonBiological: Variation of behaviors of Parkinson's diseaseCentre Hospitalier Universitaire, AmiensRecruiting18 YearsN/AAll70Phase 3France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
131NCT03775538July 5, 201825 March 2019Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical StudyA Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain DiseasesDrug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery SystemHerantis Pharma Plc.Renishaw plc.Recruiting35 Years75 YearsAll18Phase 1/Phase 2Finland;Sweden
132EUCTR2017-004335-36-ES04/07/201824 September 2018A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. - A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: ANAVEX2-73
Pharmaceutical Form: Capsule
INN or Proposed INN: ANAVEX2-73
Current Sponsor code: ANAVEX2-73
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: ANAVEX2-73
Pharmaceutical Form: Capsule
INN or Proposed INN: ANAVEX2-73
Current Sponsor code: ANAVEX2-73
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-		Anavex Life Sciences Corp.AuthorisedFemale: yes
Male: yes		120Phase 2Spain
133NCT03521635July 3, 20184 November 2019The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-DopaA Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)Parkinson DiseaseDrug: Pramipexole SR;Drug: Pramipexole IRBoehringer IngelheimNot recruiting30 YearsN/AAll98Phase 4China
134JPRN-UMIN0000334092018/07/022 April 2019Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial.Parkinson's diseasePretreatment by heparinoid
In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks.
Non-pretreatment by heparinoid.
The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks.		Wakayama Medical UniversityRecruiting20years-old85years-oldMale and Female20Phase 1Japan
135NCT03566589July 2, 201820 August 2018Effects of PS128 on Parkinsonian SymptomsEffects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot StudyParkinson DiseaseDietary Supplement: Lactobacillus plantarum PS128Professor Lu Neurological ClinicNot recruiting40 Years80 YearsAll30N/ATaiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
136JPRN-UMIN0000334542018/07/012 April 2019A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.Parkinson's Diseaserobot assisted balance training (RABT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.
traditional balance training (TBT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.		Hyogo College of MedicineRecruiting40years-old80years-oldMale and Female50Not selectedJapan
137NCT03576638July 201816 July 2018Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease PatientsAn Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release TabletIntec Pharma Ltd.Not recruiting30 YearsN/AAll12Phase 2
138NCT03562494June 28, 201822 October 2019VY-AADC02 for Parkinson's Disease With Motor FluctuationsA Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor FluctuationsParkinson DiseaseBiological: VY-AADC02;Other: PlaceboNeurocrine BiosciencesVoyager TherapeuticsRecruiting40 Years75 YearsAll42Phase 2United States
139NCT03407378June 26, 201816 September 2019A Study to Investigate a New Treatment in Patients With Parkinson's DiseaseA Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's DiseaseParkinson DiseaseDrug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatmentTools4PatientRecruiting35 YearsN/AAll120Phase 1/Phase 2United States;Belgium;France
140EUCTR2017-001420-21-DE18/06/201828 February 2019Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's DiseaseA Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.Early Parkinson's Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: P2B001
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Pramipexole dihydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Rasagiline
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Pramipexole dihydrochloride extended-release tablets		Pharma Two B LtdAuthorised Female: yes
Male: yes		525Phase 3France;United States;Canada;Spain;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
141EUCTR2017-001420-21-ES13/06/201818 June 2018Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's DiseaseA Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.Early Parkinson's Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: P2B001
Pharmaceutical Form: Capsule
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Pramipexole dihydrochloride
Pharmaceutical Form: Capsule
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Rasagiline
Pharmaceutical Form: Capsule
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Pramipexole dihydrochloride extended-release tablets
Product Name: Pramipexole dihydrochloride extended-release tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 0.375-4.5
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Pharma Two B LtdAuthorisedFemale: yes
Male: yes		525Phase 3France;United States;Canada;Spain;Germany
142NCT03439943June 13, 201820 August 2018Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseMulticenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's DiseaseParkinson DiseaseDrug: Lixisenatide;Drug: placeboUniversity Hospital, ToulouseCure Parkinson;Réseau NS-Park;EUCLID;SanofiRecruiting40 Years75 YearsAll158Phase 2France
143EUCTR2017-004006-18-NL07/06/201818 June 2018The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's diseaseTherapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's diseaseParkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia.
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Levodopa powder for inhalation
Product Code: Levodopa Cyclops
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Current Sponsor code: levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 60-90
Trade Name: Madopar 125 mg, orodispersible tablet
Pharmaceutical Form: Orodispersible tablet		Pharmaceutical Technology and Biopharmacy, University of GroningenAuthorisedFemale: yes
Male: yes		8Phase 2Netherlands
144NCT03456687June 5, 201823 April 2019Effects of Exenatide on Motor Function and the BrainEffects of Exenatide on Motor Function and the BrainParkinson's DiseaseDrug: ExenatideUniversity of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting40 Years77 YearsAll15Phase 1United States
145EUCTR2018-000346-19-SE04/06/201811 June 2018An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension StudyIdiopathic Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor
Concentration unit: µg/µl microgram(s)/microlitre
Concentration type: equal
Concentration number: 1.0-		Herantis Pharma PlcAuthorisedFemale: yes
Male: yes		18Phase 1;Phase 2Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
146NCT03684122June 1, 20187 October 2019Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).Parkinson DiseaseBiological: Injection of Umbilical cord derived MSCsUniversity of JordanRecruiting20 Years75 YearsAll10Phase 1/Phase 2Jordan
147EUCTR2017-002780-17-ES21/05/201812 November 2018Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa.A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral SuspensionParkinson’s Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: ND0612
Product Code: ND0612
Pharmaceutical Form: Solution for infusion in administration system
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
Trade Name: SINEMET Plus
Product Name: SINEMET
Pharmaceutical Form: Tablet
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: Duodopa LD/CD 20/5 mg/mL
Product Name: Duodopa LD/CD 20/5 mg/mL
Pharmaceutical Form: Intestinal gel
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-		NeuroDerm Ltd.Not RecruitingFemale: yes
Male: yes		50Phase 3France;United States;Spain;Austria;Netherlands;Italy
148EUCTR2016-004610-95-ES18/05/201818 June 2018Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARKParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB054
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: n/a
Current Sponsor code: BIIB054
Other descriptive name: BIIB054
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use		Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes		311Phase 2France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
149NCT03589066May 15, 201819 November 2018Pharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseAn Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's DiseaseParkinson DiseaseDrug: LY03003Luye Pharma Group Ltd.Not recruiting18 YearsN/AAll24Phase 1United States
150EUCTR2017-004475-31-CZ09/05/201830 April 2019Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s diseaseExcessive daytime sleepiness associated with Parkinson’s disease
MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10041349 Term: Somnolence System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1 -
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9 -
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Modiodal
Product Name: over-encapsulated Modafinil
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: MODAFINIL
CAS Number: 68693-11-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Theranexus S.A.Authorised Female: yes
Male: yes		60Phase 2France;United States;Hungary;Czech Republic;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
151NCT03637023May 8, 201822 July 2019Virtual Reality for Parkinson's DiseaseClinical and Rest-fMRI Effects of Virtual Reality Practice on Motor and Cognitive Symptoms in Parkinson's Disease, a Randomized Control TrialParkinson Disease;Virtual Reality Therapy;Functional Magnetic Resonance ImagingBehavioral: Virtual Reality;Behavioral: Exercise Therapy;Drug: Pharmacological TreatmentFarzin Hajebrahimi, PT, MScRecruiting50 Years85 YearsAll45N/ATurkey
152NCT03587649May 7, 201830 September 2019Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density LossEvaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).Alzheimer Disease;Parkinson Disease;Healthy VolunteersDrug: [18F]MNI-1126InvicroRecruiting18 Years55 YearsAll15Phase 1United States
153NCT03843944May 1, 201822 October 2019Overnight Switch From Rasagiline To SafinamideOvernight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety StudyParkinson DiseaseDrug: SafinamideIRCCS San RaffaeleNot recruiting30 Years80 YearsAll20Phase 4Italy
154NCT03230526April 20, 201825 June 2018Identification of a Biomarker Predictive of Evolution of Parkinson DiseaseBrain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?Parkinson DiseaseDrug: [18F]DPA-714 PET scanNantes University HospitalRecruiting40 Years67 YearsAll64Phase 2France
155NCT03374917April 18, 201825 March 2019A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient EnvironmentAn Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient EnvironmentParkinson's Disease (PD)Drug: ABBV-951AbbVieNot recruiting30 Years85 YearsAll20Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
156EUCTR2017-004475-31-HU17/04/201830 April 2018Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s diseaseExcessive daytime sleepiness associated with Parkinson’s disease
MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10041349 Term: Somnolence System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1 -
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9 -
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Modiodal
Product Name: over-encapsulated Modafinil
Pharmaceutical Form: Capsule
INN or Proposed INN: MODAFINIL
CAS Number: 68693-11-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use		Theranexus S.A.AuthorisedFemale: yes
Male: yes		60Phase 2France;United States;Czech Republic;Hungary;Germany
157EUCTR2017-004253-16-AT13/04/201810 September 2018Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...)Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacySubject with non-Motor symptoms of Parkinson´s disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Nabilone
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: NABILONE
CAS Number: 51022-71-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-		Medizinische Universität Innsbruck, Universitätsklinik für NeurologieAuthorisedFemale: yes
Male: yes		48Phase 3Austria
158EUCTR2017-002707-10-DK10/04/201823 July 2018Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effectsSerum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and complianceDementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10075174 Term: Mixed dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Memantin Orion
Pharmaceutical Form: Tablet
INN or Proposed INN: MEMANTINE
CAS Number: 19982-08-2
Current Sponsor code: PR1
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 10-20
Product Name: Donepezil Sandoz
Product Code: 25330
Pharmaceutical Form: Tablet
INN or Proposed INN: DONEPEZIL
CAS Number: 120014-06-4
Current Sponsor code: PR2
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 5-10		Regional Dementia Research Centre, Dept of NeurologyAuthorisedFemale: yes
Male: yes		110Phase 4Denmark
159EUCTR2016-003456-70-DE04/04/201817 September 2018A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patientsAn Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor FluctuationsLevodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal		Sunovion Pharmaceuticals Inc.AuthorisedFemale: yes
Male: yes		106Phase 3United Kingdom;Italy;Germany;Austria;Spain;France
160ChiCTR18000153312018-04-0126 March 2018Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's DiseaseDopaminergic Mechanisms of Temporal Working Memory in Parkinson's DiseaseParkinson's diseasede novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks;Institute of Psychology, Chinese Academy of SciencesRecruiting5080Bothde novo PD patients:50;de novo PD patients:50;de novo PD patients:50;OtherChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
161NCT03827746April 1, 201816 September 2019The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease PatientsThe Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease PatientsParkinson Disease;Kinesiophobia;Physical Activity;Balance;FallingOther: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy ScaleIstanbul Kültür UniversityMarmara University;Istanbul University-Cerrahpasa;Koç UniversityNot recruiting40 Years85 YearsAll60Phase 2Turkey
162NCT03446807April 201811 June 2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot recruiting50 YearsN/AAll32Phase 2United States
163EUCTR2017-004297-34-GB31/03/201823 July 2018Use of low-dose zolpidem in Parkinson's.A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson'sParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Stilnoct
Product Name: Stilnoct
Product Code: 207-3120
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Zolpidem Tartrate
CAS Number: 99294-93-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-5
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Aston UniversityAuthorisedFemale: yes
Male: yes		28Phase 2United Kingdom
164NCT03648671March 28, 20183 September 2018Pain in Parkinson's Disease With Motor Fluctuations.Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.Parkinson DiseaseDrug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks)Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaRecruiting18 Years80 YearsAll48Phase 4Italy
165EUCTR2018-000405-23-FI27/03/201830 April 2018Postitron emission tomography imaging of neuroinflammation in Parkinson´s diseaseIn vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PDParkinson´s disease
MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Product Code: [11C]SMW139
Pharmaceutical Form: Injection		Juha Rinne / PET CentreAuthorisedFemale: yes
Male: yes		14Phase 2Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
166EUCTR2016-004610-95-AT23/03/201819 November 2018Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARKParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB054
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: n/a
Current Sponsor code: BIIB054
Other descriptive name: BIIB054
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use		Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes		311Phase 2France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
167NCT03301272March 22, 20189 September 2019Effectiveness of Botox on Reducing Rest Tremor in Parkinson's DiseaseEffectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot StudyParkinson DiseaseDrug: Onabotulinumtoxin A Injection;Other: PlaceboUniversity of North Carolina, Chapel HillNot recruiting45 Years80 YearsAll16Phase 2United States
168NCT03457493March 22, 201827 May 2019TSPO-PET for Neuroinflammation in Parkinson's DiseaseUAB Neuroinflammation in Parkinson's Disease - TSPO-PET SubstudyParkinson DiseaseDrug: DPA-714-PET/MRIUniversity of Alabama at BirminghamRecruiting30 YearsN/AAll20Phase 1/Phase 2United States
169NCT03462641March 9, 201815 July 2019Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil ArmModulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil ArmParkinson DiseaseDrug: Flumazenil;Drug: PlaceboUniversity of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting50 Years99 YearsAll30Phase 1/Phase 2United States
170NCT03482882March 9, 201826 August 2019Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and DepressionAn Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and DepressionTreatment of Depression in Adults With Parkinson's Disease (PD)Drug: PimavanserinACADIA Pharmaceuticals Inc.Not recruiting50 YearsN/AAll47Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
171NCT03149809March 1, 201815 July 2019Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson DiseaseBehavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson DiseaseOveractive Bladder;Parkinson DiseaseDrug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapyVA Office of Research and DevelopmentRecruitingN/AN/AAll90Phase 3United States
172NCT03368170February 27, 201826 August 2019Efficacy and Tolerability of IRL790 in Parkinson's Disease DyskinesiaA Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease DyskinesiaParkinson DiseaseDrug: IRL790Integrative Research Laboratories ABThe Clinical Trial CompanyNot recruiting18 Years79 YearsAll75Phase 2Sweden;United Kingdom
173NCT03419806February 16, 201811 June 2018Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's DiseaseLevodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal DuodopaParkinson DiseaseDrug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa)Vastra Gotaland RegionThe Swedish Research Council;Dizlin Medical Design AB;Göteborg UniversityRecruiting30 YearsN/AAll28Phase 1Sweden
174NCT03882398February 15, 20181 April 2019Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's DiseaseEffects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled TrialParkinson Disease;Exercise;Physical Activity;Quality of LifeOther: Balance;Other: EnduranceUniversity of VigoNot recruiting60 Years80 YearsAll14N/ASpain
175NCT03496870February 8, 20181 April 2019A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: Opicapone;Drug: Carbidopa LevodopaNeurocrine BiosciencesNot recruiting18 Years85 YearsAll16Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
176NCT03189563February 6, 201814 January 2019Safety and Efficacy of DA-9805 for Parkinson's DiseaseA Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: DA-9805 45mg;Drug: DA-9805 90mg;Other: PlaceboDong-A ST Co., Ltd.Not recruiting30 Years79 YearsAll60Phase 2United States
177JPRN-UMIN0000309302018/01/292 April 2019Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.Parkinson's diseaseAdministration of febuxostat 20 mg and inosine 500 mg twice a day for 58 daysStaGen Co. Ltd.Recruiting20years-old80years-oldMale and Female30Not selectedJapan
178NCT03329508January 29, 201811 November 2019A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sA Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.Parkinson DiseaseDrug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ERPharma Two B Ltd.Recruiting35 Years80 YearsAll525Phase 3United States;Canada;Germany;Spain
179NCT03440112January 29, 201815 July 2019Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin ArmModulation of GABA-A Receptors and Axial Motor Impairments in ParkinsonParkinson DiseaseDrug: Clarithromycin;Drug: PlaceboNicolaas Bohnen, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting50 YearsN/AAll30Phase 1/Phase 2United States
180ChiCTR18000145422018-01-2229 January 2018Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's diseaseUp-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's diseaseParkinson's DiseasePD group:propofol;NPD group:propofol;Xuanwu Hospital of CCMURecruiting1865BothPD group:40;NPD group:40;OtherChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
181NCT03531086January 19, 201825 March 2019Idiopathic Parkinson's Progression and Dopamine Transporter SPECTExploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Ioflupane I 123Julie GurwellRecruiting40 Years75 YearsAll12Phase 1United States
182NCT03331848January 15, 201811 June 2018Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)Parkinson DiseaseDrug: Placebo oral capsule;Drug: PXT002331 - 20mgPrexton TherapeuticsNot recruiting35 Years85 YearsAll0Phase 2
183NCT03318523January 10, 201816 September 2019Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: BIIB054;Drug: PlaceboBiogenNot recruiting40 Years80 YearsAll311Phase 2United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
184NCT03550183January 10, 201811 June 2018Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's DiseaseSafety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem CellsParkinson's DiseaseBiological: mesenchymal stem cellsHebei Newtherapy BIo-Pharma technology Co., Ltd.Recruiting40 Years80 YearsAll20Phase 1China
185EUCTR2016-003456-70-AT04/01/20181 October 2018A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patientsAn Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor FluctuationsLevodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal		Sunovion Pharmaceuticals Inc.AuthorisedFemale: yes
Male: yes		106Phase 3France;Spain;Austria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
186NCT03321019December 12, 201727 May 2019Airway Protective Mechanisms in PD (R01)Mechanisms of Airway Protection Dysfunction in Parkinson's DiseaseParkinson DiseaseDrug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluationUniversity of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Recruiting45 Years85 YearsAll245Phase 1United States
187JPRN-UMIN0000300842017/12/012 April 2019Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's diseaseneuroinflammatory disorder, Parkinson's disease, Brain tumor[18F]GE180 is injected intravenously as 3-4 MBq/Kg. PET is dynamically scanned for 90 minutes.

Carbidopa 150mg is administrated orally 1hr before scan.[18F]FDOPA is injected intravenously as 3-4 MBq/Kg. Dynamic PET is scanned for 90 minutes.

[18F]FLT is injected intravenously as 3-4 MBq/Kg. Statical PET is scanned after 60 minutes		Kyoto UniversityNot Recruiting50years-oldNot applicableMale and Female12Phase 1,2Japan
188NCT03377322December 1, 20174 November 2019Trial of Probiotics for Constipation in Parkinson's DiseaseA Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's DiseaseParkinson DiseaseDrug: Probiotic Capsule;Drug: Placebo CapsuleUniversity of MalayaNot recruiting40 Years85 YearsAll72N/AMalaysia
189NCT03944785November 30, 201722 October 2019Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)TabletsIdiopathic Parkinson DiseaseDrug: XADAGO (safinamide)US WorldMeds LLCRecruiting30 Years80 YearsAll540N/AUnited States
190NCT03194217November 10, 201722 July 2019BEN-2001 in Parkinson Disease Patients With Excessive Daytime SleepinessDose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).Excessive Daytime Sleepiness;Parkinson DiseaseDrug: BEN-2001;Drug: PlaceboBenevolentAI BioNot recruiting50 Years80 YearsAll248Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
191NCT03305809November 9, 201711 November 2019A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)Lewy Body DementiaDrug: LY3154207;Drug: PlaceboEli Lilly and CompanyRecruiting40 Years85 YearsAll340Phase 2United States;Canada;Puerto Rico;China
192NCT02611167November 1, 201719 November 2018Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's DiseasePilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's DiseaseParkinson's DiseaseBiological: Allogeneic bone marrow-derived MSCsThe University of Texas Health Science Center, HoustonNot recruiting45 Years70 YearsAll20Phase 1/Phase 2United States
193NCT03205956October 19, 20178 April 2019Measuring Parkinson's Disease ProgressionDopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PDParkinson's DiseaseDrug: LevodopaKevin J. Black, MDThe Michael J. Fox Foundation for Parkinson's ResearchRecruiting40 Years79 YearsAll40Phase 1United States
194NCT03272165October 17, 201711 November 2019Single Ascending Dose Study of MEDI1341 in Healthy VolunteersA Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.Parkinson's DiseaseDrug: MEDI1341;Drug: PlaceboAstraZenecaCovance;MMS Holdings, Inc;CatalentRecruiting18 Years80 YearsAll48Phase 1United States;United Kingdom
195NCT03205488October 16, 20179 October 2018Nilotinib in Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's DiseaseParkinson DiseaseDrug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: PlaceboNorthwestern UniversityUniversity of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's ResearchRecruiting40 Years79 YearsAll135Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
196NCT03250117October 10, 20176 May 2019Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral RopiniroleAn Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-DopaParkinson DiseaseDrug: Ropinirole oral product;Drug: Ropinirole ImplantTitan PharmaceuticalsRecruiting30 Years80 YearsAll20Phase 1/Phase 2United States
197EUCTR2017-001673-17-FI03/10/201719 November 2018A study to evaluate the safety and tolerability of IRL752 treatment in patients with Parkinson's disease dementia.A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease DementiaDementia in Parkinson's disease
MedDRA version: 20.0 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease System Organ Class: 100000014717 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: IRL752
Pharmaceutical Form: Capsule
INN or Proposed INN: IRL752
CAS Number: 1227638-29-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use		Integrative Research Laboratories ABNot RecruitingFemale: yes
Male: yes		40Phase 2Finland;Sweden
198NCT03769896October 3, 20177 October 2019Nabilone for Non-motor Symptoms in Parkinson's DiseaseNabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal StudyParkinson DiseaseDrug: Nabilone 0.25 mg;Drug: PlaceboMedical University InnsbruckNot recruiting30 Years100 YearsAll48Phase 2Austria
199NCT03257046September 28, 201720 August 2018Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's DiseaseA Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: ITI-214;Other: PlaceboIntra-Cellular Therapies, Inc.Recruiting50 YearsN/AAll40Phase 1/Phase 2United States
200EUCTR2015-004175-73-FI27/09/201712 March 2018A clinical study to test the safety of CDNF by brain infusion in patients with Parkinson's disease.A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administered via an Investigational Drug Delivery System to Patients with Idiopathic Parkinson’s Disease (PD) of Moderate Severity.Idiopathic Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CDNF
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intracerebral use		Herantis Pharma PlcAuthorisedFemale: yes
Male: yes		18Phase 1;Phase 2Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
201NCT03295786September 26, 201715 July 2019Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's DiseasePhase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's DiseaseParkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain DiseasesDrug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery SystemHerantis Pharma Plc.Renishaw plc.Recruiting35 Years75 YearsAll18Phase 1/Phase 2Finland;Sweden
202NCT03104725September 25, 20178 April 2019Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?Parkinson DiseaseDrug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: FluoroscopyNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting18 Years99 YearsAll41Phase 1United States
203EUCTR2017-000192-86-AT15/09/201720 August 2018Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-motor symptoms (e.g.sleeping disorders,cognitive dysfunction, hallucinations, autonomic dysfunction including urinary incontinence, constipation,...)Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal StudySubjects with non-motor symptoms of Parkinson´s disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Nabilone
Pharmaceutical Form: Capsule
INN or Proposed INN: NABILONE
CAS Number: 51022-71-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-		Medizinische Universität Innsbruck, Universitätsklinik für NeurologieAuthorisedFemale: yes
Male: yes		48Phase 2Austria
204NCT03306329September 13, 201712 February 2018DNS-7801 vs. Placebo in Parkinson's DiseaseA Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor FluctuationsParkinson's DiseaseDrug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: PlaceboDart NeuroScience, LLCNot recruiting30 YearsN/AAll5Phase 2United States
205NCT03272230September 6, 20171 April 2019Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based SystemAssessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral DiseaseApathy;Frontotemporal Dementia;Parkinson Disease;Depressive SymptomsBehavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's DiseaseInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting40 Years85 YearsAll135N/AFrance
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
206JPRN-jRCTs04118001804/09/201710 September 2019Pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseAssociation between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseParkinson's disease and related diseasesTwo drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eyeMasahisa katsunoRecruiting40ageNot applicableBoth40Phase 2None
207ChiCTR-INR-170120132017-09-0124 July 2017Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's diseaseClinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's diseaseParkinson‘s disease, DepressionBTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;Shanghai Tongji Hospital, Tongji UniversityNot Recruiting1880BothBTX-A:40;Placebo:40;New Treatment Measure Clinical StudyChina
208NCT03232996September 1, 201716 December 2017Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.Parkinson Disease;ParkinsonOther: Computer game based balance and walking rehabilitation for individuals with Parkinson's DiseaseUniversity of ManitobaNot recruiting55 Years70 YearsAll30N/ACanada
209NCT03292016August 22, 201713 May 2019A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF EpisodesA Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson DiseaseDrug: APL-130277;Drug: APO-go;Drug: ApokynSunovionNot recruiting18 YearsN/AAll8Phase 2United States
210NCT03204929August 14, 201715 July 2019Dose Escalation Study of Cu(II)ATSM in Parkinson's DiseaseA Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNot recruiting30 YearsN/AAll38Phase 1Australia
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
211EUCTR2017-000877-35-CZ09/08/20179 October 2017A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)Excessive daytime sleepiness with Parkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Bavisant
Product Code: JNJ-31001074
Pharmaceutical Form: Tablet
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Bavisant
Product Code: JNJ-31001074
Pharmaceutical Form: Tablet
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Bavisant
Product Code: JNJ-31001074
Pharmaceutical Form: Tablet
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		BenevolentAI BioAuthorisedFemale: yes
Male: yes		240Phase 2United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom
212NCT03187301August 3, 201726 November 2018A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF EpisodesA Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson's Disease;Off Episodes of Parkinson DiseaseDrug: APL-130277;Drug: Placebo;Drug: MoxifloxacinSunovionNot recruiting18 YearsN/AAll42Phase 2United States;Italy
213ChiCTR-IPR-170118752017-08-0110 July 2017Effects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's DiseaseEffects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's DiseaseParkinson's DiseaseControl group:Conventional drug therapy;Baduanjin group:Baduanjin aerobic exercise;Balance function training group:Balance function training group;Affiliated Lianyungang Hospital of Xuzhou Medical UniversityNot Recruiting4080BothControl group:30;Baduanjin group:30;Balance function training group:30;Pilot studyChina
214NCT03412513July 17, 201712 February 2018Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's DiseaseMirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled TrialOveractive Bladder;Parkinson DiseaseDrug: Mirabegron;Drug: PlaceboSeoul National University HospitalRecruiting40 Years80 YearsAll144Phase 4Korea, Republic of
215NCT03026231July 15, 201720 August 2018Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease PatientsA Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's DiseaseParkinson's DiseaseBiological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)The University of Texas Health Science Center, HoustonKelsey Research FoundationNot recruiting45 Years70 YearsAll0Phase 1/Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
216NCT03185481July 6, 201723 April 2019Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsA PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASEParkinson's Disease With Motor FluctuationsDrug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QDPfizerNot recruiting40 Years87 YearsAll5Phase 2United States
217NCT03162874July 4, 201718 March 2019Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's PatientsA Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)Parkinson DiseaseDrug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2Prexton TherapeuticsRecruiting35 Years85 YearsAll165Phase 2Austria;France;Germany;Italy;Spain;United Kingdom
218NCT03288155July 1, 201716 September 2019Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)Parkinson Disease;FatigueDietary Supplement: CocoaOxford Brookes UniversityEuropean Parkinson Therapy CentreNot recruiting18 YearsN/AAll30N/AItaly
219NCT04146519July 1, 20174 November 2019Parkinson's Disease Therapy Using Cell TechnologyDevelopent and Implement a Method of Parkinson's Disease Therapy Using Cell TechnologyTransplantation:Mesenchymal Stem Cell TransplantationBiological: Autologous mesenchymal stem cellsBelarusian Medical Academy of Post-Graduate EducationNot recruiting18 YearsN/AAll12Phase 2Belarus
220EUCTR2016-003961-25-DE30/06/20174 December 2018A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing offA Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”Parkinson's Disease
MedDRA version: 19.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: tozadenant
Product Code: TOZ
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: tozadenant
CAS Number: 870070-55-6
Current Sponsor code: TOZ
Other descriptive name: TOZADENANT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 60-		Biotie TherapiesNot RecruitingFemale: yes
Male: yes		450Phase 3United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
221NCT03042416June 29, 201728 October 201918F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyCongenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain GliomaDrug: 18F-DOPAUniversity of AlbertaAlberta Health ServicesRecruitingN/AN/AAll400Phase 3Canada
222NCT03100149June 27, 20176 May 2019A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded ExtensionParkinson's DiseaseDrug: RO7046015;Drug: PlaceboHoffmann-La RocheProthena Biosciences LimitedNot recruiting40 Years80 YearsAll316Phase 2United States;Austria;France;Germany;Spain
223NCT03195231June 25, 201716 December 2017Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's DiseaseWuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.Antidepressive AgentsDrug: Wuling Powder;Drug: PlaceboBeijing HospitalTongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical UniversityNot recruiting40 YearsN/AAll120Phase 4
224NCT03083132June 13, 201726 August 2019Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's DiseaseParkinson DiseaseDrug: modafinil 50mg;Drug: Placebo oral capsuleUniversity of ArkansasNot recruiting50 Years90 YearsAll20Early Phase 1United States
225NCT03973502June 12, 201717 June 2019Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PDApplication of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.Hepatitis C;Hepatitis B;Parkinson DiseaseDrug: 18F-DOPA PETNational Taiwan University HospitalRecruiting20 YearsN/AAll230N/ATaiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
226EUCTR2017-000135-14-AT26/05/20177 January 2019A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug LevodopaA Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED StudyParkinson’s Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: foliglurax
Product Code: PXT002331
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: foliglurax
CAS Number: 1883329-52-9
Current Sponsor code: PXT002331
Other descriptive name: CVD00118-E
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: foliglurax
Product Code: PXT002331
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: foliglurax
CAS Number: 1883329-52-9
Current Sponsor code: PXT002331
Other descriptive name: CVD00118-E
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Prexton Therapeutics B.V.AuthorisedFemale: yes
Male: yes		165Phase 2Spain;Austria;Germany
227NCT03111485May 24, 201718 March 2019Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's DiseaseEffect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's DiseaseParkinson's Disease;Obstructive Sleep ApneaDrug: Sinemet CR;Drug: Placebo oral capsuleMcGill University Health CenterWeston Brain InstituteRecruiting18 YearsN/AAll42Phase 4Canada
228NCT03033498May 17, 201725 March 2019A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseA Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseParkinson's Disease (PD)Drug: ABBV-951AbbVieRecruiting45 Years85 YearsAll30Phase 1United States
229NCT03174938May 15, 201711 June 2018The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
230NCT03242499May 15, 201716 December 2017Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's DiseaseLovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized TrialParkinson DiseaseDrug: Lovastatin;Drug: PlaceboNational Taiwan University HospitalRecruiting30 Years90 YearsAll80Phase 2Taiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
231NCT03047629May 11, 201720 August 2018Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related ConstipationA Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related ConstipationParkinson's Disease;ConstipationDrug: ENT-01;Other: PlaceboEnterin Inc.Not recruiting30 Years86 YearsAll50Phase 1/Phase 2United States
232NCT03065192May 11, 20178 April 2019Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseAn Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to LevodopaIdiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian DisordersDrug: VY-AADC01Neurocrine BiosciencesVoyager TherapeuticsNot recruiting40 Years75 YearsAll16Phase 1United States
233NCT02982512May 1, 201711 June 2018Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's DiseaseEffects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's DiseaseDexmedetomidine;Deep Brain Stimulation;Parkinson DiseaseDrug: DexmedetomidineClinica Universidad de Navarra, Universidad de NavarraRecruiting18 YearsN/AAll12Phase 4Spain
234NCT02702076May 201716 December 2017Apomorphine in Parkinson's Disease Patients With Visual HallucinationsRandomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual HallucinationsParkinson's Disease;Hallucinations, VisualDrug: Apomorphine;Drug: PlaceboUniversity Medical Center GroningenRecruiting30 YearsN/AAll35Phase 2Netherlands
235NCT03119636May 201716 December 2017Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's DiseaseA Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's DiseaseParkinson's DiseaseBiological: NPC transplantation;Drug: LevodopaChinese Academy of SciencesThe First Affiliated Hospital of Zhengzhou UniversityRecruiting50 Years80 YearsAll50Phase 1/Phase 2China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
236ChiCTR-IPR-170111552017-04-2018 April 2017Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's diseaseDihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's diseaseParkinson’s diseasetreatment group:dihydroergotoxine mesylate 2.5 mg, twice daily, two weeks;intervention group:identical placebo 2.5 mg, twice daily, two weeks;Nanjing First Hospital Affiliated to Nanjing Medical UniversityRecruiting1880Bothtreatment group:10;intervention group:10;Post-marketChina
237NCT03140956April 19, 201716 December 2017Pharmacokinetic of Levodopa Study in Healthy MalesPharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male SubjectsParkinson DiseaseDrug: Levodopa, carbidopa, ODM-104Orion Corporation, Orion PharmaNot recruiting18 Years65 YearsMale20Phase 1Finland
238NCT03115827April 18, 201711 March 2019Norepinephrine-targeted Therapy for Action Control in Parkinson DiseaseNorepinephrine-targeted Therapy for Action Control in Parkinson DiseaseParkinson DiseaseDrug: Droxidopa;Drug: CarbidopaVanderbilt University Medical CenterH. Lundbeck A/S;American Academy of NeurologyNot recruiting18 YearsN/AAll15Phase 4United States
239NCT03128450April 15, 201716 December 2017A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease PatientA Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's DiseaseParkinson DiseaseBiological: human neural stem cellSecond Affiliated Hospital of Soochow UniversityRecruiting35 Years70 YearsAll12Phase 2/Phase 3China
240EUCTR2016-004629-18-NL13/04/20178 May 2017The influence of stress on Parkinson's tremorThe noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremorTremor in Parkinson's disease
;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Propranolol
Product Name: Propranolol HCl CF 40 mg tablet
Product Code: RVG 55618
Pharmaceutical Form: Tablet		Radboud University NijmegenAuthorisedFemale: yes
Male: yes		Phase 3Netherlands
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
241NCT03011476April 11, 201711 June 2018Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson DiseaseEffect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait DisturbanceParkinson DiseaseDrug: Donepezil;Drug: PlacebosKyung Hee University HospitalRecruiting40 Years75 YearsAll20Phase 4Korea, Republic of
242NCT02953665April 3, 201713 May 2019Safety and Efficacy of Liraglutide in Parkinson's DiseaseA Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's DiseaseParkinson DiseaseDrug: Liraglutide;Drug: PlaceboCedars-Sinai Medical CenterThe Cure Parkinson's Trust;Novo Nordisk A/SRecruiting25 Years85 YearsAll57Phase 2United States
243JPRN-UMIN0000261282017/04/012 April 2019Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseParkinson's diseaseadministe pilocarpine and dipivefrine
administe pilocarpine and dipivefrine		Nagoya UniversityRecruiting40years-old90years-oldMale and Female60Not selectedJapan
244NCT02970019March 30, 201711 November 2019Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseA Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.Parkinson DiseaseDrug: K0706;Drug: PlaceboSun Pharma Advanced Research Company LimitedNot recruiting18 Years65 YearsAll58Phase 1United States
245EUCTR2016-003456-70-GB22/03/20173 September 2018A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patientsAn Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor FluctuationsLevodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2-
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal		Sunovion Pharmaceuticals Inc.AuthorisedFemale: yes
Male: yes		106Phase 3United Kingdom;Italy;Germany;Austria;Spain;France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
246JPRN-UMIN0000264922017/03/157 October 2019Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's DiseaseIntervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease.Parkinson's diseaseIn this research, the duration of evaluation will be 24 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.		Osaka Red Cross HospitalClinical Research Center, Wakayama Medical UniversityNot Recruiting30years-oldNot applicableMale and Female30Not selectedJapan
247NCT02864004March 3, 201714 October 2019Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)Apomorphine Pump in Early Stage of Parkinson's DiseaseParkinson's DiseaseDrug: Apomorphine;Other: Best Medical TreatmentRennes University HospitalRecruiting18 Years65 YearsAll192Phase 3France
248NCT03068481February 20, 201715 April 2019Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseA Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseParkinson DiseaseDrug: KDT-3594;Drug: PlaceboKissei Pharmaceutical Co., Ltd.Not recruiting20 Years74 YearsAll36Phase 1Japan
249NCT02799381February 9, 201714 October 2019A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)Parkinson's Disease (PD)Drug: ABT-SLV187;Drug: optimized antiparkinsonian treatmentAbbVieNot recruiting30 YearsN/AAll63Phase 3United States;Finland;Greece;Hungary;Italy;Slovakia;Spain
250JPRN-UMIN0000256452017/02/012 April 2019Cross sectional analysis of Intestinal flora of Parkinson's disease:Parkinson's diseaseLevodopa/carbidopa intestinal gelJuntendo University School of MedicineNot RecruitingNot applicableNot applicableMale and Female20Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
251NCT03119194January 27, 201716 December 2017Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male SubjectsParkinson DiseaseDrug: [14C]-BIA 9-1067Bial - Portela C S.A.Not recruiting30 Years65 YearsMale7Phase 1United Kingdom
252JPRN-UMIN0000257032017/01/162 April 2019Effect of thiamine for the treatment of motor and non-motor symptom in hereditary neurological or neurodegenerative disordersParkinson's disease spinocerebellar ataxiafursultiamine 100mgDepartment of Neurology and Clinical Pharmacology, Ehime University Graduate School of MedicineNot Recruiting20years-oldNot applicableMale and Female50Not applicableJapan
253NCT03330470January 1, 201724 September 2018Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative DiseaseMolecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative DiseaseSubjective Cognitive Impairment;Mild Cognitive Impairment;Parkinson Disease;Healthy VolunteersBehavioral: exercise;Dietary Supplement: carnosine supplementation;Behavioral: stretching;Dietary Supplement: supplementation with placeboSlovak Academy of SciencesComenius University;University Hospital Bratislava;National Cheng Kung UniversityRecruiting55 Years80 YearsAll100N/ASlovakia;Taiwan
254NCT02954978January 201725 March 2019Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseA Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseParkinson Disease;Parkinsons Disease With DementiaDrug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna]Georgetown UniversityNot recruiting40 Years90 YearsAll75Phase 2United States
255NCT03034564January 201716 December 2017A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's DiseaseParkinson Disease;Fatigue;ParkinsonismDrug: Northera;Drug: Placebo Oral TabletThe Cooper Health SystemRecruiting18 YearsN/AAll70Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
256NCT03037203January 201710 September 2018A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive SleepinessA 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive SleepinessExcessive Sleepiness;Parkinson DiseaseOther: Placebo;Drug: JZP-110Jazz PharmaceuticalsNot recruiting35 Years80 YearsAll60Phase 2United States
257NCT02969369December 31, 201626 August 2019A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisA Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisParkinson Disease PsychosisDrug: Placebo capsule;Drug: SEP-363856SunovionRecruiting55 Years105 YearsAll36Phase 2United States
258ChiCTR-IOR-160101682016-12-2018 April 2017Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantationPropofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantationParkinson's Diseasepropofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery;dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery;West China Hospital, Sichuan UniversityRecruiting18Bothpropofol-remifentanyl group:25;dexmedetomidine group:25;OtherChina
259NCT02906020December 15, 201622 October 2019A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationMulticenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.Parkinson's DiseaseDrug: GZ/SAR402671;Drug: PlaceboGenzyme, a Sanofi CompanyRecruiting18 Years80 YearsAll243Phase 2United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom
260JPRN-UMIN0000248592016/12/142 April 2019The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.Parkinson's diseaseSwitching from Dopamine agonist to Zonisamide.

Intervention period of 12 weeks.		Medical Corporation Abe Neurology ClinicNot Recruiting30years-oldNot applicableMale and Female50Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
261NCT02789020December 20168 April 2019Image Parkinson's Disease Progression StudyImage Parkinson's Disease Progression StudyParkinson's DiseaseDrug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance TestUniversity of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting40 Years77 YearsAll116Phase 2United States
262NCT02879136December 20169 July 2018TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's DiseaseTAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot StudyParkinson's Disease, IdiopathicDrug: Methylphenidate;Other: Physical Therapy;Drug: AtomoxetineShnehal PatelRecruiting18 Years90 YearsAll42Early Phase 1United States
263NCT02934919December 201624 October 2016Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label StudyEvaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label StudyImpulse Control Disorders;Parkinson DiseaseDrug: NalmefeneUniversity Hospital, Clermont-FerrandNot recruiting18 Years80 YearsBoth30Phase 2France
264NCT02941822December 20165 March 2018Ambroxol in Disease Modification in Parkinson DiseaseA Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson DiseaseParkinson DiseaseDrug: AmbroxolUniversity College, LondonCure Parkinson's Trust;PRO.MED.CS Praha a.s - Czech RepublicNot recruiting40 Years80 YearsAll20Phase 2United Kingdom
265NCT03000569December 201622 October 2018A Study to Evaluate SAGE-217 in Subjects With Parkinson's DiseaseA Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: SAGE-217Sage TherapeuticsNot recruiting40 Years75 YearsAll29Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
266JPRN-UMIN0000245362016/11/2822 July 2019Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease.Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease. - ODYSSEI Study(Onset of Dyskinesia and Safety/Efficacy of Istradefylline)Parkinson's diseaseTreatment with istradefylline combined with optimal medical therapy.

Treatment with istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4.

From the following day of Week 4, Optimal medical therapy including istradefylline will be applied to each patient.
Optimal medical therapy without istradefylline.

Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than istradefylline will be started at Week 0.

After Week 4, Optimal medical therapy without istradefylline will be applied to each patient.		Fukuoka UniversityNot Recruiting30years-old80years-oldMale and Female280Not applicableJapan
267EUCTR2016-001690-33-FI25/11/20165 December 2016Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossaApomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossaEdennyt parkinsonin tauti
MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Dacepton 5 mg/ml infuusioneste, liuos
Product Name: Dacepton 5 mg/ml
Pharmaceutical Form: Infusion		Eero PekkonenAuthorisedFemale: yes
Male: yes		Phase 4Finland
268NCT03007888November 14, 201613 May 2019A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseA Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseAdvanced Parkinson's DiseaseDrug: IR CD-LD;Drug: ER CD-LDIMPAX Laboratories, Inc.Not recruiting40 Years100 YearsAll28Phase 2United States
269EUCTR2016-001762-29-IT08/11/20168 January 2018A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) - CTH-201Parkinson's Disease (PD)
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Trade Name: AVALOX - 400 MG COMPRESSE RIVESTITE CON FILM 5 COMPRESSE IN BLISTER PP/AL
Product Name: Avalox
Product Code: n.a.
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MOXIFLOXACINA CLORIDRATO		SUNOVION PHARMACEUTICALSAuthorisedFemale: yes
Male: yes		40Phase 2Italy
270NCT03531060November 8, 201611 June 2018A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced DyskinesiaA Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).Parkinson DiseaseDrug: IRL790;Drug: PlaceboIntegrative Research Laboratories ABNot recruiting50 Years85 YearsAll15Phase 1/Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
271ChiCTR-IPR-160093952016-11-0118 April 2017Clinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stageClinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stageParkinson’s diseaseButylphthalide group and Control group:Butylphthalide 200mg/time(2 capsules) , three time/day, for 24 weeks;Control:No treatment;The Second Affiliated Hospital of Soochow UniversityNot Recruiting35BothButylphthalide group and Control group:36;Control:36;Post-marketChina
272JPRN-UMIN0000256382016/11/012 April 2019Adenosine A2A receptors in Parkinson's diseaseParkinson's disease11C-preladenant-PET scanningTokyo Metropolitan Institute of GerontologyNot Recruiting40years-old89years-oldMale and Female40Not selectedJapan
273NCT02857244November 20168 January 2018A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson PatientsA Multidisciplinary Approach to Manage Gait Difficulty in Parkinson PatientsParkinson's DiseaseDrug: Duloxetine;Drug: Donepezil;Drug: ModafinilUniversity of ChicagoNot recruiting18 Years100 YearsAll0Phase 2United States
274NCT02968433November 201615 April 2019The Stanford Parkinson's Disease Plasma StudyThe Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's DiseaseParkinson Disease(PD)Drug: Infusions of young plasmaStanford UniversityNot recruiting50 Years80 YearsAll15Phase 1United States
275EUCTR2015-001786-10-DE24/10/20165 February 2018A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease.A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects - Safety and Biomarker Study with EPI-589 in Parkinson's DiseaseParkinson’s disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: EPI-589
Product Code: EPI-589
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Kinoquinone (proposed)
CAS Number: 1147883-03-1
Current Sponsor code: EPI-589
Other descriptive name: (R)-troloxamide quinone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-		BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)AuthorisedFemale: yes
Male: yes		40Phase 2United States;Germany;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
276EUCTR2016-002680-34-ES20/10/20167 January 2019Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.Parkinson's disease
MedDRA version: 19.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]		Trade Name: Dexdor
Product Name: Dexdor
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: DEXMEDETOMIDINE
CAS Number: 113775-47-6
Other descriptive name: DEXMEDETOMIDINA
Concentration unit: µg/kg microgram(s)/kilogram
Concentration type: range
Concentration number: 0.15-1		Clínica Universidad de Navarra/Universidad de NavarraNot RecruitingFemale: yes
Male: yes		12Phase 4Spain
277NCT02871427October 20, 20168 April 2019Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior DisorderAn Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior DisorderLewy Body Dementia;Dementia With Lewy Bodies;Parkinson's Disease Dementia;Visual Hallucinations;REM Sleep Behavior DisorderDrug: NelotanserinAxovant Sciences Ltd.Not recruiting50 YearsN/AAll80Phase 2United States
278EUCTR2016-002454-20-FR17/10/20163 April 2017Apomorphine Pump in Early Stage of Parkinson’s DiseaseApomorphine Pump in Early Stage of Parkinson’s Disease - EARLY-PUMPParkinson’s disease
MedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: APOKINON
Product Name: APOKINON
Pharmaceutical Form: Solution for infusion		CHU de RennesAuthorisedFemale: yes
Male: yes		Phase 3France
279NCT02847650October 17, 201628 January 2019Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the DiseaseA 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's DiseaseParkinson DiseaseDrug: Placebo;Drug: PF-06649751PfizerNot recruiting45 Years80 YearsAll57Phase 2United States;France;Germany;Israel
280EUCTR2015-002571-24-GB14/10/201628 February 2019A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease.A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PDParkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: AMBROSAN 60mg Tablets
Product Name: Ambroxol
Pharmaceutical Form: Tablet
INN or Proposed INN: Ambroxol hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 60-		Joint Research OfficeNot Recruiting Female: yes
Male: yes		20Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
281EUCTR2016-002391-27-GB07/10/201628 February 2019Opicapone in clinical practice (OPTIPARK)This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1Parkinson's disease (PD) patients with wearing-off motor fluctuations
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Ongentys
Product Name: Ongentys
Pharmaceutical Form: Capsule, hard		BIAL - Portela & Ca, S.A.Not Recruiting Female: yes
Male: yes		550Phase 4Germany;United Kingdom
282NCT02935842October 1, 20165 November 2018Evaluation of Intensive Language TherapyEffectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded TrialParkinson's DiseaseOther: Specific SL-therapy;Other: Rhythmic Balance-Movement Training (rBMT)University Hospital, Basel, SwitzerlandNot recruiting45 Years80 YearsAll64N/ASwitzerland
283NCT02538315October 201616 December 2017Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease PatientsUsing 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease PatientsParkinson`s DiseaseDrug: [18F]FDOPA PET/CTUniversity of SaskatchewanUniversity of ManitobaRecruiting18 YearsN/AAll30N/ACanada
284NCT02803749October 201627 May 2019Buspirone in Parkinson's DiseaseThe Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's DiseaseParkinson Disease;AnxietyDrug: Buspirone;Drug: PlaceboUniversity of RochesterMichael J. Fox Foundation for Parkinson's ResearchNot recruiting18 YearsN/AAll21Phase 2United States
285NCT02910102October 20168 January 2018Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With DementiaA Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease DementiaAlzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease DementiaDrug: RVT-101 35 mg;Drug: PlaceboAxovant Sciences Ltd.Not recruiting50 Years89 YearsAll38Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
286NCT02940912October 201616 December 2017Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseDouble Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseParkinson DiseaseDrug: Apomorphine;Drug: PlaceboClinique Beau SoleilRecruiting35 Years90 YearsAll45Phase 4France
287NCT03022799October 201616 December 2017KM-819 for Patients With Parkinson's DiseaseA First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects With Exploration of Food EffectParkinson DiseaseDrug: KM-819;Drug: PlaceboKainos Medicine Inc.Recruiting19 YearsN/AAll88Phase 1Korea, Republic of
288NCT03462680September 28, 201629 July 2019GPR109A and Parkinson's Disease: Role of Niacin in Outcome MeasuresGPR109A and Parkinson's Disease: Role of Niacin in Outcome MeasuresParkinson's DiseaseDietary Supplement: niacin;Other: placeboVA Office of Research and DevelopmentRecruiting35 YearsN/AAll80N/AUnited States
289EUCTR2015-005078-39-DE21/09/201622 January 2018-A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's diseaseSubjects with advanced Parkinson's disease
MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: levodopa/carbidopa solution
Product Code: ND0612
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-		NeuroDerm Ltd.Not RecruitingFemale: yes
Male: yes		47Phase 2United States;Austria;Israel;Germany;Italy
290JPRN-UMIN0000243122016/09/202 April 2019Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosisTreatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeksTsukuba International Clinical Pharmacology ClinicNot Recruiting20years-old80years-oldMale and Female12Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
291NCT02688465September 5, 201611 June 2018Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).Parkinson's DiseaseDrug: ApomorphineFondation Ophtalmologique Adolphe de RothschildNot recruiting18 YearsN/AAll15Phase 4France
292NCT02815800September 2, 201611 June 2018Efficacy of Ethnodyne Visio in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: ETHNODYNE VISIOUniversity Hospital, Strasbourg, FranceETHNODYNENot recruiting40 Years75 YearsAll24N/AFrance
293NCT02385500September 20167 October 2019Fesoterodine on Urgency Episodes in Parkinson's Disease PopulationRandomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease PopulationUrinary Bladder, Overactive;Parkinson DiseaseDrug: Fesoterodine;Drug: PlaceboSir Mortimer B. Davis - Jewish General HospitalNot recruiting50 Years85 YearsAll5Phase 4Canada
294NCT02601586September 20162 September 2019Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's DiseaseEvaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA TrialParkinson DiseaseDrug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placeboUniversity Hospital, ToulouseRecruiting40 Years75 YearsAll84Phase 2/Phase 3France
295NCT02897063September 201625 February 2019Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureThe Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic HypotensionDrug: Droxidopa;Drug: Midodrine;Drug: PlaceboVanderbilt University Medical CenterRecruiting40 Years80 YearsAll34Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
296NCT02939391September 201611 June 2018A Study of KW-6356 in Subjects With Early Parkinson's DiseaseAn Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's DiseaseParkinson's DiseaseDrug: KW-6356;Drug: PlaceboKyowa Hakko Kirin Co., LtdNot recruiting20 Years80 YearsAll175Phase 2Japan
297NCT03192046September 201611 February 2019Bracing for Walking in Parkinson's DiseaseImpact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PDGait Disorders, Neurologic;Parkinson DiseaseDevice: Carbon Fiber Ankle Foot Orthosis (AFO)University of Texas Southwestern Medical CenterAmerican Orthotic and Prosthetic AssociationRecruiting30 Years85 YearsAll16N/AUnited States
298EUCTR2015-005814-31-AT29/08/201624 September 2018-A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND)Subjects with advanced Parkinson's disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: levodopa/carbidopa solution
Product Code: ND0612
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-		NeuroDerm Ltd.AuthorisedFemale: yes
Male: yes		210Phase 2France;United States;Hungary;Czech Republic;Belgium;Spain;Poland;Austria;Israel;Germany;Italy
299NCT02365870August 20164 November 2019Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentAnxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentAnxiety Disorders;Parkinson DiseaseDrug: rotigotine transdermal patch;Drug: placeboJohns Hopkins UniversityNational Institute on Aging (NIA)Not recruiting21 Years89 YearsAll4Phase 4United States
300NCT02782481August 20163 December 2018A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsA Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsParkinson's DiseaseDrug: ND0612;Drug: PlaceboNeuroDerm Ltd.Not recruiting30 Years80 YearsAll1Phase 3Israel
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
301EUCTR2014-001014-25-ES20/07/20168 August 2016Brain amyloid beta burden as per florbetaben PETBrain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's diseaseParkinson's Disease
MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neuraceq
Product Name: Neuraceq
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLORBETABEN (18F)
CAS Number: 902143-01-5
Current Sponsor code: Piramal Imaging GmbH
Concentration unit: MBq/mg megabecquerel(s)/milligram
Concentration type: equal
Concentration number: 300-		Fundació Clínic per la Recerca BiomèdicaAuthorisedFemale: yes
Male: yes		Phase 4Spain
302NCT02382198July 201611 June 2018Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's DiseaseA Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's DiseaseSialorrhea;Parkinson's DiseaseDrug: Glycopyrrolate;Drug: PlaceboOttawa Hospital Research InstituteRecruiting30 YearsN/AAll28Phase 2Canada
303NCT02452723July 201615 April 2019A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's DiseaseA Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's DiseaseParkinson DiseaseBiological: ISC-hpNSCCyto Therapeutics Pty LimitedNot recruiting30 Years70 YearsAll12Phase 1Australia
304NCT02615873July 201627 August 2018A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004Parkinson's DiseaseDrug: Accordion Pill™ Carbidopa/LevodopaIntec Pharma Ltd.Recruiting30 Years100 YearsAll460Phase 3United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom
305NCT02789592July 201613 June 2016Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson DiseaseA Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson DiseaseREM Sleep Behavior Disorder;Parkinson DiseaseDrug: Clonazepam placebo;Drug: Melatonin PR placebo;Drug: Clonazepam;Drug: Melatonin PRSeoul National University HospitalKuhnil Pharmaceutical Co., Ltd.Not recruiting30 YearsN/ABoth30Phase 2Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
306NCT02818777July 201616 December 2017A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's DiseaseA Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's DiseaseParkinson's DiseaseDrug: cannabidiol;Drug: placeboUniversity of Colorado, DenverColorado Department of Public Health and Environment;GW Research LtdRecruiting45 Years78 YearsAll60Phase 2United States
307EUCTR2015-005626-19-CZ23/06/201618 June 2018A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodesA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301 35mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Product Name: CVT-301
Product Code: CVT-301 50mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 42-		Civitas Therapeutics, Inc.Not RecruitingFemale: yes
Male: yes		440Phase 3United States;Czech Republic;Canada;Poland;Spain
308EUCTR2015-005626-19-ES13/06/201611 June 2018A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodesA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 19.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301 35mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Product Name: CVT-301
Product Code: CVT-301 50mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 42-		Civitas Therapeutics, a wholly owned subsidiary of AcordaNot RecruitingFemale: yes
Male: yes		440Phase 3United States;Czech Republic;Canada;Poland;Spain
309JPRN-jRCTs05118009809/06/201622 July 2019The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's DiseaseA comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's diseaseParkinson's disease;034034L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365.		Hidefumi ItoRecruiting>=55 age old<80 age oldBoth180Phase 2none
310JPRN-UMIN0000225292016/06/012 April 2019Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's diseaseParkinson's disease8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg)
Washout 6days

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap
8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap
Washout 6days

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg)		Utano National Hospital, National Hospital OrganizationNot Recruiting20years-old85years-oldMale and Female8Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
311JPRN-UMIN0000225332016/06/012 April 2019A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's diseaseParkinson's diseaseL-Dopa/DCI only
The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + selegiline
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + zonisamide
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.		Osaka Redcross Hospital Wakayama Prefectural Medical CollegeRecruiting55years-old80years-oldMale and Female180Phase 2Japan
312NCT02642393June 201619 November 2018Study of Urate Elevation in Parkinson's Disease, Phase 3A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's DiseaseParkinson's DiseaseDrug: Inosine;Drug: PlaceboMichael Alan SchwarzschildThe Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/AAll270Phase 3United States;Puerto Rico
313NCT02785978June 201616 December 2017Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy VolunteersPilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy VolunteersParkinson Disease;Healthy VolunteersDrug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completionInstitut de Myologie, FranceNot recruiting18 YearsN/AAll30N/AFrance
314NCT02807675June 201616 December 2017A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's DiseaseParkinson's DiseaseOther: Placebo;Drug: CVT-301, LIPAcorda TherapeuticsNot recruiting30 Years85 YearsAll36Phase 1United States
315NCT02812394June 20167 November 2016A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsA Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsParkinson DiseaseDrug: CVT-301 (Dose Level 1);Drug: CVT-301 (Dose Level 2);Drug: Sinemet®Acorda TherapeuticsNot recruiting25 Years65 YearsBoth24Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
316NCT02838797June 201622 October 2019RQ-00000010 for Gastroparesis and Constipation in Parkinson's DiseaseRQ-00000010 for Gastroparesis and Constipation in Parkinson's DiseaseParkinson's Disease;Gastroparesis;ConstipationDrug: RQ-00000010;Drug: PlaceboVirginia Commonwealth UniversityMichael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc.Not recruiting18 YearsN/AAll51Phase 1United States
317EUCTR2016-000679-25-ES31/05/201628 February 2019Clinical study for the assessment of security of candesartan in Parkinson?s disease population and its potential benefit in cognitive impairment associated to Parkinson?s disease.A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with Parkinson?s disease. Exploratory study.Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Parapres
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		INSTITUT DE RECERCA HSCSPNot Recruiting Female: yes
Male: yes		56Phase 2Spain
318EUCTR2015-005078-39-AT30/05/20163 April 2017-A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's diseaseSubjects with advanced Parkinson's disease
MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: levodopa/carbidopa solution
Product Code: ND0612
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-		NeuroDerm Ltd.Not RecruitingFemale: yes
Male: yes		47Phase 2United States;Austria;Israel;Germany;Italy
319JPRN-UMIN0000090622016/05/302 April 2019An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's diseaseParkinson's diseaseTake oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dLDept. of Clinical pharmacology and NeurologyNot Recruiting20years-oldNot applicableMale and Female20Phase 1Japan
320EUCTR2016-000636-18-GB12/05/201628 February 2019Phase 3, placebo controlled study to examine the efficacy, safety and tolerability of APL-130277 in patients with Parkinson's disease.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes).Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)
MedDRA version: 19.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10 -
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride		Sunuvion Pharmaceuticals IncNot Recruiting Female: yes
Male: yes		126Phase 3United States;Canada;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
321JPRN-UMIN0000220222016/05/1023 April 2019A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson diseaseA randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson diseaseParkinson disease Chronic constipationStudy drug group:
A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment		Dokkyo Medical UniversityNot Recruiting20years-old90years-oldMale and Female64Not selectedJapan
322JPRN-UMIN0000220232016/05/102 April 2019A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-Parkinson disease Chronic constipationStudy drug group:
A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen		Dokkyo Medical UniversityNot Recruiting20years-old90years-oldMale and Female64Not selectedJapan
323JPRN-UMIN0000221872016/05/062 April 2019Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's diseaseParkinson&#39;s diseasePD group, 200 mg caffeine administration, qd, 1 day
Control group, 200 mg caffeine administration, qd, 1 day		Department of Neurology, Juntendo UniversityNot Recruiting40years-old60years-oldMale and Female20Not applicableJapan
324NCT02762591May 3, 201616 December 2017Expanded Access of Pimavanserin for Patients With PD PsychosisExpanded Access Program of Pimavanserin in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisDrug: Pimavanserin tartrateACADIA Pharmaceuticals Inc.Not recruiting40 YearsN/AAllN/A
325NCT02705755May 20167 October 2019TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic HypotensionNeurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic HypotensionDrug: TD-9855;Drug: PlaceboTheravance BiopharmaNot recruiting40 YearsN/AAll34Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
326NCT02726386May 20163 December 2018A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC InfusionA Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseParkinson's DiseaseDrug: ND0612NeuroDerm Ltd.Not recruiting30 YearsN/AAll210Phase 2United States;Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain
327NCT02728947May 201612 December 2016Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseA Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseParkinson's DiseaseDrug: ROTIGOTINELuye Pharma Group Ltd.Not recruiting18 Years99 YearsBoth28Phase 1United States
328NCT02784145May 201611 June 2018Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson DiseaseEffects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson DiseaseParkinson DiseaseDietary Supplement: Resistant starch;Other: Recommendation with regard to nutritionSaarland UniversityNot recruiting18 YearsN/AAll95N/AGermany
329NCT02812147May 201625 February 2019Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson DiseaseEffect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)Parkinson DiseaseDrug: L-DOPS;Drug: PlaceboSt. Joseph's Hospital and Medical Center, PhoenixArizona State University, TempeNot recruiting30 Years83 YearsAll20Phase 2United States
330EUCTR2015-003512-20-GB28/04/201628 February 2019Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s DiseaseA Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease PatientsParkinson's Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: SINEMET 25-100
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg
Pharmaceutical Form: Capsule
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg
Pharmaceutical Form: Capsule
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)		Intec Pharma, Ltd.Authorised Female: yes
Male: yes		420Phase 3United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
331EUCTR2015-004507-23-DE25/04/20167 January 2019Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOCParkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]Product Name: Levodopa 75 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Levodopa 100 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Levodopa 125 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Levodopa 150 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Carbidopa 65 mg capsule
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 65-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: ODM-104
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: na
Other descriptive name: ODM-104
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-		Orion CorporationNot RecruitingFemale: yes
Male: yes		80Phase 2Hungary;Finland;Latvia;Germany
332NCT02764125April 8, 201611 June 2018Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-offParkinson's DiseaseDrug: Stalevo;Drug: levodopa MROrion Corporation, Orion PharmaNot recruiting30 YearsN/AAll84Phase 2Finland;Germany;Hungary;Latvia
333NCT03034538April 8, 201616 December 2017An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseAn Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseParkinson Disease;Parkinsonism;DyskinesiasDrug: ZonegranThe Cooper Health SystemRecruiting18 YearsN/AAll20Phase 4United States
334EUCTR2015-005067-17-CZ01/04/201611 April 2016A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson’s Disease Patients with OFF episodesA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 18.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301 35mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 35-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use
Product Name: CVT-301
Product Code: CVT-301 50mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use		Civitas Therapeutics, Inc.AuthorisedFemale: yes
Male: yes		345Phase 3United States;Czech Republic;Canada;Poland;Spain
335NCT02719496April 201611 June 2018Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's DiseaseProve of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's DiseaseGastrointestinal Disorders in Parkinson's DiseaseDrug: IBEROGASTNantes University HospitalNot recruiting30 Years80 YearsAll45Phase 2France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
336NCT02729714April 201622 July 2019A Pilot Study of Suvorexant for Insomnia in Parkinson DiseaseA Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson DiseaseInsomniaDrug: Suvorexant;Drug: PlaceboBurdick, Daniel, M.D.Merck Sharp & Dohme Corp.Recruiting30 Years80 YearsAll20Phase 4United States
337NCT02775591April 20168 April 2019Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal SymptomsEffect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled TrialParkinson Disease;DyspepsiaDrug: DA-9701;Drug: DA-9701 placeboSeoul National University HospitalSamsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical CenterNot recruiting50 Years80 YearsAll147Phase 4Korea, Republic of
338NCT03173781April 20162 July 2018Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's DiseaseEffects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's DiseaseParkinson's DiseaseDrug: Placebo;Drug: droxidopaColorado Springs Neurological AssociatesH. Lundbeck A/SNot recruiting18 YearsN/AAll21N/AUnited States
339EUCTR2015-004344-19-GB31/03/20168 May 2017An international trial of deferiprone in patients with Parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215Parkinson’s disease
MedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Deferiprone 600 mg delayed release tablet
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: DEFERIPRONE
CAS Number: 30652-11-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600-
Pharmaceutical form of the placebo: Modified-release tablet
Route of administration of the placebo: Oral use		ApoPharma Inc.AuthorisedFemale: yes
Male: yes		140Phase 2France;Canada;Germany;United Kingdom
340JPRN-jRCTs06118006022/03/201610 September 2019Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's diseaseMulti-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's diseaseParkinson's disease;D010300Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)Masahiro NagaiRecruiting20 years oldNoneBoth100Phase 2none
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
341EUCTR2015-004129-15-ES07/03/201618 April 2017Subjects participating in a Parkinson Disease cohort are offered to undergo a PET imaging scan requiring an intravenous diagnostic drug (florbetaben) with the aim of identifying markers of disease progressionEvaluation of [18F] florbetaben in subjects participating in the Parkinson?s Progression Markers Initiative (PPMI) ProtocolParkinson's Disease
MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neuraceq
Product Name: 18F florbetaben
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLORBETABEN (18F)
CAS Number: 902143-01-5
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 300-		Institute for Neurodegenerative DisordersNot RecruitingFemale: yes
Male: yes		Phase 2Spain
342NCT02687542March 3, 20165 March 2018Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsA 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's DiseaseParkinson DiseaseDrug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD)PfizerNot recruiting40 Years85 YearsAll108Phase 2United States;Canada;France;Germany;Japan;Spain
343JPRN-UMIN0000212362016/03/012 April 2019Investigation in effect of aroma therapy using magnetoencepharographyNormal volunteer, Epilepsy patients, Parkinson disease patientsaroma 1
Trans-nasal administration of lavender essence
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.
aroma 2
Trans-nasal administration of grapefruit essence
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.
fragrant
Trans-nasal administration of fragrant
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.		Osaka University Graduate School of Medicine Department of NeurosurgeryNot Recruiting20years-old80years-oldMale and Female10Phase 1Japan
344NCT02994719March 1, 201618 December 2018Gait Analysis in Neurological DiseaseGait Pattern Analysis in Neurological DiseaseParkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, FrontalDrug: Anti-Parkinson medication;Device: Deep Brain StimulationBeth Israel Deaconess Medical CenterRecruiting18 Years85 YearsAll110N/AUnited States
345NCT02462603March 201629 July 2019Safety and Biomarker Study of EPI-589 in Parkinson's DiseaseA Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease SubjectsParkinson's DiseaseDrug: EPI-589Edison Pharmaceuticals IncNot recruiting21 Years75 YearsAll44Phase 2United States;Germany;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
346NCT02605434March 201626 August 2019A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's PatientsPhase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's PatientsParkinson's DiseaseDrug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- SinemetIntec Pharma Ltd.Not recruiting30 YearsN/AAll420Phase 3United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary
347NCT02668497March 20166 May 2019Kinematic-based BoNT-A Bilateral Upper Limb PD TherapyKinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A TherapyParkinson's DiseaseDrug: Botulinum Toxin Type AWestern University, CanadaNot recruiting18 Years80 YearsAll50Phase 2Canada
348NCT02708186March 20165 November 2018Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)Dementia With Lewy Bodies;REM Sleep Behavior Disorder;Parkinson's Disease DementiaDrug: Nelotanserin;Drug: PlaceboAxovant Sciences Ltd.Not recruiting50 YearsN/AAll29Phase 2United States
349NCT02618941February 2, 201616 December 2017Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 ProgramParkinson's DiseaseBiological: AFFITOPE® PD01AAffiris AGNot recruiting40 Years68 YearsAll26Phase 1Austria
350JPRN-UMIN0000202882016/02/012 April 2019Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.Parkinson's diseaseIn this research, the duration of evaluation will be 12 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.		Juntendo University Shizuoka HospitalNot Recruiting20years-oldNot applicableMale and Female30Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
351JPRN-UMIN0000205272016/02/012 April 2019Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's diseaseParkinson's diseaseInosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years
Lactose as a placebo for 2 years		Ehime University Graduate School of MedicineRecruiting20years-oldNot applicableMale and Female100Phase 2Japan
352NCT02524405February 201630 September 2019BEAM: Brain-Eye Amyloid Memory StudyThe Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and NeurodegenerationAlzheimer's Disease;Mild Cognitive Impairment;Vascular Cognitive Impairment;Parkinson's Disease;Lewy Body DiseaseOther: Pittsburgh Compound B [11C]-PIBSunnybrook Health Sciences CentreBrain Canada;Weston Brain Institute;GE Healthcare;University Health Network, Toronto;Centre for Addiction and Mental Health;Baycrest;St. Michael's Hospital, Toronto;Kensington Eye InstituteRecruiting50 Years90 YearsAll345N/ACanada
353NCT02641054February 201616 December 2017Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's DiseaseDouble-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge TestIdiopathic Parkinson DiseaseDrug: CVXL-0107;Drug: Placebo;Drug: LevodopaCleveXel PharmaNot recruiting40 Years75 YearsAll21Phase 2France
354NCT02655315February 201619 November 2018Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseConservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of DeferiproneParkinson DiseaseDrug: Deferiprone;Drug: PlaceboUniversity Hospital, LilleEuropean Commission;ApoPharmaRecruitingN/A80 YearsAll338Phase 2Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic
355NCT02680977February 201617 October 2016Mucuna Pruriens Therapy in Parkinson's DiseaseMucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.Parkinson's DiseaseOther: MP-Equivalent;Other: MP-Low;Other: MP+DDCI;Drug: LD+DDCI;Drug: LD-DDCI;Other: PlaceboASST Gaetano Pini-CTOFondazione Grigioni per il Morbo di Parkinson;Fondazione Grigioni per il Morbo di ParkinsonNot recruiting21 YearsN/ABoth18Phase 2Bolivia
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
356NCT02683629February 201627 May 2019Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's DiseaseA Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's DiseaseParkinson's DiseaseBiological: NTCELL Implantation;Other: Sham SurgeryLiving Cell TechnologiesStatistecol Consultants LimitedNot recruiting40 Years65 YearsAll18Phase 2New Zealand
357EUCTR2015-004238-85-ES27/01/201622 January 2018Brain SPECT in premotor stage of Parkinson diseaseIctal brain SPECT in the premotor stage of Parkinson diseaseParkinson disease
MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: CERETEC (TM) Estabilizado
Product Name: Ceretec
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Ceretec
CAS Number: 100504-35-6
Other descriptive name: TECHNETIUM (99MTC) EXAMETAZIME
Concentration unit: mCi millicurie(s)
Concentration type: equal
Concentration number: 25-		IDIBAPSNot RecruitingFemale: yes
Male: yes		30Phase 2Spain
358JPRN-JapicCTI-15311222/1/201616 July 2019ONO-2370 Phase 2 studyONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension studyParkinson's diseaseIntervention name : ONO-2370
INN of the intervention : Opicapone
Dosage And administration of the intervention : ONO-2370 once-daily
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Once-daily placebo equivalent to active control		ONO PHARMACEUTICAL CO.,LTD.Not Recruiting3083BOTH399Phase 2Japan
359NCT03258294January 13, 201616 December 2017Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's DiseaseEffect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled TrialParkinson's DiseaseDrug: Melatonin(Circadin®);Drug: Placebo Oral TabletKIMJisunKuhnil Pharmaceutical Co., Ltd.Recruiting55 YearsN/AAll82Phase 4
360ChiCTR-CPC-150072232016-01-0118 April 2017Characteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons DiseaseCharacteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons DiseaseParkinsons Disease; Sleep DisorderThe treatment group; The control group:Rotigotine patch;Department of Neurology, Changzheng Hospital, Second Military Medical UniversityNot RecruitingBothThe treatment group; The control group:100;Post-marketChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
361NCT02549573January 201616 December 2017Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor StateParkinson's Disease;Motor SymptomsDrug: APOKYN;Behavioral: Physical TherapyUS WorldMeds LLCNot recruiting18 Years78 YearsAll13Phase 4United States
362NCT02579473January 201630 September 2019A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose TitrationParkinson's DiseaseDrug: SER-214Serina TherapeuticsNot recruiting40 Years80 YearsAll20Phase 1United States
363NCT02589340January 201615 April 2019Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaBuspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaParkinson's Disease;Dyskinesias;Movement DisordersDrug: Buspirone;Drug: PlaceboOregon Health and Science UniversityPortland VA Medical CenterRecruiting18 Years99 YearsAll15Phase 1United States
364NCT02639221January 201610 October 2016A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsPXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsParkinson's DiseaseDrug: PXT002331Prexton TherapeuticsNot recruiting18 Years60 YearsBoth64Phase 1United Kingdom
365NCT02649608January 201611 June 2018An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease PatientsInterventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's DiseaseParkinson DiseaseDrug: Lu AE04621H. Lundbeck A/SNot recruiting45 Years75 YearsAll15Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
366NCT02768077January 201630 May 2016Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's DiseaseEffect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled TrialParkinson's DiseaseDrug: Melatonin(Circadin®);Drug: PlaceboKuhnil Pharmaceutical Co., Ltd.Recruiting55 YearsN/ABoth100Phase 4
367EUCTR2014-002600-24-SE03/12/201520 February 2017Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complicationsA TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVERESTIdiopathic Parkinson's Disease
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xadago
Product Name: safinamide
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: SAFINAMIDE
CAS Number: 133865-89-1
Other descriptive name: SAFINAMIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Xadago
Product Name: safinamide
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: SAFINAMIDE
CAS Number: 133865-89-1
Other descriptive name: SAFINAMIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-		Zambon S.P.A.Not RecruitingFemale: yes
Male: yes		556Phase 3France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden
368NCT02470780December 201516 December 2017Treating Bacterial Overgrowth in Parkinson's DiseaseTreating Bacterial Overgrowth in Parkinson's DiseaseParkinson's Disease;Small Intestinal Bacterial OvergrowthDrug: Rifaximin;Drug: PlaceboUniversity of CincinnatiNot recruiting18 YearsN/AAll24Phase 2/Phase 3United States
369NCT02610231December 20151 April 2019Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseA Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: Istradefylline 20 mg or 40 mgKyowa Hakko Kirin Pharma, Inc.Kyowa Hakko Kirin Co., LtdNot recruiting30 YearsN/AAll243Phase 3United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic
370NCT02702102December 201522 October 2019Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy BodiesImaging Inflammation in Patients With Diffuse Lewy Body DiseaseDiffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease DementiaDrug: 11C-PBR28William Charles KreislNational Institute on Aging (NIA)Not recruiting60 YearsN/AAll5Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
371EUCTR2015-002631-17-ES19/11/201528 February 2019A study comparing immediate-release oral Levodopa and L-dopa/carbidopa intestinal gel over cognition and mood in non-demented Parkinson?s disease (PD) patientsAn intra-subject, randomized, double blind, crossover study comparing immediate-release oral LD (IR-LD) and L-dopa/carbidopa intestinal gel (LCIG) over cognition and mood in non-demented advanced Parkinson?s disease (PD) patientsParkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Duodopa
Product Name: Duodopa
Pharmaceutical Form: Intestinal gel
Trade Name: Sinemet Plus
Product Name: Sinemet Plus
Pharmaceutical Form: Tablet		Institut de Recerca del Hospital de la Santa Creu i Sant PauNot Recruiting Female: yes
Male: yes		18Phase 4Spain
372NCT02565628November 16, 201516 December 2017PF-06669571 In Subjects With Idiopathic Parkinson's DiseaseA Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.Idiopathic Parkinson's DiseaseDrug: PF-06669571;Drug: PlaceboPfizerNot recruitingN/AN/AAll20Phase 1United States
373JPRN-UMIN0000196762015/11/1023 April 2019The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's diseaseThe double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease - The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's diseaseParkinson's diseasetaking modafinil (200 mg/day) after breakfast for 4 weeks, wash out for 2 weeks, taking matching placebo after breakfast for 4 weeks
taking matching placebo after breakfast for 4 weeks, wash out for 2 weeks, taking modafinil (200 mg/day) after breakfast for 4 weeks		Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of MedicineNot Recruiting20years-old100years-oldMale and Female20Not selectedJapan
374EUCTR2015-000148-40-GB09/11/201518 April 2016A trial comparing simvastatin to placebo as a neuronal protective treatment for Parkinson's disease.Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT)Parkinson's disease
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Simvastatin
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Simvastatin
CAS Number: 79902-63-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use		Plymouth Hospitals NHS TrustAuthorisedFemale: yes
Male: yes		198United Kingdom
375JPRN-UMIN0000196542015/11/062 April 2019The effect of rich-hydrogen water drinking to gut peptideParkinson's disease, healthy controlhydrogen water
natural water		Nagoya graduate school of medicine universityNot Recruiting20years-old80years-oldMale and Female40Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
376JPRN-UMIN0000190902015/11/042 April 2019Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen waterParkinson's diseasereduced form of CoQ10 300mg 16weeks
reduced form of CoQ10 600mg 16weeks
reduced form of CoQ10 600mg 16weeks
hydrogen water 500ml(Suisosui 7.0) 16weeks		Juntendo University Koshigaya HospitalNot Recruiting20years-old80years-oldMale and Female45Not selectedJapan
377JPRN-jRCTs04118007004/11/201510 September 2019Trerief Impact in PD PET StudyRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPSParkinson's disease
Parkinson's disease;D010300		[1] Zonisamide treatment group
Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
[2] Zonisamide non-treatment group
Only levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.		Yasuomi OuchiNot RecruitingnoneUnder 80 years oldBoth20N/Anone
378JPRN-JapicCTI-15305601/11/20152 April 2019ME2125 Phase II/III (ME2125-3)A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off PhenomenonParkinson's diseaseIntervention name : ME2125
INN of the intervention : safinamide
Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning.
Control intervention name : Placebo
Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning.		Meiji Seika Pharma Co., Ltd.30BOTH410Phase 2-3
379JPRN-JapicCTI-15305701/11/20152 April 2019ME2125 Phase III (ME2125-4)A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off PhenomenonParkinson's diseaseIntervention name : ME2125
INN of the intervention : safinamide
Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning.
Control intervention name : Placebo
Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning.		Meiji Seika Pharma Co., Ltd.30BOTH200Phase 3
380NCT04110678November 1, 201514 October 2019Tolerance to NeuroEPO in Parkinson DiseaseNasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead TrialParkinson DiseaseDrug: NeuroEPOInternational Center for Neurological Restoration, CubaCenter of Molecular Immunology, Cuba;University of Electronic Science and Technology of ChinaNot recruiting40 Years70 YearsAll26Phase 1/Phase 2Cuba
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
381NCT02271503November 201516 December 2017A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's DiseaseA Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's DiseaseParkinson's DiseaseDrug: CD-LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mgIMPAX Laboratories, Inc.Not recruiting40 YearsN/AAll26Phase 2United States
382NCT02577523November 201523 April 2019A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseA Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseParkinson's DiseaseDrug: ND0612 (Levodopa/Carbidopa solution)NeuroDerm Ltd.Not recruiting30 Years80 YearsAll38Phase 2United States;Austria;Israel;Italy
383NCT02632279November 20153 September 2018Tryptophan Depletion in PD Patients Treated With STN DBSTryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor FunctionsParkinson's DiseaseDietary Supplement: Tryptophan (TRP) depletion;Dietary Supplement: Placebo;Device: Stimulator ON;Device: Stimulator OFFMaastricht University Medical CenterNetherlands Brain FoundationNot recruitingN/AN/AAll7N/ANetherlands
384NCT02758730November 201515 August 2016Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA PatientsA Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBAParkinson's DiseaseBiological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active componentAffiris AGUniversity Hospital TuebingenNot recruiting40 Years80 YearsBoth0Phase 1Germany
385NCT02914366November 20151 April 2019Ambroxol as a Treatment for Parkinson's Disease DementiaAmbroxol as a Novel Disease Modifying Treatment for Parkinson's Disease DementiaParkinson's Disease DementiaDrug: Ambroxol;Other: PlaceboLawson Health Research InstituteWeston Brain Institute;University of Western Ontario, Canada;London Health Sciences CentreRecruiting50 YearsN/AAll75Phase 2Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
386EUCTR2015-003045-26-SE23/10/201516 November 2015Study of Dopamine Transporters (signal substance in central nervous system)in patients with early signs of Parkinson´s disease.[18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease.Patients with newly clinically diagnosed untreated idiopathic parkinsonism
MedDRA version: 18.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: [18F]FE-PE2I
Pharmaceutical Form: Solution for injection
INN or Proposed INN: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Current Sponsor code: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Concentration unit: MBq/kg megabecquerel(s)/kilogram
Concentration type: equal
Concentration number: 2.86-
Trade Name: DaTSCAN
Pharmaceutical Form: Solution for injection
INN or Proposed INN: IOFLUPANE (123I)
CAS Number: 155798-07-5
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 185-
Product Name: 15O H2O
Pharmaceutical Form: Solution for injection
INN or Proposed INN: [15O]H2O
Current Sponsor code: [15O]H2O
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 800-		Umeå University HospitalAuthorisedFemale: yes
Male: yes		Sweden
387JPRN-UMIN0000190822015/10/102 April 2019the effect of smell dysfunction using hydrogen gas for parkinson diseaseparkinson's diseasewe measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after room air.
we measured smell test and urine 8-OHdG before and after room air. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas.		Nagoya University Graduate School of MedicineNot RecruitingNot applicableNot applicableMale and Female20Not selectedJapan
388JPRN-UMIN0000195242015/10/012 April 2019Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) imagesRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS)Parkinson's DiseaseZonisamide treatment group:

Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
Zonisamide non-treatment group:

Only Levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.		Hamamatsu University School of MedicineNot RecruitingNot applicable80years-oldMale and Female20Not applicableJapan
389NCT02572713October 201516 December 2017Systemic Synuclein Sampling Study (S4)Systemic Synuclein Sampling Study (S4)Parkinson's DiseaseProcedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN™Michael J. Fox Foundation for Parkinson's ResearchIndiana University;University of Iowa;Banner Health;Paracelsus Elena KlinikNot recruiting40 YearsN/AAll80N/AUnited States;Canada
390NCT02562768September 30, 201516 December 2017A Study of LY3154207 in Healthy Participants and Participants With Parkinson's DiseaseMultiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: LY3154207;Drug: PlaceboEli Lilly and CompanyNot recruiting20 YearsN/AAll80Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
391NCT02549092September 9, 20157 October 2019A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS StudyAdvanced Parkinson's DiseaseDrug: ABT-SLV187AbbVieRecruiting30 Years99 YearsAll88Phase 3United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden
392NCT02542696August 31, 201514 October 2019An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseAn Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson DiseaseDrug: APL-130277SunovionRecruiting18 YearsN/AAll226Phase 3United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom
393EUCTR2014-004865-26-DE27/08/201521 November 201626-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's DiseaseAn Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS StudyNon-motor symptoms in advanced Parkinson's disease
MedDRA version: 19.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Duodopa
Pharmaceutical Form: Intestinal gel
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-		AbbVie Deutschland GmbH & Co. KGNot RecruitingFemale: yes
Male: yes		88Phase 3European Union;Canada;Spain;Australia;Germany;Italy;Sweden
394EUCTR2015-000373-13-DE18/08/201519 October 2015A study to examine the effectiveness and safety of a new drug for involuntary muscle movements in patients with Parkinson’s diseasePhase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.Parkinson’s disease levodopa induced dyskinesia (PD-LID)
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Eltoprazine Hydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ELTOPRAZINE
CAS Number: 98224-03-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 7.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Eltoprazine Hydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ELTOPRAZINE
CAS Number: 98224-03-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Eltoprazine Hydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ELTOPRAZINE
CAS Number: 98224-03-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Amarantus BioScience Holdings, Inc.Not RecruitingFemale: yes
Male: yes		60Phase 2France;United States;Germany;Sweden
395NCT02554734August 201525 January 2016Pharmacokinetic Study in Healthy VolunteersPharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and FemalesParkinson's DiseaseDrug: levodopa, carbidopa, ODM-104;Drug: levodopa, carbidopa, entacaponeOrion Corporation, Orion PharmaNot recruiting18 Years65 YearsBoth15Phase 1Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
396NCT02599753August 201522 October 2018Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease PatientsInvestigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal NeuroimagingParkinson's DiseaseDrug: 18-FDTBZChang Gung Memorial HospitalNot recruiting20 Years80 YearsAll35Phase 2Taiwan
397NCT02917122August 201510 October 2016The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's DiseaseThe Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's DiseaseParkinson Disease;DepressionDevice: active tDCS;Drug: Sertraline;Device: sham tDCSNational Cheng-Kung University HospitalNot recruiting18 Years75 YearsBoth40Phase 1/Phase 2
398NCT02337751July 31, 201516 December 2017A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: TVP-1012 1mgTakedaNot recruiting30 Years79 YearsAll198Phase 3Japan
399NCT02459886July 1, 201526 August 2019Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's DiseaseA Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's DiseaseParkinson's Disease;HealthyDrug: BIIB054;Drug: PlaceboBiogenNot recruiting40 Years80 YearsAll66Phase 1United States
400NCT02488265July 1, 201512 November 2018Protocol: Balance Training in Parkinson's DiseaseRandomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's DiseaseParkinson DiseaseOther: Balance Training;Other: Screening to prevent fallsUniversity of Sao Paulo General HospitalNot recruiting50 Years70 YearsAll150N/ABrazil
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
401NCT02415062July 201517 August 2015The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With DementiaThe Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With DementiaParkinson's DiseaseDrug: DonepezilInje UniversityRecruiting50 Years80 YearsBoth150Phase 2Korea, Republic of
402NCT02453386July 20158 April 2019Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)Idiopathic Parkinson's DiseaseDrug: tozadenant;Drug: placeboBiotie Therapies Inc.Not recruiting30 Years80 YearsAll449Phase 3United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic
403NCT02469090June 30, 20153 December 2018Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseRandomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson Disease, Off EpisodesDrug: APL-130277;Drug: PlaceboSunovionNot recruiting18 YearsN/AAll219Phase 3United States;Canada;United Kingdom
404EUCTR2014-000657-36-NL22/06/201510 July 2015Trial to investigate the efficacy of treatments in apomorphine-induced skin reactionsOpen-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions - Treatment of apomorphine-induced skin reactions: a pilot studyParkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Hydrocortisone cream 10mg/g FNA Fagron
Product Name: Hydrocortisone cream
Pharmaceutical Form: Cream
Trade Name: Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'
Product Name: Solu-Cortef
Pharmaceutical Form: Powder and solvent for solution for injection
Trade Name: APO-go
Product Name: Apomorphine
Pharmaceutical Form: Solution for infusion in pre-filled syringe		University Medical Center GroningenAuthorisedFemale: yes
Male: yes		Netherlands
405NCT02230930June 201516 December 2017Treatment of Apomorphine-induced Skin Reactions: a Pilot StudyOpen-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin ReactionsParkinson's Disease;Apomorphine-induced Skin ReactionsDrug: Apomorphine 0.25% (2.5mg/ml);Device: Massage with a spiky ball;Drug: Hydrocortisone cream 1%;Drug: Subcutaneous hydrocortisone 10mgUniversity Medical Center GroningenRecruiting30 YearsN/AAll20Phase 2Netherlands
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
406NCT02450786June 201511 February 2019Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)Parkinson's DiseaseDrug: DonepezilYonsei UniversityNot recruiting40 YearsN/AAll80Phase 2Korea, Republic of
407NCT02604914June 201513 June 2016A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal GelParkinson's DiseaseDrug: ND0612;Drug: LCIGNeuroDerm Ltd.Quotient ClinicalNot recruiting40 Years65 YearsBoth36Phase 1United Kingdom
408NCT02769793June 201511 June 2018Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ONEfficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over TrialParkinson DiseaseDrug: Levodopa dispersible;Drug: LevodopaSeoul National University HospitalSMG-SNU Boramae Medical Center;Samsung Medical CenterRecruiting31 Years80 YearsAll40Phase 4Korea, Republic of
409EUCTR2014-005422-35-GB28/05/201530 April 2019The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease.THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. - The role of buspirone in LIDs in patients with Parkinson’s disease.Levodopa induced dyskinesias within Parkinson's disease.
MedDRA version: 17.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Buspirone Hydrochloride
Product Name: Buspirone Hydrochloride
Pharmaceutical Form: Tablet
INN or Proposed INN: Buspirone Hydrochloride
Concentration type: equal
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Imperial College London-Imperial College Healthcare NHS TrustNot Recruiting Female: yes
Male: yes		24Phase 4United Kingdom
410JPRN-jRCTs06118002811/05/201510 September 2019Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetineA double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetineParkinson's disease;D010300The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.Rina AndoRecruiting20 years oldNoneBoth50Phase 2none
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
411EUCTR2010-024424-26-SK05/05/201512 November 2018Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from parkinson's diseaseA prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associated with Parkinson's diseaseParkinson's disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: masitinib
Product Code: AB1010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: masitinib mesylate
CAS Number: 790-299-79-5
Current Sponsor code: AB1010
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: masitinib
Product Code: AB1010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: masitinib mesylate
CAS Number: 790-299-79-5
Current Sponsor code: AB1010
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		AB ScienceNot RecruitingFemale: yes
Male: yes		45Phase 2France;United States;Hungary;Czech Republic;Slovakia;Spain;Romania;Bulgaria;South Africa;Germany
412NCT02439125May 20152 May 2016A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease PatientsPhase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's DiseaseParkinson's Disease;DyskinesiaDrug: Eltoprazine HCl;Drug: PlaceboAmarantus BioScience Holdings, Inc.Not recruiting30 Years85 YearsBoth60Phase 2United States
413NCT02439203May 201525 January 2016Efficacy and Safety of JM-010 in PD With Levodopa-Induced DyskinesiaA Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010Parkinson's Disease;Levodopa Induced Dyskinesia (LID)Drug: JM-010;Drug: PlaceboBukwang PharmaceuticalContera Pharma ApSNot recruiting18 YearsN/ABoth30Phase 2South Africa
414NCT02448914May 201519 October 2017A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD PatientsA Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s DiseaseParkinson's DiseaseDrug: TRIGEL;Drug: DuodopaLobSor Pharmaceuticals ABTFS Trial Form SupportNot recruiting30 YearsN/AAll11Phase 1Sweden
415NCT02452125May 201516 December 2017The Effects of Nicotine Chewing Gum in Parkinson's DiseaseThe Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's DiseaseLow Blood Pressure;Parkinsons DiseaseDietary Supplement: Nicotine gumNew York Institute of TechnologyNot recruitingN/AN/AAll10N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
416NCT02616120May 20155 November 2018Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's DiseaseEfficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease PatientsParkinson's DiseaseDrug: SQJZ herbal mixtures;Drug: PlaceboDongzhimen Hospital, BeijingRecruiting18 Years80 YearsAll240Phase 2China
417JPRN-JapicCTI-15287011/4/201523 April 2019A parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPAA phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPAParkinson's diseaseIntervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet
Dosage And administration of the control intervention : Oral, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet placebo
Dosage And administration of the control intervention : Oral, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 3
418JPRN-UMIN0000170362015/04/032 April 2019Association of ghrelin and leptin in cardiovascular autonomic dysfunction in patients with primary dysautonomia.autonomic failure such as Parkinson's diseaseblood test of Leptin and Ghrelin
blood test of Leptin and Ghrelin		Nagoya University Graduate School of MedicineNot Recruiting40years-oldNot applicableMale and Female50Not applicableJapan
419JPRN-UMIN0000165912015/04/012 April 2019Clinical trial of balance exercise "Assist"Stroke, Parkinson disease, Osteoarthrosisuse of balance exercise assist
ordinary balance exercise		Juntendo UniversityNot Recruiting20years-old75years-oldMale and Female40Not applicableJapan
420JPRN-UMIN0000167342015/04/012 April 2019The evaluation of duloxetine effect for the parkinsonism and gait freezingParkinson's diseaseDrug ; Duloxetine
Duraion; SEP012014-AUG312016
Doseage; 20mg/day or 40mg/day
Times; one time per day P.O.		Department of Neurology, Juntendo University School of MedicineNot Recruiting20years-old85years-oldMale and Female30Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
421NCT02359448April 201519 February 2015Melatonin for Nocturia in Parkinson's DiseaseSingle-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's DiseaseParkinson's Disease;NocturiaDrug: MelatoninUniversity College, LondonNot recruiting18 YearsN/ABoth20Phase 2United Kingdom
422NCT02390089April 201525 February 2019Cough According to Stimulus Type in PDAirway Protection Deficits According to Stimulus Type in Parkinson's DiseaseParkinson's DiseaseDrug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: NebulizerUniversity of FloridaNational Institute on Deafness and Other Communication Disorders (NIDCD)Not recruiting50 Years80 YearsAll158Phase 1United States
423NCT02424708April 20154 July 2016Phase IIb Study of Intranasal Glutathione in Parkinson's DiseasePhase IIb Study of Intranasal Glutathione in Parkinson's DiseaseParkinson's DiseaseDrug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: PlaceboBastyr UniversityMichael J. Fox Foundation for Parkinson's ResearchNot recruiting21 YearsN/ABoth45Phase 2United States
424NCT02486432April 20153 August 2015A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose ApproachParkinson's DiseaseDrug: Levodopa/Carbidopa (Sinemet)NeuroDerm Ltd.Quotient ClinicalNot recruiting40 Years65 YearsBoth6Phase 1
425JPRN-UMIN0000166592015/03/012 April 2019Comparative study of the effects on L-dopa formulation absorption by the acid secretion inhibitorhealty adult Parkinson's diseaseMENESIT100 1tablet once a day (p.o.)

famotidine 40mg/day for previous 1day (p.o.)
MENESIT100 1tablet once a day (p.o.)

esomeprazole 20mg for previous three days or more (p.o.)
MENESIT100 1tablet once a day (p.o.)		Utano National Hospital, National Hospital OrganaizationNot Recruiting20years-old75years-oldMale and Female3Phase 1Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
426JPRN-UMIN0000166642015/03/012 April 2019Effect of nicotine patch in Cognitive function improvement in Parkinson's diseaseParkinson's diseasenicotine patchDepartment of Clinical Pharmacology and Neurology Ehime University graduated School of MedicineRecruitingNot applicableNot applicableMale and Female20Not selectedJapan
427NCT02066571March 201514 November 2016Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's DiseaseA Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's DiseaseParkinson's Disease;Freezing of Gait;Cognitive Ability, GeneralDrug: Droxidopa;Drug: sugar pillHenry Ford Health SystemRecruiting30 YearsN/ABoth20Phase 2United States
428NCT02242487March 201526 August 2019Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Idiopathic Parkinson's DiseaseDrug: CVT-301Acorda TherapeuticsNot recruiting30 Years86 YearsAll325Phase 3United States;Canada;Czechia;Poland;Spain;Czech Republic
429NCT02373072March 201516 December 2017A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's DiseaseA Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: PF-06649751;Drug: Trimethobenzamide Hydrochloride;Drug: PlaceboPfizerNot recruitingN/AN/AAll18Phase 1United States;Belgium
430NCT02393027March 201516 December 2017Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999Idiopathic Parkinson DiseaseDrug: [18F] LBT-999 PETUniversity Hospital, ToursNot recruiting45 Years75 YearsAll16Early Phase 1France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
431NCT02452606March 20158 August 2016Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's DiseaseClock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's DiseaseParkinson Disease;Sleep DisordersDrug: Stalevo®Asan Medical CenterRecruiting20 Years79 YearsBoth100N/AKorea, Republic of
432NCT02696603March 201516 December 2017Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)Parkinson Disease;Neurodegenerative Diseases;Movement Disorders;Central Nervous System Diseases;Brain Diseases;Basal Ganglia Diseases;Parkinsonian DisordersBehavioral: Participant self-assessment surveys;Behavioral: Phonation;Behavioral: Gait and balance;Behavioral: Memory;Behavioral: Dexterity;Behavioral: Participant open-response writing;Other: Parkinson mPower mobile applicationSage BionetworksRobert Wood Johnson FoundationRecruiting18 YearsN/AAll20000N/AUnited States
433JPRN-UMIN0000164852015/02/252 April 2019Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndromeHealthy subjects, Parkinson's disease patients and Parkinson's syndrome patientsIntravenous injection of 18F-fluoro-dopa and 11C-raclopride
PET imaging		Institute of Biomedical Research and InnovationNot Recruiting35years-oldNot applicableMale and Female20Not selectedJapan
434EUCTR2014-003799-22-HU11/02/20153 July 2017A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s diseaseA Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort ControlParkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 17.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Product Name: CVT-301
Product Code: CVT-301
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 42-		Civitas Therapeutics, Inc.Not RecruitingFemale: yes
Male: yes		365Phase 3Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Poland;Romania;Germany
435NCT02337725February 201510 October 2016A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: Placebo;Drug: TVP-1012TakedaNot recruiting30 Years80 YearsBoth244Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
436NCT02337764February 20157 November 2016A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease PatientsParkinson's DiseaseDrug: TVP-1012 1mg with levodopaTakedaNot recruiting30 Years79 YearsBoth222Phase 3Japan
437NCT02339064February 201514 October 2019Infusion of Apomorphine: Long-term Safety StudyA Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on AvailableIdiopathic Parkinson's DiseaseDrug: apomorphine infusionUS WorldMeds LLCNot recruiting30 YearsN/AAll99Phase 3United States
438NCT02409823February 20152 November 2015Clinical Registry of Patients Under Treatment With Atypical AntipsychoticsClinical Registry of Patients Under Treatment With Atypical AntipsychoticsSchizophrenia;Major Depressive Disorder;Bipolar Depressive Disorder;Parkinson's Disease With HallucinationsDrug: Atypical AntipsychoticsPontifical Catholic University of ArgentinaNot recruiting18 YearsN/ABoth665N/A
439NCT02933372February 201515 July 2019Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3Parkinson's DiseaseDrug: Varenicline;Radiation: PET Scan;Other: Evaluation by InvestigatorUniversity of MichiganNot recruiting45 YearsN/AAll58Phase 2
440JPRN-JapicCTI-15276227/1/20152 April 2019A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease PatientsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease PatientsParkinson's diseaseIntervention name : TVP-1012 (1 mg/day) with levodopa
Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
Control intervention name : null		TAKEDA PHARMACEUTICAL COMPANY LTD.3079BOTH215Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
441NCT02337738January 201510 October 2016A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing OffParkinson's DiseaseDrug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: PlaceboTakedaNot recruiting30 Years79 YearsBoth404Phase 2/Phase 3Japan
442NCT02347059January 201519 February 2015L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's DiseaseA Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's DiseaseParkinson's DiseaseDrug: L-dopa;Drug: Dopamine Agonists (pramipexole, ropirinole)University of TorontoMichael J. Fox Foundation for Parkinson's ResearchRecruitingN/AN/ABoth40Phase 2Canada
443NCT02406105January 201513 April 2015An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson DiseaseAn Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in PolandParkinson DiseaseRadiation: Radiosurgical thalamotomy;Drug: CyberKnifeMaria Sklodowska-Curie Memorial Cancer Center, Institute of OncologyRecruiting18 YearsN/ABoth27Phase 2Poland
444NCT02763137January 201517 May 2016Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian PatientsA Phase IIa Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Efficacy of Intermittent Oral Administration of Standard Levodopa/Carbidopa vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Patients With Advanced Parkinson's Disease Who Suffer Motor FluctuationsParkinson DiseaseDrug: Standard LD/CD;Drug: Semi continuous intra-oral administration of LD/CDIRCCS San RaffaeleSynAgile CorporationNot recruiting35 Years75 YearsBoth18Phase 2Italy
445NCT02258152December 22, 201429 April 2019SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)Parkinson's Disease Dementia (PDD)Drug: SYN120;Drug: PlaceboBiotie Therapies Inc.Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda TherapeuticsNot recruiting50 YearsN/AAll82Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
446JPRN-JapicCTI-14274811/12/201423 April 2019Long-term study of HP-3000 in patients with Parkinson's diseaseA phase III long-term study of HP-3000 in patients with Parkinson's diseaseParkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 3
447NCT02267434December 20147 November 2016Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's DiseaseA Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesBiological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active componentAffiris AGPROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum JuelichNot recruiting45 Years70 YearsBoth36Phase 1Austria
448NCT02324426December 201411 May 2015CNS Uptake of Intranasal GlutathioneCentral Nervous System Uptake of Intranasal Glutathione in Parkinson's DiseaseParkinson's DiseaseDrug: Reduced GlutathioneUniversity of WashingtonMichael J. Fox Foundation for Parkinson's ResearchNot recruiting18 YearsN/ABoth15Phase 1United States
449NCT02480803December 20144 February 2019INfusion VErsus STimulation in Parkinson's DiseaseTreatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulationParkinson's DiseaseDrug: Continuous intrajejunal infusion of levodopa-carbidopa;Device: deep brain stimulationAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruiting18 YearsN/AAll66Phase 4Netherlands
450NCT03116308November 21, 201416 December 2017Effect of Food on OpicaponeEffect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy SubjectsParkinson DiseaseDrug: Opicapone (OPC)Bial - Portela C S.A.Not recruiting18 Years45 YearsAll28Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
451ChiCTR-DDD-170107942014-11-0818 April 2017The study on early diagnosis of Parkinson 's disease by transcranial ultrasonographythe study on early diagnosis of Parkinson 's disease by transcranial ultrasonographyParkinson's DiseaseGold Standard:Diagnosis of Parkinson disease needs to meet 3 or more: unilateral onset;resting tremor;progressive course; long term asymmetry, the most obvious symptoms is the onset side; a good response to levodopa (70% ~ 100%); levodopa induced chorea; a reaction of levodopa lasts 5 years or more; clinical course last;Index test:Laboratory apparatus
As shown in Figure 1, The ultrasound equipment, Philips IE33-BOMJH1 color Doppler ultrasonography, Model IE-ELite, with 2-4MHz phased array probe (S5-1 probe) was used for TCS to examine SN in our study.
Transcranial ultrasound study
Ultrasonography through temporal window, alon;		Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union HospitalNot Recruiting3684BothTarget condition:135;Difficult condition:0Diagnostic New Technique Clincal StudyChina
452JPRN-JapicCTI-14270201/11/201423 April 2019A Phase 1 Study of ONO-2160/CDA Phase 1 study on single and multiple oral dose administration of ONO-2160/CD in healthy adult male subjects and on multiple oral dose administration of ONO-2160/CD in Parkinson's disease patientsParkinson's diseaseIntervention name : ONO-2160/CD
Dosage And administration of the intervention : Oral administration
Control intervention name : Levodopa/carbidopa hydrate
INN of the control intervention : Levodopa/carbidopa hydrate
Dosage And administration of the control intervention : Oral administration		ONO PHARMACEUTICAL CO.,LTD.BOTH34Phase 1
453NCT02240030November 20143 June 2019Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)Idiopathic Parkinson's DiseaseDrug: CVT-301 Low Dose;Drug: CVT-301 High Dose;Other: PlaceboAcorda TherapeuticsNot recruiting30 Years85 YearsAll351Phase 3United States;Canada;Czechia;Poland;Spain;Czech Republic
454NCT02278588November 201429 April 2019Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.Parkinson's DiseaseDrug: RasagilineThomas GuttusoNot recruitingN/AN/AAll45Phase 4United States
455NCT02281474November 201428 December 2015Nilotinib in Cognitively Impaired Parkinson Disease Patients 001Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood a-SynucleinParkinson's Disease;Parkinson's Disease Dementia;Diffuse Lewy Body DiseaseDrug: NilotinibGeorgetown UniversityNot recruiting40 Years90 YearsBoth12Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
456NCT02312232November 20142 March 2015Pharmacokinetic Study in Healthy MalesPharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy MalesParkinson's DiseaseDrug: levodopa, carbidopa, ODM-104Orion Corporation, Orion PharmaNot recruiting18 Years65 YearsMale20Phase 1Finland
457EUCTR2014-000335-17-GB28/10/20144 August 2015Rotigotine and memory in Parkinson's.The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment - Rotigotine and Memory in Parkinson's.Idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 92206-54-7
Concentration unit: Other
Concentration type: up to
Concentration number: -16 mg/24 h
Product Name: levodopa CR (controlled release)
Pharmaceutical Form: Tablet
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: -1000
Product Name: Rasagiline
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
CAS Number: 1875-50-9
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: -1 mg/24h
Product Name: Selegiline
Pharmaceutical Form: Tablet
INN or Proposed INN: selegiline
CAS Number: 14611-51-9
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: -12mg/24hs		Research and Development University Hospital of North StaffordshireKeele UniversityNot RecruitingFemale: yes
Male: yes		0United Kingdom
458EUCTR2014-001131-36-ES23/10/20148 August 2016A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaA Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced DyskinesiasParkinson's Disease Subjects with Levodopa-Induced Dyskinesias
MedDRA version: 17.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 160-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 240-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 320-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		Osmotica Pharmaceutical Corp.Not RecruitingFemale: yes
Male: yes		162Phase 3France;United States;Canada;Spain;Germany
459EUCTR2014-001132-10-ES23/10/20148 August 2016A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaA Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced DyskinesiasParkinson's Disease Subjects with Levodopa-Induced Dyskinesias
MedDRA version: 17.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 160-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 240-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 320-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		Osmotica Pharmaceutical Corp.Not RecruitingFemale: yes
Male: yes		162Phase 3France;United States;Canada;Spain;Germany
460EUCTR2014-002295-87-IT13/10/201419 February 2018A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.Parkinson's disease patients who suffer motor fluctuations will participate in the study
MedDRA version: 17.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: SINEMET 100 mg + 25 mg compresse
Product Name: SINEMET 100 mg + 25 mg compresse
Product Code: NA
Pharmaceutical Form: Oral suspension		SynAgile CorporationNot RecruitingFemale: yes
Male: yes		18Phase 2Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
461NCT02183519October 201416 December 2017Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's DiseaseRespiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's DiseaseCough;Parkinson's DiseaseDrug: Capsaicin;Other: Voluntary cough testUniversity of FloridaNot recruiting55 Years85 YearsAll44Phase 1/Phase 2United States
462NCT02224664October 201416 December 2017Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s DiseaseA Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor FluctuationsParkinson`s DiseaseDrug: PF-06649751PfizerNot recruiting30 Years80 YearsAll50Phase 1United States;Belgium
463NCT02259049October 20141 February 2016The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's DiseaseThe Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's DiseaseBlood PressureDietary Supplement: L-tyrosine;Dietary Supplement: Sugar PillNew York Institute of TechnologyNot recruiting40 Years84 YearsBoth6Phase 0United States
464NCT02274324October 201419 February 2015Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson&Apos;s DiseaseDietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson's DiseaseParkinson DiseaseDietary Supplement: different dietsSheba Medical CenterTel Aviv UniversityNot recruiting40 Years80 YearsBoth20N/A
465NCT02274766October 201422 January 2018Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)Dyskinesia;Levodopa-Induced Dyskinesia (LID);Parkinson's Disease (PD)Drug: ADS-5102;Other: PlaceboAdamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll77Phase 3United States;Austria;France;Germany;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
466JPRN-UMIN0000168932014/09/2221 May 2019A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression.A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine.PD patientsThe treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.
The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.		Ehime University Hospital Dept. of Clinical pharmacology and NeurologyNot Recruiting20years-oldNot applicableMale and Female50Phase 2Japan
467NCT02236260September 3, 201416 December 2017Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain StimulationEvaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.Parkinson's DiseaseProcedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride)Nantes University HospitalNot recruiting18 Years74 YearsAll20N/AFrance
468NCT02168842September 20144 March 2019Efficacy of Isradipine in Early Parkinson DiseasePhase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson DiseaseParkinson DiseaseDrug: Isradipine;Drug: Placebo (for Isradipine)University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research;The Parkinson Study GroupNot recruiting30 YearsN/AAll336Phase 3United States;Canada
469NCT02212678September 201414 March 2016Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's DiseaseRepeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's DiseaseParkinson DiseaseDrug: N-acetylcysteine capsuleUniversity of Minnesota - Clinical and Translational Science InstituteParkinson's Disease Society of the United KingdomNot recruiting18 YearsN/ABoth9Phase 2United States
470NCT02225548September 20148 January 2018Sagene 2014 - Parkinson's Disease and Erectile DysfunctionAn Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.Parkinson's Disease;Erectile DysfunctionDrug: Selegiline;Drug: TadalafilUniversity of South FloridaRecruiting40 Years64 YearsMale10Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
471NCT02230904September 201419 October 2017A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's DiseaseA Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: Rotigotine (Test product PR 2.3.1);Drug: Rotigotine (Reference product PR 2.1.1)UCB BIOSCIENCES GmbHPharmaceutical Health Sciences;Bracket GlobalNot recruiting18 YearsN/AAll57Phase 1Germany
472NCT02256319September 201428 December 2015Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted StimulatorsEffects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted StimulatorsParkinson's DiseaseDrug: Dexmedetomidine;Drug: PropofolClinica Universidad de Navarra, Universidad de NavarraNot recruiting18 YearsN/ABoth12Phase 4Spain
473NCT02777060September 201430 May 2016Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome MeasuresExploring the Effectiveness of Sensor-based Balance Training on Patient Outcome MeasuresDiabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;StrokeProcedure: Exergame;Procedure: Home based balance trainingUniversity of ArizonaRecruiting18 YearsN/ABoth200N/AUnited States
474NCT03151460September 201416 December 2017Dopaminergic Modulation of Declarative MemoryDopaminergic Modulation of Declarative MemoryParkinson's DiseaseDrug: Dopamine AgentI.R.C.C.S. Fondazione Santa LuciaNot recruitingN/AN/AAll40Phase 4Italy
475ChiCTR-TRC-140051432014-08-2518 April 2017A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Jieyu methodA traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Yieyu methodDepressed Parkinson's diseaseChinese Medicines:Formula granule;Western Medicine group:Venlafaxine hydrochloride sustained-release capsules ;The Third Affiliated Hospital of Beijing University of Traditional Chinese MedicineRecruiting5575BothChinese Medicines:60;Western Medicine group:60;Phase 2 studyChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
476NCT02153645August 18, 201415 April 2019Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiasParkinson's Disease;Levodopa Induced Dyskinesias (LID)Drug: 240mg Amantadine HCl ER tablets;Drug: Placebo tablets;Drug: 320mg Amantadine HCl ER tabletsOsmotica Pharmaceutical US LLCNot recruiting30 Years85 YearsAll87Phase 3United States;Canada;France;Germany;Spain
477NCT02216188August 201424 August 2015Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical ActivityPhase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008Parkinson's DiseaseBiological: AFFITOPE® PD01A;Other: ControlAffiris AGNot recruiting40 Years68 YearsBoth28Phase 1Austria
478NCT02228590August 201416 December 2017A Study to Examine APL-130277 in Patients With Parkinson's DiseaseA Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: APL-130277SunovionNot recruiting18 Years80 YearsAll19Phase 2United States
479NCT02230267August 201423 May 2016High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's DiseaseHigh-intensity Exercise and Fall Prevention Boot Camp for Parkinson's DiseaseParkinson's DiseaseOther: High intensity exercise and balance training;Other: Usual care arm exerciseUniversity of Nevada, Las VegasNot recruiting45 Years85 YearsBoth27Phase 2United States
480NCT02236065August 201416 December 2017Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative DisordersA Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative DisordersBrain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's DiseaseProcedure: Umbilical cord blood therapy;Biological: FilgrastimMinYoung Kim, M.D.Not recruiting19 Years75 YearsAll10N/AKorea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
481NCT02438215August 201425 May 2015Study of IRX4204 for Treatment of Early Parkinson's DiseaseAn Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease SubjectsParkinson's DiseaseDrug: IRX4204Io TherapeuticsNot recruiting18 YearsN/ABoth15Phase 1United States
482NCT02153632July 30, 201415 April 2019Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LIDA Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiasParkinson's Disease;Levodopa Induced Dyskinesia (LID)Drug: amantadine HCl ER;Drug: PlaceboOsmotica Pharmaceutical US LLCNot recruiting30 Years85 YearsAll135Phase 3United States;Canada;France;Germany;Spain
483JPRN-UMIN0000147092014/07/012 April 2019Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2IPatients of Parkinson's disease and related disordersThe dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.Tokyo Metropolitan Institute of GerontologyRecruiting18years-oldNot applicableMale and Female200Not selectedJapan
484NCT02138682July 201419 February 2015Validation of DaTscan for Detection of Parkinson Disease Related DisordersValidation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain TissueParkinson Disease;Movement DisordersDrug: l-123 IoflupaneWisconsin Institute for Neurologic and Sleep Disorders S.C.Wisconsin Parkinson Association;Medical College of Wisconsin;GE HealthcareRecruiting75 YearsN/ABoth20Phase 4United States
485NCT02202551July 201416 December 2017Open-Label Safety Study of ADS-5102 in PD Patients With LIDOpen-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD)Drug: ADS-5102Adamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll250Phase 3United States;Austria;Canada;France;Germany;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
486NCT02206620July 201419 February 2015Effects of Cholinergic Augmentation on Measures of Balance and GaitEffects of Cholinergic Augmentation on Measures of Balance and GaitParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityMichael J. Fox Foundation for Parkinson's ResearchRecruiting30 YearsN/ABoth100Phase 2United States
487NCT02472210July 20143 August 2015The Use of Botox in Advanced Parkinson's Patients Experiencing PainA Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot StudyParkinson's DiseaseDrug: Botulinum ToxinUniversity Health Network, TorontoNot recruiting18 YearsN/ABoth14Phase 4
488EUCTR2014-000868-17-ES26/06/201418 January 2016Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulatorsEffect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulatorsParkinson's disease
MedDRA version: 16.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]		Trade Name: Dexdor
Product Name: Dexdor
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: DEXMEDETOMIDINE
CAS Number: 113775-47-6
Other descriptive name: DEXMEDETOMIDINA
Concentration unit: mg/kg/h milligram(s)/kilogram/hour
Concentration type: range
Concentration number: 0.0002-0.0014
Trade Name: Propofol-Lipuro
Product Name: Propofol-Lipuro
Pharmaceutical Form: Emulsion for infusion
INN or Proposed INN: PROPOFOL
Other descriptive name: PROPOFOL
Concentration unit: mg/kg/h milligram(s)/kilogram/hour
Concentration type: range
Concentration number: 0.5-4		Clínica Universidad de Navarra/Universidad de NavarraNot RecruitingFemale: yes
Male: yes		Spain
489ChiCTR-TRC-140047072014-06-0918 April 2017The effect of different patterns of rehabilitation training in idiopathic Parkinson's diseaseThe effect of different patterns of rehabilitation training in idiopathic Parkinson's diseaseParkinson's diseaseTai Chi group:Tai Chi;Balance function training group:Balance function training;Shanghai Tongji HospitalNot Recruiting2090BothTai Chi group:30;Balance function training group:30;OtherChina
490NCT01971242June 201428 November 2016Trial of Exenatide for Parkinson's DiseaseA Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's DiseaseParkinson's DiseaseDrug: Exenatide;Other: PlaceboUniversity College, LondonNot recruiting25 Years75 YearsBoth60Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
491NCT02157714June 201431 October 2016Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: PRX002;Other: PlaceboProthena Biosciences LimitedHoffmann-La RocheNot recruiting40 Years80 YearsBoth64Phase 1United States
492NCT02174250June 201414 September 2015The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy SubjectsParkinson's DiseaseDrug: Istradefylline 40 mg;Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 onlyKyowa Hakko Kirin Pharma, Inc.Not recruiting18 Years65 YearsBoth20Phase 1United States
493NCT02046447May 20148 January 2018Neuroimaging of DystoniaNeuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of FloridaPrimary Cervical Dystonia;DYT 1 DystoniaDrug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 DystoniaUniversity of FloridaBachmann Strauss Dystonia & Parkinson Foundation, Inc.Not recruiting7 Years70 YearsAll20N/AUnited States
494NCT02096601May 201419 February 2015A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsA Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LDParkinson's DiseaseDrug: Levodopa and carbidopa SC solution;Drug: Oral levodopa and carbidopaNeuroDerm Ltd.Michael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years80 YearsBothPhase 1/Phase 2United States;Israel
495NCT02136914May 201416 December 2017ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's DiseaseDrug: ADS-5102;Other: PlaceboAdamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll126Phase 3United States;Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
496NCT02780895May 201420 June 2016Parkinsonian Brain Repair Using Human Stem CellsHuman OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: Human Stem CellsCelavie Bioscences, LLCHospital Angeles del PedregalNot recruiting18 Years75 YearsBoth8Phase 1Mexico
497EUCTR2012-005539-10-DE29/04/20142 October 2017Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin InvestigationChronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use
Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use		Merz Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes		180Phase 3United States;Poland;Germany
498JPRN-UMIN0000155592014/04/142 April 2019Comparative study between SSRI and SNRI treatment on depressive patients with Parkinson diseasesParkinson's disease Depression, Depressive stateparoxetine 20mg
Escitalopram 10mg
Duloxetine 40mg		Osaka Redcross HospitalNot Recruiting40years-oldNot applicableMale and Female40Not selectedJapan
499NCT03314597April 2, 201416 December 2017Instrumental or Physical-Exercise Rehabilitation of Balance in Parkinson's Disease? (IPER-PD)Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease.Parkinson's Disease;RehabilitationOther: Balance exercise;Other: Mobile platform exerciseUniversity of PaviaFondazione Salvatore MaugeriNot recruiting50 Years85 YearsAll38N/A
500NCT01738178April 201416 December 2017Caffeine as a Therapy for Parkinson's DiseaseCaffeine as a Therapeutic Agent in Parkinson's DiseaseParkinson's DiseaseDrug: Caffeine;Drug: PlaceboMcGill University Health CenterPontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa HospitalNot recruiting45 Years75 YearsAll119Phase 3Brazil;Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
501NCT02111122April 201419 February 2015Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's DiseaseA Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's DiseaseSleep-wake Disturbances in Motor-phase Parkinson`s DiseaseDrug: Sodium OxybateUniversity of ZurichRecruiting18 Years90 YearsBoth16Phase 2Switzerland
502NCT02365012April 20147 September 2015Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using MidodrineTreatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using MidodrineOrthostatic Intolerance;Parkinson's DiseaseDrug: MidodrinePhiladelphia Veterans Affairs Medical CenterRecruiting22 Years89 YearsBoth50N/AUnited States
503NCT02741947April 201425 April 2016Levodopa Benserazide Generic Formulation Versus the OriginatorClinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®)Parkinson DiseaseDrug: Levodopa Benserazide Madopar;Drug: Levodopa Benserazide Teva ItaliaIRCCS San RaffaeleAgenzia Italiana del FarmacoNot recruiting30 Years75 YearsBoth44Phase 4Italy
504NCT02082249March 10, 201410 December 2018An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsAn Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsAdvanced Parkinson's DiseaseDrug: ABT-SLV187AbbVieNot recruiting30 Years99 YearsAll1Phase 3Japan;Korea, Republic of;Taiwan
505NCT02006290March 201412 October 2015Efficacy, Safety And Tolerability Study In Subjects With Parkinson's DiseaseA Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: PF-06412562;Drug: PlaceboPfizerNot recruiting30 Years75 YearsBoth19Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
506NCT02092181March 201423 July 2018A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)Parkinsons DiseaseDrug: Mirabegron;Drug: PlaceboDaniel Burdick, MDAstellas Pharma US, Inc.Not recruiting30 Years85 YearsAll30Phase 4United States
507NCT02095171March 201419 February 2015Single Ascending Dose Study of PRX002 in Healthy SubjectsA Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy SubjectsParkinson's DiseaseDrug: PRX002;Other: PlaceboProthena Biosciences LimitedHoffmann-La RocheNot recruiting21 Years65 YearsBoth40Phase 1United States
508NCT02111330March 201411 April 2016Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy VolunteersRandomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy VolunteersParkinson DiseaseDrug: PBF-509;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LNot recruiting18 Years45 YearsBoth16Phase 1Spain
509NCT02305017March 201419 October 2017Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersEffect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersParkinson's DiseaseDrug: BIA 9-1067;Drug: ParacetamolBial - Portela C S.A.Not recruiting18 Years45 YearsAll28Phase 1
510NCT02305030March 201419 February 2015Effect of Opicapone at Steady State on Warfarin PharmacokineticsEffect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy VolunteersParkinson's DiseaseDrug: BIA 9-1067;Drug: WarfarinBial - Portela C S.A.Not recruiting18 Years45 YearsBoth20Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
511NCT02445651March 201423 April 2019Physiological Effects of Nutritional Support in Patients With Parkinson's DiseasePhysiological Effects of Nutritional Support in Patients With Parkinson's DiseaseParkinson Disease;Idiopathic Parkinson DiseaseDietary Supplement: Intravenous and Oral n—acetyl cysteineThomas Jefferson UniversityNot recruiting30 Years80 YearsAll65N/AUnited States
512NCT02064166February 20143 December 2018Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System AtrophyParkinson Disease;Multiple System AtrophyDrug: Intranasal InsulinPeter NovakNot recruiting18 YearsN/AAll15Phase 2United States
513NCT02103894February 20149 January 2017Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy SubjectsAlzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;TauopathiesDrug: [18F]T807 ([18F]MNI-777)Molecular NeuroImagingInstitute for Neurodegenerative DisordersNot recruiting18 Years85 YearsBoth16Phase 1United States
514NCT02305316February 201419 October 2017Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of OpicaponeSingle-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy VolunteersParkinson DiseaseDrug: BIA 9-1067 non-micronized;Drug: BIA 9-1067 micronizedBial - Portela C S.A.Not recruiting18 Years45 YearsAll28Phase 1
515EUCTR2013-002545-10-SE08/01/201427 June 2016An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy.An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Code: OSU6162 similar to (-)-OSU 6162
Pharmaceutical Form: Coated tablet		A. Carlsson Research ABAuthorisedFemale: yes
Male: yes		240Phase 2Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
516NCT02046434January 201414 January 2019Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the BrainPhenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From BrainParkinson's DiseaseDrug: Glycerol PhenylbutyrateUniversity of Colorado, DenverNot recruiting21 Years80 YearsAll40Phase 1United States
517NCT02384512January 201420 April 2015Azilect® In Wearing-Off (AIWO)Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)Parkinson's DiseaseDrug: Azilect®Teva Pharma GmbHAnfomed GmbHNot recruiting18 YearsN/ABoth261N/AGermany
518NCT01883505December 201311 April 2016A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612Parkinson's DiseaseDrug: Levodopa and carbidopa;Drug: PlaceboNeuroDerm Ltd.Not recruiting30 YearsN/ABoth30Phase 2Israel
519NCT01968460December 201316 December 2017Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's DiseaseA Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's DiseaseParkinson's DiseaseDrug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),;Drug: Placebo;Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),Pharma Two B Ltd.Not recruiting35 Years75 YearsAll149Phase 2/Phase 3United States;Israel
520NCT02018406December 20138 April 2019Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain InjuryNeurological Diseases;Ischemic Stroke;Hemorrhagic Stroke;Cerebral Palsy;Atypical Parkinson DiseaseDrug: Combination injection of EPO and G-CSF;Drug: Injection of normal salineYonsei UniversityNot recruiting20 YearsN/AAll16Phase 1/Phase 2Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
521NCT02108704December 20134 November 2019Helicobacter Pylori Eradication Study in Parkinson's DiseaseHelicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled TrialParkinson's Disease;Helicobacter Pylori InfectionDrug: Helicobacter pylori eradication therapy;Drug: PlaceboUniversity of MalayaNot recruiting18 YearsN/AAll75N/AMalaysia
522NCT01856738November 201315 October 2018Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s DiseaseCholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.Parkinson's DiseaseDrug: Rivastigmine;Drug: Placebo (for rivastigmine)VU University Medical CenterAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and DevelopmentNot recruiting40 YearsN/AAll91Phase 4Netherlands
523NCT01927055November 201319 October 2017A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa TherapyA Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa TherapySymptomatic Neurogenic Orthostatic Hypotension;Parkinson's Disease;Multiple Systems Atrophy;Pure Autonomic Failure;Dopamine Beta Hydroxylase DeficiencyDrug: Droxidopa;Drug: PlaceboChelsea TherapeuticsNot recruiting18 YearsN/AAll61Phase 3United States
524EUCTR2013-000980-10-AT18/10/20132 October 2017Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s diseaseTOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDOParkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment
MedDRA version: 18.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
Pharmaceutical Form: Solution for infusion in pre-filled syringe
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 314-19-2
Other descriptive name: Apomorphine hydrochloride
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe
Route of administration of the placebo: Subcutaneous use		Britannia Pharmaceuticals LimitedNot RecruitingFemale: yes
Male: yes		102Phase 3France;Spain;Denmark;Austria;Netherlands;Germany
525NCT01960842October 201311 June 2018A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsAn Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationAdvanced Parkinson's DiseaseDrug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tubeAbbVieNot recruiting30 YearsN/AAll31Phase 3Japan;Korea, Republic of;Taiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
526NCT01968031October 20139 January 2017A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseA Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: PlaceboKyowa Hakko Kirin Pharma, Inc.Kyowa Hakko Kirin Co., LtdNot recruiting30 YearsN/ABoth613Phase 3United States;Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia
527NCT01973543October 20138 April 2019Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's DiseaseAn Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to LevodopaParkinson's DiseaseBiological: VY-AADC01Neurocrine BiosciencesUniversity of California, San Francisco;Veristat, Inc.;Feinstein Institute for Medical Research;Oregon Health and Science University;Voyager TherapeuticsNot recruiting40 Years70 YearsAll15Phase 1United States
528NCT02012595October 20138 June 2015[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons DiseaseParkinson's DiseaseOther: [11C]donepezil PETPer BorghammerLundbeck Foundation;Jascha Fonden;Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons SygdomNot recruiting40 Years80 YearsBoth24N/ADenmark
529NCT02055274October 20132 November 2015Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseA Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular InjectionsParkinson's DiseaseDrug: LY03003;Drug: NeuproLuye Pharma Group Ltd.Not recruiting18 YearsN/ABoth39Phase 1United States
530NCT02207387October 201313 April 2015Ambulosono Rasagiline Musical Walking StudyA Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's DiseaseParkinson's DiseaseDrug: Azilect;Behavioral: Exercise;Other: MusicUniversity of British ColumbiaTeva Pharmaceutical IndustriesRecruiting19 YearsN/ABoth60N/ACanada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
531EUCTR2013-001881-40-GB16/09/201330 April 2019Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s DiseaseParkinson's disease
MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF)
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Liatermin
Other descriptive name: r-metHuGDNF
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 9.0-11.0		North Bristol NHS Trust (NBT)Not Recruiting Female: yes
Male: yes		42Phase 2United Kingdom
532NCT01882010September 201330 May 2016Leukine (Sargramostim) for Parkinson's DiseaseLeukine (Sargramostim) for Parkinson's DiseaseParkinson's DiseaseProcedure: blood draw;Procedure: physical exam and UPDRS part III assessment;Procedure: MEG;Drug: sargramostim;Drug: placebo;Behavioral: physical exam and UPDRS part III assessment;Procedure: Motion AnalysisHoward Gendelman, MDSanofi;National Institute of Neurological Disorders and Stroke (NINDS);UNeMed;Nebraska Neuroscience AllianceNot recruiting35 Years85 YearsBoth37Phase 1United States
533NCT01923584September 201326 September 2016A Phase 2A Trial of EPI-743 for Patients With Parkinson's DiseaseA Phase 2A Trial of EPI-743 for Patients With Parkinson's DiseaseParkinson's DiseaseDrug: EPI-743 400mg;Drug: EPI-743 200mgUniversity of South FloridaEdison Pharmaceuticals IncNot recruiting40 Years75 YearsBoth15Phase 2United States
534NCT01955616September 20133 October 2016A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic ConstipationA Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current TherapyParkinson's DiseaseDrug: RM-131;Drug: PlaceboMotus Therapeutics, Inc.Michael J. Fox Foundation for Parkinson's ResearchNot recruiting18 Years80 YearsBoth18Phase 2United States
535NCT01929317August 28, 20132 July 2018A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.Parkinson DiseaseDrug: Ropinirole CR 2mg tablet;Drug: Ropinirole CR 8mg tablet;Drug: Ropinirole CR matching Placebo tabletGlaxoSmithKlineNot recruiting20 YearsN/AAll81Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
536JPRN-UMIN0000111112013/07/162 April 2019Spinal blood flow and metabolism in neurological diseasesmotor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophyPET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O		Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesRecruiting20years-oldNot applicableMale and Female70Not applicableJapan
537NCT01767129July 201322 January 2018Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease PatientsA Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.Dyskinesia;Parkinson's DiseaseDrug: AVP-923-45;Drug: PlaceboAvanir PharmaceuticalsMichael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years80 YearsAll14Phase 2United States;Canada
538EUCTR2012-001245-40-IT05/06/201311 April 2016CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)PARKINSON'S DISEASE
MedDRA version: 16.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Madopar 200+50 mg
Pharmaceutical Form: Tablet
Trade Name: LEVODOPA / BENSERAZIDE 200 + 50 MG
Pharmaceutical Form: Tablet		Not RecruitingFemale: yes
Male: yes		Italy
539JPRN-JapicCTI-13218901/6/201323 April 2019A Phase 1 Study of ONO-2160/CDA Phase 1 study on single oral dose administration of ONO-2160/CD in healthy adult male subjects and Parkinson's disease patientsParkinson's diseaseIntervention name : ONO-2160/CD
Dosage And administration of the intervention : Oral administration
Control intervention name : Levodopa/carbidopa hydrate
INN of the control intervention : Levodopa/Carbidopa Hydrate
Dosage And administration of the control intervention : Oral administration		ONO PHARMACEUTICAL CO.,LTD.BOTH42Phase 1
540NCT01850381June 201326 August 2019Phase 2A Study of GM 608 in Mild to Moderate Parkinson DiseaseGM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson DiseaseParkinson's DiseaseDrug: GM608;Drug: Placebo ComparatorGenervon Biopharmaceuticals, LLCColumbia UniversityNot recruiting30 YearsN/AAll6Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
541NCT01879748June 201319 February 2015A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of RasagilineA Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian SubjectsParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboTeva Pharmaceutical IndustriesNot recruiting20 Years50 YearsBoth64Phase 1United States
542NCT02263235June 201317 May 2016In Vivo Alzheimer ProteomicsUse of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer DiseaseProbable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brain Trauma;Acute HydrocephalyBiological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urine, salivaUniversity Hospital, MontpellierAssistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic Energy AgencyRecruiting55 Years85 YearsBoth110N/AFrance
543NCT02275884June 201319 February 2015Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's DiseaseEvaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDietary Supplement: Dark chocolate (85% cocoa);Dietary Supplement: White chocolate (0% cocoa)Technische Universität DresdenUniversity of WuerzburgRecruiting40 YearsN/ABoth30N/AGermany
544JPRN-UMIN0000107522013/05/172 April 2019A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia.Parkinson's diseasedonepezilKansai Medical UniversityNot RecruitingNot applicableNot applicableMale and Female50Not selectedJapan
545EUCTR2013-000827-15-IT11/05/201318 January 2016LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINELATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE - PARROTParkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Rotigotine
Product Name: neurpro
Product Code: SPM962
Pharmaceutical Form: Transdermal patch
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use		Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, TricaseNot RecruitingFemale: yes
Male: yes		Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
546JPRN-UMIN0000105962013/05/012 April 2019Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in JuntendoParkinson's diseaseMemantine preceding arm
Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months.

Amantadine preceding arm
Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months.		Department of Neurology, Juntendo University School of MedicineNot Recruiting20years-oldNot applicableMale40Not selectedJapan
547NCT01851850May 201319 February 2015Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical TrialContinue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical TrialParkinson DiseaseDrug: OpicaponeRabin Medical CenterNot recruiting30 Years80 YearsBoth1Phase 3Israel
548NCT01860794May 201316 December 2017Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's DiseaseInvestigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's DiseaseIdiopathic Parkinson Disease;Primary ParkinsonismDrug: Mesencephalic Neuronal Precursor CellsBundang CHA HospitalRecruiting18 Years70 YearsFemale15Phase 1/Phase 2Korea, Republic of
549NCT01877538May 201319 October 2017Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System[11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy AdultsParkinson's DiseaseOther: [11C]donepezil PETPer BorghammerLundbeck FoundationNot recruiting45 Years75 YearsMale7Phase 1Denmark
550NCT02473562May 201315 October 2018Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's DiseaseVarenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot StudyParkinson's DiseaseDrug: Varenicline;Drug: Placebo (for varenicline)VU University Medical CenterCentre for Human Drug Research, NetherlandsNot recruitingN/AN/AAll22Phase 4Netherlands
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
551NCT02500108May 201325 April 2016Domperidone and Risk of Sudden Cardiac DeathDomperidone Use in Parkinson's Disease and Risk of Sudden Cardiac DeathParkinson's DiseaseDrug: DomperidoneCanadian Network for Observational Drug Effect Studies, CNODESDrug Safety and Effectiveness Network, Canada;Canadian Institutes of Health Research (CIHR)Not recruiting50 YearsN/ABoth214962N/ACanada
552NCT03022201May 20131 April 2019Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's DiseaseTherapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority TrialParkinson's Disease,IdiopathicDrug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701Seoul National University HospitalNot recruiting20 Years80 YearsAll40Phase 4Korea, Republic of
553EUCTR2011-002827-17-EE23/04/20136 January 2015A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.Early stage Parkinson's Disease.
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: REQUIP-MODUTAB , 2mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB , 4mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB , 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		GlaxoSmithKline Research & Development LimitedNot RecruitingFemale: yes
Male: yes		210United States;Estonia;Slovakia;Russian Federation;Korea, Republic of
554EUCTR2011-002828-41-EE23/04/201310 July 2015A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease.A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.Advanced Parkinson's disease.
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: REQUIP-MODUTAB, 2mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB, 4mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB, 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		GlaxoSmithKline Research & Development LimitedNot RecruitingFemale: yes
Male: yes		406United States;Taiwan;Estonia;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of
555JPRN-UMIN0000107782013/04/102 April 2019Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1Parkinson disease5mg donepezil hydroclorideNational Hospital of UtanoNot Recruiting20years-oldNot applicableMale and Female50Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
556JPRN-UMIN0000103712013/04/082 April 2019Study of zonisamide ( TRERIEF&reg; tablet 25mg ) to tremor in patients with early Parkinson's disease.Parkinson's diseaseStart 25mg of Zonisamide and carry out observation 24weeks.
Evaluate start point, after 4weeks, after 8weeks, after 16weeks, and after 24weeks.		Department of Neurology, University of YamanashiNot RecruitingNot applicableNot applicableMale and Female10Not selectedJapan
557NCT01777555April 201320 August 2018Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF EpisodesA Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Idiopathic Parkinson's DiseaseDrug: CVT-301;Drug: PlaceboAcorda TherapeuticsNot recruiting30 Years80 YearsAll89Phase 2United States;Italy;Serbia;United Kingdom
558NCT01829867April 20138 February 2016A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 µg by Intracerebroventricular InfusionParkinson's DiseaseDrug: sNN0031Newron Sweden ABNot recruiting55 Years75 YearsBoth5Phase 1Sweden
559NCT02005029April 201319 October 2017Erythromycin in Parkinson's DiseaseErythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and PharmacodynamicsParkinson's Disease;LevodopaDrug: Erythromycin;Drug: placeboVirginia Commonwealth UniversityNot recruiting18 Years80 YearsAll18N/AUnited States
560JPRN-UMIN0000099582013/03/082 April 2019Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunctionParkinson's diseaseDonepezil hydrochloride added to standard therapy
Placebo added to standard therapy		National Hospital Organization, Sendai-Nishitaga HospitalNot Recruiting55years-old75years-oldMale and Female200Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
561EUCTR2012-002840-26-AT05/03/201331 March 2014Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's DiseaseA Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and MoodParkinson's disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-		UCB Biosciences GmbHNot RecruitingFemale: yes
Male: yes		504Phase 4United States;Serbia;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria
562NCT01736176March 201319 October 2017A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's DiseaseAn Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's DiseaseAdvanced Parkinson's DiseaseDrug: Levodopa-Carbidopa Intestinal Gel;Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J);Drug: Levodopa-carbidopa Immediate Release (LC-IR) TabletsAbbVie (prior sponsor, Abbott)Not recruiting30 YearsN/AAll39Phase 3United States
563NCT01789047March 201314 November 2016Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's DiseaseTopiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's DiseaseIdiopathic Parkinson's Disease;Drug Induced DyskinesiaDrug: Topiramate;Drug: PlaceboRush University Medical CenterMichael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years90 YearsBoth44Phase 2United States
564JPRN-UMIN0000100142013/02/282 April 2019Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson DiseaseParkinson's disesasehydrogen water made by "Suisosui5.0"
placebo-water (nitrogen filling water)		Juntendo University School of Medicine, NeurologyNot Recruiting20years-oldNot applicableMale and Female200Not selectedJapan
565EUCTR2012-000801-64-GB09/02/201319 November 2018A study of the effects of medication on memory in Parkinson's DiseaseA Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease. - Medication and Memory in Parkinson’s Disease (MeMory PaD)Idiopathic Parkinson's Disease
MedDRA version: 17.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Mirapexin extended release various strengths
Product Name: Pramipexole dihydrochloride monohydrate extended release
Product Code: N/A
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: pramipexole dihydrochloride monohydrate
CAS Number: 104632-26-0
Current Sponsor code: not available
Other descriptive name: Mirapexin
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 3.15-
Trade Name: Requip prolonged release
Product Name: Ropinirole hydrochloride prolonged release
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: Ropinirole (as hydrochloride)
CAS Number: 91374-21-9
Current Sponsor code: not available
Other descriptive name: Requip XL prolonged-release
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 24-		University Hospital of North StaffordshireKeele UniversityNot RecruitingFemale: yes
Male: yes		55Phase 4United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
566NCT01766128February 201319 February 2015Study of Zonisamide in Early Parkinson DiseaseRandomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson DiseaseParkinson DiseaseDrug: ZonisamideMazandaran University of Medical SciencesNot recruiting45 Years85 YearsBoth60Phase 2/Phase 3
567NCT01789385February 201319 February 2015Anesthesia for Deep Brain StimulationAnesthesia for Deep Brain Stimulation for the Treatment of Parkinsons DiseaseParkinsons DiseaseDrug: DexmedetomidineDiskapi Teaching and Research HospitalNot recruiting19 Years85 YearsBoth26Phase 4Turkey
568NCT02059733February 20139 October 2018Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and ParkinsonismDeveloping a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PETParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNot recruiting20 Years80 YearsAll72Phase 2Taiwan
569EUCTR2012-002608-42-DE10/01/201326 August 2013A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's DiseaseA Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainParkinson’s disease
MedDRA version: 16.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-		UCB Biosciences GmbHNot RecruitingFemale: yes
Male: yes		64United States;Hungary;Slovakia;Poland;Germany;United Kingdom
570JPRN-UMIN0000176952013/01/012 April 2019Oxybuprocaine for apraxia of lid opening in Parkinson's diseaseapraxia of lid opening in Parkinson's diseaseArm 1 intervention consisted of 4%oxybuprocaine eye drop treatment, washout for 24 hours or more, and a saline eye drop treatment
Arm 2 intervention consisted of saline eye drop treatment, a washout period, and an oxybuprocaine treatment		Utano National Hospital, National Hospital OrganizationNot RecruitingNot applicableNot applicableMale and Female10Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
571NCT01500707January 201319 February 2015Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: SCH 900800Merck Sharp & Dohme Corp.Not recruiting30 Years85 YearsBoth0Phase 1
572NCT01803945January 201312 October 2015A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's DiseaseA Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: AVE8112;Drug: PlaceboMichael J. Fox Foundation for Parkinson's ResearchSanofiNot recruiting35 Years70 YearsBoth32Phase 1United States
573NCT02100176January 201319 February 2015MIRT and Rotigotine in the Early Stage of PDMultidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.Parkinson's DiseaseOther: Multidisciplinary intensive rehabilitation treatment;Drug: RotigotineOspedale Generale Di Zona Moriggia-PelasciniRecruiting50 Years75 YearsBoth40N/AItaly
574NCT03651856January 201310 September 2018Atomoxetine for Freezing of Gait in Parkinson's DiseaseA Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's DiseaseParkinson's Disease;Freezing of GaitDrug: ATM FOG in PDMedical University of South CarolinaNot recruiting18 Years80 YearsAll10Phase 3United States
575NCT01725802December 201211 April 2016A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD PatientsA Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD PatientsParkinson's DiseaseDrug: levodopa and carbidopa solution for SC administration;Drug: PlaceboNeuroDerm Ltd.Not recruiting30 YearsN/ABoth8Phase 1/Phase 2Israel
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
576NCT01741701December 201219 October 2017A Pilot Study of Oxaloacetate in Subjects With Treated PDA Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)Parkinson's DiseaseDrug: Oxaloacetate (OAA);Drug: PlaceboUniversity of Kansas Medical CenterTerra Biological LLCNot recruiting30 YearsN/AAll33Phase 2/Phase 3United States
577NCT01770145December 201216 December 2017Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa ActionParkinson's Disease;Motor Symptoms;Akinesia;Hypomobility;Delayed Levodopa OnsetDrug: APOKYN;Drug: L-dopa;Drug: TrimethobenzamideUS WorldMeds LLCNot recruiting18 YearsN/AAll127Phase 4United States
578NCT02112812December 201219 February 2015Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's DiseaseA Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's DiseaseResponse to Levodopa;Motor Outcomes;Quality of Life OutcomesDrug: Eradication therapy for H.pylori infection;Drug: Eradication of Helcobacter Pylori;Drug: Eradication therapy for Helicobacter pyloriNational University of MalaysiaNot recruiting17 YearsN/ABoth82N/AMalaysia
579NCT01683253November 201211 June 2018Remission of ICD by Switching Dopamine Agonist to Levodopa/CarbidopaThe REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement TherapyImpulse Control DisorderDrug: Levodopa/Carbidopa(200mg/50mg);Drug: Dopaminergic AgonistsSandozNot recruiting30 Years80 YearsAll150Phase 4
580NCT01721460November 201216 December 2017Effects of Dexmedetomidine on Activity in the Subthalamic NucleusEffects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation SurgeryParkinson's Disease;Deep Brain Stimulation SurgeryDrug: DexmedetomidineUniversity of Wisconsin, MadisonNot recruiting18 Years85 YearsAll6Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
581NCT01723228November 201219 October 2017Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseA 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboTeva Branded Pharmaceutical Products, R&D Inc.Not recruiting45 Years80 YearsAll170Phase 4United States
582NCT01738191November 201211 April 2016Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)Parkinson's Disease;Cognitive ImpairmentDrug: Atomoxetine;Drug: PlaceboMedical University of South CarolinaMichael J. Fox Foundation for Parkinson's ResearchNot recruiting35 Years75 YearsBoth30Phase 2United States
583NCT03652363October 25, 20123 September 2018GDNF in ideopathicParkinsons DiseaseA Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s DiseaseIdiopathic Parkinson DiseaseDrug: glial cell line-derived neurotrophic factorNorth Bristol NHS TrustNot recruiting35 Years75 YearsAll42Phase 2
584JPRN-UMIN0000090992012/10/012 April 2019The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormiaParkinson's diseaselidocaine injection into the external oblique
normal saline injection into the external oblique		Parkinson's disease and Movement Disorder CenterRecruiting20years-oldNot applicableMale and Female10Not applicableJapan
585NCT01560754October 201212 October 2015Disease-modifying Potential of Transdermal NICotine in Early Parkinson's DiseaseA Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USAParkinson's DiseaseDrug: nicotine transdermal patchJames BOYD MDMichael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, GermanyNot recruiting30 YearsN/ABoth160Phase 2United States;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
586NCT01563913October 201211 July 2016Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty AcidsReducing Dyskinesia in Parkinson Disease With Omega-3 Fatty AcidsParkinson's DiseaseDrug: Docosahexaenoic Acid (DHA);Drug: PlaceboVA Office of Research and DevelopmentOregon Health and Science University;Oregon Health and Science UniversityNot recruiting21 Years99 YearsBoth40Phase 1United States
587NCT01603069October 201219 February 2015A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's DiseaseA Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: AZD3241 300 mg BID;Drug: AZD3241 600 mg BID;Drug: PlaceboAstraZenecaNot recruiting30 Years80 YearsBoth51Phase 2United States
588NCT01691924October 201211 April 2016Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy VolunteersRandomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy VolunteersParkinson DiseaseDrug: PBF-509;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LNot recruiting18 Years45 YearsMale56Phase 1Spain
589NCT01723904October 201219 October 2017A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's DiseaseAn Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3BAdvanced Parkinson's DiseaseDrug: RotigotineUCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.Not recruiting30 Years80 YearsAll90Phase 3Australia;Korea, Republic of;Malaysia;Singapore;Taiwan
590NCT01796483October 20123 June 2019EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PDExploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de ParkinsonParkinson DiseaseDevice: Clonidine (Catapressan);Device: Placebo 90 minutes before EEGHospices Civils de LyonNot recruiting40 Years70 YearsAll37N/AFrance
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
591EUCTR2011-003866-34-GB24/09/201216 November 2015Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s DiseaseParkinson's disease
MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF)
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Liatermin
Other descriptive name: r-metHuGDNF
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 9.0-11.0
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intracerebral use		North Bristol NHS Trust (NBT)AuthorisedFemale: yes
Male: yes		United Kingdom
592ChiCTR-OCS-120027202012-09-0118 April 2017Pharmacogenetics study of anti-parkinson's disease drug levodopaThe association between polymorphisms of DRD2, DRD2, SLC6A3 and the levodopa responseParkinson's DiseaseA:levodopa;Institute of Clinical Pharmacology, Central South UniversityNot Recruiting3872BothA:200;Post-market
593NCT01662791September 201219 October 2017Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial OvergrowthWeight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial OvergrowthParkinson's DiseaseDrug: RifaximinMayo ClinicNot recruiting18 YearsN/AAll49Phase 3United States
594NCT01676103September 201219 February 2015The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's DiseaseThe Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar PillNew York Institute of TechnologyMichael J. Fox Foundation for Parkinson's ResearchNot recruiting50 Years80 YearsBoth40Phase 1/Phase 2United States
595NCT01684475September 201219 February 2015A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASEA STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASEParkinson's DiseaseDrug: CJH1 (CLR4001)Alexandra Marine and General HospitalRecruiting40 Years85 YearsBoth21Phase 1/Phase 2Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
596NCT01711866September 201219 October 2017A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's DiseaseAn Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4Advanced Idiopathic Parkinson's DiseaseDrug: RotigotineUCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.Not recruiting30 Years80 YearsAll87Phase 4United States;Korea, Republic of;Malaysia;Singapore;Taiwan
597EUCTR2012-000122-21-DK10/08/201219 March 2018Improving the blood pressure regulating system in patients with parkinsons diseaseAcethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons diseaseOrtostatic hypotension in patients with Parkinsons disease
MedDRA version: 14.1 Level: PT Classification code 10031127 Term: Orthostatic hypotension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]		Trade Name: Mestinon
Product Name: Mestinon
Pharmaceutical Form: Capsule
INN or Proposed INN: PYRIDOSTIGMINE BROMIDE
CAS Number: 101-26-8
Current Sponsor code: SJ-193
Other descriptive name: Mestinon
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 60-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use		Department of Neurology, Roskilde HospitalNot RecruitingFemale: yes
Male: yes		20Phase 2Denmark
598EUCTR2012-001530-34-NL09/08/201226 March 2018Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s DiseaseVarenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA)Idiopathic Parkinson's disease
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Champix
Pharmaceutical Form: Coated tablet
INN or Proposed INN: VARENICLINE
CAS Number: 375815-87-5
Other descriptive name: VARENICLINE TARTRATE
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 0.5-3
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use		VU University Medical CenterCenter Human Drug ResearchNot RecruitingFemale: yes
Male: yes		32Phase 3Netherlands
599NCT00947037August 20127 December 2015Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension StudyAn Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease SubjectsParkinson's DiseaseDrug: AP-CD/LDIntec Pharma Ltd.Not recruiting30 Years95 YearsBoth0Phase 2Israel
600NCT02419313August 201219 October 2017Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized ApproachInvestigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized ApproachParkinson;TremorDrug: incobotulinumtoxinA;Drug: SalineYale UniversityNot recruiting18 YearsN/AAll33Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
601NCT02764892August 201217 May 2016A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's DiseaseAn Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male VolunteersParkinson's DiseaseDrug: V81444Vernalis (R&D) LtdNot recruiting25 Years55 YearsMale6Phase 1
602JPRN-UMIN0000084772012/07/192 April 2019Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease.Parkinson diseaseSelegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points.Department of Neurology, Juntendo Koshigaya HospitalNot Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
603JPRN-UMIN0000081382012/07/012 April 2019Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's diseaseParkinson's diseaseSilodosin 8mg BIDJuntendo University School of MedicineNot RecruitingNot applicableNot applicableMale100Not selectedJapan
604NCT01398748July 201216 December 2017Intranasal Glutathione in Parkinson's DiseaseA Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's DiseaseParkinson's Disease (PD)Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal DeliveryBastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Not recruiting21 Years100 YearsAll34Phase 1United States
605NCT01491022July 201216 December 2017A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseA Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseParkinson's DiseaseDrug: Ampyra first, then Placebo;Drug: placebo first, then AmpyraUniversity of MiamiAcorda TherapeuticsNot recruiting45 Years80 YearsAll22Phase 1/Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
606NCT01602549July 201219 October 2017A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingA Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingGastroparesisDrug: GSK962040 (25 mg tablet);Drug: PlaceboGlaxoSmithKlineNot recruiting40 Years80 YearsAll58Phase 2Australia;Germany;Sweden;United Kingdom
607NCT01646255July 201211 June 2018Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease PatientsA Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On LevodopaIdiopathic Parkinson's DiseaseDrug: Rotigotine;Drug: Placebo Patch;Drug: L-dopaUCB PharmaUCB Trading (Shanghai) Co. Ltd.Not recruiting30 YearsN/AAll346Phase 3China
608NCT01646268July 201219 October 2017Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease PatientsA Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's DiseaseIDIOPATHIC PARKINSON'S DISEASEDrug: Rotigotine;Drug: Placebo PatchUCB PharmaNot recruiting30 YearsN/AAll249Phase 3China
609JPRN-JapicCTI-12188011/6/20122 April 2019Phase II clinical study in patients with Parkinson's disease not taking L-DOPAA randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease not taking L-DOPAParkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 2
610JPRN-JapicCTI-12187907/6/20122 April 2019Phase II clinical study in patients with Parkinson's disease taking L-DOPAA randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease taking L-DOPAParkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
611NCT01892176June 201219 February 2015Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseEffects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseParkinson DiseaseDietary Supplement: coenzyme q10National University Hospital, SingaporeNot recruiting21 MonthsN/ABoth20Phase 2/Phase 3Singapore
612NCT01993680June 201212 October 2015Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -TreatmentA Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson`s DiseaseAutonomic Disturbances in Parkinson`s DiseaseDrug: Pyridostigmine bromide;Drug: fludrocortisoneUniversity of ZurichNot recruiting50 Years80 YearsBoth18Phase 2Switzerland
613NCT02786667June 201216 December 2017Non Motors Aspects in De Novo Parkinson's DiseaseNon Motors Aspects in De Novo Parkinson's Disease: Clinical and Physiopathological Description; Dopamine Agonist Treatment Effects.Parkinson Disease;ApathyDrug: Rotigotine;Drug: PlaceboUniversity Hospital, GrenobleNot recruiting30 Years72 YearsAll199Phase 3France
614EUCTR2012-001218-40-IT21/05/201231 July 2012EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTSEFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTSPatients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an incomplete control of motor signs, in particular presence of early morning akinesia, as well as gait deficits in the morning.
MedDRA version: 14.1 Level: PT Classification code 10056242 Term: Parkinsonian gait System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: NEUPRO*7CER 4MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 9-
Trade Name: NEUPRO*7CER 6MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 13.5-
Trade Name: NEUPRO*7CER 8MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 18-
Trade Name: NEUPRO*28CER 2MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 4.5-
Trade Name: NEUPRO*28CER 4MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 9-
Trade Name: NEUPRO*28CER 6MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 13.5-
Trade Name: NEUPRO*28CER 8MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 18-		FONDAZIONE SANTA LUCIAAuthorisedFemale: yes
Male: yes		Italy
615JPRN-UMIN0000078962012/05/012 April 2019Levodopa challenge test for Parkinson's disease and other parkinsonian syndromesParkinson's disease and other parkinsonian syndromesThe patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.
The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.		Kansai Medical UniversityRecruitingNot applicableNot applicableMale and Female100Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
616NCT01652313May 201219 February 2015Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenA Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenParkinson's DiseaseDrug: RasagilineH. Lundbeck A/SNot recruiting18 Years45 YearsBoth12Phase 1China
617EUCTR2011-004438-32-GB25/04/201228 February 2019The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingA randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoCInvestigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 20.1 Level: PT Classification code 10051153 Term: Diabetic gastroparesis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: GSK962040
Product Code: GSK962040
Pharmaceutical Form: Tablet
INN or Proposed INN: GSK962040
CAS Number: 923565-21-3
Current Sponsor code: GSK962040
Other descriptive name: GSK962040
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: GSK962040
Product Code: GSK962040
Pharmaceutical Form: Tablet
INN or Proposed INN: GSK962040
CAS Number: 923565-21-3
Current Sponsor code: GSK962040
Other descriptive name: GSK962040
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: GSK962040
Product Code: GSK962040
Pharmaceutical Form: Tablet
INN or Proposed INN: GSK962040
CAS Number: 923565-21-3
Current Sponsor code: GSK962040
Other descriptive name: GSK962040
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		GlaxoSmithKline Research and Development LimitedNot Recruiting Female: yes
Male: yes		70Phase 2Germany;United Kingdom;Sweden
618EUCTR2012-000181-37-GB25/04/201221 January 2013A study investigating the safety of CVT-301 in patients with Parkinson's DiseaseA Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response Fluctuations (“Off” Episodes)Parkinson's Disease
MedDRA version: 14.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use
Trade Name: Sinemet®
Product Name: SINEMET® Plus 25 mg/100 mg Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-		Civitas Therapeutics, Inc.Not RecruitingFemale: yes
Male: yes		24Phase 2Serbia;Israel;United Kingdom
619EUCTR2011-005839-91-ES02/04/201229 January 2018Gabapentin in the disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo.Gabapentin int he disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. - IMULPARKPARKINSON´S DISEASE
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: GABAPENTINA KERN PHARMA
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: GABAPENTINA
CAS Number: 60142-96-3
Other descriptive name: GABAPENTIN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		ASOCIACIÓN INSTITUTO BIODONOSTIANot RecruitingFemale: yes
Male: yes		100Phase 2Spain
620NCT01494532April 2, 20122 July 2018A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseA Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's DiseaseParkinson DiseaseDrug: ropinirole/L-dopa;Drug: placebo/L-dopaGlaxoSmithKlineNot recruiting30 YearsN/AAll352Phase 4United States;Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
621ChiCTR-TTRCC-120027512012-04-0118 April 2017Clinical pharmacology study of anti-parkinson's drug pramipexoleA rondomised clinical trial of the potential drug-drug interaction between pramipexole and metforminParkinson's diseaseA:Given pramipexole only;B:Given pramipexole and metformin simultaneously ;Institute of Clinical Pharmacology, Central South UniversityNot Recruiting1926MaleA:18;B:18;Phase 1 studyChina
622JPRN-JapicCTI-12200001/4/20122 April 2019Long-term study of FPF1100NW monotherapyLong-term study on FPF1100NW monotherapy with early Parkinson's disease patientsEarly Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null		FP Pharmaceutical Corp.BOTH130Phase 2
623JPRN-UMIN0000076172012/04/012 April 2019Effect of lidocaine injection for postural deformities in Parkinson's diseaseParkinson's diseaseintramuscular injection of lidocaineDept. of Clinical pharmacology and Neurology, Ehime UniversityRecruiting20years-old80years-oldMale and Female30Not selectedJapan
624NCT01331122April 201219 February 2015Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's DiseaseA Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's DiseaseGait Disorders, NeurologicDrug: droxidopaChelsea TherapeuticsNot recruiting30 YearsN/ABoth0Phase 1/Phase 2United States;Canada
625NCT01486628April 201211 April 2016Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersA Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersParkinson's DiseaseDrug: ND0612;Drug: PlaceboNeuroDerm Ltd.Not recruiting18 Years40 YearsMale36Phase 1Israel
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
626NCT01491529April 201219 February 2015Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseDyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia AgentsDrug: AFQ056;Drug: PlaceboNovartis PharmaceuticalsNot recruiting30 Years80 YearsBoth154Phase 2United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey
627NCT01523301April 201219 October 2017Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsDouble Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseDrug: Rotigotine;Drug: PlaceboUCB Korea Co., Ltd.Not recruiting20 YearsN/AAll380Phase 4Korea, Republic of
628NCT01527695April 201219 February 2015PET Study in Parkinson's Disease PatientsA Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ER tablet 25 mg AZD3241;Drug: ER tablet 100 mg AZD3241;Drug: Placebo for AZD3241 25 mg;Drug: Placebo for AZD3241 100 mgAstraZenecaNot recruiting45 Years75 YearsBoth24Phase 2Sweden
629NCT01550484April 201216 December 2017A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement DisordersAn Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain DiagnosisParkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's DiseaseDrug: 18F-AV-133Avid RadiopharmaceuticalsNot recruiting40 YearsN/AAll170Phase 2/Phase 3United States;Australia
630NCT01556165April 201219 October 2017Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaRandomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaParkinson's DiseaseDrug: rasagiline;Drug: placeboH. Lundbeck A/SNot recruiting35 YearsN/AAll130Phase 3China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
631NCT01491932March 201216 December 2017Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasAn Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasDyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia AgentsDrug: AFQ056Novartis PharmaceuticalsNot recruitingN/AN/AAll129Phase 2United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey
632NCT01538329March 201217 May 2016Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's DiseaseImpact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)Parkinson DiseaseDrug: placebo;Drug: AmantadineUniversity Hospital, ToulouseRecruiting35 YearsN/ABoth202Phase 2France
633NCT01565395March 201216 December 2017Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease;Amyotrophic Lateral SclerosisDrug: Incobotulinum Toxin A;Drug: placeboBeth Israel Deaconess Medical CenterMerz PharmaceuticalsNot recruiting20 Years80 YearsAll0Phase 2United States
634NCT01653132March 201216 December 2017Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/ParkinsonismRandomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/ParkinsonismSialorrheaDrug: Incobotulinum Toxin A;Drug: PlaceboBeth Israel Deaconess Medical CenterNot recruiting18 Years90 YearsAll10Phase 2United States
635NCT02039024March 201225 January 2016Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETImaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETParkinson's DiseaseDrug: 18F- DTBZChang Gung Memorial HospitalNational Science Council, TaiwanNot recruiting20 Years80 YearsBoth18Phase 2Taiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
636NCT03061513February 28, 201216 December 2017Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial BiomarkersUbiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial BiomarkersParkinson DiseaseDrug: Ubiquinol;Dietary Supplement: PlaceboWeill Medical College of Cornell UniversityNot recruiting40 Years75 YearsAll11Phase 2
637EUCTR2011-004803-19-SE22/02/201218 February 2013PET study in PD patientsA Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s DiseaseParkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: AZD3241 Extended release tablets 25 mg
Product Code: AZD3241
Pharmaceutical Form: Prolonged-release film-coated tablet
Current Sponsor code: AZD3241
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: AZD3241 Extended release tablets 100 mg
Product Code: AZD3241
Pharmaceutical Form: Prolonged-release film-coated tablet
Current Sponsor code: AZD3241
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: [11C]PBR28
Product Code: [11C]PBR28
Pharmaceutical Form: Solution for injection
Current Sponsor code: [11C]PBR28
Concentration unit: µg microgram(s)
Concentration type: up to
Concentration number: 5-
Product Name: [18F]FE-PE2I
Product Code: [18F]FE-PE2I
Pharmaceutical Form: Solution for injection
Current Sponsor code: [18F]FE-PE2I
Concentration unit: µg microgram(s)
Concentration type: up to
Concentration number: 5-		AstraZeneca ABNot RecruitingFemale: yes
Male: yes		24Phase 2AFinland;Sweden
638NCT01525641February 201219 October 2017Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's DiseaseSpecial Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Mirapex LABoehringer IngelheimNot recruitingN/AN/AAll615N/AJapan
639NCT01568099February 201224 August 2015Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's DiseaseA Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's DiseaseParkinson's DiseaseBiological: AFFITOPE® PD01A;Other: ControlAffiris AGNot recruiting40 Years65 YearsBoth32Phase 1Austria
640NCT01673724February 201216 December 2017Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseEffect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized StudyParkinson's DiseaseDrug: pramipexole;Drug: BromocriptineSandozNot recruiting30 YearsN/AAll121Phase 4Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
641NCT01485172January 31, 20122 July 2018A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseA Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's DiseaseParkinson DiseaseDrug: ropinirole monotherapy;Drug: placebo monotherapyGlaxoSmithKlineNot recruiting30 YearsN/AAll186Phase 4United States;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland
642NCT01470027January 201211 June 2018N-Acetylcysteine for Neuroprotection in Parkinson's DiseaseN-Acetylcysteine for Neuroprotection in Parkinson's DiseaseParkinson DiseaseDrug: N-acetylcysteine;Drug: PlaceboWeill Medical College of Cornell UniversityNational Institute on Aging (NIA)Not recruiting50 Years75 YearsAll50Phase 1/Phase 2United States
643NCT01497652January 201228 December 2015A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyA Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyParkinson's DiseaseDrug: Rasagiline/Placebo;Drug: RasagilineGeorgetown UniversityTeva Neuroscience, Inc.Not recruiting40 YearsN/ABoth34Phase 4United States
644NCT01515410January 201219 October 2017Study in Advanced Parkinson's Disease Patients With Predictable Motor FluctuationsA Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor FluctuationsParkinson's Disease;Motor FluctuationsDrug: DM-1992;Drug: Sinemet IRDepomedNot recruiting30 YearsN/AAll34Phase 2United States
645NCT01536015January 201219 October 2017Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal DysfunctionA Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal DysfunctionAdvanced Parkinson's DiseaseDrug: Rotigotine;Drug: PlaceboUCB PharmaNot recruiting30 YearsN/AAll25Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
646EUCTR2009-017412-32-IT13/12/201115 July 2013RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - NDRANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - NDParkinson disease
MedDRA version: 9.1 Level: LLT Classification code 10013363		Trade Name: BOTOX
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Botulinum toxin
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 100-
Trade Name: NEUROBLOC
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Botulinum toxin
Concentration unit: IU/ml international unit(s)/millilitre
Concentration type: equal
Concentration number: 5000-		AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESINot RecruitingFemale: yes
Male: yes		Italy
647NCT01351168December 201119 February 2015Use of Zolpidem in Parkinson's DiseaseA Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pillRush University Medical CenterNot recruiting30 Years75 YearsBoth0Phase 2United States
648NCT01470859December 201119 October 2017The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Diseasea Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: pramipexole;Drug: Sinemet CRHuashan HospitalBoehringer IngelheimNot recruiting30 Years75 YearsAll30N/AChina
649NCT01479530December 201119 October 2017Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaRandomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaParkinson's DiseaseDrug: Placebo;Drug: Azilect®H. Lundbeck A/SNot recruiting30 YearsN/AAll321Phase 3China
650NCT01519271December 201116 December 2017Mild Cognitive Impairment in Parkinson's DiseaseA Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's DiseaseParkinson's Disease;Mild Cognitive ImpairmentDrug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo PatchesUniversity of PennsylvaniaNot recruiting40 Years85 YearsAll28Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
651NCT01521117December 201119 February 2015The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseA Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's DiseaseParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityRecruitingN/AN/ABoth12Phase 4United States
652NCT02302144December 201116 December 2017A Multifactorial Exercise Program to Reduce Falls in People With Parkinson DiseaseA Multifactorial Exercise Program to Reduce Falls in People With Parkinson DiseaseParkinson DiseaseBehavioral: Balance & Strengthening ExercisesBoston University Charles River CampusNot recruiting18 YearsN/AAll32N/AUnited States
653NCT01385592November 201119 February 2015Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseDyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian DisordersDrug: AFQ056;Drug: PlaceboNovartis PharmaceuticalsNot recruiting30 Years80 YearsBoth78Phase 2United States;Canada;France;Germany;Hungary;Italy;Spain
654NCT01457807November 201119 February 2015To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy VolunteersA Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female VolunteersParkinson's DiseaseDrug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2AstraZenecaNot recruiting30 Years65 YearsBoth24Phase 1United Kingdom
655NCT01556100November 20118 January 2018Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionLong-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionParkinson DiseaseDrug: 18F-DTBZ AV-133Chang Gung Memorial HospitalNot recruiting20 YearsN/AAll40Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
656NCT01736891November 201119 February 2015Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor FluctuationsEvaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)Parkinson´s DiseaseDrug: Rasagiline;Drug: PlaceboChongqing Fortune Pharmaceutical Co., Ltd.Beijing Bionovo Medicine Development Co., Ltd.Not recruiting30 Years75 YearsBoth268Phase 3China
657JPRN-JapicCTI-11167312/10/201123 April 2019Phase II clinical study in patients with Parkinson's disease.Pharmacokinetic study of HP-3000 in patients with Parkinson's disease.Parkinson's diseaseIntervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co., Inc.2079BOTHPhase 2
658EUCTR2011-000056-42-GB07/10/201110 December 2012Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's diseaseA MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE - sleep efficiency assessed by polysomnography in advanced Parkinson's DiseaseAdvanced Parkinson's Disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neupro 4mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 6mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 8mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use		UCB Celltech, UK - Registered Branch of UCB Pharma SANot RecruitingFemale: yes
Male: yes		United Kingdom
659JPRN-UMIN0000065212011/10/012 April 2019Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's diseaseParkinson's diseaseRapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks.Department of Neurology, Juntendo UniversityRecruiting20years-oldNot applicableMale and Female30Not selectedJapan
660NCT01385735October 201119 February 2015Emotion, Mood and Executive Function in Parkinson`s Disease (PD)Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson`s DiseaseParkinson DiseaseDrug: Rasagiline;Drug: PlaceboSt. Josef Hospital BochumNot recruiting30 Years75 YearsBoth70Phase 4Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
661NCT01439100October 201119 February 2015A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated PainParkinson's Disease With Severe PainDrug: Oxycodone/Naloxone Prolonged Release tablets;Drug: PlaceboMundipharma Research GmbH & Co KGNot recruiting25 YearsN/ABoth172Phase 3Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom
662NCT01442610October 20111 February 2016Effects of Rasagiline on Sleep Disturbances in Parkinson's DiseaseEffects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV TrialSleep Disturbances;Parkinsons's DiseaseDrug: Rasagiline;Drug: PlaceboTechnische Universität DresdenTeva Pharmaceutical IndustriesNot recruiting50 Years85 YearsBoth30Phase 4Germany
663NCT01446614October 201119 February 2015Mesenchymal Stem Cells Transplantation to Patients With Parkinson's DiseasePhase?/?Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.Parkinson's DiseaseBiological: bone marrow derived mesenchymal stem cellsGuangzhou General Hospital of Guangzhou Military CommandRecruiting30 Years65 YearsBoth20Phase 1/Phase 2China
664NCT01479127October 201119 October 2017Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's DiseaseAn Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's DiseaseAdvanced Parkinson's DiseaseDrug: ABT-SLV187;Drug: Oral Levodopa/Carbidopa;Device: Infusion Pump: CADD-Legacy® 1400 Pump;Device: NJ-Tube: Silicon ED Tube;Device: Adaptor: Hakko AdaptorAbbVie (prior sponsor, Abbott)Abbott Japan Co.,LtdNot recruiting30 Years99 YearsAll8Phase 2Japan
665NCT02427646October 201126 August 2019Kinematic-guided BoNT-A Treatment for ET and PD TremorUse of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson DiseaseTremorDrug: BoNT-AWestern University, CanadaNot recruiting18 Years80 YearsAll54Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
666EUCTR2011-000612-26-IT19/09/201110 March 2014Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARKOpen-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding - FINTOURPARKSyndrome Gilles de la Tourette's disease Parkinosn Pounding
MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: PROSCAR*30CPR RIV 5MG
Pharmaceutical Form: Tablet
INN or Proposed INN: Finasteride
Concentration unit: mg milligram(s)
Concentration number: 5-		AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARIAuthorisedFemale: yes
Male: yes		Italy
667EUCTR2011-001148-31-GB13/09/201119 March 2012A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1Parkinson's diseaseTrade Name: Ferrprox (Deferiprone)
Product Name: Deferiprone (Ferriprox)
Pharmaceutical Form: Oral liquid
INN or Proposed INN: Deferiprone
Concentration unit: mg/ml milligram(s)/millilitre
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use		Imperial College LondonAuthorisedFemale: yes
Male: yes		United Kingdom
668NCT01178047September 201119 February 2015Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's DiseaseA Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)Parkinson's DiseaseDrug: RasagilineUniversity of ZurichH. Lundbeck A/SNot recruiting40 YearsN/ABoth1Phase 4Switzerland
669NCT01461083September 201119 February 2015Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1aPhase I Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a in Subjects With Parkinson Disease and Healthy SubjectsParkinson DiseaseDrug: [18F]MPPFInstitute for Neurodegenerative DisordersNot recruiting18 Years90 YearsBoth19Phase 1United States
670NCT01515774September 201119 February 2015Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson DiseaseParkinson's DiseaseDrug: Mirapex ERSeoul National University HospitalRecruiting30 Years80 YearsBoth200Phase 4Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
671NCT01545856September 201116 December 2017Cardiovascular Events in Parkinson's Disease PatientsBackground Incidence of Cardiovascular Ischaemic Events in Treated Parkinson's Disease Patients in the Impact DatabaseCardiovascular Event;Parkinson DiseaseDrug: levodopaGlaxoSmithKlineNot recruiting20 YearsN/AAll1N/A
672NCT02170376September 201119 October 2017The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsThe Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy SubjectsParkinson's Disease (PD)Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa/carbidopaBial - Portela C S.A.Not recruiting18 Years45 YearsAll80Phase 1France
673EUCTR2010-020299-42-DE30/08/201127 February 2017A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients.A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PDEarly PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed
MedDRA version: 16.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Pharmaceutical Form: Transdermal patch
CAS Number: 54-11-5
Other descriptive name: NICOTINE
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 7-28
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Pharmaceutical Form: Transdermal patch
CAS Number: 54-11-5
Other descriptive name: NICOTINE
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 7-28
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use		Philipps-University MarburgNot RecruitingFemale: yes
Male: yes		160Phase 2United States;Germany
674NCT01370811August 201119 February 2015A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's DiseaseA Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's DiseaseSialorrhoeaDrug: OC oral solution treatment A;Drug: OC oral solution treatment B;Drug: OC oral solution treatment C;Drug: OC oral solution treatment DOrient Pharma Co., Ltd.Not recruiting40 Years80 YearsBoth24Phase 2United States
675NCT01411137August 201116 December 2017Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety StudyAn Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PDParkinson's DiseaseDrug: IPX066IMPAX Laboratories, Inc.Michael J. Fox Foundation for Parkinson's ResearchNot recruiting30 YearsN/AAll43Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
676NCT01437189August 201119 February 2015The Effects of Sertraline on Depression in Parkinson's DiseaseClinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's DiseaseDepression;Parkinson's DiseaseDrug: SertralineZhejiang UniversityRecruiting35 Years75 YearsBoth35N/AChina
677NCT01461109August 201119 February 2015Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy ControlsEvaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy SubjectsParkinson Disease;Alzheimer DiseaseDrug: [18F] CFPyPBInstitute for Neurodegenerative DisordersNot recruiting18 Years90 YearsBoth4Phase 1United States
678NCT01634568August 201119 February 2015A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy MenA Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male VolunteersParkinson's DiseaseDrug: V81444Vernalis (R&D) LtdNot recruiting18 Years45 YearsMale49Phase 1United Kingdom
679NCT01759888August 201119 February 2015Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismFrom Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNational Science Council, TaiwanNot recruiting20 Years80 YearsBoth49Phase 2Taiwan
680NCT01397422July 201116 December 2017Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)Dyskinesia;Levodopa Induced Dyskinesia;Parkinson's DiseaseDrug: ADS-5102 (extended release amantadine HCl)Adamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll83Phase 2/Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
681NCT01427517July 201111 November 2019Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseIntravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseParkinson's Disease;Gaucher's DiseaseDrug: N-acetylcysteineUniversity of MinnesotaRare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS);National Institute of Neurological Disorders and Stroke (NINDS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting18 YearsN/AAll9Phase 1United States
682EUCTR2011-001092-39-DE29/06/201127 January 2014efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesiasA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesiasL-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias
MedDRA version: 14.1 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: AQW051
Product Code: AQW051
Pharmaceutical Form: Capsule, hard
Current Sponsor code: AQW051
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: AQW051
Product Code: AQW051
Pharmaceutical Form: Capsule, hard
Current Sponsor code: AQW051
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes		72Italy;Germany;United States;France
683NCT01382342June 201119 February 2015The Effect of Rasagiline on Cognition in Parkinson's DiseaseParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboBrown UniversityTeva Pharmaceuticals USANot recruiting40 YearsN/ABoth50Phase 4United States
684NCT01528592June 201111 June 2018PharmacoMRI of Parkinson DiseaseA Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's DiseaseParkinson's DiseaseDrug: Carbidopa-LevodopaNorthwestern UniversityNot recruiting30 YearsN/AAll18N/AUnited States
685NCT01652534June 201116 December 2017Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's DiseaseEfficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Amantadine;Drug: PlaceboNorthwestern UniversityNot recruiting18 Years85 YearsAll1Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
686NCT02253563June 201123 May 2016Resistance Versus Balance Training in Parkinson's DiseaseResistance Training Versus Balance Training to Improve Postural Control in Patients With Parkinson's Disease - a Randomized Controlled Rater Blinded TrialParkinson's DiseaseBehavioral: Resistance Training;Behavioral: Balance TrainingUniversity of KielNot recruiting40 Years100 YearsBoth40N/A
687EUCTR2010-022517-25-DE30/05/20113 December 2012Safety, tolerability and efficacy of ADX48621 in patients with Parkinson's diseasePhase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's diseaseLevodopa induced dyskinesia in Parkinson's disease patients
MedDRA version: 13.1 Level: PT Classification code 10013916 Term: Dyskinesia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: ADX48621
Product Code: ADX48621
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Dipraglurant
CAS Number: 872363-17-2
Current Sponsor code: ADX48621
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Addex Pharma SAAuthorisedFemale: yes
Male: yes		90Phase 2United States;France;Austria;Germany
688EUCTR2010-022200-46-FI13/05/201125 September 2012Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson’s disease and end-of-dose motor fluctuations. - PARPOCParkinson's disease
MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: ODM-101
Product Code: 75
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 65-
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: ODM-101
Product Code: 100
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 65-
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: ODM-101
Product Code: 125
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: na
Other descriptive name: na
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 65-		Orion CorporationNot RecruitingFemale: yes
Male: yes		100Finland;Germany;Latvia;Lithuania
689EUCTR2007-002964-90-BE05/05/201121 August 2017A trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in patients with Parkinson’s Disease with motor fluctuations, treated with levodopa and who may be receiving a dopamine agonist, an anticholinergic and/or amantadine.A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. - Safinamide in IPD with motor fluctuations, as add-on to levodopaIdiopathic Parkinson's Disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Newron Pharmaceuticals SpANot RecruitingFemale: yes
Male: yes		605Phase 3United States;Estonia;Taiwan;Slovakia;Finland;Spain;Thailand;Austria;Israel;United Kingdom;Switzerland;India;France;Czech Republic;Hungary;Canada;Belgium;Malaysia;Australia;Germany;Netherlands;New Zealand;Korea, Republic of
690NCT01119131May 201119 October 2017Effects of Vitamin D in Parkinson's Disease (PD)The Effects of Vitamin D on Balance in Persons With PDParkinson Disease;Accidental FallsDrug: Vitamin D3;Dietary Supplement: calcium;Other: PlaceboVA Office of Research and DevelopmentOregon Health and Science UniversityNot recruiting50 Years99 YearsAll101Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
691NCT01361009May 201119 October 2017a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease PatientsSafety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing SurveillanceParkinson DiseaseDrug: pramipexoleBoehringer IngelheimNot recruiting30 Years75 YearsAll2017N/AChina
692NCT01364545May 201119 February 2015Ketogenic Diets for Symptoms of Parkinson's DiseaseKetogenic Diets for Symptoms of Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Ketone ester drink;Dietary Supplement: Placebo (carbohydrate containing) drinkUniversity of OxfordRecruiting42 YearsN/ABoth20N/AUnited Kingdom
693NCT01462708May 201119 February 2015Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy SubjectsEvaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy ControlsParkinson DiseaseDrug: [18F]MK-9470Institute for Neurodegenerative DisordersNot recruiting18 Years90 YearsBoth16Phase 1United States
694NCT01504178May 201116 December 2017Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's DiseaseEvaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's DiseaseParkinson's DiseaseDrug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of placebo of apomorphine;Drug: L-Dopa;Drug: injection of placebo of L-DopaUniversity Hospital, ToulouseFrench Parkinson AssociationNot recruiting30 Years70 YearsAll28Phase 3France
695NCT01520987May 201119 October 2017Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsRandomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsParkinson DiseaseDrug: BIA 9-1067;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years65 YearsAll105Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
696NCT01766258May 201119 February 2015Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsEfficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsParkinson's DiseaseDrug: ODM-101 65mg Carbidopa;Drug: ODM-101 105mg Carbidopa;Drug: StalevoOrion Corporation, Orion PharmaNot recruiting30 YearsN/ABoth117Phase 2
697NCT01856439May 201126 August 2019Long Term Safety and Efficacy Study of ProSavin in Parkinson's DiseaseA Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.Parkinson's DiseaseDrug: ProSavinAxovant Sciences Ltd.Oxford BioMedicaNot recruitingN/AN/AAll15Phase 1/Phase 2France;United Kingdom
698JPRN-UMIN0000054032011/04/012 April 2019A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson DiseaseParkinson disease5mg of donepezil hydrochloride
placebo		Designated Research, National Hospital OrganizationNot Recruiting20years-old80years-oldMale and Female142Phase 3Japan
699NCT01313819April 201119 February 2015The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic TherapyA Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic TherapyParkinson`s Disease;Freezing of GaitDrug: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml injSeoul National University HospitalRecruiting30 Years80 YearsBoth20Phase 4Korea, Republic of
700NCT01336088April 201119 February 2015ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's DiseasePhase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ADX48621;Drug: PlaceboAddex Pharma S.A.Not recruiting30 Years75 YearsBoth83Phase 2United States;Austria;France;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
701NCT01338896April 201119 February 2015Study to Compare Adhesiveness of Two Different Rotigotine Patch FormulationsA Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: Rotigotine transdermal patchUCB PharmaNot recruiting18 YearsN/ABoth56Phase 1Austria;Germany;United Kingdom
702NCT01662414April 201119 February 2015Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's DiseaseEffect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain FunctionParkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Central Nervous System Diseases;Nervous System Diseases;Movement Disorders;Neurodegenerative DiseasesDietary Supplement: Whey protein;Dietary Supplement: Soy proteinChulalongkorn UniversityNot recruiting30 Years80 YearsBoth38Phase 4Thailand
703NCT01937078April 201119 February 2015Famotidine for Levodopa-induced Dyskinesia in PDAn 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's DiseaseDyskinesiaDrug: FamotidineUniversity Health Network, TorontoNot recruiting18 Years80 YearsBoth7Phase 2Canada
704EUCTR2010-021394-37-DE08/03/201116 September 2013Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptomsMULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE - SP0976Parkinson's disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neupro 2mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 4mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 6mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 8mg/24h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use		UCB Pharma SANot RecruitingFemale: yes
Male: yes		345Phase 4Czech Republic;Hungary;Spain;Belgium;Austria;Bulgaria;Germany;Italy;Switzerland
705NCT01227655March 201119 October 2017Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.Parkinson's DiseaseDrug: BIA 9-1067;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa;Drug: BenserazideBial - Portela C S.A.Not recruiting30 Years83 YearsAll427Phase 3Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
706NCT01264861March 201116 December 2017A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingOpen-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease PatientsParkinson DiseaseDrug: SafinamideNewronNot recruiting40 Years80 YearsAll5Phase 2United States
707NCT01280123March 201119 October 2017Pioglitazone in Early Parkinson's DiseaseA Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's DiseaseParkinson's DiseaseDrug: Pioglitazone;Drug: placeboUniversity of RochesterNational Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's ResearchNot recruiting30 YearsN/AAll210Phase 2United States
708NCT01283594March 201128 January 2019Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffA Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing OffParkinson's DiseaseDrug: Tozadenant (SYN115) 60 mg BID;Drug: Placebo;Drug: Levodopa (L-dopa);Drug: Tozadenant (SYN115) 120 mg BID;Drug: Tozadenant (SYN115) 180 mg BID;Drug: Tozadenant (SYN115) 240 mg BIDBiotie Therapies Inc.Not recruiting30 Years80 YearsAll420Phase 2/Phase 3United States;Argentina;Canada;Chile;Romania;Ukraine
709NCT01323855March 201119 October 2017A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal ImpairmentParkinson DiseaseDrug: PreladenantMerck Sharp & Dohme Corp.Not recruiting18 Years75 YearsAll46Phase 1Germany
710NCT01330290March 201119 October 2017Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver SupportA Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver SupportIdiopathic Parkinson's DiseaseDrug: Neupro®UCB PharmaNot recruiting18 YearsN/AAll148N/AGermany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
711NCT01341431March 201119 February 2015Bee Venom for the Treatment of Parkinson DiseaseEvaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson DiseaseParkinson DiseaseDrug: bee venomAssistance Publique - Hôpitaux de ParisNot recruiting40 YearsN/ABoth50Phase 2France
712EUCTR2010-022363-35-DE18/02/201119 March 2012Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.Parkinson's disease
MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: Madopar LT
Product Name: Levodopa / Benserazid
Product Code: LD / BE
Pharmaceutical Form: Dispersible tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: LD
Other descriptive name: -
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: BENSERAZIDE HYDROCHLORIDE
CAS Number: 14919-77-8
Current Sponsor code: BE
Other descriptive name: -
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 28.5-
Trade Name: Neupro
Product Name: Rotigotin
Product Code: RO
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Current Sponsor code: RO
Other descriptive name: -
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Pharmaceutical form of the placebo: Medicated plaster
Route of administration of the placebo: Cutaneous use		Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-UniversityAuthorisedFemale: yes
Male: yes		Germany
713NCT01294800February 201119 October 2017A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402)Parkinson's DiseaseDrug: Preladenant;Drug: Placebo tablet to match PreladenantMerck Sharp & Dohme Corp.Not recruiting30 Years85 YearsAll450Phase 2Japan
714NCT01296464February 201119 February 2015Comparing Different Levodopa/Carbidopa/Entacapone Treatment RegimensDuration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off SymptomsParkinson's DiseaseDrug: CarbidopaOrion Corporation, Orion PharmaNot recruiting30 YearsN/ABoth27Phase 2Finland;Sweden
715NCT01313845February 201119 February 2015Effect of Intravenous Amantadine on Gait Freezing in Parkinson's DiseaseRandomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: amantadine sulfate;Drug: 0.9% sodium chlorideJee-Young LeeSeoul National University Boramae Hospital;Samsung Medical Center;Seoul National University Bundang Hospital;Hanyang UniversityNot recruiting30 Years79 YearsBoth46Phase 4Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
716NCT02880033February 201115 July 2019Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesModulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral SclerosisParkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron OverloadDrug: deferiprone;Drug: placeboUniversity Hospital, LilleNot recruiting18 Years80 YearsAll90N/AFrance
717EUCTR2010-022915-21-FI10/01/201119 March 2012Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTESTDuration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTESTParkinson's disease
MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: carbidopa 20 mg
Product Code: NA
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: carbidopa 27.5 mg
Product Code: NA
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 27.5-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Stalevo 100/25/200 mg
Product Name: NA
Product Code: NA
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Stalevo 150/37.5/200 mg
Product Name: NA
Product Code: NA
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 37.5-
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Current Sponsor code: NA		Orion CorporationNot RecruitingFemale: yes
Male: yes		27Finland;Sweden
718NCT01229332January 201119 February 2015A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease PatientsA Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseDrug: Saline;Drug: CarbidopaNeuroDerm Ltd.Not recruiting30 YearsN/ABoth24Phase 1/Phase 2Israel
719NCT01268891January 201119 October 2017Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in KoreaRandomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in KoreaParkinson's DiseaseDrug: Placebo;Drug: Azilect®H. Lundbeck A/SNot recruiting30 YearsN/AAll132Phase 3Korea, Republic of
720NCT01301573January 201119 February 2015Long Term Follow-Up Study for rAAV-GAD Treated SubjectsParkinson's DiseaseBiological: rAAV-GADNeurologix, Inc.Not recruiting30 Years90 YearsBoth40N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
721NCT01340885January 201119 February 2015Cognitive Decline in Non-demented PDCognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot StudyParkinson's DiseaseDrug: Strattera;Drug: Exelon;Other: PlaceboOregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting18 YearsN/ABoth50Phase 4United States
722NCT01489982January 201128 April 2015Treatments for Insomnia in Patients With Parkinson's DiseaseTreatments for Insomnia in Patients With Parkinson's Disease: A Pilot StudyParkinson's Disease;InsomniaDevice: Light box (Litebook company);Behavioral: CBT and sleep hygiene;Drug: Doxepin and Zopiclone;Device: Light box ( Litebook company)McGill University Health CenterNot recruiting18 YearsN/ABoth20Phase 0Canada
723NCT01003002December 201018 April 2016Natural History of Levodopa-Induced Dyskinesia (LID)Determining the Natural History of Levodopa-Induced Dyskinesia (LID)Parkinson's DiseaseDrug: Levodopa (delivered intravenously)Oregon Health and Science UniversityOregon Clinical and Translational Research InstituteNot recruiting21 Years100 YearsBoth0N/AUnited States
724NCT01244269December 201019 February 2015The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease.Parkinson's DiseaseDrug: Methylphenidate;Drug: Placebo 10;Drug: Placebo 20Laval UniversityFonds de la Recherche en Santé du Québec;Quebec Memory and Motor Skills Disorders Research CenterNot recruitingN/A75 YearsBoth6Phase 4Canada
725NCT01256905December 201019 February 2015Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy BodiesAttention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy BodiesParkinsons Disease;Lewy Bodies DiseaseDrug: ArmodafinilNew York UniversityCephalonRecruiting50 Years80 YearsBoth20N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
726EUCTR2010-020109-34-ES29/11/201019 March 2012Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo. A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo. A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.Cognition in non-demented patients with idiopathic Parkinson's disease Cognición en sujetos no dementes con Enfermedad de Parkinson idiopática
MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Safinamida
Product Code: NW-1015
Pharmaceutical Form: Film-coated tablet
CAS Number: 133865-89-1
Current Sponsor code: NW-1015
Other descriptive name: Safinamida
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Merck Serono S.A. - GenevaAuthorisedFemale: yes
Male: yes		100Phase 2Spain;Italy
727EUCTR2010-021860-13-HU11/11/201019 January 2015EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY IEFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY - BIPARK STUDY IAdjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: BIA 9-1067
Product Code: BIA 9-1067
Pharmaceutical Form: Capsule*
INN or Proposed INN: BIA 9-1067
CAS Number: 923287-50-7
Current Sponsor code: BIA 9-1067
Other descriptive name: BIA 9-1067
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Comtan®
Product Name: Over-encapsulated Entacapone Tablets
Product Code: Over-encapsulated Entacapone Tablets
Pharmaceutical Form: Capsule*
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: BIA 9-1067
Product Code: BIA 9-1067
Pharmaceutical Form: Capsule*
INN or Proposed INN: BIA 9-1067
CAS Number: 923287-50-7
Current Sponsor code: BIA 9-1067
Other descriptive name: BIA 9-1067
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: BIA 9-1067
Product Code: BIA 9-1067
Pharmaceutical Form: Capsule*
INN or Proposed INN: BIA 9-1067
CAS Number: 923287-50-7
Current Sponsor code: BIA 9-1067
Other descriptive name: BIA 9-1067
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		BIAL - Portela & Ca, S.A.Not RecruitingFemale: yes
Male: yes		550Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy
728NCT01060878November 201019 February 2015Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 WeeksParkinson's DiseaseDrug: PYM50028;Drug: PlaceboPhytopharmNot recruiting35 Years75 YearsBoth425Phase 2United States;Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom
729NCT01190553November 201019 February 2015Pilot Study of Maintenance Therapy With Intravenous AMANTADINEMaintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson MedicationsParkinson DiseaseDrug: AmantadineRabin Medical CenterNot recruiting30 Years80 YearsBoth20N/A
730NCT01215227November 201019 October 2017An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)Parkinson Disease;Idiopathic Parkinson DiseaseDrug: Preladenant;Drug: Rasagiline;Drug: Placebo to preladenant;Drug: Placebo to rasagilineMerck Sharp & Dohme Corp.Not recruiting30 Years85 YearsAll839Phase 3Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
731NCT01227265November 201019 October 2017Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease.Parkinson Disease;Idiopathic Parkinson Disease;Idiopathic Parkinson's DiseaseDrug: Preladenant;Drug: PlaceboMerck Sharp & Dohme Corp.Not recruiting30 Years85 YearsAll476Phase 3Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
732NCT01270711November 201019 October 2017Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)Parkinson's Disease;HyperprolactinemiaDrug: Study DrugPfizerNot recruitingN/AN/AAll22014N/A
733NCT01341080November 201016 December 2017Varenicline for Gait and Balance Impairment in Parkinson DiseaseVarenicline for the Treatment of Postural and Gait Dysfunction in Parkinson DiseaseParkinson DiseaseDrug: Varenicline;Drug: Sugar pillRush University Medical CenterRecruiting40 Years90 YearsAll40Phase 2United States
734EUCTR2010-018534-44-GB22/10/201018 September 2012Investigation of Cogane (PYM50028) in early stage Parkinson's diseaseA Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks - CONFIDENT-PDEarly-Stage Parkinson’s Disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: PYM50028
Product Code: PYM50028
Pharmaceutical Form: Oral solution
INN or Proposed INN: SMILAGENIN
CAS Number: 126-18-1
Current Sponsor code: PYM50028
Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 3-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
Product Name: PYM50028
Product Code: PYM50028
Pharmaceutical Form: Oral solution
INN or Proposed INN: SMILAGENIN
CAS Number: 126-18-1
Current Sponsor code: PYM50028
Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 6-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
Product Name: PYM50028
Product Code: PYM50028
Pharmaceutical Form: Oral solution
INN or Proposed INN: SMILAGENIN
CAS Number: 126-18-1
Current Sponsor code: PYM50028
Other descriptive name: (3ß, 5ß, 25R)-spirostan-3-ol
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 9-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use		Phytopharm plcAuthorisedFemale: yes
Male: yes		408Phase 2Poland;United States;Romania;France;Serbia;Canada;United Kingdom;Czech Republic;Germany;Hungary
735EUCTR2009-015928-28-SE07/10/201022 October 2012A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09Dyskinesias related to levodopa treatment in Parkinson´s diseaseProduct Name: Eltoprazine HCl
Product Code: Eltoprazine HCl
Pharmaceutical Form: Capsule, hard
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		PsychoGenics IncNot RecruitingFemale: yes
Male: yes		24Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
736NCT01192529October 201019 February 2015Evaluation of a Diet in Patients With Senile DementiaClinical Evaluation of an Specific Diet for People With Dementia DiseaseAlzheimer's Disease;Parkinson's Disease;Senile DementiaDietary Supplement: Supressi. T-Diet plus Range;Dietary Supplement: High Protein. T-Diet plus RangeVegenat, S.A.Recruiting70 YearsN/ABoth184N/ASpain
737NCT01216904October 201019 February 2015Nicotine Treatment of Impulsivity in Parkinson's DiseaseNicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot StudyParkinson's DiseaseDrug: nicotine patch;Drug: placeboUniversity of VermontParkinson's Disease Foundation;The Parkinson Study GroupRecruiting18 YearsN/ABoth20Phase 4United States
738EUCTR2009-017238-39-FR15/09/20103 April 2012A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s DiseaseA Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s DiseaseIdiopathic Parkinson’s Disease (paralysis agitans)
MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: IPX066
Product Code: IPX066-95
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 23.75-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 95-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-145
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 36.25-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 145-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-195
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 48.75-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 195-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-245
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 61.25-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 245-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Nacom 100
Pharmaceutical Form: Tablet
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)		Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)AuthorisedFemale: yes
Male: yes		56Germany;France;Italy
739NCT01162226September 201019 February 2015Computer-Based Balance Training for People With Parkinson's DiseasePD Wii: Computer-based Gait and Balance Training for Parkinson's Patients.Parkinson's DiseaseBehavioral: gait and balance training programUniversity of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth62Phase 2United States
740NCT01211587September 201019 February 2015A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseA Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive ImpairmentParkinson's Disease With Cognitive ImpairmentsDrug: safinamide;Drug: placeboNewronNot recruiting45 Years80 YearsBoth103Phase 2United States;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
741NCT01536574September 201016 December 2017Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528Parkinson DiseaseDrug: Requip PRGlaxoSmithKlineNot recruiting30 YearsN/AAll295Phase 3China
742EUCTR2009-017253-35-GB20/08/201010 July 2015Long-term study of patients who received ProSavin in the PS1/001/07 clinical trial.A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s diseasePatients with bilateral, idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: ProSavin
Pharmaceutical Form: Suspension for injection
INN or Proposed INN: ProSavin		Oxford BioMedica (UK) LtdAuthorisedFemale: yes
Male: yes		27United Kingdom
743EUCTR2009-015161-31-FI17/08/201013 May 2013A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P04938)Parkinson's disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Preladenant
Product Code: SCH 420814
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Preladenant
CAS Number: 377727-87-2
Current Sponsor code: SCH 420814
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 2-10
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Trade Name: Azilect
Product Name: Azilect
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESYLATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Azilect
Product Name: Azilect
Product Code: N04BD02
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESYLATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Schering-Plough Research Institute, a division of Schering CorporationNot RecruitingFemale: yes
Male: yes		750Phase 3United States;Portugal;Finland;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;India;France;Czech Republic;Canada;Poland;Brazil;Peru;Bulgaria;Germany;Netherlands;Sweden
744EUCTR2010-020769-25-FR10/08/201019 March 2012Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médicalEvaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médicalParkinson's disease
MedDRA version: 12.1 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated		Trade Name: DUODOPA
Pharmaceutical Form: Gel
Pharmaceutical Form:
INN or Proposed INN: LEVODOPA/CARBIDOPA
CAS Number: 59-92-7
Pharmaceutical Form:
INN or Proposed INN: LEVODOPA/BENZERASIDE
CAS Number: 59-92-7
Pharmaceutical Form:
INN or Proposed INN: PERGOLIDE
CAS Number: 66104221
Pharmaceutical Form:
INN or Proposed INN: LISURIDE
CAS Number: 18016803
Pharmaceutical Form:
INN or Proposed INN: BROMOCRIPTINE
CAS Number: 25614033
Pharmaceutical Form:
INN or Proposed INN: ROPINIROLE
CAS Number: 91374219
Pharmaceutical Form:
INN or Proposed INN: PRAMIPEXOLE
CAS Number: 104632-26-0
Pharmaceutical Form:
INN or Proposed INN: IPRONIAZID
CAS Number: 54922
Pharmaceutical Form:
CAS Number: 71320-77-9
Other descriptive name: MOCLOBEMIDE
Pharmaceutical Form:
INN or Proposed INN: AMANTADINE
CAS Number: 768945
Pharmaceutical Form:
INN or Proposed INN: CLOZAPINE
CAS Number: 5786-21-0
Pharmaceutical Form:
INN or Proposed INN: SELEGILINE
CAS Number: 14611519
Pharmaceutical Form:
INN or Proposed INN: RASAGILINE
CAS Number: 136236-51-6
Pharmaceutical Form:
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Pharmaceutical Form:
INN or Proposed INN: TOLCAPONE
CAS Number: 134308-13-7		CHU de PoitiersAuthorisedFemale: yes
Male: yes		France
745NCT01190735August 201028 April 2015Caffeine for Motor Manifestations of Parkinson's DiseaseCaffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.Parkinson's DiseaseDrug: Caffeine alkaloidRon PostumaCanadian Institutes of Health Research (CIHR)Not recruiting18 YearsN/ABoth28Phase 2Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
746NCT01191944August 201019 October 2017Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) PatientsA Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With LevodopaParkinson DiseaseDrug: pramipexole immediate release tablet;Drug: pramipexole extended release tabletBoehringer IngelheimNot recruiting30 YearsN/AAll475Phase 3China
747NCT01228851August 201019 February 2015Balance Training in Parkinson's Disease Using the Wii Balance BoardA Pilot Study of the Effects of Balance Training Using the Wii Balance Board on Balance and Ambulation in Adults With Parkinson's DiseaseParkinson's DiseaseOther: Balance TrainingRehabilitation Institute of ChicagoNot recruiting18 YearsN/ABoth10N/AUnited States
748NCT01785628August 201019 October 2017The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's DiseaseParkinson's Disease With DementiaDietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo CapsuleChina Medical University HospitalNational Science Council, TaiwanNot recruitingN/AN/AAll30N/ATaiwan
749NCT01824056August 201019 February 2015The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission TomographyThe Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)Parkinson's DiseaseDrug: 18F-FDGChang Gung Memorial HospitalNational Science Council, TaiwanNot recruiting20 Years80 YearsBoth120Phase 2Taiwan
750NCT01155466July 14, 201016 December 2017A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)Parkinson DiseaseDrug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Placebo to Preladenant Tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo to Rasagiline capsuleMerck Sharp & Dohme Corp.Not recruiting30 Years85 YearsAll778Phase 3Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
751EUCTR2010-018650-12-FR13/07/20103 October 2016Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOXEvaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOXmaladie de Parkinson
MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: CYMBALTA
Product Name: duloxetine
Pharmaceutical Form: Capsule*
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: APOKINON
Product Name: apomorphine
Pharmaceutical Form: Solution for injection
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Trade Name: MODOPAR
Product Name: levodopa
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: MOTILIUM
Product Name: dompéridone
Pharmaceutical Form: Tablet		CHU de ToulouseNot RecruitingFemale: yes
Male: yes		Phase 3France
752EUCTR2009-017182-38-LT10/07/201019 March 2012An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s DiseaseAn Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s DiseaseIdiopathic Parkinson´s disease (paralysis agitans)
MedDRA version: 12.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: IPX066
Product Code: IPX066-95
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 23.75-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 95-
Product Name: IPX066
Product Code: IPX066-145
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 36.25-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 145-
Product Name: IPX066
Product Code: IPX066-195
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 48.75-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 195-
Product Name: IPX066
Product Code: IPX066-245
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 61.25-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 245-		Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)Not RecruitingFemale: yes
Male: yes		500Germany;Estonia;Spain;Latvia;Poland;Lithuania
753NCT01155479July 6, 201016 December 2017A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's DiseaseParkinson DiseaseDrug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo for Rasagiline 1 mg capsule;Drug: Placebo for PreladenantMerck Sharp & Dohme Corp.Not recruiting30 Years85 YearsAll1022Phase 3Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
754NCT01149811July 201019 February 2015A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's DiseaseA Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving LevodopaParkinson's DiseaseDrug: Fipamezole ODT;Drug: Fipamezole ODT Cohort 2Valeant Pharmaceuticals International, Inc.Not recruiting30 Years75 YearsBoth27Phase 1/Phase 2United States
755NCT01171313July 201019 February 2015A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease SubjectsA Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor FluctuationsParkinson's DiseaseDrug: XP21279 and carbidopa (experimental);Drug: Sinemet (comparator);Drug: Placebo for XP21279 and carbidopa;Drug: Placebo for SinemetXenoPort, Inc.Not recruiting30 Years80 YearsBoth35Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
756NCT01174004July 201019 October 2017A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisA Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's DiseaseParkinson's Disease PsychosisDrug: pimavanserin tartrate;Drug: placeboACADIA Pharmaceuticals Inc.Not recruiting40 YearsN/AAll199Phase 3United States;Canada
757NCT01435915June 28, 20102 July 2018Ropinirole PR Pharmacokinetics Study Among Chinese Healthy SubjectsA Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female SubjectsParkinson DiseaseDrug: RopiniroleGlaxoSmithKlineNot recruiting18 Years45 YearsAll24Phase 1China
758NCT01140841June 201019 February 2015A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving LevodopaA Randomized, Double-Blind, Placebo-Controlled, Ascending Dose-Escalation Study of Safety and Tolerability of Oromucosal Fipamezole ODT in Adult Subjects With Parkinson's Disease Who Are Receiving LevodopaParkinson's DiseaseDrug: Fipamezole ODT;Drug: PlaceboValeant Pharmaceuticals International, Inc.Not recruiting30 Years75 YearsBoth40Phase 1United States
759NCT01141023June 201026 August 2019Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease ProgressionThe Parkinson's Progression Markers Initiative (PPMI)Parkinson DiseaseDrug: DaTscanKen Marek, MDInstitute for Neurodegenerative DisordersRecruiting30 YearsN/AAll680Phase 2United States;Australia;Austria;France;Germany;Greece;Israel;Italy;Norway;Spain;United Kingdom
760NCT01176240June 201019 October 2017A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseaseA Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's DiseaseOrthostatic Hypotension;Parkinson's DiseaseDrug: Droxidopa;Other: PlaceboChelsea TherapeuticsNot recruiting18 YearsN/AAll225Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
761NCT01227681June 201019 October 2017Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's DiseaseA Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's DiseaseParkinson DiseaseDrug: G-CSF;Drug: PlaceboBuddhist Tzu Chi General HospitalNot recruiting40 Years65 YearsAll4Phase 2Taiwan
762EUCTR2010-018904-94-IT31/05/201027 January 2014EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASEEFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASEOsteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria
MedDRA version: 14.1 Level: SOC Classification code 10028395 Term: Musculoskeletal and connective tissue disorders System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Trade Name: NERIXIA*IM EV 1F 25MG
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Bisphosphonates
Other descriptive name: Neridronic acid
Concentration unit: mg milligram(s)
Concentration number: 25-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intramuscular use		FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONEAuthorisedFemale: yes
Male: yes		Italy
763EUCTR2010-019354-40-AT26/05/201019 March 2012Überprüfung des Einflusses der STN-Stimulation auf die Schmerzschwelle von Patienten mit Idiopathischem ParkinsonsyndromÜberprüfung des Einflusses der STN-Stimulation auf die Schmerzschwelle von Patienten mit Idiopathischem ParkinsonsyndromParkinson's disease
MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: Madopar
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: Ci/mg curie(s)/milligram
Concentration type: range
Concentration number: 50-200
INN or Proposed INN: BENSERAZIDE
CAS Number: 322350
Concentration unit: Ci/mg curie(s)/milligram
Concentration type: range
Concentration number: 12,5-50		Universitätsklinik für Neurologie InnsbruckNot RecruitingFemale: yes
Male: yes		15Austria
764EUCTR2010-019396-29-IT18/05/201027 January 2014Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease.Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PDPatients with idiopathic Parkinson's Disease.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 125-
Trade Name: COMTAN
Pharmaceutical Form: Tablet
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration number: 200-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 125-
Trade Name: STALEVO*100CPR 50/12,5/200MG
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor
Concentration unit: mg milligram(s)
Concentration number: 262.5-
Trade Name: STALEVO*100CPR 100/25/200MG
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor
Concentration unit: mg milligram(s)
Concentration number: 325-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 275-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 275-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 275-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 275-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 125-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 125-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration number: 125-
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa and decarboxylase inhibitor		AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELEAuthorisedFemale: yes
Male: yes		Italy
765JPRN-UMIN0000036012010/05/012 April 2019Comparative study of ropinirole and entacapone for the treatment of wearing-off in advanced Parkinson's disease patientsParkinson's diseaseIncrease dosage of ropinirole
Addition of entacapone		Kansai Medical UniversityNot Recruiting20years-old75years-oldMale and Female30Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
766NCT01130493May 20104 November 2019A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's DiseaseParkinson's DiseaseDrug: IPX066;Drug: CLEImpax Laboratories, LLCNot recruiting30 YearsN/AAll110Phase 3United States;France;Germany;Italy
767NCT01283347May 201019 February 201518F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingPhase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNot recruiting50 Years80 YearsBoth100Phase 2Taiwan
768NCT01532115May 201019 February 2015Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenA Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenParkinson DiseaseDrug: BIA 9-1067;Drug: Placebo;Drug: moxifloxacinBial - Portela C S.A.Not recruiting18 Years55 YearsBoth64Phase 1France
769EUCTR2009-018137-37-GB14/04/201020 March 2012An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trialAn open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trialParkinson's disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders		Trade Name: Byetta 5 micrograms
Product Name: Exenatide 5 micrograms
Pharmaceutical Form: Solution for injection
Trade Name: Exenatide 10 micrograms
Product Name: Exenatide 10 micrograms
Pharmaceutical Form: Solution for injection		University College LondonAuthorisedFemale: yes
Male: yes		Phase 2United Kingdom
770JPRN-JapicCTI-10119801/4/20102 April 2019A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)Parkinson's diseaseIntervention name : Zonisamide
Dosage And administration of the intervention : Oral
Control intervention name : null		Dainippon Sumitomo Pharma Co., Ltd.2074BOTH360Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
771NCT00988117April 201019 October 2017The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking ProblemsThe Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking ProblemsDrug: Rivastigmine Patch 9.5 cm2University of California, San FranciscoNovartisNot recruiting55 YearsN/AAll15Phase 4United States
772NCT01103011April 201019 February 2015Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611Parkinson's DiseaseDrug: ND0611NeuroDerm Ltd.Not recruiting18 Years50 YearsMale8Phase 1Israel
773NCT01113320April 201019 February 2015Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsA Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced DyskinesiasParkinson's DiseaseDrug: Placebo;Drug: SafinamideNewronNot recruiting30 YearsN/ABoth26Phase 2Austria;Canada;France;Germany;South Africa
774NCT01484990April 201016 December 2017A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's DiseaseA Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's DiseaseParkinson DiseaseDrug: Levodopa-CarbidopaAbbVieQuintiles, Inc.Not recruiting30 Years99 YearsAll19Phase 1Germany;Sweden
775EUCTR2009-017174-20-DE15/03/20104 March 2013A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease.A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias. - LID studyIdiopathic Parkinson's disease
MedDRA version: 14.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Safinamide
Product Code: NW-1015E, EMD 1195686, MSC2191632B
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015E, EMD 1195686, MSC2191632B
Other descriptive name: (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Merck Serono S.A. - GenevaNot RecruitingFemale: yes
Male: yes		24France;Canada;Austria;South Africa;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
776EUCTR2009-013886-24-DE03/03/201031 March 2014A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease - HARPS-2Excessive daytime sleepiness in Parkinson’s Disease
MedDRA version: 12.0 Level: LLT Classification code 10015595 Term: Excessive daytime sleepiness
MedDRA version: 12.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism		Product Name: Pitolisant
Product Code: BF2.649
Pharmaceutical Form: Capsule*
INN or Proposed INN: Pitolisant
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: Pitolisant
Product Code: BF2.649
Pharmaceutical Form: Capsule*
INN or Proposed INN: Pitolisant
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: Pitolisant
Product Code: BF2.649
Pharmaceutical Form: Capsule*
INN or Proposed INN: Pitolisant
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 05-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		BIOPROJETNot RecruitingFemale: yes
Male: yes		246Czech Republic;Germany;Sweden
777NCT01092065March 201019 February 2015Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaA 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced DyskinesiaParkinson's DiseaseDrug: AFQ056 with L-dopa;Drug: PlaceboNovartisNot recruiting30 Years80 YearsBoth23Phase 2United States
778NCT01096186March 201016 December 2017An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseAn Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: IPX066 95 mg;Drug: IPX066 145 mg;Drug: IPX066 195 mg;Drug: IPX066 245 mgIMPAX Laboratories, Inc.Not recruiting30 YearsN/AAll617Phase 3United States;Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine
779NCT01097421March 201019 October 2017Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s DiseaseInfluence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's DiseaseParkinson DiseaseDrug: Pramipexole Extended ReleaseBoehringer IngelheimNot recruiting30 YearsN/AAll329N/ASweden
780NCT01503944March 201019 February 2015A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly VolunteersDementia With Lewy Bodies;Alzheimer's Disease;Parkinson's DiseaseDrug: 18F-AV-45;Drug: 18F-AV-133Avid RadiopharmaceuticalsNot recruiting50 YearsN/ABoth30Phase 1/Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
781NCT02101190March 201019 October 2017Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentOpen-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentParkinson's DiseaseDrug: BIA 9-1067Bial - Portela C S.A.Not recruiting18 Years65 YearsAll16Phase 1France;Russian Federation
782EUCTR2009-016360-37-SE06/02/201019 March 2012TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDYTREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDYParkinsons disease is complicated by dyskinesias and dystonia. Due stabilizing properties, we believe (-)-OSU6162 may alleviate dyskinesias, without causing parkinsonism. Aim: To evaluate in a double-blind cross over pilot study whether OSU6162 attenuates dyskinesias without worsening parkinsonism in PD patients with motor complications using clinical examination and patient diaries.Product Name: not available
Product Code: OSU 6162 similar to (-)-OSU 6162
Pharmaceutical Form: Coated tablet
INN or Proposed INN: not available
CAS Number: 146798-66-5
Current Sponsor code: OSU 6162 similar to (-)-OSU 6162
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use		Björn HolmbergAuthorisedFemale: yes
Male: yes		Sweden
783NCT01154166February 201019 October 2017A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-DopaA Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-DopaParkinson DiseaseDrug: ReQuip PR;Drug: PlaceboGlaxoSmithKlineNot recruiting30 YearsN/AAll347Phase 3China
784NCT01568047February 201019 October 2017Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsMulticentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (Wearing-off Phenomenon)Parkinson's DiseaseDrug: Placebo;Drug: BIA 9-1067;Drug: Levodopa/Carbidopa;Drug: Levodopa/BenzerazideBial - Portela C S.A.Not recruiting30 YearsN/AAll40Phase 2Romania;Ukraine
785NCT02169414February 201019 October 2017Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa PharmacokineticsEffect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy SubjectsParkinson's Disease (PD)Drug: BIA 9-1067 5 mg;Drug: BIA 9-1067 25 mg;Drug: levodopa/carbidopa 100/25;Drug: Placebo;Drug: levodopa/benserazide 100/25 mgBial - Portela C S.A.Not recruiting18 Years45 YearsAll74Phase 1France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
786EUCTR2009-017416-33-DE18/01/201024 June 2013Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.Male and female patients with Parkinson´s disease meeting UKPDS criteria
MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's ;Male and female patients with Parkinson´s disease meeting UKPDS criteria
MedDRA version: 12.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: Tasmar
Product Name: Tolcapon
Product Code: TO
Pharmaceutical Form: Coated tablet
INN or Proposed INN: TOLCAPONE
CAS Number: 134308-13-7
Current Sponsor code: TO
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: Comtess
Product Name: Entacapon
Product Code: EN
Pharmaceutical Form: Coated tablet
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Current Sponsor code: EN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Isicom
Product Name: Levodopa/Carbidopa
Product Code: LD/CD
Pharmaceutical Form: Coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: LD
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
CAS Number: 38821-49-7
Current Sponsor code: CD
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 26.99-
Product Name: Tolcapon
Product Code: TO
Pharmaceutical Form: Coated tablet
INN or Proposed INN: TOLCAPONE
CAS Number: 134308-13-7
Current Sponsor code: TO
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Trade Name: Comtess
Product Name: Entacapon
Product Code: EN
Pharmaceutical Form: Coated tablet
INN or Proposed INN: ENTACAPONE
CAS Number: 130929-57-6
Current Sponsor code: EN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Isicom
Product Name: Levodopa/Carbidopa
Product Code: LD/CD
Pharmaceutical Form: Coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: LD
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
CAS Number: 38821-49-7
Current Sponsor code: CD
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 26.99-		Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-UniversityNot RecruitingFemale: yes
Male: yes		Germany
787EUCTR2009-012643-42-NL06/01/201019 March 2012Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's diseaseFreezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option - Freezing of gait in Parkinson's diseaseParkinson's disease, in particular the symptom Freezing of GaitTrade Name: Ritalin
Product Name: Not applicable
Product Code: Not applicable
Pharmaceutical Form: Tablet
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
CAS Number: 298599
Current Sponsor code: RVG 03957
Other descriptive name: Ritalin
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		University Medical Center GroningenAuthorisedFemale: yes
Male: yes		Netherlands
788JPRN-UMIN0000030802010/01/012 April 2019Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's DiseaseParkinson's diseaseDonepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks)
Placebo		Clinical Research Center, Utano National Hospital, National Hospital OrganizationNot Recruiting40years-old75years-oldMale and Female30Not applicableJapan
789JPRN-UMIN0000074972010/01/012 April 2019Trial of molecular hydrogen water in Parkinson diseaseParkinson diseaseThe subjects should make 1000 ml of molecular hydrogen water which contains 1.6 ppm dissolved hydrogen by Aquerable, and consume for 48 weeks.
Placebo water which is not contained molecular hydrogen water made from pseudo-machine. The subjects consume for48 weeks.		Department of Neurology, Juntendo University School of MedicineNot Recruiting20years-oldNot applicableMale and Female18Not applicableJapan
790NCT01007864January 201019 February 2015Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine AgonistsInfluence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine AgonistsIdiopathic Parkinson's DiseaseDrug: piribedil;Drug: pramipexole or ropiniroleDesitin Arzneimittel GmbHFGK Clinical Research GmbHNot recruiting35 Years80 YearsBoth80Phase 3Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
791NCT01018264January 201019 October 2017Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseURGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseOveractive Bladder in Parkinson's DiseaseDrug: solifenacin succinate (VESIcare);Drug: placeboUniversity of South FloridaNot recruiting40 Years80 YearsAll23Phase 4United States
792NCT01058291January 201016 December 2017Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)Parkinson's DiseaseDrug: KW-6500;Drug: KW-6500 PlaceboKyowa Hakko Kirin Co., LtdNot recruiting20 YearsN/AAll31Phase 3Japan
793NCT01063621January 201016 December 2017Extended Long-Term Safety Study of KW-6500Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)Parkinson's DiseaseDrug: KW-6500Kyowa Hakko Kirin Co., LtdNot recruiting20 YearsN/AAll27Phase 3Japan
794NCT01071395January 201019 October 2017Validation of Dyskinesia Rating ScalesValidation of Dyskinesia Rating ScalesParkinson's DiseaseDrug: Amantadine;Drug: PlaceboRush University Medical CenterMichael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years90 YearsAll68Phase 4United States;Austria;Canada;France
795NCT01417598January 201021 September 2015BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical ActivityImproving Balance Function in Elderly by Progressive and Specific Training and Physical Activity- a Randomized Controlled Study.Elderly;Parkinsons Disease;OsteoporosisOther: Gait and balance group training;Other: Nordic walking (only osteoporosis group)Karolinska InstitutetThe Swedish Research CouncilNot recruiting60 YearsN/ABoth200N/ASweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
796EUCTR2009-014688-37-DE15/12/20091 May 2012A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s DiseaseA Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s DiseaseAdvanced Parkinson’s Disease subjects with motor fluctuations
MedDRA version: 12.0 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: IPX066
Product Code: IPX066-95
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 28860-95-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 23.75 -
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 95-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: SINEMET®-Plus Tablets
Product Name: IR CD-LD
Pharmaceutical Form: Tablet
INN or Proposed INN: CARBIDOPA
CAS Number: 28860-95-9
Current Sponsor code: CD
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: LD
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-145
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 28860-95-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 36.25 -
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 145-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-195
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA
CAS Number: 28860-95-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 48.75 -
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 195-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-245
Pharmaceutical Form: Capsule*
INN or Proposed INN: CARBIDOPA		Impax Laboratories, Inc.Not RecruitingFemale: yes
Male: yes		350Germany;France;Spain;Poland
797EUCTR2009-012419-16-DE03/12/200910 February 2014Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PDInfluence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PDidiopathic Parkinson's disease
MedDRA version: 12.0 Level: PT Classification code 10061536 Term: Parkinson's disease		Trade Name: Clarium 50 mg Retardtabletten
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: piribedil
CAS Number: 3605-01-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-		Desitin Arzneimittel GmbHNot RecruitingFemale: yes
Male: yes		Germany
798NCT00660387December 200919 October 2017Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's SubjectsA Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor FluctuationsAdvanced Parkinson's DiseaseDrug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo Gel;Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tubeAbbVie (prior sponsor, Abbott)Quintiles, Inc.Not recruiting30 YearsN/AAll35Phase 3United States;New Zealand
799NCT01032486December 200919 February 2015Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's DiseaseAn Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease SubjectsParkinson's DiseaseDrug: Rasagiline mesylateTeva Pharmaceutical IndustriesNot recruitingN/AN/ABoth120Phase 4Canada
800NCT01036139December 200919 February 2015Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's DiseaseA Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension PhaseParkinson's DiseaseDrug: BF2.649 (pitolisant)BioprojetNot recruiting30 Years80 YearsBoth268Phase 3France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
801NCT01049984December 200919 October 2017Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseA Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's DiseaseParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboTeva Neuroscience, Inc.H. Lundbeck A/SNot recruiting30 YearsN/AAll328Phase 4United States
802NCT01070628December 200919 February 2015Levodopa Concentration Profile With Stalevo 75/125 mgLevodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel GroupsParkinson's DiseaseDrug: Stalevo (levodopa/ carbidopa/ entacapone);Drug: Sinemet (levodopa/carbidopa)Orion Corporation, Orion PharmaNot recruiting18 Years70 YearsBoth20Phase 1Finland
803NCT01168596December 200919 October 2017Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's DiseaseRasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)Parkinson's DiseaseDrug: Rasagiline;Drug: PlaceboUniversity of FloridaNot recruiting40 Years85 YearsAll30Phase 4United States
804NCT00660673November 13, 200918 December 2018Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PDOpen-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous StudiesAdvanced Parkinson's DiseaseDrug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pumpAbbVie (prior sponsor, Abbott)Quintiles, Inc.Not recruiting30 Years99 YearsAll262Phase 3United States;Australia;Canada;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;Czech Republic
805EUCTR2009-013885-14-ES12/11/200919 March 2012A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.Excessive daytime sleepiness in Parkinson?s Disease Somnolencia diurna excesiva en la enfermedad de Parkinson.
MedDRA version: 12.0 Level: LLT Classification code 10015595 Term: Excessive daytime sleepiness
MedDRA version: 12.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism		Product Name: Pitolisant
Product Code: BF2.649
Pharmaceutical Form: Capsule*
INN or Proposed INN: Pitolisant
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 5-20
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		BIOPROJETAuthorisedFemale: yes
Male: yes		246France;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
806EUCTR2009-013004-31-IT02/11/200914 March 2016Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline - Early combined ropinirole and rasagiline therapy in patients with Parkinsons diseaseEarly combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline - Early combined ropinirole and rasagiline therapy in patients with Parkinsons diseasePatients with Parkinson`s diesease
MedDRA version: 12.0 Level: LLT Classification code 10061536 Term: Parkinson's disease		Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Ropinirole
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-		UNIVERSITA` DEGLI STUDI DI PARMANot RecruitingFemale: yes
Male: yes		Italy
807NCT01007630November 200919 February 2015A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's PatientsA Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboThe Parkinson's InstituteTeva Neuroscience, Inc.Not recruitingN/A90 YearsBoth36Phase 4United States
808NCT01023282November 200919 February 2015Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease PatientsRandomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary MeasureParkinson's Disease;TolerabilityDrug: ACR325;Drug: PlaceboNeuroSearch A/SNot recruiting30 Years75 YearsBoth22Phase 1Germany
809NCT01028209November 200915 April 2019Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological ConditionsAlzheimer Disease;Parkinson Disease;Multiple SclerosisDrug: [18F] PBR06Institute for Neurodegenerative DisordersNot recruiting18 YearsN/AAll12Phase 1United States
810NCT01052831November 200919 October 2017Naltrexone for Impulse Control Disorders in Parkinson's DiseaseRandomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's DiseaseImpulse Control Disorder;Parkinson DiseaseDrug: Naltrexone;Drug: PlaceboUniversity of PennsylvaniaMichael J. Fox Foundation for Parkinson's ResearchNot recruiting18 Years85 YearsAll50Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
811NCT01519284November 200919 October 2017Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticA Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy SubjectsParkinson DiseaseDrug: BIA 9-1067 5 mg;Drug: Entacapone;Drug: Placebo;Drug: levodopa/carbidopa;Drug: BIA 9-1067 15 mg;Drug: BIA 9-1067 30 mgBial - Portela C S.A.Not recruiting18 Years45 YearsAll82Phase 1Portugal
812NCT01532128November 200919 October 2017Effect of BIA 9-1067 on Rasagiline PharmacokineticsEffect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy SubjectsParkinson DiseaseDrug: rasagiline;Drug: BIA 9-1067Bial - Portela C S.A.Not recruiting18 Years45 YearsAll24Phase 1France
813NCT01532141November 200919 October 2017Effect of Rasagiline on BIA 9-1067 PharmacokineticsEffect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy SubjectsParkinson DiseaseDrug: BIA 9-1067;Drug: RasagilineBial - Portela C S.A.Not recruiting18 Years45 YearsAll25Phase 1France
814EUCTR2009-011541-24-GB09/10/200919 March 2012A trial to follow-up subjects with Parkinson's disease who participated to the ADAGIO study in order to study the long-term effects of the drug rasagilineAn Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-UpParkinson's Disease
MedDRA version: 13.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: AZILECT
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
CAS Number: 161735-79-1
Current Sponsor code: TVP-1012
Other descriptive name: Rasagiline mesylate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-		Teva Pharmaceutical Industries LtdAuthorisedFemale: yes
Male: yes		700Hungary;Portugal;Germany;Netherlands;France;Italy;Israel;United Kingdom;Canada;Argentina;Romania;Spain;United States
815NCT00957203October 200919 February 2015Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease PatientsLong-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)Parkinson's DiseaseDrug: IstradefyllineKyowa Hakko Kirin Company, LimitedNot recruiting20 YearsN/ABoth308Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
816NCT00957918October 200919 February 2015Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa TherapyRandomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa TherapyParkinson's DiseaseDrug: nicotine;Other: placebo comparatorNeuraltus Pharmaceuticals, Inc.Not recruiting30 Years83 YearsBoth65Phase 1/Phase 2United States
817NCT01016470October 200919 February 2015Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s DiseaseEfficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s DiseaseParkinson`s DiseaseDietary Supplement: VIUSID/ALZER;Dietary Supplement: PlaceboCatalysis SLNot recruiting20 Years90 YearsBoth100Phase 3Cuba
818NCT01028586October 200919 February 2015MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistIdiopathic Parkinson's DiseaseDrug: Safinamide, MAO-B inhibitor;Drug: PlaceboNewronNot recruiting30 Years80 YearsBoth507Phase 3Switzerland
819NCT01631825October 200919 October 2017A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease PatientsAn Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopaParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.Not recruitingN/AN/AAll321Phase 3Japan
820ChiCTR-TRC-120021502009-09-2918 April 2017Study on Optimization of The Comprehensive Therapeutic Plan for Parkinson's Disease in Different StagesStudy on Optimization of The Comprehensive Therapeutic Plan by Stages for Parkinson's DiseaseParkinson's DiseaseThe early treatment group:Xifeng Dingchan Pill;The early control group:Madopar tablets;Interim treatment group:Xifeng Dingchan Pill, Madopar tablets and Piribedil tablets;Henan University of Traditional Chinese MedicineRecruiting5075BothThe early treatment group:80;The early control group:80;Interim treatment group:160;OtherChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
821NCT01371682September 18, 20092 July 2018A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and ArandaAn Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and ArandaParkinson DiseaseDrug: Ropinirole XLGlaxoSmithKlineNot recruiting18 Years50 YearsAll50Phase 1Belgium
822NCT00794313September 200916 December 2017Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's DiseaseQuantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's DiseaseParkinson's DiseaseDrug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar PillOregon Health and Science UniversityNot recruiting21 YearsN/AAll3N/AUnited States
823NCT00907972September 200919 February 2015The Effects of Vitamin D and Bone Loss in Parkinson's DiseaseEffect of Vitamin D3 Supplementation in Parkinson's Disease Patients - A Pilot StudyParkinson DiseaseDietary Supplement: Vitamin D3;Other: PlaceboMemorial Medical CenterDepartment of DefenseNot recruiting18 YearsN/ABoth23Phase 2United States
824NCT00909883September 200919 February 2015Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Parkinson's Disease;Foot DystoniaDrug: Botulinum Toxin: Xeomin;Drug: PlaceboUniversity Hospital, Clermont-FerrandMerz Pharma FranceRecruiting30 Years75 YearsBoth45Phase 3France
825NCT00974974September 200916 December 2017A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's DiseaseParkinson's DiseaseDrug: IPX066;Drug: IR CD-LDIMPAX Laboratories, Inc.Not recruiting30 YearsN/AAll471Phase 3United States;Canada;France;Germany;Poland;Romania;Spain;Ukraine
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
826NCT00985517September 200915 July 2019Safety and Efficacy of CERE-120 in Subjects With Parkinson's DiseaseA Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's DiseaseIdiopathic Parkinson's DiseaseBiological: CERE-120: Adeno-Associated Virus Delivery of Neurturin;Procedure: Sham SurgerySangamo TherapeuticsNot recruiting35 Years70 YearsAll57Phase 1/Phase 2United States
827NCT00986245September 200919 October 2017Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-dailyAn Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson DiseaseParkinson DiseaseDrug: Ropinirole Prolonged releaseSeoul National University HospitalNot recruiting30 Years80 YearsAll82Phase 4Korea, Republic of
828NCT01026428September 200919 February 2015A Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsA Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: Safinamide + Levodopa;Other: Placebo + LevodopaNewronNot recruiting30 YearsN/ABoth24Phase 1/Phase 2Italy
829NCT00970333August 200919 February 2015Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological ConditionsEvaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological ConditionsAlzheimer Disease;Parkinson Disease;Multiple SclerosisDrug: [18F]-FEPPAInstitute for Neurodegenerative DisordersNot recruiting18 YearsN/ABoth3Phase 1United States
830NCT01580787August 200919 February 2015Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual EnvironmentFunctional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual EnvironmentParkinson´s DiseaseDevice: Balance Training with Nintendo Wii Fit;Other: Physical TherapySao Camilo University CenterNot recruiting65 Years85 YearsBoth32N/A
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
831EUCTR2009-011736-35-FR27/07/200919 March 2012Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYSEtude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYSMaladie de Parkinson
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: LODALÈS®
Product Code: simvastatine
Pharmaceutical Form: Capsule*
Current Sponsor code: simvastatine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		CHU de BordeauxAuthorisedFemale: yes
Male: yes		10Phase 2France
832NCT00909545July 200919 October 2017Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson DiseaseA Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson DiseaseParkinson DiseaseDrug: Isradipine CR 5mg;Drug: Isradipine CR 10mg;Drug: Isradipine CR 20mg;Drug: PlaceboNorthwestern UniversityMichael J. Fox Foundation for Parkinson's Research;Northwestern University Dixon Fund;The Parkinson Study GroupNot recruiting30 YearsN/AAll99Phase 2United States;Canada
833NCT00918177July 200919 February 2015An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's DiseaseDual Release Gastric Retentive AP09004, Vs. Active Control; a Pharmacokinetic/Pharmacodynamic, Comparative, Safety Evaluation in Parkinson's PatientsParkinson's DiseaseDrug: AP09004;Drug: Carbidopa/Levodopa, immediate releaseIntec Pharma Ltd.Not recruiting18 YearsN/ABoth72Phase 2Israel
834NCT00955318July 200916 December 2017Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseasePhase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: KW-6500Kyowa Hakko Kirin Co., LtdNot recruiting20 YearsN/AAll58Phase 3Japan
835NCT00955526July 200919 February 2015Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking LevodopaPlacebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)Parkinson's DiseaseDrug: Istradefylline;Drug: PlaceboKyowa Hakko Kirin Company, LimitedNot recruiting20 YearsN/ABoth373Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
836NCT00955604July 200916 December 2017Azilect + Antidepressant Chart ReviewInvestigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart ReviewSerotonin SyndromeDrug: Group R+AD Rasagiline + Antidepressant;Drug: Group R Rasagiline;Drug: Group AD Anti-PD + AntidepressantTeva Pharmaceutical IndustriesNot recruitingN/AN/AAll1500N/AUnited States
837NCT00970229July 200916 December 2017Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy ControlsParkinson Disease;Huntington DiseaseDrug: [123I]MNI-420Institute for Neurodegenerative DisordersNot recruiting18 YearsN/AAll19Phase 1United States
838EUCTR2009-012529-12-FR10/06/200919 March 2012A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIPA randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease - REQUIPparkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: REQUIP-LP
Product Name: ropinirole
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP
Product Name: ropinirole
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		CHU de ToulouseAuthorisedFemale: yes
Male: yes		10France
839EUCTR2009-010193-38-LT02/06/200919 March 2012A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's DiseaseA Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's DiseaseIdiopathic Parkinson's disease (paralysis agitans)
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: IPX066
Product Code: IPX066-95
Pharmaceutical Form: Capsule*
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 95-
INN or Proposed INN: CARBIDOPA
CAS Number: 28860959
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 23.75-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-145
Pharmaceutical Form: Capsule*
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 145-
INN or Proposed INN: CARBIDOPA
CAS Number: 28860959
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 36.25-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-195
Pharmaceutical Form: Capsule*
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 195-
INN or Proposed INN: CARBIDOPA
CAS Number: 28860959
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 48.75-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: IPX066
Product Code: IPX066-245
Pharmaceutical Form: Capsule*
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 245-
INN or Proposed INN: CARBIDOPA
CAS Number: 28860959
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 61.25-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.Not RecruitingFemale: yes
Male: yes		350Estonia;Latvia;Lithuania
840NCT00921128June 2, 200916 December 2017Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s DiseaseConvection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's DiseaseParkinson's DiseaseDrug: MuscimolNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll0Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
841NCT00360568June 200919 October 2017Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's SubjectsOpen-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease SubjectsDyskinesias;Parkinson's Disease;Severe Motor FluctuationsDrug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tubeAbbVie (prior sponsor, Abbott)Quintiles, Inc.Not recruiting30 YearsN/AAll62Phase 3United States;Germany;New Zealand
842NCT00669461June 200919 October 2017Lubiprostone as a Treatment for Constipation in Parkinson's DiseaseLubiprostone as a Treatment for Constipation in Parkinson's DiseaseConstipation;Parkinson's DiseaseDrug: LubiprostoneUniversity of ArkansasTakedaNot recruiting50 Years85 YearsAll1N/AUnited States
843NCT00833690June 200919 October 2017Safety of Urate Elevation in Parkinson's DiseaseA Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's DiseaseParkinson DiseaseDrug: Placebo;Drug: inosineThe Parkinson Study GroupMassachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fox Foundation for Parkinson's ResearchNot recruiting30 YearsN/AAll75Phase 2United States
844NCT01519856June 20098 February 2016PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term TherapyEfficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive FunctionParkinson's DiseaseDrug: piribedil (Clarium)Desitin Arzneimittel GmbHNot recruiting18 YearsN/ABoth908N/AGermany
845NCT01536366June 200919 October 2017Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideEffect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy VolunteersParkinson DiseaseDrug: BIA 9-1067;Drug: RepaglinideBial - Portela C S.A.Not recruiting18 Years45 YearsAll27Phase 1Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
846NCT02169440June 200919 October 2017Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinEffect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy VolunteersParkinson's Disease (PD)Drug: BIA 9-1067;Drug: WarfarinBial - Portela C S.A.Not recruiting18 Years45 YearsAll20Phase 1Portugal
847EUCTR2008-004146-88-FI19/05/200921 January 2013An extension trial to investigate the long-term efficacy and safety of safinamide, as add-on therapy in patients with early Parkinson’s disease treated with a stable dose of a dopamine agonistA phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918Idiopathic Parkinson's Disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Coated tablet
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Coated tablet
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use		Newron PharmaceuticalsNot RecruitingFemale: yes
Male: yes		498Phase 3United States;Portugal;Slovakia;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Peru;South Africa;Bulgaria;Germany
848EUCTR2008-008712-98-FI18/05/200919 March 201213-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s diseasemoderate to severe levodopa induced dyskinesias in patients with Parkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10013916 Term: Dyskinesia		Product Name: AFQ056
Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: AFQ056
Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: AFQ056
Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Novartis Pharma AGNot RecruitingFemale: yes
Male: yes		198Finland;Germany;France;Spain;Italy
849EUCTR2008-001966-10-HU04/05/200924 July 2012A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine - Safinamide in PD with motor fluctuations, as add-on to levodopa. Extension to trial 27919Idiopathic Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use		Merck Serono SA - GenevaNot RecruitingFemale: yes
Male: yes		416Phase 3Hungary;United Kingdom;Estonia;Austria
850NCT00767546May 200919 February 2015Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian PatientsBotulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian PatientsParkinson Disease;Parkinsonism;Seborrheic DermatitisDrug: Botulinum toxinRabin Medical CenterNot recruiting18 YearsN/ABoth40Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
851NCT00892450May 200919 February 2015Anticholinergic Therapy for Overactive Bladder in Parkinson's DiseaseAnticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot StudyParkinson's Disease;Overactive BladderDrug: Oxybutynin and darifenacinDepartment of Veterans AffairsNot recruitingN/AN/ABoth12N/AUnited States
852NCT00906763May 200919 February 2015Effects of Chocolate on Motor Symptoms of Parkinson's DiseaseEffects of Chocolate on Motor Symptoms of Parkinson's Disease - A Monocenter, Prospective, Observer-blinded Interventional TrialParkinson's DiseaseDietary Supplement: ChocolateTechnische Universität DresdenRecruiting18 YearsN/ABoth23N/AGermany
853NCT00907595May 200919 February 2015Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With RamelteonTreating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled TrialHuntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian DysregulationDrug: Ramelteon;Drug: PlaceboMassachusetts General HospitalNot recruiting20 Years90 YearsBoth0N/AUnited States
854NCT00914602May 200919 February 2015An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsAn Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects With Motor FluctuationsParkinson's DiseaseDrug: XP21279;Drug: Sinemet®;Drug: Lodosyn®XenoPort, Inc.Not recruiting30 Years75 YearsBoth14Phase 1/Phase 2United States
855NCT01515891May 200919 October 2017Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesAn Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral AdministrationParkinson DiseaseDrug: BIA 9-1067Bial - Portela C S.A.Not recruiting40 Years55 YearsMale4Phase 1Switzerland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
856EUCTR2008-002769-30-IT30/04/200919 March 2012A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokineticsA randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson?s disease - A study to assess the effect of safinamide on levodopa pharmacokineticsParkinson Disease
MedDRA version: 9.1 Level: LLT Classification code 10013113		Product Name: Safinamide
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Safinamide
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Pharmaceutical Form: Tablet
INN or Proposed INN: NACOM levodopa+cardidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-		MERCK SERONO SANot RecruitingFemale: yes
Male: yes		Italy
857EUCTR2008-005492-94-IT30/04/20099 October 2012OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS - NDIDIOPATHIC PARKINSON`S DISEASE
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: SAFINAMIDE
Product Code: NW-1015
Pharmaceutical Form: Coated tablet
CAS Number: 202825-46-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Product Name: SAFINAMIDE
Product Code: NW-1015
Pharmaceutical Form: Coated tablet
CAS Number: 202825-46-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-		MERCK SERONO SAAuthorisedFemale: yes
Male: yes		700Hungary;Portugal;Germany;Netherlands;France;Bulgaria;Italy;Austria;United Kingdom;Czech Republic;Belgium;Estonia;Spain
858EUCTR2008-008210-38-FR16/04/200919 March 2012Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I” - FOGG-IEffet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I” - FOGG-IPatients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease
MedDRA version: 9.1 Level: PT Classification code 10061536 Term: Parkinson's disease		Trade Name: EBIXA®
Product Name: mémantine
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: L-Dopa/ MODOPAR
Product Name: L-Dopa
Pharmaceutical Form: Capsule*		Chru de LilleAuthorisedFemale: yes
Male: yes		28France
859EUCTR2008-005085-30-DE06/04/200919 March 2012Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with RasagilineEinfluss von Rasagilin auf das Riechvermögen von Patienten mit idiopathischem Parkinson-Syndrom (Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatment with Rasagiline) - OlfactionIdiopathic Parkinson syndrome (IPS), State according to Hoehn & Yahr: maximum III
MedDRA version: 13.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Azilect
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagilin
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Technische Universität DresdenNot RecruitingFemale: yes
Male: yes		Germany
860EUCTR2008-000400-81-PT03/04/20091 May 2012A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and DyskinesiaA Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Disease Experiencing Motor Fluctuations and DyskinesiaAdvanced Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Mirapex
Product Name: pramipexole
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: pramipexole
CAS Number: 104632-26-0
Current Sponsor code: Pramipexole
Other descriptive name: pramipexole dihydrochloride monohydrate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.125-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Mirapex
Product Name: Pramipexole
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pramipexole
CAS Number: 104632-26-0
Current Sponsor code: Pramipexole
Other descriptive name: pramipexole dihydrochloride monohydrate		Solvay Pharmaceuticals BVNot RecruitingFemale: yes
Male: yes		50Portugal;Germany;Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
861JPRN-JapicCTI-09088801/4/20092 April 2019A Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopaA Double-Blind, 3-Arm, Parallel Group, Placebo-and Ropinirole-Controlled Study of SPM 962 in Subjects with Parkinson's Disease Treated Concomitantly with L-dopaParkinson's Disease Treated Concomitantly with L-dopaIntervention name : SPM 962
Dosage And administration of the intervention : SPM 962: transdermal application, 1 time per day. Initial dose:4.5mg/day, weekly increment of 4.5mg/day, maximal maintenance dose : 36.0mg/day. Placebo of ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day
Control intervention name : Ropinirole
Dosage And administration of the control intervention : placebo SPM 962: transdermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Ropinirole: oral application 3 times per day. Initial dose:0.75mg/day, weekly increment of 0.75mg/day (up to 3.0mg/day), then 1.5mg/day (up to 15.0mg/day), maximal maintenance dose 15.0 mg/day.
Control intervention name : Placebo
Dosage And administration of the control intervention : placebo SPM 962: transermal application, 1 time per day. Initial dose: 4.5mg placebo/day, weekly increment of 4.5mg placebo/day, maximal maintenance dose : 36.0mg placebo/day. Placebo ropinirole: oral application 3 times per day. Initial dose:0.75mg placebo/day, weekly increment of 0.75mg placebo/day (up to 3.0mg placebo/day), then 1.5mg placebo/day (up to 15.0mg placebo/day), maximal maintenance dose 15.0 mg placebo/day.		Otsuka Pharmaceutical Co., Ltd.3079BOTH400Phase 3
862JPRN-UMIN0000018412009/04/012 April 2019A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of lifeParkinson diseaseVitamin D3
placebo		Jikei University School of MedicineNot Recruiting45years-old85years-oldMale and Female120Not selectedJapan
863NCT00845000April 200919 October 2017Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated PatientsParkinson DiseaseDrug: SCH 420814 10 mg;Drug: SCH 420814 100 mg;Drug: Placebo;Drug: Levodopa;Drug: CarbidopaMerck Sharp & Dohme Corp.Oregon Health and Science UniversityNot recruiting18 YearsN/AAll12Phase 1United States
864NCT00865579April 200916 December 2017Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsOpen-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsParkinson's DiseaseDrug: SafinamideNewronNot recruiting30 YearsN/AAll964Phase 3Romania
865NCT00875316April 200919 February 2015Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease PatientsA Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One MonthParkinson's DiseaseDrug: Cogane™ (PYM50028)PhytopharmNot recruiting40 Years80 YearsBoth36Phase 1United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
866NCT00880620April 20094 November 2019A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's DiseaseA Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: Placebo;Drug: IPX066 95 mg LD;Drug: IPX066 145 mg LD;Drug: IPX066 195 mg LD;Drug: IPX066 245 mg LDImpax Laboratories, LLCNot recruiting30 YearsN/AAll381Phase 3United States;Canada;Estonia;Latvia;Lithuania;Romania;Ukraine
867NCT00914134April 200919 February 2015Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's DiseaseEffect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Levodopa infusionHelsinki UniversitySolvay PharmaceuticalsNot recruiting40 Years80 YearsBoth12Phase 4Finland
868NCT00758368March 200912 November 2018Comparison of Continuous and Pulsatile Apomorphine in Parkinson's DiseaseComparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced DyskinesiaParkinson's DiseaseDrug: ApomorphineOregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting21 YearsN/AAll0Phase 2United States
869NCT00823836March 200919 October 2017Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's DiseaseClinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's DiseaseParkinson DiseaseDrug: ropinirole PR/XR;Drug: ropinirole IRGlaxoSmithKlineNot recruiting20 YearsN/AAll302Phase 3Japan
870NCT00866502March 200919 February 2015A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseA Randomized, Double-blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed® II Pump.Parkinson's DiseaseDrug: sNN0031;Drug: PlaceboNewron Sweden ABMedtronic;QuintilesNot recruiting30 Years75 YearsBoth12Phase 1/Phase 2Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
871NCT00870974March 200916 December 2017A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsEvaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric ConditionsParkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive ImpairmentDrug: [18F]FPEBInstitute for Neurodegenerative DisordersNot recruiting18 Years85 YearsAll48Phase 1United States
872NCT00940914March 200919 February 2015Dopaminergic Loss and Pain in Parkinson's DiseaseEvaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without PainParkinson's Disease;PainDrug: ioflupane 123I (DATSCAN®)University Hospital, ToulouseNot recruiting30 Years70 YearsBoth20Phase 2France
873NCT01399905March 200919 February 2015High and Low Dose Carbidopa Treatment of Parkinson's DiseaseA Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.Parkinson's DiseaseDrug: carbidopaOregon Health and Science UniversityNot recruiting35 Years85 YearsBoth12Phase 2United States
874NCT01533077March 200919 October 2017Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaPharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy SubjectsParkinson DiseaseDrug: BIA 9-1067;Drug: Sinemet® 100/25 mgBial - Portela C S.A.Not recruiting18 Years45 YearsAll18Phase 1Canada
875NCT01533116March 200919 October 2017Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideEffect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy SubjectsParkinson DiseaseDrug: BIA 9-1067;Drug: Placebo;Drug: levodopa/carbidopa;Drug: levodopa/benserazideBial - Portela C S.A.Not recruiting25 Years45 YearsAll52Phase 1Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
876EUCTR2008-006278-13-NL04/02/200919 March 2012Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.patients with advanced (>5 years) Parkinson's disease and visual hallucinations.
MedDRA version: 9.1 Level: LLT Classification code 10047570 Term: Visual hallucinations
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: Reminyl Retard
Pharmaceutical Form: Capsule*
Trade Name: Sinemet 125 mg
Pharmaceutical Form: Tablet		UMCGAuthorisedFemale: yes
Male: yes		10Netherlands
877NCT00806468February 200919 February 2015Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson DiseaseA Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson DiseaseParkinson DiseaseDrug: DesmotabsJohannes Gutenberg University MainzNot recruiting18 Years85 YearsMale1Phase 4Germany
878NCT00873392February 200919 February 2015Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's DiseaseEfficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.Idiopathic Parkinson's DiseaseDrug: Transdermal nicotine;Other: Usual drug treatment of Parkinson's diseaseAssistance Publique - Hôpitaux de ParisNot recruiting35 Years70 YearsBoth40Phase 2France
879NCT00908076February 200919 October 2017Amitiza in Constipation Associated With PD (Parkinson's Disease)Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's DiseaseParkinson's DiseaseDrug: LUBIPROSTONEBaylor College of MedicineUniversity of South FloridaNot recruiting18 Years85 YearsAll78Phase 4United States
880NCT01421719February 200916 December 2017Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's DiseaseOnabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and EfficacyParkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum Toxin Adverse ReactionDrug: Cystoscopic injection of Botox into the urinary bladderStanford UniversityAllerganNot recruiting50 Years85 YearsAll20Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
881EUCTR2007-007853-30-SE28/01/200919 March 2012A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump.A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump.Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III)Product Name: sNN0031
Product Code: sNN0031
Pharmaceutical Form: Concentrate for solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intracisternal use		NeuroNova ABNot RecruitingFemale: yes
Male: yes		Sweden
882EUCTR2009-015833-66-IT20/01/200924 April 2012Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate releaseRopinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate releaseParkinson's Disease
MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: REQUIP*28CPR 8MG R.P.
Pharmaceutical Form: Prolonged-release capsule, hard
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Trade Name: REQUIP*21CPR 5MG
Pharmaceutical Form: Tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Trade Name: MIRAPEXIN*30CPR 0,7MG
Pharmaceutical Form: Tablet
INN or Proposed INN: PRAMIPEXOLE
CAS Number: 104632-26-0
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: .7-		CASA DI CURA PRIVATA S.RAFFAELE - PISANANot RecruitingFemale: yes
Male: yes		Italy
883EUCTR2008-004906-15-FR05/01/200919 March 2012EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de ParkinsonEVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE - dénervation dopaminergique et douleur dans la maladie de ParkinsonMaladie de Parkinson
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: DATSCAN
Pharmaceutical Form: Solution for injection		CHU ToulouseAuthorisedFemale: yes
Male: yes		France
884NCT00357994January 200919 October 2017Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's SubjectsA Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor FluctuationsAdvanced Parkinson's DiseaseDrug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo gel;Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tubeAbbVie (prior sponsor, Abbott)Quintiles, Inc.Not recruiting30 YearsN/AAll36Phase 3United States;Germany
885NCT00857532January 200919 October 2017Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease PatientsA Phase 2 Trial of Florbetapir F18 PET Imaging of ß-amyloid in Parkinson's Disease Patients With Cognitive ImpairmentParkinson's DiseaseDrug: florbetapir F 18Avid RadiopharmaceuticalsNational Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting60 YearsN/AAll31Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
886NCT02169466January 200919 October 2017Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazidePharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male SubjectsParkinson's Disease (PD)Drug: BIA 9-1067;Drug: Placebo;Drug: Madopar® HBSBial - Portela C S.A.Not recruiting18 Years45 YearsMale22Phase 1Portugal
887EUCTR2009-014341-84-DE18 April 2012Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms.Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastrointestinal symptoms.idiopathic Parkinson's disease
MedDRA version: 12.0 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Neupro 2 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 2mg/24h(10cm2)
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Trade Name: Neupro 4 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 4mg/24h (20cm2)
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-
Trade Name: Neupro 6 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 6mg/24h (30cm2)
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Trade Name: Neupro 8 mg/24 h transdermal patch
Product Name: Rotigotine transdermal patch 8mg/24h (40cm2)
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-		Schwarz Pharma Deutschland GmbH, UCB GroupAuthorisedFemale: yes
Male: yes		Germany
888EUCTR2008-003966-25-DE23/12/20083 June 2013Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPADouble-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPAEffect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome
MedDRA version: 9.1 Level: LLT Classification code 10064016 Term: Nocturnal polyuria
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Desmotabs® 0,2 mg Tabletten
Product Name: Desmotabs® 0,2mg Tabletten
Pharmaceutical Form: Capsule*
INN or Proposed INN: Desmopressin Acetat
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,2-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Universität Mainz, Klinik und Poliklinik für NeurologieNot RecruitingFemale: no
Male: yes		20Germany
889NCT00740714December 200819 October 2017Effects of Coenzyme Q10 (CoQ) in Parkinson DiseaseEffects of Coenzyme Q10 in Parkinson Disease - Phase IIIParkinson DiseaseDrug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin EWeill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterNot recruiting30 YearsN/AAll600Phase 3United States;Canada
890NCT00809302December 200819 February 2015Efficacy and Safety Study of Aplindore in Patients With Early Parkinson DiseaseA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)Early Parkinson DiseaseDrug: aplindore MR tablets or PlaceboNeurogen CorporationNot recruiting30 YearsN/ABoth9Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
891EUCTR2008-004943-12-SK24/11/20083 April 2017The Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens StudyThe Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens StudyEarly Stage Parkinson’s Disease
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: Pardoprunox hydrochloride
Other descriptive name: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Mirapex
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
CAS Number: 104632-26-0
Current Sponsor code: Pramipexole
Other descriptive name: pramipexole dihydrochloride monohydrate
Concentration unit: mg milligram(s)		Solvay Pharmaceuticals B.V.AuthorisedFemale: yes
Male: yes		320Phase 2Slovakia
892EUCTR2007-006721-27-GB11/11/200819 March 2012A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease.A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease.idiopathic Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: CERE-120
Product Code: CERE-120
Pharmaceutical Form: Suspension for injection
Current Sponsor code: CERE-120
Concentration type: equal
Concentration number: 6.7E+12 vg/ml-		Ceregene Inc.Not RecruitingFemale: yes
Male: yes		50Phase 2United Kingdom
893EUCTR2007-003035-22-GB05/11/200828 February 2019A safety and tolerability study of ACP-103 in patients with Parkinson's Disease PsychosisA Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease - ACP-103-015Psychosis in Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10037241 Term: Psychosis NOS System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Pimavanserin tartrate
Product Code: pimavanserin (ACP-103)
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pimavanserin tartrate
CAS Number: 706782-28-7
Current Sponsor code: pimavanserin (ACP-103)
Other descriptive name: N/a
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-		ACADIA Pharmaceuticals Inc.Not Recruiting Female: yes
Male: yes		400Phase 3United States;Portugal;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden
894NCT00629161November 200819 February 2015Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson DiseaseParkinson DiseaseDrug: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant);Drug: placeboFudan UniversityRecruiting50 YearsN/ABoth144Phase 2/Phase 3China
895NCT00869791November 200816 December 2017A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-LevodopaA Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-LevodopaParkinson's DiseaseDrug: IPX066;Drug: IR CD-LDIMPAX Laboratories, Inc.Not recruiting30 YearsN/AAll27Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
896EUCTR2007-006721-27-AT20/10/200811 April 2016A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease.A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease.idiopathic Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: CERE-120
Product Code: CERE-120
Pharmaceutical Form: Suspension for injection
Current Sponsor code: CERE-120
Concentration type: equal
Concentration number: 6.7E+12 vg/ml-		Ceregene Inc.Not RecruitingFemale: yes
Male: yes		50Phase 2Austria;United Kingdom
897EUCTR2008-003869-72-PT03/10/200819 March 2012A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITORA DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE, AND ERYTHROCYTE SOLUBLE CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN PARKINSON'S DISEASE PATIENTS CONCOMITANTLY TREATED WITH LEVODOPA/DOPA-DECARBOXYLASE INHIBITORParkinson
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Code: BIA 9-1067
Pharmaceutical Form: Capsule*
CAS Number: 923287-50-7
Current Sponsor code: BIA 9-1067
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: -25
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: SINEMET 25/100
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
CAS Number: 28860959
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Product Code: BIA 9-1067
Pharmaceutical Form: Capsule*
CAS Number: 923287-50-7
Current Sponsor code: BIA 9-1067
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: -100		Bial - Portela & Cª, S.A.Not RecruitingFemale: yes
Male: yes		12Portugal
898NCT00611481October 200819 February 2015Study of Tai Chi Exercise and Balance in Persons With Parkinson's DiseasePhase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's DiseaseParkinson's DiseaseBehavioral: Tai Chi;Behavioral: Strength training;Behavioral: Low-Impact Exercise ControlOregon Research InstituteNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting40 Years85 YearsBoth195Phase 2United States
899NCT00906828October 200819 February 2015Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) InhibitorsPharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT InhibitorsParkinson DiseaseDrug: levodopa/carbidopa;Drug: entacapone;Drug: tolcaponeUppsala UniversitySwedish Parkinson's Disease Foundation;Swedish Society for Medical ResearchNot recruiting30 Years90 YearsBoth10Phase 4Sweden
900NCT01048229October 200819 February 2015Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseEvaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseEarly-stage Parkinson's DiseaseDrug: Rasagiline;Drug: PramipexoleQualissimaH. Lundbeck A/SNot recruiting18 Years70 YearsBoth112Phase 4
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
901NCT02092168October 200819 October 2017Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young SubjectsSingle-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young SubjectsParkinson DiseaseDrug: BIA 9-1067Bial - Portela C S.A.Not recruiting18 YearsN/AMale24Phase 1France
902NCT02169453October 200819 October 2017Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaPharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male SubjectsParkinson's Disease (PD)Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® CR 100/25Bial - Portela C S.A.Not recruiting18 Years45 YearsMale12Phase 1Canada
903EUCTR2007-003051-36-AT10/09/200818 April 2012A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s DiseaseA Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s DiseasePsychosis in Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10037241 Term: Psychosis NOS		Product Name: Pimavanserin tartrate
Product Code: ACP-103
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pimavanserin tartrate
CAS Number: 706782-28-7
Current Sponsor code: ACP-103
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pimavanserin tartrate
Product Code: ACP-103
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Pimavanserin tartrate
CAS Number: 706782-28-7
Current Sponsor code: ACP-103
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Acadia Pharmaceuticals IncNot RecruitingFemale: yes
Male: yes		280Portugal;Spain;Austria;Sweden
904EUCTR2008-003225-16-FI10/09/20087 October 2014Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilaillaAivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilaillaVaikeahoitoinen Parkinsonin tauti potilailla, joille on aiemmin asetettu aivostimulaattori, tai on päädytty päivittäisten oireiden vuoksi aloittamaan Duodopa-infuusio.
MedDRA version: 9.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS		Trade Name: DuodopaOrganisation name was not enteredNot RecruitingFemale: yes
Male: yes		Finland
905NCT00758849September 200819 February 2015Fipamezole in Neurogenic Orthostatic HypotensionA Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's DiseaseSymptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System AtrophyDrug: Placebo;Drug: FipamezoleJuvantia Pharma LtdSanthera PharmaceuticalsNot recruiting30 Years80 YearsBoth24Phase 2France;Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
906NCT02169479September 200819 October 2017Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/CarbidopaPharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male SubjectsParkinson's Disease (PD)Drug: BIA 9-1067;Drug: Placebo;Drug: Sinemet® 100/25Bial - Portela C S.A.Not recruiting18 Years45 YearsMale16Phase 1Canada
907NCT02169895September 200819 October 2017Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazidePharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Benserazide: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male SubjectsParkinson's Disease (PD)Drug: BIA 9-1067;Drug: Placebo;Drug: Prolopa®Bial - Portela C S.A.Not recruiting25 Years45 YearsMale16Phase 1Canada
908EUCTR2007-004235-37-GB19/08/200819 March 2012Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PDLong-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PDMale or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.375-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		Boehringer IngelheimNot RecruitingFemale: yes
Male: yes		390Hungary;Czech Republic;United Kingdom;Spain;Italy;Poland;Austria;Sweden
909NCT00601978August 200819 February 2015Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing OffA 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event-Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease and End-of-Dose Wearing OffParkinson's DiseaseDrug: carbidopa/levodopa;Drug: Carbidopa/Levodopa/EntacaponeNovartis PharmaceuticalsNot recruiting45 Years75 YearsBoth0Phase 4United States
910NCT00656253August 200819 February 2015Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson DiseaseParkinson's DiseaseDrug: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.);Drug: PlaceboFudan UniversityChina's Ministry of Health; Administration of Traditional Chinese Medicine (SATCM)Not recruiting50 YearsN/ABoth158Phase 2/Phase 3China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
911NCT00745277August 200819 February 2015High and Low Dose Treatment of Carbidopa in Parkinson's DiseaseA Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.Parkinson's DiseaseDrug: Carbidopa-Levodopa;Drug: Carbidopa- LevodopaOregon Health and Science UniversityParkinson Disease Research, Education and Clinical Center at Portland VA Hospital;RJG Foundation;Oregon Clinical and Translational Research InstituteNot recruiting35 Years85 YearsBoth12Phase 2United States
912NCT01010802August 200814 October 2019Safety Study of Erythropoietin (EPO) in Parkinson's DiseasePhase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)Parkinson DiseaseDrug: Erythropoietin human recombinant (EPOrh)International Center for Neurological Restoration, CubaCentro de Immunologia Molecular, CubaNot recruiting45 Years75 YearsAll10Phase 1Cuba
913EUCTR2008-003581-26-SE18/07/200819 March 2012Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMTPharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMTParkinson's disease (G20.9), advanced, patients presently on Duodopa treatment.
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: Duodopa
Pharmaceutical Form: Gel
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: carbidopa
CAS Number: 28860-95-9
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-
Trade Name: Comtess
Pharmaceutical Form: Tablet
INN or Proposed INN: entacapone
CAS Number: 130929-57-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Tasmar
Pharmaceutical Form: Tablet
INN or Proposed INN: tolcapone
CAS Number: 134308-13-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-		Dept of Neuroscience, Uppsala UniversityAuthorisedFemale: yes
Male: yes		Sweden
914EUCTR2008-001336-13-FR16/07/200819 March 2012Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2Maladie Parkinson
MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease		Trade Name: Nicorette 5 mg/ 16 h
Product Name: Nicorette 5 mg/ 16 h
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Nicotine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8.3-
Product Name: Nicorette 10mg/ 16 h
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Nicotine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 16.6-
Product Name: Nicorette 15 mg/ 16 h
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Nicotine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 24.9-		ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)AuthorisedFemale: yes
Male: yes		France
915EUCTR2007-003134-42-DE19/06/200826 June 2012A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off.A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson’s Disease and End-of-Dose Wearing Off.Idiopathic Parkinson’s disease and end-of-dose wearing off.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten
Product Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
CAS Number: 28860959
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: ENTACAPONE
CAS Number: 130929576
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Nacom 100
Product Name: Nacom
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59927
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 27-		Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes		20Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
916NCT00822913June 200819 February 2015Botulinum A Toxin in Patients With Parkinson's DiseaseThe Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity.Parkinson's Disease;Multiple System Atrophy;Detrusor OveractivityDrug: Intravesical injection of Botulinum A toxinUniversity Of PerugiaUniversity of Roma La SapienzaRecruiting18 Years80 YearsBoth20Phase 4
917EUCTR2007-004009-93-IT20/05/20087 January 2013Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopramPrevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopramDepression, anxiety and ICD
MedDRA version: 14.1 Level: SOC Classification code 10037175 Term: Psychiatric disorders System Organ Class: 10037175 - Psychiatric disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: CIPRALEX
Pharmaceutical Form: Tablet
INN or Proposed INN: Escitalopram
Concentration unit: mg milligram(s)
Concentration number: 10-
Trade Name: CIPRALEX
Pharmaceutical Form: Tablet
INN or Proposed INN: Escitalopram
Concentration unit: mg milligram(s)
Concentration number: 20-		LUNDBECK ITALIANot RecruitingFemale: yes
Male: yes		Italy
918EUCTR2007-004890-24-FR07/05/200819 March 2012A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHNA Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHNNeurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's
MedDRA version: 9.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy		Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets
Product Code: JP-1730/F01
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Fipamezole hydrochloride
CAS Number: 150586-72-4
Current Sponsor code: JP-1730
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 90-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use
Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets
Product Code: JP-1730/F02
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Fipamezole hydrochloride
CAS Number: 150586-72-4
Current Sponsor code: JP-1730
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 60-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use
Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets
Product Code: JP-1730/F03
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Fipamezole hydrochloride
CAS Number: 150586-72-4
Current Sponsor code: JP-1730
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use		Juvantia Pharma LtdAuthorisedFemale: yes
Male: yes		24Phase 2Portugal;France
919NCT01238926May 200819 February 2015Vitamin B6, B12, Folic Acid and Exercise in Parkinson's DiseaseEffects of Vitamin Supplementation and Strength Training in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: PD vitamin supplementation;Other: PD exercise intervention;Other: PD vitamin + exerciseNew York Institute of TechnologyStony Brook UniversityNot recruiting50 Years80 YearsBoth40N/AUnited States
920NCT01416818May 200819 February 2015Treatment of Depression in Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled Study of Xiaoyao Pill Treatment of Depression in Patients With Parkinson's DiseaseDepression in Parkinson's DiseaseDrug: Xiaoyao Pill;Drug: Bupleurum+Ginkgo;Drug: placeboXuanwu Hospital, BeijingRecruiting30 Years80 YearsBoth60Phase 2China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
921NCT00605553April 200816 December 2017Study to Evaluate SYN115 in Parkinson's DiseaseA Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's DiseaseParkinson's DiseaseDrug: Placebo;Drug: TozadenantBiotie Therapies Inc.Not recruiting40 Years75 YearsAll30Phase 2United States
922NCT00651183April 200819 October 2017Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole TreatmentNon-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole TreatmentParkinson DiseaseDrug: Pramipexole immediate releaseBoehringer IngelheimNot recruiting18 YearsN/AAll286Phase 4Austria
923NCT00753636April 200819 October 2017Parkinson's Disease Isradipine Safety StudyPhase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage IIParkinson's DiseaseDrug: Dynacirc CR (Isradipine)Northwestern UniversityNorthwestern Memorial HospitalNot recruiting30 Years75 YearsAll31Phase 2United States
924NCT02071810April 200819 October 2017Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male VolunteersParkinson's Disease (PD)Drug: BIA 9-1067;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years45 YearsMale34Phase 1France
925EUCTR2007-001095-36-HU27/03/200819 March 2012The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh StudyThe Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - The Van Gogh Studyadvanced stage of idiopathic PD with dose-dependent motor fluctuations.
MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308		Solvay PharmaceuticalsNot RecruitingFemale: yes
Male: yes		625Hungary
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
926EUCTR2007-001096-10-HU27/03/200819 March 2012An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh StudyAn Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations - An Extension of the Van Gogh Studyadvanced stage of idiopathic PD with dose-dependent motor fluctuations.
MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pardoprunox hydrochloride
CAS Number: 269718-83-4
Current Sponsor code: SLV308 hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Pardoprunox
Product Code: SLV308		Solvay PharmaceuticalsNot RecruitingFemale: yes
Male: yes		500Hungary
927EUCTR2007-005033-11-DE27/03/200819 March 2012A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s DiseaseA Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s DiseasePatients with Parkinson's DiseaseProduct Name: Levodopa-Carbidopa Multilayer Extended Release Tablet
Product Code: Levodopa-Carbidopa XL tablet (M)
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Trade Name: Sinemet® CR
Product Name: Sinemet CR
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-		CombinatoRx, IncNot RecruitingFemale: yes
Male: yes		Germany
928NCT00607451March 200811 June 2018Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced DyskinesiaA Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced DyskinesiaLevodopa-induced DyskinesiaDrug: Neu-120Neurim Pharmaceuticals Ltd.Not recruiting30 Years80 YearsAll8Phase 1/Phase 2Israel
929NCT00642356March 200819 October 2017Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing OffAn 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing OffParkinson's DiseaseDrug: Carbidopa/levodopa/entacapone;Drug: Immediate release carbidopa/levodopaNovartisNot recruiting30 Years85 YearsAll14Phase 4United States
930NCT00658567March 200816 December 2017A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisDrug: Pimavanserin tartrate (ACP-103)ACADIA Pharmaceuticals Inc.Not recruiting40 YearsN/AAll123Phase 3United States;Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
931NCT00727727March 200819 February 2015SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.Parkinson's DiseaseDrug: PiribedilDesitin Arzneimittel GmbHNot recruiting18 YearsN/ABoth750N/AGermany
932NCT00761137March 200819 October 2017Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease PatientsA Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease PatientsSialorrhea Secondary to Parkinson's DiseaseDrug: 0.3 mg tropicamide;Drug: 1 mg tropicamide;Drug: 3 mg tropicamide;Drug: 0 mg tropicamideNeuroHealing Pharmaceuticals Inc.Michael J. Fox Foundation for Parkinson's ResearchNot recruiting50 Years80 YearsAll19Phase 2Argentina
933EUCTR2007-002195-34-FR04/02/200819 March 2012Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.Fatigue symptoms in Parkinson's disease.
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: DEBRUMYL
Product Code: DC158AM
Pharmaceutical Form: Oral solution
INN or Proposed INN: Heptaminol hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 180-
INN or Proposed INN: Deanol pyroglutamate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use		PIERRE FABRE MEDICAMENTAuthorisedFemale: yes
Male: yes		France
934NCT00624741February 200819 February 2015Compassionate Use Study of Pergolide in Patients With Parkinson's DiseaseCompassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's DiseaseParkinson DiseaseDrug: PergolideValeant Pharmaceuticals International, Inc.Not recruitingN/AN/ABothN/A
935NCT00888186February 200819 February 2015Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsDifferent Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsParkinson Disease;DyskinesiasDrug: levodopa/carbidopaUppsala UniversitySwedish Parkinson's Disease Foundation;Swedish Society for Medical ResearchNot recruiting30 Years90 YearsBoth5Phase 4Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
936NCT02236728February 200819 February 2015Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With PramipexoleObservational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole by Neurologists in France (ETAP)Parkinson DiseaseDrug: PramipexoleBoehringer IngelheimNot recruitingN/AN/ABoth497N/A
937EUCTR2007-002467-27-GB24/01/200819 March 2012Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramateAntidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramatePatients with idiopathic Parkinson's disease and levodopa-induced dyskinesias
MedDRA version: 13.1 Level: PT Classification code 10013916 Term: Dyskinesia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 13.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 13.1 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 10029205 - Nervous system disorders		Product Name: Topiramate
Pharmaceutical Form: Capsule*
INN or Proposed INN: TOPIRAMATE
CAS Number: 97240794
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Salford Royal NHS Foundation TrustNot RecruitingFemale: yes
Male: yes		United Kingdom
938EUCTR2007-000350-31-FR22/01/200826 January 2015A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).Mild to moderately severe dementia associated with Parkinson’s disease (PDD).
MedDRA version: 9.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease		Trade Name: Exelon
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: rivastigmine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Trade Name: Exelon
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: rivastigmine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Trade Name: Exelon
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: rivastigmine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Trade Name: Exelon
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: rivastigmine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 6.0-
Trade Name: Exelon 4.6 mg/24 h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rivastigmine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Trade Name: Exelon 9.5 mg/24 h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rivastigmine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-		Novartis Pharma AGNot RecruitingFemale: yes
Male: yes		550France;Spain;Italy
939NCT00335153January 200819 October 2017Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's DiseaseAn Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease MedicationsAdvanced Parkinson's DiseaseDrug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tubeAbbVie (prior sponsor, Abbott)Quintiles, Inc.Not recruiting30 YearsN/AAll354Phase 3United States;Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;Greece
940NCT00562198January 200819 February 2015PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingEffects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an Open, Randomised, Active-Controlled,Two-Period Crossover Study.Parkinson´s DiseaseDrug: entacapone and carbidopa;Drug: Sinemet 200mg/50mgOrion Corporation, Orion PharmaNot recruiting45 Years80 YearsBoth16Phase 2Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
941NCT00600093January 200819 February 2015Perioperative Treatment of Parkinsonian Patients With Parenteral AmantadinePerioperative Treatment of Parkinsonian Patients With Parenteral AmantadineParkinson Disease;Perioperative CareDrug: AmantadineRabin Medical CenterNot recruitingN/AN/ABoth20Phase 2Israel
942NCT00608231January 200819 February 2015Dexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationDexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationParkinson's Disease;Essential Tremor;DystoniaDrug: Dexmedetomidine Hydrochloride Infusion;Drug: Normal SalineVanderbilt UniversityNot recruiting18 YearsN/ABoth0Phase 2/Phase 3United States
943NCT00612872January 200815 April 2019Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy SubjectsEvaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy SubjectsParkinson Disease;Alzheimer Disease;Healthy Controls;Multiple SclerosisDrug: [123I]CLINDEInstitute for Neurodegenerative DisordersNot recruiting30 Years50 YearsAll46Phase 1United States
944NCT00623103January 200819 October 2017Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)Parkinson's Disease DementiaDrug: Rivastigmine capsule;Drug: Rivastigmine transdermal patchNovartisNot recruiting50 Years85 YearsAll583Phase 3United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom
945NCT00623324January 200819 February 2015The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseA Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's DiseaseEarly Stage Parkinson's DiseaseDrug: Aplindore;Drug: PlaceboLigand PharmaceuticalsNot recruiting30 YearsN/ABoth40Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
946NCT00627588January 200819 February 2015Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's DiseaseA Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.Parkinson's DiseaseBiological: ProSavinOxford BioMedicaNot recruiting48 Years65 YearsBoth15Phase 1/Phase 2France;United Kingdom
947NCT00664209January 200816 December 2017Treating H. Pylori in Parkinson's Patients With Motor FluctuationsHelicobacter Pylori Eradication and Motor Fluctuations in Parkinson's DiseaseParkinson's Disease;Helicobacter Infections;Motor FluctuationsDrug: clartihromycin, amoxicillin, and omeprazole;Drug: placeboUniversity of California, Los AngelesMichael J. Fox Foundation for Parkinson's ResearchNot recruitingN/AN/AMale64Phase 3United States
948NCT00725478January 200819 February 2015SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's DiseaseStabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.Parkinson's DiseaseDrug: PiribedilDesitin Arzneimittel GmbHNot recruiting18 YearsN/ABoth250N/A
949NCT01628965January 200819 October 2017A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease PatientsAn Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopaParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.Not recruitingN/AN/AAll143Phase 2/Phase 3Japan
950EUCTR2008-004447-11-DE1 April 2013A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effects Associated With Parkinson’s DiseaseA Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effects Associated With Parkinson’s DiseaseUnpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
MedDRA version: 11 Level: LLT Classification code 10067209 Term: 		Product Name: Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed
Product Code: VR040
Pharmaceutical Form: Inhalation powder, pre-dispensed
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372 20 7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.8-
Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed
Route of administration of the placebo: Inhalation use
Product Name: Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed
Product Code: VR040
Pharmaceutical Form: Inhalation powder, pre-dispensed
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372 20 7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.8-
Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed
Route of administration of the placebo: Inhalation use
Product Name: Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed
Product Code: VR040
Pharmaceutical Form: Inhalation powder, pre-dispensed
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372 20 7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.0-
Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed
Route of administration of the placebo: Inhalation use
Product Name: Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed
Product Code: VR040
Pharmaceutical Form: Inhalation powder, pre-dispensed
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372 20 7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5.8-
Pharmaceutical form of the placebo: Inhalation powder, pre-dispensed
Route of administration of the placebo: Inhalation use		Vectura LimitedNot RecruitingFemale: yes
Male: yes		66Phase 2bGermany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
951EUCTR2007-004400-12-ES27/12/200719 March 2012ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA - Rasagiline and ApathyENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA - Rasagiline and ApathyApatía en la Enfermedad de Parkinson
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Azilect
Pharmaceutical Form: Tablet
INN or Proposed INN: RASAGILINE
CAS Number: 136236516
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Institut de Recerca de l'Hospital de la santa Creu i Sant PauAuthorisedFemale: yes
Male: yes		Spain
952EUCTR2007-004654-81-GB20/12/200719 March 2012A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patientsA phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patientsSialorrhoea associated with Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10059812 Term: Sialorrhoea		Trade Name: Catapres ampoules
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Clonidine hydrochloride
Concentration unit: µg/ml microgram(s)/millilitre
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
Trade Name: Ditropan elixir
Pharmaceutical Form: Oral solution
INN or Proposed INN: Oxybutynin hydrochloride
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use		Summit (Cambridge) Ltd.Not RecruitingFemale: yes
Male: yes		Phase 2aUnited Kingdom
953EUCTR2007-002963-28-FI12/12/200728 January 2013A trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in patients with early Parkinson's Disease treated with a single dopamine agonist.A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist. - Safinamide in early IPD, as add-on to dopamine agonistIdiopathic Parkinson's Disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Newron Pharmaceuticals SpANot RecruitingFemale: yes
Male: yes		839Phase 3Portugal;United States;Finland;Spain;Chile;Colombia;Italy;India;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Croatia;Bulgaria;South Africa;Germany
954NCT00526630December 200719 October 2017Methylphenidate for the Treatment of Gait Impairment in Parkinson's DiseaseMethylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over StudyParkinson's Disease;Gait ImpairmentDrug: Methylphenidate (MPD);Drug: PlaceboUniversity of CincinnatiMichael J. Fox Foundation for Parkinson's ResearchNot recruiting35 Years85 YearsAll23Phase 4United States
955NCT00584025December 200711 June 2018Keppra IV for the Treatment of Motor Fluctuations in Parkinson's DiseaseParkinson's DiseaseDrug: levetiracetam;Drug: PlaceboUniversity of South FloridaNot recruiting30 Years80 YearsAll0Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
956EUCTR2007-004985-41-SE29/11/200719 March 2012Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia studyDifferent dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics - The dyskinesia studyParkinson's disease, G20.9. Different dyskinesias related to advanced Parkinson's disease will be investigated.Trade Name: Duodopa
Pharmaceutical Form: Gel
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: carbidopa
CAS Number: 28860-95-9
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-		Department of Neuroscience, neurologyNot RecruitingFemale: yes
Male: yes		Sweden
957EUCTR2007-002906-23-GB14/11/200719 March 2012A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's DiseaseA Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's DiseasePsychosis in Parkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10037241 Term: Psychosis NOS		Product Name: Pimavanserin tartrate
Product Code: ACP-103
Pharmaceutical Form: Tablet
INN or Proposed INN: Pimavanserin tartrate
CAS Number: 706782-28-7
Concentration unit: mg milligram(s)
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Acadia Pharmaceuticals IncNot RecruitingFemale: yes
Male: yes		280United Kingdom;Bulgaria;France
958EUCTR2007-002496-14-FI05/11/200719 March 2012Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study.Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study.Parkinson’s disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Stalevo®
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Sinemet®
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Product Name: 11C-Raclopride
Pharmaceutical Form: Solution for injection
Other descriptive name: 11C-Raclopride
Concentration unit: Sv sievert
Concentration type: equal
Concentration number: 0.0017-		Orion Corporation Orion PharmaNot RecruitingFemale: yes
Male: yes		Finland
959ChiCTR-TRC-070000272007-11-0118 April 2017A randomized controlled clinical study of Pramipexole for Parkinson's diseaseA randomized controlled clinical study of Pramipexole for Parkinson's diseasePrimary Parkinson's diseaseGroup 1:Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks;Group 3:Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1;Group 2:Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease;First Affiliated Hospital of Xinjiang Medical UniversityNot Recruiting3080BothGroup 1:45;Group 3:45;Group 2:45;Post-marketChina
960NCT00537017November 200719 October 2017Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)Parkinson Disease;Neurodegenerative Diseases;Central Nervous System Diseases;Movement Disorders;Brain DiseasesDrug: Preladenant;Drug: L-dopa;Drug: Other Parkinson's Disease treatmentsMerck Sharp & Dohme Corp.Not recruiting30 YearsN/AAll140Phase 2Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
961NCT00558337November 200719 February 2015Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's DiseaseAn Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease PatientsParkinson's DiseaseDrug: levodopa-carbidopaOsmotica Pharmaceutical Corp.Not recruiting30 Years80 YearsBoth78Phase 2Argentina
962NCT00560508November 200719 October 2017A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment PeriodA Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ERParkinson DiseaseDrug: Pramipexole Immediate Release;Drug: Pramipexole Extended ReleaseBoehringer IngelheimNot recruiting1 YearN/AAll112Phase 2/Phase 3Japan
963NCT00584090November 200719 February 2015Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's DiseaseUrinary Incontinence;Parkinson's DiseaseDrug: Solifenacin Succinate (VESIcare);Drug: PlaceboUniversity of South FloridaNot recruiting30 Years80 YearsBoth0Phase 4United States
964NCT00610103November 200716 December 2017Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa TherapyA Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: apomorphine hydrochlorideKyowa Hakko Kirin Co., LtdNot recruiting20 YearsN/AAll16Phase 2Japan
965NCT00632762November 200719 February 2015Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.Parkinson's DiseaseDrug: mantadixUniversity Hospital, ToulouseNot recruiting30 Years80 YearsBoth80Phase 4France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
966NCT01301651November 200719 February 2015Effects of Virtual Reality Training in Patients With Parkinson's DiseaseEffects of Virtual Reality Augmented Balance Training for Postural Control in Patients With Parkinson's DiseaseParkinson's DiseaseBehavioral: balance trainingNational Taiwan University HospitalNational Science Council, TaiwanNot recruiting50 Years80 YearsBoth42Phase 1Taiwan
967EUCTR2007-004234-16-NL29/10/200719 March 2012Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.375-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		Boehringer Ingelheim bvNot RecruitingFemale: yes
Male: yes		520Finland;Hungary;Czech Republic;Netherlands;France;Austria
968EUCTR2007-001717-42-FR25/10/200719 March 2012A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/AA Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID - N/APatients with Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and DyskinesiasProduct Name: SCH 420814
Product Code: N/A
Pharmaceutical Form: Capsule, hard
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-		Schering Plough Research InstituteAuthorisedFemale: yes
Male: yes		200Phase 2France;Spain
969EUCTR2007-003353-90-NL23/10/200719 March 2012A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ER or Pramipexole IR.A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ER or Pramipexole IR.Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.375-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: Sifrol
Product Name: Pramipexole
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole		Boehringer IngelheimAuthorisedFemale: yes
Male: yes		145Germany;Netherlands;France
970EUCTR2007-002900-16-DE01/10/200719 March 2012A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopaA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias, and the safety and tolerability of AFQ056 in combination with L-dopaThe main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias.Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
CAS Number: 543906-09-8
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
CAS Number: 543906-09-8
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes		34Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
971NCT00547911October 200719 October 2017Augmenting Effects of L-DOPS With Carbidopa and EntacaponeL-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and EntacaponeParkinson Disease;Multiple System Atrophy;Autonomic Nervous System DiseasesDrug: Droxidopa;Drug: Carbidopa;Drug: EntacaponeNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll14Phase 1/Phase 2United States
972NCT00559871October 200719 February 2015Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's DiseaseA Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.Parkinson's DiseaseDrug: fipamezoleJuvantia Pharma LtdSanthera PharmaceuticalsNot recruiting30 YearsN/ABoth180Phase 2United States;India
973NCT00566462October 200717 September 2018Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTAssessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTParkinson's DiseaseDrug: perampanel;Drug: placeboEisai Inc.Not recruiting30 YearsN/AAll1Phase 2United States
974NCT00582673October 200719 February 2015Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopaA Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopaParkinson's DiseaseDrug: AFQ056;Drug: PlaceboNovartisNot recruiting30 Years85 YearsBoth31Phase 2Germany
975NCT01520727October 200719 October 2017A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsA Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male SubjectsParkinson DiseaseDrug: BIA 9-1067;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years45 YearsMale64Phase 1France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
976EUCTR2007-002899-34-GB18/09/200719 March 2012Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's DiseasePilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's DiseaseCognitive impairment in Parkinson's DiseaseProduct Name: Sage leaf
Pharmaceutical Form: Capsule, hard		Newcastle Upon tyne Hospitals NHS Foundation TrustNot RecruitingFemale: yes
Male: yes		United Kingdom
977EUCTR2007-002874-75-IT10/09/200719 March 2012Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005Psycosis associated to Parkinson's Disease
MedDRA version: 9.1 Level: HLT Classification code 10027361 Term: Mental disorders due to a general medical condition NEC		Product Name: Melperon
Pharmaceutical Form: Syrup
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-		OVATION PHARMACEUTICALS INCNot RecruitingFemale: yes
Male: yes		90Italy
978NCT00524914September 200719 February 2015Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging StudyApomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study.Parkinson's DiseaseDrug: apomorphine;Drug: placeboUniversity Hospital, ToulouseNot recruiting30 Years70 YearsBoth16N/AFrance
979NCT00537485September 200719 October 2017A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease PatientsA Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopaEarly Parkinson's DiseaseDrug: SPM 962;Drug: placeboOtsuka Pharmaceutical Co., Ltd.Not recruiting30 Years79 YearsAll180Phase 2/Phase 3Japan
980EUCTR2007-003512-57-FR24/08/200719 March 2012Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)Excessive daytime sleepiness associated to Parkinson disease
MedDRA version: 9.1 Level: LLT Classification code 10041014 Term: Sleepiness
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: BF 2.649
Product Code: BF 2.649
Pharmaceutical Form: Capsule*
Current Sponsor code: BF 2.649
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: BF 2.649
Product Code: BF 2.649
Pharmaceutical Form: Capsule*
Current Sponsor code: BF 2.649
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Product Name: BF 2.649
Product Code: BF 2.649
Pharmaceutical Form: Capsule*
Current Sponsor code: BF 2.649
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Product Name: BF 2.649
Product Code: BF 2.649
Pharmaceutical Form: Capsule*
Current Sponsor code: BF 2.649
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-		BioprojetAuthorisedFemale: yes
Male: yes		130France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
981EUCTR2007-000801-30-CZ01/08/200719 March 2012A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor FluctuationsA Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor FluctuationsParkinson's Disease
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: E2007
Product Code: MARS
Pharmaceutical Form: Film-coated tablet
Current Sponsor code: E2007
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-		Eisai LimitedNot RecruitingFemale: yes
Male: yes		726Hungary;Czech Republic;France;Estonia;Spain;Italy;Latvia;Poland;Lithuania
982NCT00335374August 200719 February 2015An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD PatientsAn Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD PatientsEarly Stage Parkinson's DiseaseDrug: PardoprunoxSolvay PharmaceuticalsNot recruiting30 YearsN/ABoth202Phase 3United States;Australia;Czech Republic;Estonia;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Taiwan;Thailand;France;Spain;United Kingdom
983NCT00407095August 200719 February 2015An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.Advanced Stage Parkinson's DiseaseDrug: PardoprunoxSolvay PharmaceuticalsNot recruiting30 YearsN/ABoth140Phase 3United States;Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine
984NCT00442780August 200719 February 2015Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's DiseaseParkinson's DiseaseDrug: BIIB014;Drug: PlaceboBiogen IdecNot recruiting30 YearsN/ABoth36Phase 2Israel;Poland;Serbia;Former Serbia and Montenegro
985EUCTR2006-005318-11-FR06/07/200719 March 2012Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons.Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons.maladie de Parkinson
MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Trade Name: APOKINON
Pharmaceutical Form: Solution for injection
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use		CHU ToulouseAuthorisedFemale: yes
Male: yes		France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
986NCT00515437July 200713 May 2019A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease PatientsA Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease PatientsDroolingBiological: Botulinum Toxin Type B (Myobloc);Biological: Matched placebo to MyoblocSolstice NeurosciencesNot recruiting18 Years85 YearsAll54Phase 2United States
987NCT00522379July 200719 October 2017Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal PatchA Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's DiseaseParkinson's DiseaseDrug: Rotigotine;Other: PlaceboUCB PharmaNot recruiting30 YearsN/AAll514Phase 3United States;Chile;India;Mexico;Peru
988NCT00550238July 200725 June 2018A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisA Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's DiseaseParkinson's Disease PsychosisDrug: Pimavanserin tartrate (ACP-103)ACADIA Pharmaceuticals Inc.Not recruiting40 YearsN/AAll459Phase 3United States;Austria;Belgium;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom
989NCT00556764July 200719 February 2015Development of Cognitive Assessment Tools in Parkinson DiseaseDevelopment of Cognitive Assessment Tools in Parkinson DiseaseParkinson DiseaseDrug: [123I] IBVM and SPECT imaging;Drug: Subjects will undergo the 123-I IBVM imaging visitInstitute for Neurodegenerative DisordersDepartment of Defense;University of OklahomaNot recruiting30 YearsN/ABoth75Phase 0United States
990NCT00593606July 200719 October 2017Safety and Tolerability Trial of Switching From Ropinirole to RotigotineA Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: RotigotineUCB PharmaNot recruiting18 YearsN/AAll124Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
991EUCTR2006-000678-57-CZ18/06/200719 March 2012A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyA multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease. - The Vermeer studyParkinson 's Disease early stage
MedDRA version: 8.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
CAS Number: 269718-83-4
Current Sponsor code: SLV308
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
CAS Number: 269718-83-4
Current Sponsor code: SLV308
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
CAS Number: 269718-83-4
Current Sponsor code: SLV308
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
CAS Number: 269718-83-4
Current Sponsor code: SLV308
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308
Pharmaceutical Form: Film-coated tablet
CAS Number: 269718-83-4
Current Sponsor code: SLV308
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.0-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Solvay pharmaceuticalsNot RecruitingFemale: yes
Male: yes		330Portugal;United Kingdom;Germany;Czech Republic;Netherlands;France;Estonia;Italy;Lithuania
992EUCTR2007-000073-39-CZ18/06/200719 March 2012A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.375-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Tablet		Boehringer Ingelheim RCV GmbH & Co KGNot RecruitingFemale: yes
Male: yes		500Hungary;Finland;Czech Republic;Austria
993EUCTR2006-005438-19-DE12/06/200719 March 2012An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOSAn explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. - NEUPOSidiopathic Parkinson´s disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Neupro 2 mg/24 h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4,5 mg-
Trade Name: Neupro 4 mg/24 h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9,0 mg-
Trade Name: Neupro 6 mg/24 h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13,5 mg-
Trade Name: Neupro 8 mg/24 h transdermal patch
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18,0 mg-		SCHWARZ PHARMA Deutschland GmbHNot RecruitingFemale: yes
Male: yes		30Germany
994EUCTR2006-005861-21-IT11/06/20077 January 2013A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC.A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERAPY, IN PATIENTS WITH IDIOPATHIC PARKINSON`S DISEASE WITH MOTOR FLUCTUATIONS, TREATED WITH A STABLE DOSE OF LEVODOPA AND WHO MAY BE RECEIVING CONCOMITANT TREATMENT WITH STABLE DOSES OF A DOPAMINE AGONIST, AND/OR AN ANTICHOLINERGIC.Patients with idiopathic Parkinson's disease with motor fluctuations
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Tablet
INN or Proposed INN: Monoamine oxidase B inhibitors
Concentration unit: mg milligram(s)
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oromucosal use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Tablet
INN or Proposed INN: Monoamine oxidase B inhibitors
Concentration unit: mg milligram(s)
Concentration number: 50-		NEWRON PHARMACEUTICALSNot RecruitingFemale: yes
Male: yes		500Phase 3Italy
995EUCTR2006-006684-22-FR08/06/200719 March 2012Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSKEvaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. - AMANDYSKmaladie de parkinson
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's
MedDRA version: 9.1 Level: LLT Classification code 10013916 Term: Dyskinesia		Trade Name: MANTADIX
Pharmaceutical Form: Capsule*
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		CHU ToulouseAuthorisedFemale: yes
Male: yes		France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
996JPRN-UMIN0000007802007/06/012 April 2019A randomized, double-blind, placebo-controlled, cross-over, multi-center study concerning the efficacy and safety of amantadine hydrochloride in treatment of dyskinesias in Parkinson's diseaseParkinson's diseaseAn observation period (2 to 3 weeks)

An administration of amantadine hydrochloride (27 days)

A wash out period (15 days)

An administration of placebo (27 days)
An observation period (2 to 3 weeks)

An administration of placebo (27 days)

A wash out period (15 days)

An administration of amantadine hydrochloride (27 days)		Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disordersMusashi Hospital, National Center of Neurology and Psychiatry, Japan Ehime University HospitalNot Recruiting20years-old75years-oldMale and Female60Not applicableJapan
997NCT00460954June 200719 February 2015A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy SubjectsAn Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy SubjectsParkinson's DiseaseDrug: Sinemet® controlled release (Carbidopa/levodopa)Bristol-Myers SquibbNot recruiting50 Years75 YearsBoth20N/ACanada
998NCT00462254June 200719 February 2015Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's DiseaseRamelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's DiseaseParkinson's DiseaseDrug: ROZEREM;Drug: RamelteonSouthern California Institute for Research and EducationNot recruiting45 Years85 YearsBoth4Phase 4United States
999NCT00477672June 200716 December 2017A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisA Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's DiseaseParkinson's Disease PsychosisDrug: Pimavanserin tartrate (ACP-103);Drug: PlaceboACADIA Pharmaceuticals Inc.Not recruiting40 YearsN/AAll298Phase 3United States;Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom
1000NCT00485069June 200719 October 2017REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 StudyPost-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -Parkinson Disease;Parkinson's DiseaseDrug: ROP;Drug: ROP+L-DopaGlaxoSmithKlineNot recruiting20 YearsN/AAll123Phase 4Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1001NCT00571285June 200716 December 2017Clinical Effects of Vitamin D Repletion in Patients With Parkinson's DiseaseClinical Effects of Vitamin D Repletion in Patients With Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Vitamin D3;Dietary Supplement: Vitamin D3 - high dose;Dietary Supplement: PlaceboEmory UniversityNot recruiting18 Years89 YearsAll31Phase 4United States
1002NCT00696215June 200719 February 2015The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's DiseaseThe Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 MonthsParkinson's DiseaseDrug: placebo;Drug: rasagilineIstanbul UniversityRecruitingN/AN/ABoth40Phase 4Turkey
1003EUCTR2007-000073-39-DE29/05/20073 June 2013A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)Male or female patients with idiopathic Parkinson’s disease (PD), diagnosed within 5 years, having Modified Hoehn and Yahr stage of 1 to 3.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.375-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Other descriptive name: Prolonged release tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Tablet		Boehringer Ingelheim Pharma GmbH & Co. KGNot RecruitingFemale: yes
Male: yes		500Hungary;Czech Republic;Finland;Austria;Germany
1004EUCTR2007-000074-23-GB11/05/200719 March 2012A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.375-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.0-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: SIFROL
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y		Boehringer Ingelheim LimitedNot RecruitingFemale: yes
Male: yes		516Hungary;United Kingdom;Spain;Italy;Austria;Sweden
1005EUCTR2006-006752-35-FI09/05/200716 October 2012RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - RecoverRECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - RecoverParkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Neupro 2mg/24 h transdermal patch
Product Code: ND1587
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-mg
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 4mg/24 h transdermal patch
Product Code: ND1589
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-mg
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 6mg/24 h transdermal patch
Product Code: ND1590
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-mg
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro 8 mg/24 h transdermal patch
Product Code: ND1702
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-mg
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use		Schwarz Biosciences GmbHNot RecruitingFemale: yes
Male: yes		400Phase 3BHungary;Finland;Spain;Austria;Germany;United Kingdom;Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1006NCT00477802May 200719 February 2015Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's DiseaseBotulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design StudyParkinson DiseaseBiological: Botulinum Toxin Type A;Biological: PlaceboUniversity of CincinnatiAllerganNot recruiting35 Years75 YearsBoth8Phase 4United States
1007NCT00489255May 200719 October 2017Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentA Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent Off Episodes, With Phased Withdrawal of Subjects From Tigan® to PlaceboParkinson's DiseaseDrug: Tigan®;Drug: PlaceboIpsenINC Research LimitedNot recruiting18 YearsN/AAll117Phase 4United States
1008NCT00505843May 200719 February 2015A Study of MK0657 in Parkinson's Disease Patients (0657-006)A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: MK0657;Drug: Comparator: Placebo (unspecified);Drug: Comparator: levodopa;Drug: Comparator: carbidopaMerck Sharp & Dohme Corp.Not recruiting40 Years80 YearsBoth18Phase 1United States
1009EUCTR2007-000307-15-IT24/04/200719 March 2012Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.Psicosi associata al morbo di Parkinson
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's		Product Name: Melperon
Pharmaceutical Form: Syrup
INN or Proposed INN: melperon
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Syrup
Route of administration of the placebo: Oral use		OVATION PHARMACEUTICALS INCNot RecruitingFemale: yes
Male: yes		90Italy
1010NCT00434304April 9, 200716 December 2017Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -Parkinson DiseaseDrug: Ropinirole prolonged release/extended release(PR/XR)GlaxoSmithKlineNot recruiting20 YearsN/AAll62Phase 2Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1011NCT00459420April 200728 April 2015Caffeine for Excessive Daytime Somnolence in Parkinson's DiseaseCaffeine for Excessive Daytime Somnolence in Parkinson's DiseaseParkinson's Disease;Excessive Daytime SomnolenceDrug: Caffeine 100-200 mg BID;Drug: placeboRon PostumaCanadian Institutes of Health Research (CIHR);University of TorontoNot recruiting18 YearsN/ABoth58Phase 2/Phase 3Canada
1012NCT00460148April 20077 November 2016Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of RopiniroleAn Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets.Parkinson DiseaseDrug: RopiniroleGlaxoSmithKlineNot recruiting30 Years85 YearsBoth28Phase 2Germany;South Africa
1013NCT00466167April 200719 October 2017Pivotal Study in Advanced Parkinsons Disease PatientsA Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).Parkinson DiseaseDrug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: PlaceboBoehringer IngelheimNot recruiting32 YearsN/AAll517Phase 3Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom
1014NCT00623363April 200719 February 2015Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's DiseaseParkinson's DiseaseDrug: piclozotan;Drug: 0.9% sodium chloride (normal saline)Asubio Pharmaceuticals, Inc.Not recruiting40 Years85 YearsBoth27Phase 2United States;Guatemala;Romania
1015EUCTR2006-006209-94-DE15/03/200719 March 2012An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.Parkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Requip-Modutab
Product Name: Requip-Modutab
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Trade Name: Requip-Modutab
Product Name: Requip-Modutab
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Trade Name: Requip-Modutab
Product Name: Requip-Modutab
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Product Name: Ropinirole
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12-		GlaxoSmithKline Research & Development LimitedNot RecruitingFemale: yes
Male: yes		36Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1016NCT00406588March 200719 February 2015SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor FluctuationsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.Advanced Stage Parkinson's DiseaseDrug: Pardoprunox;Drug: Placebo ComparatorSolvay PharmaceuticalsNot recruiting30 YearsN/ABoth295Phase 3United States;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine
1017NCT00437125March 200719 October 2017Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's DiseaseAn Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's DiseaseMajor Depressive Disorder;Idiopathic Parkinson DiseaseDrug: Duloxetine hydrochlorideEli Lilly and CompanyNot recruiting30 Years75 YearsAll151Phase 4Italy
1018NCT00443872March 200719 October 2017Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine AgonistsAdding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing ComplicationsParkinson's DiseaseDrug: orally disintegrating selegiline (Zelapar)Parkinson's Disease and Movement Disorder Center of Boca RatonValeant Pharmaceuticals International, Inc.Not recruiting30 Years90 YearsAll77Phase 4United States
1019NCT00449865March 200719 October 2017NET-PD LS-1 Creatine in Parkinson's DiseaseA Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)Parkinson's DiseaseDrug: creatine;Other: placeboUniversity of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/AAll1741Phase 3United States;Canada
1020NCT00451633March 200719 February 2015The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor FluctuationsA Randomized, Double Blind, Placebo-Controlled Study To Investigate The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor FluctuationsParkinson's DiseaseDrug: E2007Eisai Inc.Not recruiting30 Years80 YearsBoth0Phase 2Germany;Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1021NCT00455507March 200719 February 2015A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaPlacebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study)Parkinson's DiseaseDrug: Istradefylline;Drug: PlaceboKyowa Hakko Kirin Company, LimitedNot recruiting20 YearsN/ABoth363Phase 2Japan
1022NCT01693081March 200719 February 2015Phase IIa Multicentre Study Investigating of VR040 in Parkinson's DiseaseA Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's DiseaseParkinson's DiseaseDrug: VR040/Aspirair® inhaler;Drug: placeboSouth Glasgow University Hospitals NHS TrustVectura LimitedNot recruiting30 Years90 YearsBoth47Phase 2Serbia;United Kingdom
1023EUCTR2006-002408-32-ES27/02/200719 March 2012Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa.Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa.Fluctuaciones motoras, cognitivas y del humor en la enfermedad de Parkinson.
MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease		Trade Name: Stalevo 150
Product Name: Levodopa-carbidopa-entacapone
Pharmaceutical Form: Capsule, hard
Trade Name: Sinemet
Product Name: Levodopa/Carbidopa
Pharmaceutical Form: Capsule, hard		Institut de Recerca del Hospital de la Santa Creu i Sant PauAuthorisedFemale: yes
Male: yes		20Spain
1024EUCTR2006-005714-12-IT27/02/200719 March 2012A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213A randomized, double blind, placebo-controlled study to investigate the effect of E2007 on pharmacodynamic responses to levodopa among patients with Parkinson's disease who experience dyskinesia and motor fluctuations. - E2007-E044-213Patients with idiopathic Parkinson's disease who respond to levodopa treatment but who experience peak-effect levodopa-induced dyskinesia and end-of-dose 'wearing-off' motor fluctuations
MedDRA version: 6.1 Level: HLT Classification code 10034005		Product Name: E2007
Product Code: E2007
Pharmaceutical Form: Tablet
INN or Proposed INN: OTHER NERVOUS SYSTEM DRUGS
Current Sponsor code: E2007
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: SINEMET
Pharmaceutical Form: Tablet
INN or Proposed INN: levodopa-carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 275-		EISAI LTD UKNot RecruitingFemale: yes
Male: yes		24Italy
1025NCT00332917February 200719 February 2015An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD PatientsAn Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD PatientsEarly Stage Parkinson's DiseaseDrug: PardoprunoxSolvay PharmaceuticalsNot recruiting30 YearsN/ABoth224Phase 3United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1026NCT00427011February 200719 October 2017A Study of E2007 In Patients With Parkinson's DiseaseA Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing-Off Motor FluctuationsParkinson's DiseaseDrug: E2007Eisai Inc.Not recruiting18 YearsN/AAll25Phase 2United States
1027NCT00480701February 200719 February 2015Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer DiseaseEvaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer DiseaseAlzheimer Disease;Parkinson DiseaseDrug: [123I]-IBVMInstitute for Neurodegenerative DisordersNot recruiting50 YearsN/ABoth26Phase 2United States
1028EUCTR2006-003732-30-DE31/01/200719 March 2012Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS - TULEP 1Early Parkinson's Disease
MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease		Product Name: Lisuride TTS 10cm²
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: LISURIDE
CAS Number: 18016803
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2,5-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Sifrol 0,088
Pharmaceutical Form: Capsule*
INN or Proposed INN: PRAMIPEXOLE
CAS Number: 104632260
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,088-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: Lisuride TTS 20cm²
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: LISURIDE
CAS Number: 18016803
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5,0-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Sifrol 0,18
Pharmaceutical Form: Capsule*
INN or Proposed INN: PRAMIPEXOLE
CAS Number: 104632260
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,18-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Sifrol 0,35
Pharmaceutical Form: Capsule*
INN or Proposed INN: PRAMIPEXOLE
CAS Number: 104632260
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,35-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Sifrol 0,7
Pharmaceutical Form: Capsule*
INN or Proposed INN: PRAMIPEXOLE
CAS Number: 104632260
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,7-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Axxonis Pharma AGAuthorisedFemale: yes
Male: yes		350Germany;Italy;Poland
1029NCT00427674January 200719 February 2015Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease PatientsPhase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human SubjectsParkinson DiseaseDrug: [123I] mZINT injection and serial dynamic SPECT imagingInstitute for Neurodegenerative DisordersMolecular NeuroImagingNot recruiting18 Years70 YearsBoth28Phase 1United States
1030NCT00465452January 200719 February 2015Impact of Switching to Continuous Release Dopamine AgonistsThe Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side EffectsParkinson DiseaseDrug: Continuous Release Dopamine AgonistsUniversity of Toledo Health Science CampusNot recruiting55 YearsN/ABoth15Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1031NCT00640159January 200719 February 2015Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's DiseaseTolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.Parkinson's DiseaseDrug: ZelaparBaylor College of MedicineNot recruiting30 Years90 YearsBoth55Phase 4United States
1032NCT01187966January 200719 February 2015Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseaseA Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an AnticholinergicParkinson's DiseaseDrug: Safinamide;Drug: PlaceboNewronNot recruiting30 Years80 YearsBoth669Phase 3
1033EUCTR2006-005509-79-GB21/12/20068 August 2016A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s DiseaseA Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients with Established Idiopathic Parkinson’s DiseaseIdiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor “off” periodsProduct Name: apomorphine hydrochloride
Product Code: VR040
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: VR040
Concentration unit: µg microgram(s)
Concentration type: range
Concentration number: 3200-9000
Pharmaceutical form of the placebo: Inhalation powder
Route of administration of the placebo: Inhalation use		Vectura Group plcNot RecruitingFemale: yes
Male: yes		42Phase 2United Kingdom
1034EUCTR2006-003490-27-GB19/12/200619 March 2012A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with LevodopaA Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with LevodopaParkinson's disease
MedDRA version: 8.1 Level: PT Classification code 10061536 Term: Parkinson's disease		Product Code: BIIB014
Pharmaceutical Form: Capsule, hard
CAS Number: 442908-10-3
Current Sponsor code: BIIB014
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: BIIB014
Pharmaceutical Form: Capsule, hard
CAS Number: 442908-10-3
Current Sponsor code: BIIB014
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: BIIB014
Pharmaceutical Form: Capsule, hard
CAS Number: 442908-10-3
Current Sponsor code: BIIB014
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		BIOGEN IDEC LTDNot RecruitingFemale: yes
Male: yes		137United Kingdom
1035EUCTR2006-005860-14-IT19/12/200619 March 2012A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - NDA phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson?s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist and/or an anticholinergic - NDPATIENTS WITH IDIOPATHIC PARKINSON?S DISEASE WITH MOTOR FLUCTUATIONS
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Buccal use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-		NEWRON PHARMACEUTICALSNot RecruitingFemale: yes
Male: yes		600Phase 3Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1036EUCTR2006-005140-89-NL11/12/200619 March 2012A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge studyA PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge studyThis postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
MedDRA version: 9.1 Level: PT Classification code 10061536		Trade Name: Selegiline HCl 5 PCH
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Nardil
Pharmaceutical Form: Tablet
Product Name: Rasagiline 1mg tablet
Product Code: TVP-1012
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
CAS Number: 161735-79-1
Current Sponsor code: TVP-1012
Other descriptive name: Rasagiline mesilate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Rasagiline 2 mg tablet
Product Code: TVP-1012
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
CAS Number: 161735-79-1
Current Sponsor code: TVP-1012
Other descriptive name: Rasagiline mesilate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		TEVA Pharmaceuticals Industries LtdAuthorisedFemale: yes
Male: yes		160Phase 1Netherlands
1037NCT00036296December 200619 February 2015Effects of Talampanel on Patients With Advanced Parkinson's DiseaseEffects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)Dyskinesias;Parkinson Disease;Movement DisordersDrug: talampanelTeva Pharmaceutical IndustriesNot recruiting40 Years85 YearsBoth22Phase 1/Phase 2United States;Canada
1038NCT00853879December 200625 May 2015An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's DiseaseAn Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Folic Acid, Vitamin B6, Vitamin B12;Dietary Supplement: B6, B12, L-methylfolate;Dietary Supplement: B6, B12, PlaceboNorth Shore Long Island Jewish Health SystemNot recruiting30 YearsN/ABoth150N/AUnited States
1039NCT01631812December 200619 October 2017A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsAn Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopaParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.Not recruitingN/AN/AAll130Phase 2Japan
1040NCT01964573December 200619 February 2015Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean SubjectsA Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean SubjectsParkinson's DiseaseDrug: Rotigotine;Other: PlaceboUCB PharmaNot recruiting19 Years45 YearsBoth48Phase 1Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1041EUCTR2006-004112-51-IT14/11/200619 March 2012A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - NDA randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Disease PD patients compared to standard levodopa/carbidopa Sinemet oral tablets - NDParkinson s disease
MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: SIRIO*30CPR EFF 25MG+100MG
Pharmaceutical Form: Effervescent tablet
INN or Proposed INN: Melevodopa and decarboxylase inhibitor
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Effervescent tablet
Route of administration of the placebo: Oral use
Trade Name: SINEMET*50CPR 100MG+25MG
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA DC.IT FU
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA FU
CAS Number: 28860-95-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		VERNALIS DEVELOPMENT LIMITEDNot RecruitingFemale: yes
Male: yes		Italy
1042EUCTR2006-004582-33-GB03/11/20068 August 2016A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s DiseaseA Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s DiseaseHypomobility (off or freezing) episodes associated with advanced Parkinson's diseaseProduct Name: Apomorphine hydrochloride
Product Code: VR040
Pharmaceutical Form: Inhalation powder
Pharmaceutical form of the placebo: Inhalation powder
Route of administration of the placebo: Inhalation use		Vectura Group plcNot RecruitingFemale: yes
Male: yes		48Phase 2United Kingdom
1043NCT00335166November 200619 February 2015SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson DiseaseA Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.Early Stage Parkinson DiseaseDrug: Placebo Comparator;Drug: pramipexole;Drug: PardaprunoxSolvay PharmaceuticalsNot recruiting30 YearsN/ABoth330Phase 3United States;Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom
1044NCT00360308November 200619 October 2017Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsA Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseDrug: Placebo;Drug: E2007Eisai LimitedNot recruiting30 YearsN/AAll723Phase 3France
1045NCT00387075November 200615 April 2019A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseParkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson DiseaseParkinson DiseaseProcedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CITInstitute for Neurodegenerative DisordersUnited States Department of Defense;Molecular NeuroImagingNot recruiting50 YearsN/AAll3000Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1046NCT00397228November 20069 January 2017ALTROPANE® SPECT Imaging in Patients With Parkinson DiseaseOptimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson DiseaseParkinson DiseaseDrug: ALTROPANE®Molecular NeuroImagingInstitute for Neurodegenerative DisordersNot recruiting30 YearsN/ABoth27Phase 2United States
1047NCT00397696November 200619 February 2015Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons DiseaseEvaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease SubjectsParkinson DiseaseDrug: [123I] 5-IAInstitute for Neurodegenerative DisordersDepartment of DefenseNot recruiting21 YearsN/ABoth9Phase 2United States
1048NCT00402233November 200619 October 2017A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) PatientsA Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)Parkinson DiseaseDrug: Pramipexole;Drug: PlaceboBoehringer IngelheimNot recruiting31 YearsN/AAll312Phase 4United States
1049NCT00404170November 200615 April 2019Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson DiseaseAssessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT CohortParkinson DiseaseDrug: B-CIT and SPECT imagingInstitute for Neurodegenerative DisordersUnited States Department of DefenseNot recruiting30 YearsN/AAll396Phase 2United States
1050NCT00406029November 200619 October 2017Dyskinesia in Parkinson's Disease (Study P04501)A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and DyskinesiasParkinson Disease;Movement Disorders;Central Nervous System Diseases;Neurodegenerative Diseases;Brain DiseasesDrug: Preladenant;Drug: Placebo;Drug: L-dopa;Drug: Other Parkinson's Disease treatmentsMerck Sharp & Dohme Corp.Not recruiting30 YearsN/AAll253Phase 2Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1051NCT00468078November 200625 January 2016Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor PatientsThe Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor PatientsParkinson's DiseaseProcedure: PET/CT;Drug: F-18 FPCITAsan Medical CenterNot recruiting40 YearsN/ABoth78Phase 3Korea, Republic of
1052NCT00491998November 200619 February 2015PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral TabletsRandomised, Double-blind, Double-dummy, Two-period, Cross-over Study to Determine the PK, PD and Safety of Multiple Doses of V1512 Effervescent Tablets in Parkinson's Disease Patients Compared to Sinemet® Oral TabletsParkinson's DiseaseDrug: V1512;Drug: V1512 and EntacaponeVernalis (R&D) LtdCita NeuroPharmaceuticals;INC ResearchNot recruiting30 YearsN/ABoth27Phase 1/Phase 2Italy
1053EUCTR2005-002038-36-GB31/10/200611 September 2012A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesPatients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease ;Patients with Parkinson’s disease dementia or dementia with Lewy Bodies
MedDRA version: 8.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease		Trade Name: Ebixa
Product Name: Ebixa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Code: Lu 00-800
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: memantine hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: Ebixa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Code: Lu 00-800
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: memantine hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		H. Lundbeck A/SAuthorisedFemale: yes
Male: yes		200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
1054NCT00360412October 200619 October 2017A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsA Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseDrug: E2007Eisai Inc.Not recruiting30 YearsN/AMale997Phase 3Germany
1055NCT00373087October 200619 February 2015COMT Polymorphism and Entacapone EfficacyInfluence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's DiseaseParkinson's DiseaseDrug: entacapone;Drug: l dopa versus placeboAssistance Publique - Hôpitaux de ParisNot recruiting30 YearsN/ABoth60Phase 4France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1056NCT00391898October 200619 October 2017Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-offA 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With LevodopaParkinson's DiseaseDrug: Levodopa/carbidopa/entacapone;Drug: Levodopa/carbidopaNovartisNot recruiting30 Years80 YearsAll95Phase 4Spain
1057NCT00399477October 200619 February 2015A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's DiseaseOpen-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)Parkinson's DiseaseDrug: rasagiline mesylate;Drug: Rasagiline mesylate plus Mirapex;Drug: Rasagiline mesylate with Levodopa;Drug: Rasagiline mesylate with RequipTeva Neuroscience, Inc.Not recruiting30 YearsN/ABoth200Phase 4United States
1058NCT00590122October 200619 February 2015Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison StudyCOMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIALParkinson's DiseaseDrug: Parcopa;Drug: carbidopa-levodopaBaylor College of MedicineUCB PharmaNot recruiting31 Years80 YearsBoth20Phase 4United States
1059NCT03103399September 26, 200616 December 2017Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff PhenomenonA Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/BenserazideParkinson DiseaseDrug: Comtan®;Drug: Nebicapone;Drug: Levodopa/DDCI;Drug: PlaceboBial - Portela C S.A.Not recruiting30 Years80 YearsAll254Phase 2
1060EUCTR2005-002038-36-AT22/09/200611 September 2012A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesA randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesPatients with Parkinson’s disease dementia or dementia with Lewy BodiesTrade Name: Ebixa
Product Name: Ebixa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Ebixa
Product Name: Ebixa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: Ebixa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Ebixa
Product Name: Ebixa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MEMANTINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		H. Lundbeck A/SNot RecruitingFemale: yes
Male: yes		200Germany;United Kingdom;France;Spain;Italy;Greece;Austria
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1061EUCTR2005-005146-39-IT14/09/200619 March 2012A Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - NDA Phase-2, 12-week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a range of SCH 420814 Doses 1 mg BID, 2 mg BID, 5 mg BID and Possibly 10 mg BID in Subjects With Moderate to Severe Parkinson s Disease Experiencing Motor Fluctuations and Dyskinesias. - NDModerate to severe Parkinson s disease with motor fluctuation and dyskinesias.
MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Code: SCH 420814
Pharmaceutical Form: Capsule, hard
CAS Number: 377727-87-2
Current Sponsor code: SCH 420814
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Code: SCH 420814
Pharmaceutical Form: Capsule, hard
CAS Number: 377727-87-2
Current Sponsor code: SCH 420814
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Schering Plough Research InstituteNot RecruitingFemale: yes
Male: yes		160Italy
1062NCT00208611September 200619 February 2015Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's DiseaseAssessment of Cobalamin Status and Responses to Supplementation in Patients With Parkinson's Disease : a Pilot StudyParkinson's DiseaseDietary Supplement: Vitamin B12 SupplementationEmory UniversityNational Institutes of Health (NIH)Not recruiting21 YearsN/ABoth57Phase 2/Phase 3United States
1063NCT00355927September 200619 February 2015Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation.Movement Disorders;Parkinson Disease;Parkinsonian Disorders;Dystonia;Tourette SyndromeProcedure: Sedation with IV propofolHadassah Medical OrganizationRecruitingN/AN/ABoth20N/AIsrael
1064NCT00462007September 20064 May 2015Study to Evaluate Initiation of Stalevo in Early Wearing-offEfficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease PatientsParkinson's DiseaseDrug: StalevoOrion Corporation, Orion PharmaNot recruiting35 YearsN/ABoth115Phase 4Germany;Sweden;United Kingdom
1065NCT00507715September 200619 February 2015Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata HuskClinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata HuskParkinson's Disease, IdiopathicDrug: Plantago ovata husk;Other: hemicellulose crystallineRottapharm SpainNot recruiting60 Years80 YearsBoth18Phase 1Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1066EUCTR2006-001755-36-SE09/08/20061 May 2012Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSEEfficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients - SENSEParkinson’s disease
MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 37.5-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-		Orion Corporation Orion Pharma, FI-02200 Espoo, FinlandNot RecruitingFemale: yes
Male: yes		100United Kingdom;Germany;Sweden
1067NCT00368108August 200619 October 2017Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsA Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseDrug: 2 mg perampanel;Drug: 4 mg perampanel;Drug: placebo comparatorEisai Inc.Not recruiting30 YearsN/AAll752Phase 3United States;Canada
1068NCT00640952August 200623 November 2015Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's DiseaseAcamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's DiseaseParkinson's DiseaseDrug: acamprosateBaylor College of MedicineNational Parkinson FoundationNot recruiting18 YearsN/ABoth0N/AUnited States
1069EUCTR2006-001793-24-AT31/07/200619 March 2012A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not availableA MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not availablePatients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (wearing-off) phenomenon although currently treated with levodopa/DDCI.
MedDRA version: 7 Level: LLT Classification code 10061536		Product Name: Nebicapone
Product Code: BIA 3-202
Pharmaceutical Form: Tablet
CAS Number: 274925-86-9
Current Sponsor code: BIA 3-202
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Entacapone
Pharmaceutical Form: Tablet
INN or Proposed INN: Entacapone
CAS Number: 130929-57-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Product Name: Nebicapone
Product Code: BIA 3-202
Pharmaceutical Form: Tablet
CAS Number: 274925-86-9
Current Sponsor code: BIA 3-202
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Nebicapone
Product Code: BIA 3-202
Pharmaceutical Form: Tablet
CAS Number: 274925-86-9
Current Sponsor code: BIA 3-202
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		BIAL - Portela & Cª, SANot RecruitingFemale: yes
Male: yes		250Portugal;Austria
1070NCT03097211July 17, 200616 December 2017Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgA Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgParkinson DiseaseDrug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: NebicaponeBial - Portela C S.A.Not recruiting18 Years45 YearsAll38Phase 1Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1071EUCTR2006-000680-28-ES07/07/20062 February 2015Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y “wearing-off” A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBIEstudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y “wearing-off” A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBIEnfermedad de Parkinson (Parkinson Disease)Trade Name: Stalevo 100
Product Name: Stalevo (levodopa/carbidopa/entacapona)
Pharmaceutical Form: Coated tablet
INN or Proposed INN: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: ENTACAPONA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Sinemet plus
Product Name: Sinemet plus (levodopa/carbidopa)
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: Stalevo 150
Product Name: Stalevo (levodopa/carbidopa/entacapona)
Pharmaceutical Form: Coated tablet
INN or Proposed INN: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 37.5-
INN or Proposed INN: ENTACAPONA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-		NOVARTIS FARMACEUTICA, S.ANot RecruitingFemale: yes
Male: yes		200Spain
1072NCT00346827July 200622 July 2019Apomorphine Nasal Powder in the Treatment of Parkinson's Disease Off Periods.Parkinson's DiseaseDrug: Apomorphine Nasal PowderBritannia Pharmaceuticals Ltd.Not recruiting18 Years85 YearsAll36Phase 2/Phase 3
1073NCT00354133July 20062 July 2018Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's DiseaseThe Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)Parkinson DiseaseDevice: Kinetra and Soletra (neurostimulator, Medtronic);Drug: Best Medical TreatmentGerman Parkinson Study Group (GPS)University of Schleswig-Holstein;Assistance Publique - Hôpitaux de Paris;KKS NetzwerkNot recruiting18 Years60 YearsAll251Phase 4France;Germany
1074EUCTR2006-000361-11-GB23/06/200619 March 2012A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201)A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients - Parkinson's Disease FPFS-1169 Proof of Concept Study (RD639/24201)Treatment of Parkinson's Disease
MedDRA version: 8.0 Classification code 10029205		Product Name: FPFS-1169
Pharmaceutical Form: Solution for injection
INN or Proposed INN: R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride
CAS Number: 265130-22-1
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 6-		Fujimoto Pharmaceutical CorporationAuthorisedFemale: yes
Male: yes		10United Kingdom
1075NCT00331149June 20, 200616 December 2017A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson'sA Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.Parkinson DiseaseDrug: Ropinirole prolonged release;Drug: ropinirole immediate releaseGlaxoSmithKlineNot recruiting30 YearsN/AAll343Phase 3Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1076EUCTR2005-005423-34-DE19/06/200619 March 2012A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.Parkinson's diseaseProduct Name: Ropinirole PR/XR Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SKF101468-A
Other descriptive name: Ropinirole hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Ropinirole PR/XR Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SKF101468-A
Other descriptive name: Ropinirole hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Ropinirole PR/XR Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SKF101468-A
Other descriptive name: Ropinirole hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8.0-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Ropinirole IR Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SKF101468-A
Other descriptive name: Ropinirole hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Ropinirole IR Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: Ropinirole
CAS Number: 91374-20-8
Current Sponsor code: SKF101468-A
Other descriptive name: Ropinirole hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Ropinirole IR Tablets
Pharmaceutical Form: Tablet		GlaxoSmithKline Research & Development LtdNot RecruitingFemale: yes
Male: yes		516Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy
1077EUCTR2006-000391-32-GB06/06/200619 March 2012A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's DiseaseA 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's DiseaseAlleviation of acute episodes of motor symptoms associated with Parkinson's Disease
MedDRA version: 8.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Product Name: Apomorphine Nasal Powder
Pharmaceutical Form: Nasal powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate
Concentration unit: % (W/W) percent weight/weight
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Nasal powder
Route of administration of the placebo: Nasal use		Britannia Pharmaceuticals LimitedNot RecruitingFemale: yes
Male: yes		130Germany;United Kingdom;Netherlands
1078NCT00269516June 200619 February 2015SLV308 for Treatment of Patients With Early Parkinson's DiseaseA Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's DiseaseEarly Stage Parkinson's DiseaseDrug: pardoprunox;Drug: Pardoprunox;Drug: PlaceboSolvay PharmaceuticalsNot recruiting30 YearsN/ABoth468Phase 3United States;Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;Former Serbia and Montenegro
1079NCT00291733May 200619 February 2015Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's DiseaseLevetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover TrialLevodopa Induced DyskinesiaDrug: Levetiracetam;Drug: Placebo1st Hospital of Social Security ServicesUCB PharmaNot recruiting30 Years80 YearsBoth50Phase 2Greece
1080NCT00321854May 200619 October 2017Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.Parkinson DiseaseDrug: pramipexoleBoehringer IngelheimNot recruiting30 Years79 YearsAll535Phase 4United States;Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1081NCT00324896May 200619 October 2017Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of EszopicloneTreatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of EszopicloneParkinson's Disease;InsomniaDrug: eszopiclone;Other: placeboUniversity of Medicine and Dentistry of New JerseySunovionNot recruiting35 Years85 YearsAll30Phase 3United States
1082NCT00329056May 200619 February 2015A Trial of MitoQ for the Treatment of People With Parkinson's DiseaseA Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinson's DiseaseParkinson's DiseaseDrug: MitoQAntipodean Pharmaceuticals, Inc.Not recruiting30 YearsN/ABoth128Phase 2Australia;New Zealand
1083NCT03094156April 26, 200616 December 2017Effect of BIA 6-512 at Steady-state on the Levodopa PharmacokineticsA Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Entacapone 200 mgParkinson DiseaseDrug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan®Bial - Portela C S.A.Not recruiting18 Years45 YearsAll39Phase 1Portugal
1084EUCTR2005-005791-32-GB24/04/20063 April 2012Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney.
MedDRA version: 9.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes)		Product Name: HF0220
Product Code: HF0220
Pharmaceutical Form: Powder for oral suspension
Current Sponsor code: HF0220
Other descriptive name: 7-beta-hydroxyepiandrosterone
Concentration unit: g gram(s)
Concentration type: range
Concentration number: 0.001-0.22-
Pharmaceutical form of the placebo: Oral suspension
Route of administration of the placebo: Oral use		Hunter-Fleming LtdAuthorisedFemale: yes
Male: yes		40United Kingdom;Sweden
1085EUCTR2005-006033-32-FI20/04/200619 March 2012A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt studyA Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rembrandt studyParkinson's Disease Early StageProduct Name: SLV308 (mono) hydrochloride
Product Code: SLV308 (mono) hydrochloride
Pharmaceutical Form: Film-coated tablet
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308 (mono) hydrochloride
Pharmaceutical Form: Film-coated tablet
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308 (mono) hydrochloride
Pharmaceutical Form: Film-coated tablet
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308 (mono) hydrochloride
Pharmaceutical Form: Film-coated tablet
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308 (mono) hydrochloride
Pharmaceutical Form: Film-coated tablet
Other descriptive name: SLV308 (mono) hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.0-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Product Name: SLV308 (mono) hydrochloride
Product Code: SLV308 (mono) hydrochloride
Pharmaceutical Form: Film-coated tablet
Other descriptive name: SLV308 (mono) hydrochloride		Solvay PharmaceuticalsNot RecruitingFemale: yes
Male: yes		440Finland;Slovakia;Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1086EUCTR2005-004949-34-AT18/04/20061 May 2012A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start StudyA randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start StudyParkinson's disease
MedDRA version: 6.1 Level: pref Classification code 10061536		Product Name: Sifrol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,088-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Sifrol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,18-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Sifrol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,35-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Boehringer Ingelheim Austria GmbHNot RecruitingFemale: yes
Male: yes		500Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden
1087EUCTR2005-001006-12-AT02/04/20067 August 2012Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSODouble-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSOPatients with advanced Parkinson’s disease with motor fluctuations and “OFF” periods refractory to conventional treatment.Product Name: Lisparin
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Lisuride Hydrogenmaleate
CAS Number: 018016803
Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 2.0-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Subcutaneous use
Trade Name: Sifrol, 0,35 mg Tablette
Product Name: Pramipexol
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pramipexol
CAS Number: 104632260
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.35-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Sifrol, 0,70 mg Tablette
Product Name: Pramipexol
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Pramipexol
CAS Number: 104632260
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.7-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Cabaseril, 1,0 mg Tablette
Product Name: Cabergoline
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Cabergoline
CAS Number: 081409907
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Cabaseril, 2,0 mg Tablette
Product Name: Cabergoline
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Cabergoline
CAS Number: 081409907		Axxonis Pharma GmbHNot RecruitingFemale: yes
Male: yes		60Phase 2Germany;Czech Republic;Italy;Austria
1088NCT00294554April 200616 December 2017Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and DementiaDouble-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and DementiaParkinson's Disease;Cognitive Impairment;DementiaDrug: Memantine;Drug: Placebo Oral TabletJohns Hopkins UniversityForest LaboratoriesNot recruiting50 YearsN/AAll20N/AUnited States
1089NCT00349310April 200619 February 2015Profile of Depressive Symptoms in Parkinsons DiseaseProfile of Depressive Symptoms in Parkinson's Disease (PRODEST-PD)Parkinson Disease;DepressionDrug: PramipexoleBoehringer IngelheimNot recruiting18 YearsN/ABoth1018Phase 4Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
1090NCT00461942April 200619 February 2015Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease PatientsA Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease PatientsParkinson's DiseaseDrug: Green Tea Polyphenols (EGCG/ECG)Xuanwu Hospital, BeijingMinistry of Health, China;Michael J. Fox Foundation for Parkinson's ResearchNot recruiting30 YearsN/ABoth480Phase 2China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1091NCT00467597April 200619 October 2017Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)Dyskinesias;Movement Disorders;Parkinson DiseaseDrug: Levodopa (delivered intravenously)VA Office of Research and DevelopmentOregon Health and Science UniversityNot recruiting21 YearsN/AAll36N/AUnited States
1092NCT00646204April 200619 February 2015Namenda (Memantine) for Non-Motor Symptoms in Parkinson's DiseaseA 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASEParkinson's DiseaseDrug: placebo;Drug: MemantineBaylor College of MedicineForest LaboratoriesNot recruiting18 Years80 YearsBoth40Phase 4United States
1093EUCTR2005-004109-27-SE24/03/200619 March 2012A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDDA double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDDParkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.Trade Name: Ebixa
Product Name: Ebixa
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Neuropsychiatric clinicAuthorisedFemale: yes
Male: yes		60Sweden
1094EUCTR2005-001032-72-PT23/03/200619 March 2012A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First StepA 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First StepParkinson diseaseTrade Name: Stalevo
Product Code: ELC200
Pharmaceutical Form: Capsule*
INN or Proposed INN: levodopa/carbidopa/entacapone
Current Sponsor code: ELC200
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100/25/200-
Trade Name: SINEMET
Product Name: sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: levodopa/carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25/100-		Novartis Pharma AGNot RecruitingFemale: yes
Male: yes		424Portugal;Czech Republic;Italy
1095NCT00282152March 200616 December 2017Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)Safety and Tolerability of Neurostimulation in Early Stage Parkinson's DiseaseParkinson's DiseaseDevice: B-STN DBS;Drug: Optimal drug therapyVanderbilt University Medical CenterNot recruiting50 Years75 YearsAll37N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1096NCT00305331March 200619 February 2015Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's DiseasePhase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's DiseaseParkinson's Disease;Peripheral EdemaDrug: Domperidone (drug)University Health Network, TorontoNot recruiting30 Years90 YearsBoth25Phase 2Canada
1097NCT00307450March 200619 February 2015Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's DiseaseEfficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV StudyParkinson's DiseaseDrug: LevetiracetamTechnische Universität DresdenUCB GmbH, Huettenstrasse 205, 50170 Kerpen, GermanyNot recruiting30 Years80 YearsBoth34Phase 4Germany
1098NCT00393562March 20063 August 2015Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's DiseaseComparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: modafinil;Drug: methylphenidateDepartment of Veterans AffairsNot recruiting50 Years80 YearsBoth0N/AUnited States
1099NCT00630500February 200610 August 2015Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy BodiesDementia Associated With Parkinson's Disease;Dementia With Lewy BodiesDrug: Memantine;Drug: PlaceboHelse Stavanger HFKing's College London;Lund UniversityNot recruitingN/AN/ABoth75Phase 2Norway;Sweden;United Kingdom
1100EUCTR2005-004290-19-DE25/01/20063 April 2012A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's diseaseA double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's diseaseadvanced-stage, idiopathic Parkinson's disease
MedDRA version: 8.1 Level: LLT Classification code 10061536		Product Name: Rotigotine Nasal Spray
Product Code: ND1421
Pharmaceutical Form: Nasal spray, solution
INN or Proposed INN: Rotigotine hydrochloride
CAS Number: 125572-93-2
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Nasal spray, solution
Route of administration of the placebo: Nasal use		Schwarz Biosciences GmbHNot RecruitingFemale: yes
Male: yes		100United Kingdom;Germany;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1101NCT03095105January 24, 200616 December 2017Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young SubjectsAn Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol)Parkinson DiseaseDrug: 200 mg BIA 6-512Bial - Portela C S.A.Not recruiting18 YearsN/AAll25Phase 1Germany
1102EUCTR2005-004314-33-EE17/01/200618 April 2012A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor FluctuationsA Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor FluctuationsLevodopa treated Parkinson's disease patients with motor fluctuations
MedDRA version: 8.1 Classification code 10061536		Product Name: MARS
Product Code: E2007
Pharmaceutical Form: Film-coated tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: MARS
Product Code: E2007
Pharmaceutical Form: Film-coated tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Eisai LimitedNot RecruitingFemale: yes
Male: yes		1260Portugal;Hungary;Germany;United Kingdom;Estonia;Spain;Italy;Lithuania;Sweden
1103EUCTR2005-003788-22-GB06/01/200618 April 2012A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptomsTrade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,088-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,18-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,35-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Trade Name: Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
Pharmaceutical Form: Tablet
INN or Proposed INN: Pramipexole
Current Sponsor code: SND 919 CL2 Y
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0,7-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Boehringer Ingelheim LimitedAuthorisedFemale: yes
Male: yes		318Finland;Germany;United Kingdom;Spain;Italy;Sweden
1104NCT00272688January 200618 January 2016Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefitContinuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic EvaluationParkinson DiseaseDrug: Levodopa (drug), intraduodenal administrationUniversity Hospital, AkershusSolvay PharmaceuticalsNot recruitingN/AN/ABoth10Phase 4Norway
1105NCT00273351January 200619 February 2015Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk FamiliesAssessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.Parkinson Disease;Parkinsonian SyndromeDrug: [123I]B-CITInstitute for Neurodegenerative DisordersDepartment of Defense;Molecular NeuroImagingNot recruiting21 YearsN/ABoth62Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1106NCT00275275January 200619 October 2017Pramipexole Conversion to Ropinirole Controlled Release (CR)An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.Parkinson DiseaseDrug: Requip PR;Drug: MirapexRajesh Pahwa, MDGlaxoSmithKlineNot recruiting18 YearsN/AAll61Phase 3United States
1107NCT00279825January 20064 November 2019Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: CD-LD IR;Drug: CD-LD CR;Drug: IPX054 200 mg Placebo;Drug: IPX054 250 mg Placebo;Drug: CD-LD IR Placebo;Drug: CD-LD CR PlaceboImpax Laboratories, LLCNot recruiting30 YearsN/AAll16Phase 2United States
1108NCT00292227January 200619 October 2017Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's DiseaseDouble-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.Parkinson's DiseaseDrug: Rotigotine;Other: Placebo;Drug: Moxifloxacin infusion;Other: Placebo infusionUCB PharmaNot recruiting18 YearsN/AAll130Phase 1South Africa
1109NCT00315250January 200619 February 2015Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseDevelopment of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseParkinson's Disease;Parkinsonian SyndromeDrug: [123I]ß-CITInstitute for Neurodegenerative DisordersDepartment of Defense;Molecular NeuroImagingNot recruiting22 YearsN/ABoth225Phase 2United States
1110NCT01683292January 200619 February 2015Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's DiseaseAn Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's DiseaseParkinson's DiseaseDrug: Inhaled VR040;Drug: Placebo for VR040South Glasgow University Hospitals NHS TrustVectura LimitedNot recruiting30 YearsN/ABoth29Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1111NCT02772614January 200623 May 2016Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesAn Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral AdministrationParkinson's DiseaseDrug: BIA 3-202 (200 mg)Bial - Portela C S.A.Not recruiting40 Years55 YearsMale4Phase 1Switzerland
1112EUCTR2006-006907-35-DE1 May 2012Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVERLong-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTION, SLEEP QUALITY, AND NOCTURNAL AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE - Long-term extension of RECOVERParkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease		Trade Name: Neupro 2mg/24h transdermal patch
Product Code: ND1587
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-mg
Trade Name: Neupro 4mg/24h transdermal patch
Product Code: ND1589
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-mg
Trade Name: Neupro 6mg/24h transdermal patch
Product Code: ND1590
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-mg
Trade Name: Neupro 8mg/24h transdermal patch
Product Code: ND1702
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-mg		Schwarz Biosciences GmbHNot RecruitingFemale: yes
Male: yes		270Phase 3BHungary;Finland;United Kingdom;Germany;Spain;Italy;Austria
1113EUCTR2005-005120-13-GB21/12/20058 August 2016A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s DiseaseA clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson’s DiseaseHypomobility (“off” or “freezing”) episodes associated with advanced Parkinson’s diseaseProduct Name: Apomorphine hydrochloride
Product Code: VR040
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: VR040
Concentration unit: µg microgram(s)
Concentration type: range
Concentration number: 400 to-1600
Pharmaceutical form of the placebo: Inhalation powder
Route of administration of the placebo: Inhalation use		Vectura Group plcNot RecruitingFemale: yes
Male: yes		24Phase 2United Kingdom
1114EUCTR2005-002010-38-DE21/11/200519 March 2012Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot studyAssessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot studyAdvanced Parkinson´s DiseaseProduct Name: Trivastal
Product Code: S 90049
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Piribedil
Current Sponsor code: S 90049
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-		Institut de Recherches Internationales Servier (I.R.I.S.)Not RecruitingFemale: yes
Male: yes		80Germany
1115NCT00250393November 200519 February 2015A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseasePlacebo-Controlled , Crossover , Double-Blind Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Monotherapy]Parkinson's DiseaseDrug: Istradefylline (KW-6002)Kyowa Hakko Kirin Company, LimitedNot recruiting30 YearsN/ABoth64Phase 2Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1116NCT00253084November 20054 November 2019Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: IPX054 200 mg;Drug: CD-LD IR;Drug: IPX054 Placebo;Drug: CD-LD IR PlaceboImpax Laboratories, LLCNot recruiting30 YearsN/AAll12Phase 2United States
1117NCT00256204November 200519 October 2017A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's DiseaseA Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease SubjectsParkinson's DiseaseDrug: Rasagiline Mesylate;Other: PlaceboTeva Pharmaceutical IndustriesNot recruiting30 Years80 YearsAll1174Phase 3Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
1118NCT00260793November 200519 February 2015Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's DiseaseOpen Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's DiseaseParkinson's DiseaseDrug: Ropinirole HydrochlorideAgarwal, Pinky, M.D.Colorado Neurology;GlaxoSmithKlineRecruiting25 YearsN/ABoth20Phase 3United States
1119EUCTR2005-000314-12-ES14/10/200519 March 2012Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPIEffect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPIParkinson's Disease aggravated
MedDRA version: 7.0 Level: LLT Classification code 10034006		Product Name: piribedil
Product Code: S 90049 - F36
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: piribedil
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use
Product Name: piribedil
Product Code: S 90049 - F38
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: piribedil
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use		Institut de Recherches Internationales ServierAuthorisedFemale: yes
Male: yes		80Germany;Spain
1120NCT00134251October 200519 February 2015Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's DiseaseParkinson's DiseaseDrug: SLV308Solvay PharmaceuticalsNot recruiting30 YearsN/ABothPhase 3Bulgaria;Malta;Serbia;Former Serbia and Montenegro
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1121NCT00199381October 200519 October 2017An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.Parkinson's DiseaseDrug: IstradefyllineKyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/AAll504Phase 3United States
1122NCT00239564October 20054 November 2019Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's DiseaseAn Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: IPX054 100 mg;Drug: IPX054 150 mg;Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: IPX054 300 mgImpax Laboratories, LLCNot recruiting30 YearsN/AAll12Phase 1/Phase 2United States
1123NCT00472355October 200510 December 2018Low Dose Apomorphine and ParkinsonismDoes Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism?Parkinson's DiseaseDrug: apomorphineOregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting35 Years85 YearsAll0Phase 2United States
1124NCT00517842October 200519 February 2015A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's DiseaseA Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's DiseaseParkinson DiseaseDrug: ViNeuroHospital Authority, Hong KongVigconic (International) Ltd.Not recruiting30 YearsN/ABoth160N/AChina
1125NCT00912808October 200511 June 2018Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's DiseaseA Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson'sParkinson's DiseaseDrug: Donepezil;Drug: Sugar Pill (placebo)Oregon Health and Science UniversityNot recruiting21 YearsN/AAll23N/A
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1126EUCTR2005-001416-42-GB15/09/200524 April 2012A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOParkinson's Disease
MedDRA version: 7.1 Level: PT Classification code 10061536		Trade Name: Azilect
Product Name: rasagiline tablets
Product Code: TVP-1012
Pharmaceutical Form: Tablet
INN or Proposed INN: rasagiline
CAS Number: 161735-79-1
Current Sponsor code: TVP-1012
Other descriptive name: rasagiline mesilate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5, 1, 2-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Rasagiline
Product Code: TVP-1012
Pharmaceutical Form: Tablet		Teva Pharmaceuticals Industries LtDAuthorisedFemale: yes
Male: yes		1100Portugal;Hungary;Germany;United Kingdom;Spain;Italy
1127NCT00165789September 200519 October 2017A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor FluctuationsA Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor FluctuationsParkinson's DiseaseDrug: E2007Eisai Inc.Not recruiting18 YearsN/AAll75Phase 2United States
1128NCT00224263September 200519 February 2015Efficacy and Safety of Lingzhi in Patients With Early Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCIParkinson's DiseaseDrug: Lingzhi (Ganoderma)Xuanwu Hospital, BeijingNot recruiting30 Years80 YearsBoth360Phase 2China
1129NCT02774564September 200530 May 2016Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/CarbidopaPharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single Dose of Controlled-release 200/50 mg Levodopa/Carbidopa (Sinemet® cr 200/50): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy VolunteersParkinson's DiseaseDrug: BIA 3-202;Drug: Placebo;Drug: Sinemet®Bial - Portela C S.A.Not recruiting18 Years45 YearsBoth16Phase 1Portugal
1130NCT02778594September 200527 June 2016Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/BenserazidePharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy VolunteersParkinson's Disease (PD)Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mgBial - Portela C S.A.Not recruiting18 Years45 YearsBoth17Phase 1Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1131EUCTR2005-002654-21-SE08/08/200519 March 2012A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNEA long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNETreatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.Trade Name: Duodopa intestinal gel
Pharmaceutical Form: Gastroenteral suspension
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20 -
INN or Proposed INN: Carbidopa
CAS Number: 28860-95-9
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-		Solvay Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes		Sweden
1132NCT00134966August 200516 December 2017A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaA 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring LevodopaParkinson's DiseaseDrug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)NovartisNot recruiting30 Years80 YearsAll493Phase 3United States;Canada;Czechia;Israel;Italy;Poland;Portugal;Turkey;Czech Republic
1133NCT00692328August 200525 May 2015Expectation and Response to Levodopa and Acupuncture in Parkinson's DiseaseExpectation and Response to Levodopa & Acupuncture in Parkinson's DiseaseParkinson's DiseaseBehavioral: Levodopa or acupunctureOregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)Not recruiting18 Years80 YearsBoth63N/AUnited States
1134NCT00125138July 200519 October 2017Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's DiseaseSafety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's DiseaseParkinson's Disease;Psychotic DisordersDrug: Melperone HCl;Drug: PlaceboLundbeck LLCNot recruitingN/AN/AAll90Phase 2United States;India;Italy
1135NCT00143026July 200516 December 2017Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United StatesStudy to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.Parkinson's DiseaseDrug: carbidopa, levodopa, entacaponeNovartisNot recruiting30 YearsN/AAll184Phase 4Australia;Philippines;Taiwan;Thailand
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1136EUCTR2005-000444-84-AT22/06/200529 April 2013An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-OAn open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-OTreatment-Associated Dyskinesia in Parkinson's DiseaseProduct Code: EMD128130
Pharmaceutical Form: Tablet
INN or Proposed INN: Sarizotan hydrochloride
CAS Number: 195068-07-6
Current Sponsor code: EMD128130
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-		Merck KGaANot RecruitingFemale: yes
Male: yes		800Phase 3Finland;Spain;Austria;Italy;United Kingdom
1137NCT00086190June 200519 October 2017Study of Antidepressants in Parkinson's DiseaseStudy of Antidepressants in Parkinson's DiseaseParkinson Disease;DepressionDrug: paroxetine;Drug: venlafaxine;Other: placeboUniversity of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/AAll115Phase 3United States;Canada;Puerto Rico
1138NCT00139880June 200519 February 2015A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's DiseaseA Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's DiseaseParkinson's DiseaseDrug: ParcopaUCB PharmaNot recruiting40 YearsN/ABothPhase 3United States
1139NCT00148369June 200519 February 2015A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of LiaterminA Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of LiaterminIdiopathic Parkinson's DiseaseDrug: Safety observationAmgenMedtronicNot recruiting35 Years70 YearsBoth31N/ACanada;United Kingdom;United States
1140NCT00642889June 200519 February 2015Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.Parkinson's DiseaseDrug: Safinamide;Drug: PlaceboNewronNot recruiting30 Years80 YearsBoth227Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1141EUCTR2004-005234-39-GB27/05/20051 May 2012Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOPMulticentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off - SEWOPParkinson's disease
MedDRA version: 7.0 Level: LLT Classification code 10061536		Trade Name: Stalevo
Product Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Stalevo
Product Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Sinemet
Product Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
Trade Name: Sinemet
Product Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-		Orion Corporation, ORION PHARMA, FinlandAuthorisedFemale: yes
Male: yes		240Finland;Germany;United Kingdom;Denmark;Ireland;Latvia;Lithuania;Sweden
1142NCT03095092May 23, 200516 December 2017Effect of Food on BIA 6-512 (Trans-resveratrol)The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy SubjectsParkinson DiseaseDrug: BIA 6-512 400 mgBial - Portela C S.A.Not recruiting18 Years45 YearsAll24Phase 1Portugal
1143EUCTR2004-005034-39-GB17/05/200519 March 2012Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's diseaseNicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's diseaseIdiopathic Parkinson's diseaseTrade Name: Nicotinamide
Product Name: NICOTINAMIDE
Pharmaceutical Form: Tablet
INN or Proposed INN: Nicotinamide
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-		Queen Elizabeth HospitalAuthorisedFemale: yes
Male: yes		United Kingdom
1144EUCTR2004-002608-13-GB16/05/200528 February 2019Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s diseasePragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s diseaseParkinson's Disease with psychosisTrade Name: Seroquel
Product Name: Seroquel
Pharmaceutical Form: Film-coated tablet
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Seroquel
Product Name: Seroquel
Pharmaceutical Form: Film-coated tablet
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		King’s College London & King’s College HospitalNot Recruiting Female: yes
Male: yes		60Phase 4United Kingdom
1145NCT03093389May 11, 200516 December 2017Tolerability and Steady-state Pharmacokinetics of BIA 6-512A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy VolunteersParkinson DiseaseDrug: BIA 6-512;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years45 YearsAll40Phase 1Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1146NCT00163085May 200519 February 2015The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)PfizerNot recruiting30 Years80 YearsBoth12Phase 2United States
1147NCT00199433May 20058 August 2016A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) PatientsA Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's DiseaseParkinson's Disease;Movement Disorder SyndromeDrug: Istradefylline (KW-6002)Kyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/ABoth160Phase 2United States
1148EUCTR2004-001485-41-AT20/04/200522 April 2013A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/AA single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/AApproximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).Trade Name: Sinemet
Product Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: carbidopa/levodopa
Trade Name: Cabaseril
Product Name: Cabaseril
Pharmaceutical Form: Tablet
INN or Proposed INN: Cabergoline
Trade Name: DaTSCAN
Product Name: DatSCAN
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Ioflupane [123 I]
Concentration unit: Bq/ml becquerel(s)/millilitre		Institute for Neurodegenerative DisordersAuthorisedFemale: yes
Male: yes		120Spain;Austria;United Kingdom
1149EUCTR2004-004139-74-DK20/04/20053 October 2016Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect. (Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/AParkinson’s Disease: PET scan and evaluation of memantines pharmacological effect. (Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/AParkinson's DiseaseTrade Name: Ebixa
Product Name: Ebixa
Pharmaceutical Form: Tablet
INN or Proposed INN: memantine
Concentration unit: mg/g milligram(s)/gram
Concentration type: equal
Concentration number: 10 mg-		Neurologisk afdeling FAuthorisedFemale: yes
Male: yes		12Phase 2Denmark
1150NCT00108667April 200519 February 2015Talampanel to Treat Parkinson's DiseaseAMPA Receptor Antagonist Treatment of Parkinson's DiseaseParkinson DiseaseDrug: IV Levodopa;Drug: TalampanelNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth40Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1151NCT00199355April 200519 February 2015A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaPlacebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa]Parkinson's DiseaseDrug: Istradefylline (KW-6002)Kyowa Hakko Kirin Company, LimitedNot recruiting30 YearsN/ABoth75Phase 2Japan
1152NCT00203957March 200519 February 2015Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on LevodopaA Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa TherapyParkinson's DiseaseDrug: IstradefyllineUniversity of ChicagoNot recruiting18 YearsN/ABoth10Phase 3United States
1153NCT02834507March 20058 August 2016Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsA Double-blind, Randomised, Placebo- and Active-controlled, Cross-over Study to Investigate the Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsParkinson's Disease (PD)Drug: Placebo;Drug: BIA 3-202;Drug: Comtan®;Drug: Sinemet®Bial - Portela C S.A.Not recruiting30 Years75 YearsBoth19Phase 2
1154EUCTR2004-002844-93-LT08/02/20059 October 2012A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa Therapy -Parkinson's Disease Product Name: Istradefylline
Product Code: KW-6002
Pharmaceutical Form: Tablet
INN or Proposed INN: Istradefylline
Current Sponsor code: KW-6002
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-		Kyowa Hakko U.K. LimitedNot RecruitingFemale: yes
Male: yes		1175United Kingdom;Estonia;Spain;Italy;Latvia;Lithuania
1155EUCTR2004-002650-59-GB03/02/200521 August 2012A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/aA phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/aIdiopathic Parkinson's diseaseProduct Name: rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotine
CAS Number: 99755-59-6
Current Sponsor code: SPM 962
Concentration unit: mg/m2 milligram(s)/square meter
Concentration type: range
Concentration number: 4.5, 9.0, -13.5, 18		SCHWARZ BIOSCIENCESAuthorisedFemale: yes
Male: yes		130Phase 3bUnited Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1156NCT00153972February 200519 February 2015Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's DiseaseDopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's DiseaseParkinson's DiseaseDrug: Cabergoline;Drug: LevodopaTechnische Universität DresdenPfizerNot recruiting40 Years85 YearsBoth39Phase 4Germany
1157EUCTR2004-002641-12-AT21/01/200522 April 2013A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseA multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's diseaseProduct Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-
Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-		Schwarz Biosciences GmbHNot RecruitingFemale: yes
Male: yes		220Phase 3bSpain;Austria;Italy;United Kingdom
1158NCT00286949January 6, 200516 December 2017Treatment of Executive Dysfunction in Parkinson's DiseaseAtomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label StudyParkinson's DiseaseDrug: AtomoxetineJohns Hopkins UniversityEli Lilly and CompanyNot recruiting21 Years65 YearsAll12N/AUnited States
1159NCT00103597January 200519 February 2015Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyEfficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyParkinson's Disease;Multiple System Atrophy;Orthostatic HypotensionDrug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic HypotensionRoyal Brisbane and Women's HospitalNot recruiting40 Years95 YearsBoth50Phase 1Australia
1160NCT00129181January 200519 February 2015Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's DiseaseA Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's DiseaseParkinson Disease;Parkinsonian SyndromeDrug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imagingInstitute for Neurodegenerative DisordersPfizer;GE HealthcareNot recruiting40 YearsN/ABoth30N/AAustria;Germany;Italy;Spain;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1161NCT00144300January 200519 October 2017Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) PatientsA Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease PatientsParkinson DiseaseDrug: Mirapex;Drug: RequipBoehringer IngelheimNot recruiting30 YearsN/AAll246Phase 4United States
1162NCT00219284January 200516 December 2017Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's DiseaseA Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing OffParkinson's Disease With End of Dose Wearing OffDrug: Carbidopa/levodopa/entacaponeNovartis PharmaceuticalsNot recruiting30 Years85 YearsAll359Phase 4United States;Puerto Rico
1163NCT01634243January 200519 October 2017A Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsA Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsParkinson's DiseaseDrug: SPM 962Otsuka Pharmaceutical Co., Ltd.Not recruiting30 Years79 YearsAll64Phase 2Japan
1164EUCTR2004-001594-25-FI30/12/200419 March 2012A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2Treatment-Associated Dyskinesia in Parkinson's DiseaseProduct Code: EMD128130
Pharmaceutical Form: Tablet
INN or Proposed INN: Sarizotan hydrochloride
CAS Number: 195068-07-6
Current Sponsor code: EMD128130
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Merck KGaANot RecruitingFemale: yes
Male: yes		600Phase 3Finland;Spain
1165EUCTR2004-002598-21-AT22/12/200422 April 2013A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's diseaseA phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's diseaseParkinson's DiseaseProduct Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-
Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-		Schwarz Biosciences GmbHNot RecruitingFemale: yes
Male: yes		50Phase 3bAustria;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1166EUCTR2004-002609-66-DE06/12/200419 March 2012A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's diseaseA phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's diseaseParkinson's DiseaseProduct Name: Rotigotine
Product Code: SPM962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Product Name: Rotigotine
Product Code: SPM962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-
Product Name: Rotigotine
Product Code: SPM962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Product Name: Rotigotine
Product Code: SPM962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-
Trade Name: Requip
Product Name: Requip
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ropinirole
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-
Trade Name: Requip
Product Name: Requip
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ropinirole
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Trade Name: Requip
Product Name: Requip
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ropinirole
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Trade Name: Requip
Product Name: Requip
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Ropinirole
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-		Schwarz Biosciences GmbHNot RecruitingFemale: yes
Male: yes		60Phase 3Germany;Italy
1167EUCTR2004-000835-27-IT03/12/200419 March 2012A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonistA phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonistParkinson's Disease
MedDRA version: 6.1 Level: PT Classification code 10061536		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Capsule, hard
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-		NEWRON PHARMACEUTICALSNot RecruitingFemale: yes
Male: yes		Phase 3Spain;Italy
1168EUCTR2004-000833-12-ES02/12/200419 March 2012A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients with early idiopathic parkinson’s disease treated with a stable dose of a single dopamine agonist.Early idiopathic Parkinson’s disease
MedDRA version: 7.0 Level: LLT Classification code 10013113		Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Safinamide
Product Code: NW-1015
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Safinamide
CAS Number: 202825-46-5
Current Sponsor code: NW-1015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Newron Pharmaceuticals S.p.A.AuthorisedFemale: yes
Male: yes		250Phase 3Spain;Italy
1169EUCTR2004-001593-10-IT02/12/200429 May 2012A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)Treatment-Associated Dyskinesia in Parkinson's DiseaseProduct Name: Sarizotan hydrochloride
Product Code: EMD 128130
Pharmaceutical Form: Tablet
INN or Proposed INN: Sarizotan hydrochloride
CAS Number: 195068-07-6
Current Sponsor code: EMD 128130
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-		MERCK S.P.A.Not RecruitingFemale: yes
Male: yes		Phase 3United Kingdom;Italy
1170NCT00643045December 200419 February 2015Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistA Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistIdiopathic Parkinson's DiseaseDrug: Safinamide;Drug: PlaceboNewronNot recruiting30 Years80 YearsBoth269Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1171NCT03091868November 3, 200416 December 2017Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa PharmacokineticsA Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mgParkinson DiseaseDrug: Placebo oral capsule;Drug: Sinemet® 100/25;Drug: Comtan®;Drug: BIA 6-512 25 mg;Drug: BIA 6-512 100 mgBial - Portela C S.A.Not recruiting18 Years45 YearsAll80Phase 1Portugal
1172NCT00199394November 20048 August 2016A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseA 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.Parkinson's DiseaseDrug: Istradefylline (KW-6002)Kyowa Hakko Kirin UK, Ltd.Not recruiting30 YearsN/ABoth405Phase 3United Kingdom
1173NCT00296946November 200426 February 2018Ipratropium Spray for Drooling Saliva in Parkinson's DiseasePhase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ipratropium bromide (drug)University Health Network, TorontoParkinson's Disease FoundationNot recruiting30 YearsN/AAll20Phase 2Canada
1174NCT01518309November 200416 December 2017An Open-label Safety Study of Pimavanserin in Parkinson's Disease PatientsParkinson's Disease PsychosisDrug: pimavanserin tartrate (ACP-103)ACADIA Pharmaceuticals Inc.Not recruitingN/AN/AAll39Phase 2United States
1175EUCTR2004-000817-20-LV22/10/20043 September 2012A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.Parkinson's DiseaseProduct Name: Istradefylline
Product Code: KW-6002
Pharmaceutical Form: Capsule*
INN or Proposed INN: Istradefylline
Current Sponsor code: KW-6002
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Trade Name: Comtess
Product Name: Comtess
Pharmaceutical Form: Capsule*
INN or Proposed INN: Entacapone
CAS Number: 130929-57-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use		Kyowa Hakko U.K. LimitedNot RecruitingFemale: yes
Male: yes		405Spain;Italy;Latvia;Lithuania
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1176EUCTR2004-000361-35-CZ18/10/200419 March 2012A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH “WEARING OFF” MOTOR FLUCTUATIONS AND “ON” PERIOD DYSKINESIAS.A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH “WEARING OFF” MOTOR FLUCTUATIONS AND “ON” PERIOD DYSKINESIAS.Parkinson's DiseaseProduct Name: MARS
Product Code: E2007
Pharmaceutical Form: Coated tablet
Current Sponsor code: E2007
Other descriptive name: MARS
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Current Sponsor code: E2007
Other descriptive name: MARS
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Current Sponsor code: E2007
Other descriptive name: MARS
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-		Eisai LimitedNot RecruitingFemale: yes
Male: yes		225Czech Republic;Italy
1177NCT00199368October 20048 August 2016An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.Parkinson's DiseaseDrug: Istradefylline ( KW-6002)Kyowa Kirin Pharmaceutical Development, Inc.Kyowa Hakko Kirin UK, Ltd.Not recruiting30 YearsN/ABoth1100Phase 3United States
1178NCT00105508September 30, 200420 August 2018Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaA Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaParkinson's Disease;DyskinesiaDrug: Sarizotan;Drug: PlaceboEMD SeronoNot recruiting30 YearsN/AAll506Phase 3United States
1179EUCTR2004-000185-12-FI21/09/200419 March 2012A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PDA long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation of levodopa therapy. - STRIDE-PDParkinson's disease
MedDRA version: 7.0 Level: LLT Classification code 10061536		Trade Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Stalevo
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: Entacapone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
Trade Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
Trade Name: Sinemet
Pharmaceutical Form: Tablet
INN or Proposed INN: Levodopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Carbidopa
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-		Orion Corporation, ORION PHARMANot RecruitingFemale: yes
Male: yes		740Finland;United Kingdom;Italy;Sweden
1180EUCTR2004-003355-39-AT14/09/200422 April 2013A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.Dementia associated with Parkinson's diseaseTrade Name: Aricept 5 mg-Filmtabletten
Product Name: Aricept 5mg-Filmtabletten
Pharmaceutical Form: Tablet		Eisai LimitedNot RecruitingFemale: yes
Male: yes		468Austria
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1181NCT00099268September 200419 October 2017Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyA Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyParkinson's DiseaseDrug: Carbidopa/levodopa/entacapone;Drug: Immediate release carbidopa/levodopaNovartis PharmaceuticalsOrion Corporation, Orion PharmaNot recruiting30 Years70 YearsAll747Phase 3United States;Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom
1182NCT00105521September 200416 December 2017Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated DyskinesiaA Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaParkinson's Disease;DyskinesiaDrug: Sarizotan HC1EMD SeronoNot recruiting30 YearsN/AAll594Phase 3United States
1183NCT00296959September 200419 February 2015Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's DiseaseAnti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced DyskinesiasParkinson's DiseaseDrug: topiramate (drug)University Health Network, TorontoNot recruiting30 Years75 YearsBoth20Phase 2Canada
1184NCT00641186September 200419 February 2015Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's DiseaseParkinson DiseaseDrug: sodium oxybateBaylor College of MedicineJazz PharmaceuticalsNot recruiting30 Years75 YearsBoth30N/A
1185NCT00089622August 4, 200416 December 2017Lisuride Patch to Treat Parkinson's DiseaseTranscutaneous Lisuride Therapy of Parkinson's DiseaseParkinson DiseaseDrug: Intravenous Levodopa;Drug: Lisuride Transdermal SystemNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting40 Years80 YearsAll40Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1186EUCTR2004-000148-26-FI30/07/200417 December 2012A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AA multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseProduct Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Other descriptive name: (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0, 13.5, 18.0-amount per patch		Schwarz BioSciences Inc.Not RecruitingFemale: yes
Male: yes		360Phase 3Czech Republic;Hungary;Finland;Spain;Italy;Sweden
1187NCT00174239July 200419 February 2015Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.Parkinson DiseaseDrug: cabergoline;Drug: controlled-release levodopa / carbidopaPfizerNot recruiting18 Years80 YearsBoth220Phase 4Australia;Italy;Spain;United Kingdom
1188NCT00199420July 20048 August 2016A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaA 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.Parkinson's DiseaseDrug: Istradefylline (KW-6002)Kyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/ABoth580Phase 3United States
1189NCT00304161July 200419 October 2017Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's DiseaseDepression Diagnosis and Treatment in Parkinson DiseaseDepressive Disorder;Parkinson DiseaseDrug: Atomoxetine;Drug: PlaceboUniversity of PennsylvaniaNational Institute of Mental Health (NIMH)Not recruiting30 Years79 YearsAll55Phase 4United States
1190NCT00359723July 200410 December 2018Methylphenidate and Parkinson's DiseaseSubacute Trial of Methylphenidate in Parkinson's DiseaseParkinson's DiseaseDrug: methylphenidateOregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting21 YearsN/AAll13Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1191NCT00086294June 25, 200416 December 2017ACP-103 to Treat Parkinson's Disease5HT2A/C Serotonin Blockade in Parkinson's DiseaseParkinson's Disease;DyskinesiasDrug: Intravenous Levodopa;Drug: ACP-103National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 Years80 YearsAll40Phase 2United States
1192NCT00199407June 20048 August 2016A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaA 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.Parkinson's DiseaseDrug: Istradefylline (KW-6002)Kyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/ABoth230Phase 3United States
1193NCT00203138June 200419 February 2015Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's DiseaseA Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: rasagiline mesylateTeva Pharmaceutical IndustriesNot recruiting35 YearsN/ABoth306Phase 3United States
1194NCT00211588June 200419 February 2015Galantamine Executive Function in Parkinson's DiseaseInvestigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's DiseaseParkinson's DiseaseDrug: galantamineMemorial Hospital of Rhode IslandOrtho-McNeil Neurologics, Inc.Not recruiting60 Years85 YearsBoth90N/AUnited States
1195NCT03091543May 4, 200416 December 2017Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa PharmacokineticsA Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mgParkinson DiseaseDrug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg doseBial - Portela C S.A.Not recruiting18 Years45 YearsAll20Phase 1Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1196NCT01172379May 200419 February 2015A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period DyskinesiasA Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period DyskinesiasParkinson's DiseaseDrug: E2007;Other: Placebo ComparatorEisai LimitedNot recruiting30 Years75 YearsBoth2Phase 2Czech Republic;France;Germany;Italy;Serbia;Spain
1197NCT00087542March 200419 February 2015Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational DrugHallucinations;Psychoses;Parkinson's DiseaseDrug: ACP-103ACADIA Pharmaceuticals Inc.Not recruitingN/AN/ABoth60Phase 2United States
1198NCT00200447March 200419 February 2015An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)Parkinson's DiseaseDrug: carbidopa/l-dopa;Drug: carbidopa/l-dopa/entacapone;Drug: Stalevo;Procedure: [123I]-IBZM imagingMolecular NeuroImagingNot recruiting30 YearsN/ABoth3Phase 2
1199NCT00244387March 200419 February 2015Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on LevodopaA Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on LevodopaParkinson Disease, IdiopathicDrug: SPM 962UCB PharmaNot recruiting30 YearsN/ABoth506Phase 3Germany
1200NCT00096720February 200419 February 2015Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseInvestigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson'sParkinson Disease;Parkinsonian SyndromeDrug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imagingInstitute for Neurodegenerative DisordersBoehringer Ingelheim;Department of DefenseNot recruiting30 YearsN/ABoth112Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1201NCT00632736February 200416 December 2017An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s DiseaseAn Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169Parkinson Disease;Parkinson's DiseaseDrug: Ropinirole XL (formerly CR)GlaxoSmithKlineNot recruiting30 YearsN/AAll419Phase 3United States;Belgium;Czech Republic;France;Hungary;Italy;Poland;Spain;United Kingdom;Germany;Philippines
1202NCT00673088February 200429 January 2018A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted ConditionsA Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted ConditionsParkinson's Disease;Restless Leg SyndromeDrug: Ropinirole HydrochlorideRoxane LaboratoriesNot recruiting18 Years45 YearsAll30N/A
1203NCT00674310February 200429 January 2018A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsA Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsParkinson's Disease;Restless Leg SyndromeDrug: Ropinirole HydrochlorideRoxane LaboratoriesNot recruiting18 Years45 YearsAll29N/A
1204NCT02248181February 200419 February 2015Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's DiseasePost Marketing Surveillance Study of Sifrol® - Monotherapy in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: PramipexoleBoehringer IngelheimNot recruitingN/AN/ABoth442N/A
1205NCT00076492January 200419 February 2015NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's DiseaseParkinson DiseaseDrug: CoQ10;Drug: GPI 1485University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/ABoth195Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1206NCT00076674January 20043 October 2016Levetiracetam Treatment of L-dopa Induced DyskinesiasLevetiracetam Treatment of L-dopa Induced DyskinesiasDyskinesias;Parkinson DiseaseDrug: Intravenous LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth40Phase 2United States
1207NCT00139867January 200419 February 2015A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's DiseaseA Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's DiseaseParkinson's DiseaseDrug: PARCOPAUCB PharmaNot recruiting18 YearsN/ABothPhase 3United States
1208NCT00212693January 200419 February 2015Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in JapanControlled Study of ONO-2506PO in Patients With Parkinson's Disease in JapanParkinson's DiseaseDrug: ONO-2506POOno Pharmaceutical Co. LtdNot recruiting20 Years79 YearsBoth165Phase 2
1209NCT00220272January 200419 February 2015Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's DiseaseA Phase II, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients With Early Parkinson's DiseaseParkinson DiseaseDrug: SR57667BSanofiNot recruiting35 YearsN/ABoth183Phase 2Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom
1210NCT02231905January 200419 February 2015Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's DiseaseOpen Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to PramipexoleParkinson DiseaseDrug: BI-Sifrol®Boehringer IngelheimNot recruiting20 YearsN/ABoth29Phase 4
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1211NCT00111982December 200319 February 2015Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of LiaterminMulti-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)Parkinson's DiseaseBiological: LiaterminAmgenMedtronicNot recruiting35 Years70 YearsBoth34Phase 1/Phase 2United States
1212NCT00363727December 200316 December 2017Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson'sA Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.Parkinson's Disease;Parkinson Disease;DyskinesiasDrug: ropinirole controlled-release (REQUIP CR) for RLSGlaxoSmithKlineNot recruiting30 Years70 YearsAll209Phase 3United States
1213NCT01941732November 200319 February 2015Motor Response to Sildenafil in PDMotor Response to Acute Challenge to Sildenafil in Parkinsons DiseaseParkinsons Disease;Erectile DysfunctionDrug: SildenafilBispebjerg HospitalNot recruiting18 Years80 YearsMale8Phase 4Denmark
1214NCT00234676October 200319 February 2015POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's DiseaseA Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's DiseaseParkinson's DiseaseDrug: Premarin ®The Parkinson Study GroupWyeth is now a wholly owned subsidiary of Pfizer;Joseph and Rosalyn Newman FoundationNot recruitingN/A75 YearsFemale23Phase 2United States
1215NCT00615472October 200319 October 2017Intravenous Versus Inhalational Anesthesia in Parkinson's DiseaseIntravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's DiseaseParkinson's DiseaseDrug: Isoflurane;Drug: Remifentanil;Drug: PropofolColumbia UniversityNot recruiting18 YearsN/AAll58N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1216NCT00180037September 200319 February 2015Coenzyme Q10 as a Symptomatic Treatment in Parkinson's DiseaseMulticenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: PlaceboTechnische Universität DresdenDeutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad HomburgNot recruiting40 Years75 YearsBoth132Phase 3Germany
1217NCT01177319September 200319 February 2015Glutathione (GSH) In The Treatment of Parkinson's DiseaseGlutathione (GSH) In The Treatment of Parkinson's DiseaseParkinson's DiseaseDrug: GlutathioneUniversity of South FloridaWellness Health & Pharmaceuticals, Inc.Not recruiting18 YearsN/ABoth20Phase 2United States
1218NCT00215904August 200319 February 2015D-serine Adjuvant Treatment for Parkinson's DiseaseD-serine Adjuvant Treatment for Parkinson's DiseaseParkinson's DiseaseDrug: D-serine (~2g/day)Herzog HospitalNot recruiting30 Years75 YearsBoth13Phase 4Israel
1219NCT00070941July 200319 October 2017SAM-e for the Treatment of Depression in Patients With Parkinson's DiseaseSAM-e Treatment of Depression in Parkinson's Disease.Parkinson's Disease;DepressionDrug: SAM-e;Drug: oral escitalopram;Drug: placeboNew York University School of MedicineNational Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS)Not recruiting30 Years80 YearsAll29Phase 2/Phase 3United States
1220NCT00095810July 200319 February 2015Aripiprazole in Patients With Psychosis Associated With Parkinson's DiseaseAn Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's DiseaseParkinson's Disease;PsychosesDrug: aripiprazoleOtsuka Pharmaceutical Development & Commercialization, Inc.Otsuka America PharmaceuticalNot recruiting50 YearsN/ABoth50Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1221NCT00160576July 200319 February 2015Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome DyskinesiasA Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: LevetiracetamUCB PharmaNot recruiting30 YearsN/ABoth30Phase 2
1222NCT00228150July 200319 February 2015Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's DiseaseA Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's DiseaseParkinson DiseaseDrug: SR57667BSanofiNot recruiting35 YearsN/ABoth564Phase 2Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom
1223NCT00240409July 200319 February 2015Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseaseA Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole Tablets and Bromocriptine Tablets in Patients With Parkinson's Disease.Parkinson DiseaseDrug: Pramipexole;Drug: BromocriptineBoehringer IngelheimNot recruiting30 Years80 YearsBoth208Phase 3China
1224NCT00666653July 200319 February 2015Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's DiseaseEffects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease: a Double-Blind Placebo Controlled Crossover StudyParkinson's DiseaseDrug: pramipexoleOregon Health and Science UniversityBoehringer IngelheimNot recruiting30 Years80 YearsBoth13Phase 1United States
1225NCT00062738June 200319 October 2017Treatment of Depression in Parkinson's Disease TrialTreatment of Depression in Patients With Parkinson's DiseaseParkinson Disease;DepressionDrug: paroxetine;Drug: Nortriptyline;Other: placeboRutgers, The State University of New JerseyGlaxoSmithKlineNot recruiting35 Years80 YearsAll52Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1226NCT00148486June 200319 February 2015A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)Parkinson DiseaseDrug: NS 2330Boehringer IngelheimNot recruiting40 Years80 YearsBoth261Phase 2United States;Canada
1227NCT00381472June 200316 December 2017Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopaA Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopaParkinson DiseaseDrug: RopiniroleGlaxoSmithKlineNot recruiting30 YearsN/AAll393Phase 3United States;Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain
1228NCT00063193May 20031 February 2016National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection TrialA Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's DiseaseParkinson's DiseaseDrug: minocycline;Drug: creatineUniversity of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/ABoth195Phase 2United States
1229NCT00058721April 200319 February 2015Single Photon Emission Computed Tomography to Study Receptors in Parkinson's DiseaseSPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's DiseaseParkinson DiseaseDrug: I-123-5-IA85380National Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth60N/AUnited States
1230NCT00058838April 200319 February 2015Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's DiseaseA Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.Parkinson DiseaseDrug: sumanirolePfizerNot recruiting30 YearsN/ABoth854Phase 3United States;Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1231NCT00115427March 200319 February 2015Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's DiseaseMulticenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: Liatermin (r-metHuGDNF)AmgenNot recruiting35 Years70 YearsBothPhase 1United States
1232NCT00148512March 200319 February 2015A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor FluctuationsA Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)Parkinson DiseaseDrug: 1. Tesofensine (NS 2330)Boehringer IngelheimNot recruiting42 Years80 YearsBoth254Phase 2Austria;France;Germany;Netherlands;Spain;United Kingdom;El Salvador
1233NCT00056524February 20038 August 2016Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.Alzheimer's Disease;Stroke;Parkinson's Disease;Traumatic Brain InjuryDrug: AVP-923Avanir PharmaceuticalsNot recruiting18 Years80 YearsBoth600Phase 3United States
1234NCT00129675February 200319 February 2015Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic UncertaintyDevelopment of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's SymptomsParkinsonian SyndromeDrug: [123I]ß CITInstitute for Neurodegenerative DisordersMolecular NeuroImagingNot recruiting21 YearsN/ABoth169Phase 2United States
1235NCT00237263February 200316 December 2017An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United StatesAn Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-offParkinson's DiseaseDrug: EntacaponeNovartisNot recruiting20 YearsN/AAll285Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1236NCT00206687January 200319 February 2015STEPS Trial - Spheramine Safety and Efficacy StudyStudy of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's DiseaseParkinson DiseaseBiological: Spheramine (BAY86-5280);Procedure: PlaceboBayerTitan PharmaceuticalsNot recruiting30 Years70 YearsBoth71Phase 2United States;Germany;Spain;Austria;France
1237NCT00451815January 200319 February 2015BIIB014 Phase 2a MonotherapyA Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s DiseaseParkinson's DiseaseDrug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;Drug: placeboBiogen IdecNot recruiting30 Years78 YearsBothPhase 2
1238NCT02248207January 200319 February 2015Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's DiseaseManagement of Parkinson's Disease Patients at Their First Visits in a Neurological PracticeParkinson DiseaseDrug: PramipexoleBoehringer IngelheimNot recruitingN/AN/ABoth1293N/A
1239NCT00247247December 200219 February 2015Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off PhenomenonParkinson's DiseaseDrug: Comtess®Orion Corporation, Orion PharmaNot recruiting60 YearsN/ABoth300Phase 4Germany
1240NCT00209508November 200219 February 20152 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PDRandomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.Parkinson's DiseaseDrug: GPI 1485Eisai Inc.Symphony Neuro Development CompanyNot recruiting40 Years80 YearsBoth200Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1241NCT00165815August 200219 February 2015The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With DementiaDementia With Parkinson's DiseaseDrug: ARICEPTEisai LimitedNot recruiting40 YearsN/ABothPhase 3Germany;Ireland
1242NCT00594386August 200219 October 2017An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's DiseaseAn Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.Parkinson's DiseaseDrug: RotigotineUCB PharmaNot recruiting31 YearsN/AAll258Phase 3United States;Canada
1243NCT00599196August 200219 October 2017An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's DiseaseAn Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's DiseaseEarly Stage Parkinson's DiseaseDrug: RotigotineUCB PharmaNot recruiting30 YearsN/AAll381Phase 3Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom
1244NCT00955045August 20028 August 2016A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyA Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyParkinson's DiseaseDrug: istradefyllineKyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/ABothPhase 2/Phase 3United States
1245NCT00043849July 200219 February 2015Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)Dementia;Parkinson DiseaseDrug: QuetiapineNational Institute on Aging (NIA)Not recruiting50 YearsN/ABoth60Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1246NCT00314288July 200216 December 2017Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaA Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaParkinson's Disease;DyskinesiaDrug: Sarizotan HClEMD SeronoNot recruiting30 YearsN/AAll360Phase 2United States;Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom
1247NCT00040209June 200219 February 2015JP-1730 to Treat Parkinson's DiseaseAlpha-2 Adrenergic Antagonist Treatment of Parkinson's DiseaseParkinson DiseaseDrug: JP 1730;Drug: IV Levodopa;Drug: IV ApomorphineNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth30Phase 2United States
1248NCT00594165June 200219 October 2017An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.Early-Stage Parkinson's DiseaseDrug: RotigotineUCB PharmaNot recruiting31 YearsN/AAll217Phase 3United States;Canada
1249NCT00203164May 200219 February 2015Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease PatientsA Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa TherapyParkinson's DiseaseDrug: rasagiline mesylateTeva Pharmaceutical IndustriesNot recruiting30 YearsN/ABoth254Phase 3United States
1250NCT00650104May 200219 October 2017Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164Parkinson DiseaseDrug: Ropinirole XL (formerly CR)GlaxoSmithKlineNot recruiting30 YearsN/AAll76Phase 3United States;Belgium;France;Netherlands;Norway
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1251NCT01044992May 200219 February 2015Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) StudyMotor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic ChallengeMultisystemic AtrophyRadiation: H215O PET;Drug: LevodopaUniversity Hospital, ToulouseNot recruiting40 Years75 YearsBoth38N/AFrance
1252NCT00456586April 20028 August 201612-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaA 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyParkinson's DiseaseDrug: KW-6002 (istradefylline)Kyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/ABoth180Phase 2United States
1253NCT00032812March 200219 February 2015The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's DiseaseMotor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEGParkinson Disease;HealthyDrug: RacloprideNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth64N/AUnited States
1254NCT00040404March 200219 February 2015Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's DiseaseParkinson DiseaseDrug: CEP-1347 10mg;Drug: CEP1347 25mg;Drug: CEP-1347 50mg;Other: Placebo ComparatorCephalonH. Lundbeck A/S;The Parkinson Study GroupNot recruiting30 YearsN/ABoth806Phase 2/Phase 3United States;Canada;Puerto Rico
1255NCT00456794March 20028 August 201612-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaA 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/CarbidopaParkinson's DiseaseDrug: Istradefylline (KW-6002)Kyowa Kirin Pharmaceutical Development, Inc.Not recruiting30 YearsN/ABoth325Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1256NCT02248168March 200219 February 2015Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's DiseaseMirapex PMS Study Final ReportParkinson DiseaseDrug: PramipexoleBoehringer IngelheimNot recruitingN/AN/ABoth1449N/A
1257NCT00030979February 200219 February 2015Donepezil to Treat Dementia in Parkinson's DiseaseDonepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover TrialParkinson DiseaseDrug: DonepezilNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth28Phase 4United States
1258NCT02162979February 200211 June 2018Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's DiseaseA Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's DiseaseParkinson's DiseaseDrug: sildenafil;Drug: PlaceboLoma Linda UniversityNot recruiting18 Years80 YearsAll2Phase 2United States
1259NCT02231255February 200219 February 2015Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's DiseaseSwitch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Sifrol®Boehringer IngelheimNot recruitingN/AN/ABoth1216N/A
1260NCT00407212January 200219 February 2015A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and EfficacyA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's DiseaseParkinson's DiseaseDrug: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)NovartisNot recruiting30 Years80 YearsBoth301Phase 1/Phase 2United States;Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1261NCT00036218December 200119 February 2015Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.Parkinson DiseaseDrug: sumanirole;Drug: ropinirolePfizerNot recruiting30 YearsN/ABoth600Phase 3United States;Argentina;Mexico;Puerto Rico
1262NCT00203177October 200119 February 2015Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.Parkinson's DiseaseDrug: rasagiline mesylate;Drug: rasagiline mesylate 1.0 mgTeva Pharmaceutical IndustriesNot recruiting30 YearsN/ABoth254Phase 3United States;Canada
1263NCT02772627September 200123 May 2016Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 in Healthy Volunteers.Parkinson's DiseaseDrug: Nebicapone;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years45 YearsBoth22Phase 1Portugal
1264NCT00200525July 200119 February 2015Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons DiseaseA Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing-Off Effects Associated With Late-Stage PD After Apomorphine UseParkinson DiseaseDrug: apomorphine HCl injectionMylan Bertek PharmaceuticalsNot recruiting18 YearsN/ABoth60Phase 3
1265NCT02763839April 200117 May 2016Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy VolunteersParkinson's DiseaseDrug: BIA 3-202;Drug: Placebo;Drug: Sinemet 25/100Bial - Portela C S.A.Not recruiting18 Years45 YearsBoth19Phase 1Portugal
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1266NCT02763852April 200117 May 2016Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy VolunteersParkinson's DiseaseDrug: BIA 3-202;Drug: Placebo;Drug: Madopar® 125Bial - Portela C S.A.Not recruiting18 Years45 YearsBoth18Phase 1Portugal
1267NCT00013624March 200119 February 2015Riluzole to Treat Parkinson's DiseaseEffect of Antiglutamatergic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth20Phase 2United States
1268NCT00117819March 200119 February 2015A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's DiseaseDynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian SyndromeParkinsonian SyndromeDrug: [123I]ß CIT and SPECT imagingInstitute for Neurodegenerative DisordersIndiana University;Albany Medical CollegeNot recruiting22 YearsN/ABoth232Phase 2United States
1269NCT00145171February 200119 February 2015A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.Parkinson DiseaseDrug: apomorphine HCl injectionMylan Bertek PharmaceuticalsNot recruiting18 YearsN/ABoth56Phase 3
1270NCT00009048January 200119 February 2015EMD 128130 for the Treatment of Parkinson's DiseaseEffect of Serotoninergic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: EMD 128130;Drug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth30Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1271NCT00006337October 200019 February 2015KW-6002 to Treat Parkinson's DiseaseAdenosine A2A Blockade With KW-6002 in Parkinson's DiseaseParkinson's DiseaseDrug: KW-6002;Drug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth16Phase 2United States
1272NCT00006488October 200019 February 2015Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: recombinant-methionyl human glial cell line-derived neurotrophic factorNational Center for Research Resources (NCRR)Not recruiting18 Years75 YearsBothPhase 1United States
1273NCT00203125October 200019 February 2015A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)Parkinson's DiseaseDrug: rasagiline mesylate;Other: tyramineTeva Pharmaceutical IndustriesNot recruitingN/AN/ABoth55Phase 3United States
1274NCT00070928September 200019 February 2015Valerian to Improve Sleep in Patients With Parkinson's DiseasePolysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's DiseaseInsomnia;Parkinson's DiseaseDrug: valerianNational Center for Complementary and Integrative Health (NCCIH)Not recruiting30 Years80 YearsBoth80Phase 2United States
1275NCT02763800September 200017 May 2016Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202Double-Blind, Randomised, Placebo-Controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202, in Young Healthy VolunteersParkinson's DiseaseDrug: BIA 3-202;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years35 YearsMale33Phase 1United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1276NCT00006077August 200019 February 2015Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's DiseaseEffects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's DiseaseParkinson's DiseaseDrug: NS2330;Drug: Levodopa and DomperidoneNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth50Phase 2United States
1277NCT00036205August 200019 February 2015Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's DiseaseOpen-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.Parkinson DiseaseDrug: sumanirolePfizerNot recruiting30 YearsN/ABoth984Phase 3United States;Argentina;Colombia;Puerto Rico
1278NCT02231294July 200019 February 2015The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's DiseaseThe Effect of SIFROL® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease Patients.Parkinson DiseaseDrug: Sifrol®Boehringer IngelheimNot recruitingN/AN/ABoth1464N/A
1279NCT00203034May 200019 February 2015Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor FluctuationsA Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsParkinson's DiseaseDrug: rasagiline mesylate;Drug: 1.0 mg rasagiline mesylate;Other: PlaceboTeva Pharmaceutical IndustriesNot recruiting30 YearsN/ABoth472Phase 3United States
1280NCT00134784April 200019 October 2017Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's DiseaseParkinson DiseaseDrug: [123I]B-CIT SPECT imagingInstitute for Neurodegenerative DisordersUnited States Department of DefenseNot recruiting22 YearsN/AAll142Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1281NCT02763787April 200023 May 2016Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Single Doses of BIA 3-202 in Healthy Volunteers.Parkinson's DiseaseDrug: BIA 3-202;Drug: PlaceboBial - Portela C S.A.Not recruiting18 Years35 YearsMale71Phase 1United Kingdom
1282NCT00004576February 200019 February 2015Study of LY300164 for the Treatment of Parkinson's DiseaseAMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's DiseaseDyskinesias;Parkinson DiseaseDrug: LY300164National Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth20Phase 2United States
1283NCT00761436February 200019 February 2015Pilot Study of Safety and Efficacy of SpheramineStereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.Parkinson's DiseaseBiological: Spheramine (BAY86-5280)BayerTitan PharmaceuticalsNot recruiting40 Years70 YearsBoth6Phase 2United States
1284NCT00037830November 199919 October 2017GM1 Ganglioside Effects on Parkinson's DiseaseThe Study of GM1 Ganglioside, A Potential New Parkinson's Disease MedicationParkinson DiseaseDrug: GM1 ganglioside;Drug: PlaceboThomas Jefferson UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting39 Years85 YearsAll94Phase 2United States
1285NCT00200512September 199919 February 2015Continued Efficacy of Apomorphine After Previous Exposure of at Least Three MonthsA Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing Off Effects Associated With Late Stage Parkinson's DiseaseParkinson DiseaseDrug: apomorphine HCl injectionMylan Bertek PharmaceuticalsNot recruiting18 YearsN/ABoth16Phase 2/Phase 3United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1286NCT00142545July 199919 February 2015Long Term Safety and Efficacy of SC Apomorphine in Treatment of Off Episodes in Late-Stage Parkinson's DiseaseLong-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s DiseaseParkinson DiseaseDrug: apomorphine HCl injectionMylan Bertek PharmaceuticalsNot recruiting18 YearsN/ABoth800Phase 3United States
1287NCT00001931May 199919 February 2015Treatment of Parkinson's Disease With a Transdermal Skin PatchTransdermal Application of Dopamine Agonist N-0923 in Parkinson's DiseaseParkinson DiseaseDrug: N-0923National Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth20Phase 2United States
1288NCT02172573April 199919 February 2015Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseaseA Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's DiseaseParkinson DiseaseDrug: Pramipexole;Drug: Bromocriptine;Drug: Placebo pramipexole;Drug: Placebo bromocriptineBoehringer IngelheimNot recruiting20 YearsN/ABoth315Phase 3
1289NCT00001929March 199919 February 2015Treatment of Parkinson's Disease With EliprodilNMDA-Receptor Blockade With Eliprodil in Parkinson's DiseaseMovement Disorders;Parkinson DiseaseDrug: EliprodilNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth20Phase 2United States
1290NCT00274131December 199819 February 2015Long-term Administration Study of SND 919 Tablets in Parkinson's DiseaseLong-term Administration Study of SND 919 Tablets in Parkinson's DiseaseParkinson DiseaseDrug: Pramipexole 0.125 mg tablets;Drug: Pramipexole 0.5 mg tabletsBoehringer IngelheimNot recruiting20 YearsN/ABoth170Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1291NCT02177357November 199819 February 2015Pramipexole in Untreated and Levodopa-treated Parkinson's Disease PatientsPramipexole: Efficacy, Safety and Tolerability Study in Untreated and Levodopa-Treated Parkinson's Disease Patients, a Multinational StudyParkinson DiseaseDrug: Pramipexole;Drug: PlaceboBoehringer IngelheimNot recruiting30 YearsN/ABoth150Phase 3
1292NCT02248220October 199819 February 2015Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's DiseaseObservation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: PramipexoleBoehringer IngelheimNot recruitingN/AN/ABoth657N/A
1293NCT00004731September 199819 February 2015Parkinson's Disease Treatment With Coenzyme Q10Effects of Coenzyme Q10 in Early Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/ABothPhase 2United States
1294NCT02233023June 199819 February 2015Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseMatched Pair, Assessor Blinded, Open Label Clinical Trial to Assess the Ophthalmologic Safety of Long Term Oral Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Pramipexole;Drug: Bromocriptine and other dopamine agonistsBoehringer IngelheimNot recruitingN/AN/ABoth705Phase 4
1295NCT00004451March 199819 February 2015Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease PatientsParkinson DiseaseDrug: GlucoseNational Institute of Mental Health (NIMH)University of VirginiaNot recruiting18 YearsN/ABoth120N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1296NCT00004733January 199819 February 2015Timing of Levodopa Treatment in Parkinson's DiseaseEarlier Versus Later L-Dopa in Parkinson's DiseaseParkinson's DiseaseDrug: levodopaNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/ABothPhase 3United States
1297NCT00226460August 199730 March 2015Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.Parkinson's DiseaseDrug: Fetal porcine cells, Neurocell-PDGenzyme, a Sanofi CompanyDiacrin/Genzyme Corporation LLCNot recruiting40 Years70 YearsBothPhase 2United States
1298NCT00203060July 199719 February 2015Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With LevodopaA Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With LevodopaParkinson's DiseaseDrug: Rasagiline Mesylate;Drug: placeboTeva Neuroscience, Inc.Not recruiting35 YearsN/ABoth404Phase 3United States
1299NCT00038116May 199519 February 2015Embryonic Dopamine Cell Implants for Parkinson's DiseaseEmbryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind StudyParkinson DiseaseProcedure: embryonic dopamine cell implant surgery;Procedure: placeboUniversity of Colorado, DenverNot recruiting20 Years75 YearsBoth40Phase 3United States
1300NCT00004826October 19937 April 2015Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: clozapineMemorial Hospital of Rhode IslandNot recruitingN/AN/ABoth60N/A
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1301NCT00001365July 199319 February 2015Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous SystemNMDA Receptor Antagonist Treatment of Neurodegenerative DiseaseNeurodegenerative Disease;Parkinson's DiseaseDrug: dextromethorphanNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth42Phase 2United States
1302NCT00132626September 199215 April 2019Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian SyndromeDynamic SPECT Imaging With [123I]ß-CIT in Patients With ParkinsonismParkinson's Disease;Parkinsonian SyndromeDrug: [123I]ß-CIT and SPECT imagingInstitute for Neurodegenerative DisordersMolecular NeuroImaging;National Institutes of Health (NIH)Not recruiting35 YearsN/AAll500Phase 2
1303JPRN-JapicCTI-05009923 April 2019Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's diseaseDouble blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's diseaseParkinson's diseaseIntervention name : AD-810N (zonisamide)
Dosage And administration of the intervention : oral		Dainippon Sumitomo Pharma Co., Ltd.2079BOTHNA
1304JPRN-JapicCTI-07037723 April 2019Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's diseaseDouble-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's diseaseParkinson's diseaseIntervention name : AD-810N (zonisamide)
Dosage And administration of the intervention : oral		Dainippon Sumitomo Pharma Co., Ltd.2074BOTHPhase 3
1305JPRN-JapicCTI-1010202 April 2019Phase II study on FPF1100NW monotherapyStudy on FPF1100NW monotherapy with early Parkinson's disease patients (Phase II study)Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null		FP Pharmaceutical Corp.2074BOTH90Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1306JPRN-JapicCTI-1116992 April 2019Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's DiseaseAn Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects with Advanced Parkinson's DiseaseAdvanced Parkinson's diseaseIntervention name : ABT-SLV187
Dosage And administration of the intervention : Usually 2-6 ml/hour (40-120 mg levodopa/hour), dose will be individually optimized for each subject based on the subject's symptoms
Control intervention name : null		Abbott Japan Co., Ltd.30BOTH8Phase 2
1307JPRN-JapicCTI-1219542 April 2019Phase III study on FPF1100NW monotherapyRandomized, double-blind, placebo-controlled study on FPF1100NW monotherapy with early Parkinson's disease patients (Phase III study)Early Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null		FP Pharmaceutical Corp.2074BOTH280Phase 3

先頭へ